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Glycosylation Events in C-mannosylation and the Biosynthesis of 
Kijanimicin  
Publication No._____________ 
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The University of Texas at Austin, 2010 
Supervisor:  Hung-wen Liu 
In this work, we examine two disparate aspects of glycosylation. The first 
project involves the elucidation of the glycosylation of the novel tetronolide 
natural product, kijanimicin. The biosynthesis of the deoxysugar TDP-L-
digitoxose from the kijanimicin natural product pathway was achieved in vitro. 
The genes were identified from the cluster, cloned, expressed and the products 
were purified. Activity was demonstrated for the novel enzymes and the pathway 
was reconstructed in vivo using Streptomyces lividans. These strains of S. lividans 
were used to examine kijanimicin glycosyltransferase activity. We were able to 
demonstrate activity for 3 of 4 digitoxosyltransferases in the biosynthetic pathway 
and propose a biosynthetic scheme by which the tetrasaccharide chain is formed. 
We identified two putative glycosidases with novel folds, and one 
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glycosyltransferase that appears to have unprecedented activity, attaching 2 if not 
3 sugars in sequence. 
In the second portion of this work, we attempted to identify the eukaryotic 
C-mannosyltransferase enzyme and demonstrate its activity in vitro and in vivo. 
Here, we describe our efforts to identify the CMT. Through in silico analysis, 
putative C-mannosyltransferase genes were identified. These genes were 
expressed in E. coli and S. cerevisiae, however gene expression was apparently 
toxic to E. coli. S. cerevisiae expression was acceptable, but extraction proved to 
be somewhat problematic. We describe our efforts to develop a CMT assay for 
use in vitro by expressing the putative CMT in insect cells, which was much more 
promising. We also attempted to knock down the putative CMT genes using 
shRNA, which demonstrated that the genes of unknown function that were 
identified were essential for cellular viability. 
This work has contributed to the fields of both C-mannosylation and 
natural product glycosylation. We have elucidated the biosynthetic pathway of a 
novel deoxysugar, and identified potentially valuable tools for glycoengineering 
including a glycosyltransferase that appears to exhibit novel polymeric activity, as 
well as identifying two glycosyltransferase proteins that are apparent 
glycosidases. Our attempts to identify the CMT provided valuable insight into the 
future development of a C-mannosylation assay, and we have identified several 
promising protein candidates that are apparently essential for H. sapiens cellular 
viability.
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1 An Overview of Eukaryotic and Prokaryotic Glycosylation 
Glycosylation is the most common and most diverse post-translational 
modification that newly synthesized proteins may undergo.
1
 Covalent linkages between
proteins and carbohydrates have been found in all organisms, including archaea, 
prokaryotes and eukaryotes.
2
 It has been argued that glycosyltransfer reactions are, on
quantitative terms, the most important biological transformations on Earth, since they 
account for the biosynthesis and hydrolysis of the bulk of biomass.
3
 Thus, one may also
argue that the most important enzymes are those involved in glycosylation reactions, 
including sugar donor biosynthesis, glycosyltransferases or enzymes which catalyze the 
transfer of sugar moieties from activated donor molecules to specific acceptor molecules 
to form glycosidic bonds, and glycosidases, which catalyze the removal of sugar moieties 
from glycosylated acceptor molecules. Notably, the biosynthesis of disaccharides, 
oligosaccharides and polysaccharides involves the action of literally hundreds of different 
glycosyltransferases.
4
Eukaryotic glycosylation encompasses multiple forms of protein post-
translational modifications including N, O and the newly discovered C-glycosylation. 
Glycosylation in prokaryotes is more limited, with protein modifications involving 
simple  N- and O-glycosylation only, although myriad secondary metabolites and other 
natural products are highly decorated with diverse glycoforms. In this Chapter, a brief 
overview of prokaryotic and eukaryotic glycosylation will be presented, with an emphasis 
on the respective similarities and differences between the systems. To demonstrate the 
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importance of all forms of glycosylation in both prokaryotes and eukaryotes, model or 
unique pathways will be described including S-layer glycans involving N- and O-
glycosylation, lipopolysaccharide biosynthesis (prokaryotic O-glycosylation), prokaryotic 
N-glycosylation, natural product glycosylation in prokaryotes, which includes C-, O- and 
N-linkages, several forms of eukaryotic O-glycosylation, eukaryotic N-glycosylation, and 
finally C-mannosylation, which is found only in eukaryotes. 
1.1 ROLE OF PROKARYOTIC GLYCOSYLATION 
Prokaryotes possess an extreme variety of carbohydrates as cell surface 
constituents. These carbohydrates are either attached to lipids or are part of elongated 
glycan chains. Glycoconjugates that are linked to proteins or peptides generated by 
ribosomes had never been reported prior to the identification of an S-layer glycopeptide 
found in an archaeal halophile.
5
 While this S-layer glycan was proposed to play a role in
maintaining cell shape, little research followed as S-layer glycans were not considered to 
be medically relevant.
5
 Prokaryotic glycosylation regained attention when glycosylated
proteins were identified in bacterial pathogens. In fact, most glycoproteins in Gram-
negative bacteria are associated with virulence factors of medically significant 
pathogens.
6, 7
 Since the discovery of prokaryotic protein glycosylation, surface protein
glycosylation has been linked to important steps in pathogenesis. Specifically, bacterial 
protein glycosylation may have specific functions in infection and pathogenesis, while 
interfering with inflammatory immune responses.
7
 It has been suggested that these
glycans serve multiple functions in infectious pathogens. Prokaryotic protein 
glycosylation has been suggested to include the maintenance of protein conformation, 
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surface recognition, increasing resistance against proteolytic digestion, enzymatic 
activity, cell adhesion and immune evasion, and has been shown in some pathogens to 
function in intercellular interactions such as adhering to host cells.
7
 The relationship
between pilin glycosylation and cellular adhesion clearly demonstrates the link between 
glycosylation and pathogenesis in bacterial infection.
7
 It has also been suggested that
another role of prokaryotic glycosylation is to modulate immune response by interacting 
with antibodies from the host.
7
 Modulation of immune response could result from
altering pathogenic glycoforms, which would in turn affect host antibody production, 
thus influencing the infection.
7
1.1.1 Secondary Cell Wall Polymers 
S-layer or “surface layer” glycosylation is the oldest known and perhaps the best 
studied prokaryotic glycosylation, although glycosylated enzymes, antigens and cell-
envelope components have also been identified.
2
 The first S-layer glycoprotein was found
in halophile archaeon Halobacterium halobium.
8, 9
 After the initial identification of S-
layer glycoproteins, this type of glycosylation was also found in prokaryotic organisms, 
mainly in low G+C Gram-positive bacteria.
2
 Since the identification of S-layer
glycoproteins, linkage regions has been identified and S-layer proteins have been cloned 
and sequenced.
2
 in addition, some information about the glycan biosynthetic pathways is
also available.
2
In bacteria and archaea, the outermost cell envelope layers are 5-20 nm thick and 
cover the cell surface completely.
2
 Subunits composing the cell envelope are 40-200 kDa
and are arranged in lattice structures spaced 2.5-35 nm apart. 
2
 These glycans protrude
30-40 nm from the cell surface  to create a polysaccharide coat similar to that of LPS 
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antigens of Gram-negative bacteria.
2
 S-layer glycans are planar assemblies of weakly
acidic glycoproteins found in archaea and Gram-positive organisms with isoelectric 
points ranging from pH 4 to pH 6. 
2, 10, 11
 Proteins in S-layers are frequently post-
translationally modified by glycosylation, phosphorylation, and protein termini (N- and 
C-) are trimmed.
2
  S-layer glycans are comparable to the lipopolysaccharide (LPS) coat
of Gram-negative bacteria, however the difference is how the glycans are anchored to the 
cell wall.
2, 12
 In bacterial S-layers, the glycan is anchored through a core structure, much
like LPS are anchored via lipid A, while in archaea the S-layer anchor is a polypeptide, 
linked by N- or O-glycosylation.
12
 The existence of a core-oligosaccharide connecting the
bacterial S-layer polysaccharide and the protein portion has been experimentally 
determined. 
13-15
 This data leads to the deduction of a tripartite architecture for these cell-
surface macromolecules.
2
 The overall structure consists of long, variable O-antigen-like
carbohydrate chains and the oligosaccharide core is glycosidically linked to the S-layer 
polypeptide. 
2
In archaea, N-linkages predominate whereas in bacteria,  O-linkages such as β-
Gal→Tyr, β-Glc→Tyr or β-GalNAc→Thr  and β-GalNAc→Ser/Thr are most abundant.2
Bacterial S-layer glycans may also be attached through a rare Rha→Asn N-linkage, 
although O- and N-linkages are never found on the same protein. In contrast,  archaeal S-
layers contain N- and O-linkages on the same protein, including N-linkages of Glc→Asn, 
GalNac→Asn, Rha→Asn  and O-linkages to Thr.2 Other differences between bacterial
and archaeal S-layer glycans are the number of glycans attached to the protomer and the 
polymer size. Bacteria have fewer attachment sites (2-6), and longer polymers (20-50) in 
repeating units of 2-6 saccharides.
2
 In contrast, archaea generally have a higher number
of attachment sites (3-25 per protein), shorter polymers (up to 10 saccharides), and have 
no repeating saccharide units.
2, 16
 Generally, a single type of carbohydrate chain is
 21 
generally found per organism, although archaea may exhibit up to 3 different types of 
glycans on one protomer. These glycans may vary in chain length, and glycosylation sites 
on the protein including amino acid acceptor sequence variation.
2
 
In bacteria, these polymers can be linear or branched structures, and include a 
wide range of hexoses, deoxysugars, N-acetylated aminosugars, uronic acids, which can 
also be derivatized with phosphate, sulfate and glycerol groups. 
17-19
 It should be noted 
that several sugars are found exclusively in the LPS of Gram-negative bacteria, such as 
D-rhamnose 3-N-acetyl- D-fucosamine, D-glycero-D-manno-heptose and others, which 
have been isolated from bacterial S-layer glycans.
20, 21
 
 
1.1 Examples of S-Layer Glycans from Archaea 
 
 
 
 
 
 
 
 
 
In bacteria and archaea, N-glycans are found to link to the consensus sequence N-
X-S/T where X is any amino acid except proline.
2
 It should be noted that S-layer 
glycosylation is not restricted to conventional sequences: i.e. e., asparagine for N-
glycosidic linkages and threonine, serine and hydroxyproline or hydroxylysine for O-
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glycosidic linkages, but also include tyrosine as potential glycosylation sites.
22
 O-
glycosylation may occur in Pro rich domains as in eukaryotes, but may also be found on 
consensus sequences such as D-S, D-T-T, or V-Y. 
22
  
 
1.1.1.1 Biosynthesis of S-Layer Glycans 
Forty S-layer glycoprotein structures have been partially or fully elucidated, but 
much less is known with respect to the biosynthesis of these glycans.
23
 Archaeal O-
glycosylation pathways are almost completely unknown.
23
 It was previously assumed that 
archaeal pathways follow the general format of N-glycosylation in other organisms such 
that sugars are assembled into a polymer on a lipid carrier. The lipid carrier will be 
translocated across the cellular membrane followed by protein glycosylation. Archaea are 
known to use both dolichol phosphate and undecaprenyls for lipid anchors in 
glycosylation.
5, 23, 24
 As in other forms of N-glycosylation, the glycans are assembled on 
the lipid anchor in archaea.
25
 Once the oligosaccharide is complete, it is translocated 
across the membrane by unidentified cellular machinery.
25
 A few enzymes involved in 
these biosynthetic pathways have been characterized.
23
 But due to the diversity of glycan 
structures, S-layer pathways from each organism must be individually characterized.
23
 
Much research remains to be done in elucidating the biosynthetic pathways of 
nucleotidyl activated sugar substrates in archaea, although studies in methanogens and 
Thermococcales demonstrated that these pathways generally follow the bacterial 
biosynthetic routes.
26
  Some glycosyltransferase genes and their products in the archaeal 
S-layer pathway have been characterized. In M. voltae, AglC and AglA add the 
penultimate and the terminal 2,3-diacetamido-2,3-dideoxy-β-glucuronic acid moieties, 
respectively, while AglH, a homolog of the yeast Alg7 protein, is involved in addition of 
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the Asn-bound linking sugar, GlcNAc.
27, 28
 In H. volcanii, AglD, AglE, AglF, AglG, and 
AglI transfer the second to the fifth sugar subunits of the partially characterized 
pentasaccharide linked to the S-layer glycoprotein.
25, 29, 30
   
More work remains to be done in this area to elucidate these biosynthetic 
pathways. However, these examples cited here serve to demonstrate current evidence for 
the stepwise addition of sugars by dedicated glycosyltransferases to the lipid carrier for 
the production of a lipid-linked oligosaccharide.  
 
1.2 Archaeal S-Layer Pathways from H. volcanii and M. voltae 
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1.1.1.2 Archaeal S-Layer N-Glycosyltransferase 
In both M. voltae and H. volcanii, aglB encodes the archaeal OST, which 
comprises a single subunit homologous to the core STT3 subunit of the multimeric 
eukaryotic OT complex.
23
 As in eukaryotes, the canonical N-X-S/T motif is a sufficient 
condition governing the site of glycosylation in archaea.
25
 In archaea, however, the 
replacement of Ser with Val, Leu, or Asn does not prevent glycosylation, which suggests 
the presence of an N-glycosyltransferase enzyme which is more promiscuous  than those 
found in bacteria or eukaryotes.
31
 However, the N-glycan profile of the H. salinarum S-
layer glycoprotein reveals the presence of two different oligosaccharides, each linked to 
selected Asn residues through either glucose or GlcNAc subunits, which suggests that the 
archaeal OT may tolerate a range of sugar substrates, unlike its eukaryotic or bacterial 
OT homologs.
26
 
A crystal structure of the C-terminal domain of the aglB enzyme was solved to 
2.7 Å. This data  provided  important structural information regarding the archaeal OST 
and could be related to the bacterial and eukaryotic OT proteins.
32
 The crystal structure 
showed a central core domain consisting of α-helices that includes the WWDYG catalytic 
motif, with β strands surrounding the central core.23 Alignments of Stt3 (OT) homologs 
from eukaryotes, bacteria and archaea enables the discovery of a conserved DXXK 
motif.
23
 According to the crystal structure, the conserved Asp and Lys residues are 
located on a helical face near the catalytic motif. Thus, it was proposed that the DXXK 
motif may interact with the pyrophosphate moiety of the lipid carrier.
23
 Subsequent site-
directed mutagenesis in yeast provided experimental support for the catalytic 
involvement of the DXXK motif in N-glycosylation.
23
  In the archaeal AglB, 
DWQMASTDAK is found instead of the DXXK motif, which suggests that the 
disruption of the widely conserved DXXK motif may correlate with the use of dolichol 
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mono- rather than pyrophosphate as the oligosaccharide-charged lipid carrier in these 
organisms.
26
 
 
1.1.1.3 Role of S-Layer Glycans 
When aglB is removed by mutation from M. voltae and H. volcanii, the cells 
remain viable. Thus, N-glycosylation does not appear to be essential for cell survival in 
archaea, unlike eukaryotes.
29
 However, the inability to perform N-glycosylation renders 
archaea unable to grow at elevated salt concentrations and to display unstructured and 
defective S-layers.
29
 In M. voltae, lack of N-glycosylation results in the reduction of 
flagella (overall) and the cells also display motility defects. 
29
  
The function of prokaryotic glycans has been experimentally demonstrated in 
several cases, and those in the S-layer of the organism are the most well studied.
5
 S-layer 
glycans have been shown to provide a framework for cell shape, aid in cell division 
process, involve cell adhesion, surface recognition, protective coats, act as molecular 
sieves or molecule and ion traps, and provide adhesion for enzymes.
2
 Taken together, 
these data suggest that while not essential, N-glycosylation provides adaptive benefit for 
archaeal cells that may allow these organisms to adapt and thrive in extreme 
environments.
26
 
Initially, there a lack of interest in S-layer glycans until they were identified in 
pathogens, and these glycans received even more attention when protein glycosylation 
was correlated with prokaryotic pathogenicity.
7, 33
 Early reports of S-layer involvement in 
infectious capacity of organisms described a glycoenzyme and a platelet aggregation-
associated glycoprotein of Streptococcus sp. strains.
34, 35
 Further reports contained 
detailed structural analysis of the 45-kDa soluble antigen of Mycobacterium tuberculosis, 
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which was found to contain short α-linked mannose chains in O-linkage to Thr residues 
near the N- and C- termini.
36
  These early reports led to the investigation of other 
glycosylated cell surface appendages, which will be discussed in a later section. 
 
1.3 Multiple S-layer Glycans May Coexist on One Protomer 
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1.1.2 BACTERIAL PROTEIN GLYCOSYLATION 
There exists in prokaryotes a greater diversity of glycan composition and 
glycosylation sequences than eukaryotes.
22
  There are two possible pathways for protein 
glycosylation in Gram-negative bacteria. One pathway requires supplementation from the 
lipopolysaccharide or lipooligosaccharide (LPS, LOS) biosynthesis pathways for sources 
of activated carbohydrate precursors, the necessary biosynthetic enzymes and 
glycosyltransferases as in the case in E. coli and Pseudomonas O-glycosylation.
37, 38
 The 
second methodology employed by bacteria to glycosylate proteins involves the evolution 
or acquisition of separate gene clusters that encode all genes required for precursor and 
glycan synthesis as well as glycosyltransferases for attachment.
7, 39
 It is the second 
methodology employed by C. jejuni and other organisms that use the pgl locus to 
accomplish protein N-glycosylation. 
 
1.1.2.1 N-glycosylation “Pgl” in C. jejuni 
In eukaryotic proteins, N-glycans are found at an expanded consensus sequence 
N-X-S/T where X is any amino acid except proline. However, an expanded D/E-Z-NX-
S/T sequon motif, where Z and X are not prolines, is required for C. jejuni N-
glycosylation. 
22, 40
 Another notable difference is in the structure of prokaryotic glycans. 
The latter differ from those of eukaryotes in their lack of antennary structures.
22
 The 
biosynthesis of glycans in prokaryotes is also different. In eukaryotes, most N- and O-
glycosylation occurs in the endoplasmic reticulum and Golgi apparatus. However, there 
are no membrane bound organelles in most prokaryotes. Thus, glycan biosynthesis must 
occur in the cytosol of the organism, employing the cell membrane when biosynthesis 
requires lipid-bound substrates.
22
 The lipid carrier employed by bacterial glycosylation 
machinery is also different from eukaryotes. Bacterial systems utilize undecaprenyl 
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pyrophosphate, while eukaryotic systems use dolichol pyrophosphate.
41
 Nevertheless, 
overall biosynthetic pathways remain quite similar, as lipid bound and nucleotidyl 
activated sugars are used as substrates in oligosaccharide chain assembly. 
22
  
The most well-characterized prokaryotic N-glycosylation pathway (figure 1.1) is 
found in Campylobacter jejuni, a human gut mucosal pathogen that is a main cause of 
bacterial gastroenteritis worldwide.
24
  The proposed functions of  proteins encoded by the 
pgl locus in C. jejuni are based on previous studies of this organism and on published 
reports of similar protein sequences in Neisseria meningitidis and other organisms. The 
first step in prokaryotic N-glycan biosynthesis is the attachment of an N-
acetylhexosamine (HexNAc) residue to a lipid carrier, undecaprenyl pyrophosphate by 
PglC.
39
 The HexNAc is subsequently converted to bacillosamine on the lipid by the 
sequential actions of PglF (dehydratase), PglE (aminotransferase) and PglD 
(acetyltransferase).
39
 In N. meningitidis, PglA is the glycosyltransferase responsible for 
the transfer of α-1,3-linked galactose to bacillosamine and possibly to GlcNAc, therefore, 
it is proposed that PglA in C. jejuni adds the α-1,3-linked GalNAc to bacillosamine.39, 42 
PglH and PglJ have similar amino acid sequences and it has been demonstrated that PglH 
is an α-1,4-GalNAc transferase.39 In addition, mutation experiments performed on PglH 
and PglJ demonstrated that they are both functional.
43
 Thus, both proteins could be 
involved in transferring the next four α-1,4-linked GalNAc residues. The remaining 
single-branched glucose residue could be added in sequence or after the GalNAc polymer 
is assembled, and the remaining glycosyltransferase, PglI, is proposed to be responsible 
for the addition of this sugar residue.
39
 Both WlaJ and pglG are omitted from this 
glycosylation model. The former was not considered due to its unknown function and the 
latter was shown to be non-essential.
39, 44, 45
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In the current proposal, the assembled heptasaccharide is flipped across the inner 
membrane by the ABC transporter, WlaB.
39
 This is analogous to the eukaryotic pathway 
where the assembled sugars are flipped into the lumen of the endoplasmic reticulum 
(Figure 1.4).
46
 It should be noted that at this stage of biosynthesis in both the bacterial 
and eukaryotic systems, the potential N-glycan is a lipid-linked heptasaccharide 
containing one branched sugar.
39, 46
 In eukaryotes, the heptasaccharide is further 
processed to a tetradecasaccharide, which is then transferred to proteins by the 
oligosaccharyltransferase protein complex, including the PglB homologue, Stt3.
46
  
 
1.4 The pgl N-Glycosylation Pathway of C. jejuni 
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1.1.2.2 PglB- the Model Prokaryotic N-glycosyltransferase 
The key glycosyltransferase enzyme in the pgl gene locus is PglB. This protein 
shows significant amino acid similarity to the staurosporine- and temperature-sensitive 
yeast protein 3 (Stt3) subunit of the N-linked oligosaccharyltransferase (OT) complex of 
Saccharomyces cerevisiae.
45
 Stt3 has recently been shown to play a central role as the 
glycosyltransferase or as the catalytic subunit of the nine-member OT complex.
47
  Stt3 
homologs are found in several eukaryal and archaeal species and are characteristically 
large proteins (700–970 amino acids) with 10–12 potential membrane-spanning regions 
and a conserved C-terminal catalytic domain (WWDYG) similar to PglB.
44, 47
 In C. 
jejuni, the OT homolog PglB appears to be the only protein required for glycosyltransfer 
of the glycan to the common N-linked sequon.
39
 Another deviation from eukaryotic N-
glycosylation systems is a lack of evidence for further processing of the 
heptasaccharide.
39
  In contrast to the eukaryotic system, in which N-glycosylation targets 
proteins to folding chaperones in the ER, the N-glycosylation system in prokaryotes 
appears to modify proteins that have already been folded.
48
 Thus, it has been proposed 
that the N-glycosylation system in bacteria modifies flexible parts of proteins, and does 
not play a direct role in protein folding.
48
 
The Campylobacter PglB protein is the first bacterial N-linked OT that has been 
experimentally verified, although many oligosaccharyltransferases have been identified 
with the sequencing of bacterial genomes.
39
 Thus, the presence of an Stt3 homolog in the 
pgl locus suggests a glycosylation model analogous to N-linked glycan assembly in 
higher organisms. This finding may also support the proposals that both prokaryotic and 
eukaryotic glycosylation systems have evolved from a common ancestor.
46
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1.1.2.3 O-Glycosylation “Fla” in C. jejuni 
The Campylobacter flagellin protein is one of the most extensively modified 
bacterial proteins characterized to date, with approximately 10% of the total mass of the 
glycoprotein consisting of O-linked carbohydrates.
39
 Campylobacter flagellins were 
shown to bind to a sialic-acid-specific lectin, although it was later determined that the 
sugars on these flagellin are monosaccharide analogues of the related sugar, pseudaminic 
acid, which is a nine-carbon sugar and a member of the 5,7-diamino-3,5,7,9-
tetradeoxynon-2-ulosonic acids.
45
 Glycosylation is confined to 19 Ser and Thr residues in 
the central domain of the flagellin protein of C. jejuni (residues 81–176), in the region 
known to be on the surface of the flagellar filament.
45
 As in eukaryotes, the sites of O-
glycosylation are found at a distance from charged residues in hydrophobic patches of the 
target protein.
45
 
Analysis of the gene cluster has identified 50 genes that may be involved in pilin 
O-glycosylation, however genetic analysis cannot find a GT in the cluster.
45
 The same 
analysis identified multiple homologues of sialic acid biosynthetic genes in C. jejuni 
NCTC 11168 sequence and several of these genes, Cj1311 (neuA2), Cj1317 (neuB3), 
Cj1327 (neuB2), Cj1328 (neuC2), and Cj1331 (neuA3), reside in the flagellar 
glycosylation locus.
45
 These genes have been determined to be involved in pseudaminic 
acid biosynthesis.
49
 Other genes in the cluster remain hypothetical and are predicted to 
encode proteins involved in motility variation, or are proteins of unknown function.
24
 
Bacterial O-glycosylation is believed to occur in the cytosol or inner membrane of 
the organism, with NDP-activated sugars as substrates.
24
 Similar to eukaryotic O-
glycosylation, it is proposed that O-glycans are assembled sequentially, and no lipid 
carriers are involved in this process.
24
 Recent evidence also suggests that the O-antigen 
biosynthetic pathway may also be a source for pilin glycosylation precursors.
7
  Examples 
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of shared enzymes have been found in multiple bacterial strains, including E. coli, 
Haemophilus influenza, H. pylori, N. meningitidis, Aneurinibacillus thermoaerophilius, 
and are proposed to occur in others.
24
 Sharing enzymes between biosynthetic pathways 
such as those involved in pilin glycosylation and O-antigen biosynthesis may allow 
prokaryotes to avoid redundancy and maintain compact genomes.
24
 
 
1.1.2.4 Bacterial O-Antigens 
O-Antigens are important outer membrane components of Gram-negative 
bacteria, and are not glycopeptides.
50
 The corresponding bacterial glycosylation pathway 
is briefly reviewed here not only due to the apparent functional similarities of the O-
antigen to O-GalNAc derived glycans (mucins) and glycosaminoglycans (GAG) in higher 
eukaryotes but also due to its biosynthetic similarity to S-layer glycans in Gram-positive 
bacteria and archaea. The most extensively studied O-antigens are found in E. coli and 
Salmonella enterica, with 186 and 54 different antigens documented, respectively.
50
  The 
diversity of structures precludes a succinct summary of biosynthetic pathways, if detailed 
descriptions of each structure were attempted. Thus, only a basic biosynthetic summary 
of these pathways and their roles in prokaryotic biology will be presented here. 
 
1.1.2.5 O-Antigen Biosynthesis 
O-Antigen biosynthesis can be divided into three steps, nucleotide sugar 
biosynthesis, sequential attachment of the activated sugars to the lipid carrier followed by 
membrane translocation, and final assembly of the O-antigen units to form the 
heteropolymer.
50
 Common sugars such as, Glu, Gal, Rha, Man and their derivatives, and 
less common sugar moieties such as colitose, paratose, abequose, tyvelose, ascarylose 
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and others, are found in O-antigens.
50, 51
 O-Chains of different organisms are very 
structurally diverse and are comprised of a variety of sugars.
52
 Many biosynthetic genes 
for common sugars are found elsewhere in the bacterial genome, while biosynthetic 
genes for specialized sugars are located in the O-antigen gene cluster.
50
 After sugar 
biosynthesis, sugar moieties are assembled sequentially to create the “O-unit” on 
undecaprenyl phosphate, which serves as the lipid carrier in the bacterial membrane.
50
  
The heteropolymer is generally flipped at this time by flippase Wzx, and polymerized by 
Wzy polymerase, which creates a 3-sugar main chain with 2-sugar side branch or a 2-
sugar main chain with 3- sugar side branch.
50, 53
 The polymer length is determined by 
Wzz, and the finished product is exported by Wzm and Wzt.
50
  The finished product is 
anchored on Lipid A, and may be subsequently modified by further glycosylation or 
acetylation.
50, 54
 
 
1.1.2.6 Roles of Prokaryotic Surface N- and O-Glycosylation 
Early reports of bacterial glycosylation led to the investigation of other 
glycosylated cell surface appendages, such as pili and flagella.
7, 33, 55
 The pili of the 
pathogenic bacteria Neisseria gonorrhoeae, N. menigitidis, and P. aeruginosa are 
composed mainly of the glycoprotein pilin.
56, 57
 Pilin glycosylation genes were 
discovered in these bacteria and the encoded enzymes transfer rare sugars, such as a 
modified version of pseudaminic acid, a nine-carbon sugar that resembles sialic acid.
33, 49, 
57
 The pilins of gonococci and meningococci were found to be glycosylated at Ser63, but 
instead of GlcNAc, a novel saccharide, 2,4-diacetamido-2,4,6-trideoxyhexose, was 
identified as the O-linked sugar residue.
56, 58
 Subsequent work in Campylobacter jejuni 
led to the identification of a similar trideoxyhexose, termed bacillosamine.
39
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Prokaryotic glycans appear to be more complex than initially supposed. Other 
than the cell envelope, glycosylated flagella are also important cell surface appendages of 
bacteria, as motility is a key factor in the adaptation of many bacterial pathogens.
6
 These 
structures have been found in Gram-negative pathogens and methanogenic archaea, such 
as M. voltae and H. halobium.
7, 33, 59, 60
 Interestingly, the N-linked glycans of the 
individual flagellins are similar but not identical to the Glc→Asn-linked glycan chains 
present in the halobacterial S-layer glycoprotein in H. halobium. Complex flagella 
assembled from two or more structural flagellin proteins have been found in a diverse 
range of Gram-negative bacteria, including Caulobacter, Campylobacter, Aeromonas, 
Vibrio, Pseudomonas, and Helicobacter.
57, 61
 As in the pilin of P. aeruginosa, various 
derivatives of pseudaminic acid were identified in various bacterial organisms.
49
 
Mounting evidence also indicates glycosylation involvement in the flagellar assembly 
process.
57
 
The function of bacterial N-glycosylation is not well documented. Loss of N-
glycosylation does not render archaea inviable. Protein N-glycosylation in C. jejuni 
appears to play a role in protein complex formation or assembly in the inner membrane.
24
 
Nearly all N-glycosylated proteins in C. jejuni have a signal peptide, such that most of 
these proteins have an extracytoplasmic location.
24
 Possible functions of these proteins 
include protection from proteolytic cleavage, protein stability, or perhaps serving as 
cellular sorting signals.
24, 62
 
O-Antigens are found in both pathogenic and non-pathogenic bacteria. Certain 
types of O-antigens are major virulence factors in infectious bacteria, exhibiting 
pyrogenicity and lethal toxicity in higher organisms. They are also important for bacterial 
survival.
52
 For example, E. coli strains that have acidic sugars in their O-antigens often 
cause dysentery-like diseases.
63
 GalNAcA(N), a rare acidic sugar, is also present in the P. 
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aeruginosa O6 O-antigen.
63
 O-Antigens such as O157, O111 and O26 associated with 
EHEC (enterohaemorrhagic E. coli) are of particular significance in human diseases.
64
 
First isolated from infantile diarrhea, O26 and O121 strains were recently implicated in 
serious enteric disorders, such as hemolytic uremic syndrome.
63, 64
 E. coli O26 has a low 
infectious dose, and is a major concern in food-borne illness, as cattle are the main 
bacterial reservoir.
64
  E. coli O121 strains have been isolated from multiple clinical 
specimens and have been implicated in a waterborne outbreak of infection.
63
 Shigella 
dysenteria O7 antigen was recently found to have the same structure as the E. coli O121 
antigen, thus suggesting that common O-antigen structures may result in common disease 
states, even though the bacterial sources of the antigens may differ.
63
 
In summary, the role of bacterial protein glycosylation is as varied as 
glycosylation in eukaryotes, and many subjects of research remain to be investigated.  
 
1.1.3 BACTERIAL NATURAL PRODUCTS 
Turning now to a completely different form of bacterial glycosylation, some 
bacteria produce and secrete bioactive secondary metabolites. These natural products take 
many forms, and may be antibiotics, virulence factors, or toxins.
65
 Bioactive natural 
products may also be produced by marine organisms or plants, although here we confine 
our discussion to bacterial natural products, and specifically the role of glycosylation in 
the activity of these compounds.  
The majority of natural products produced by bacteria follow several routes of 
biosynthesis including isoprene assembly, non-ribosomal peptide (NRPS) biosynthesis or 
polyketide (PKS) assembly.
65
 Excellent reviews on these biosyntheses are readily 
available and will not be discussed in this work.
66, 67
 Many of these secondary metabolites 
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are decorated with various deoxysugars that provide an additional level of complexity to 
the intricate natural product scaffolds.
65
 The addition of deoxysugars through 
glycosylation can have a dramatic impact on the biological activity, bioavailability and 
pharmacology of these compounds. 
65
 Glycosylated natural products include macrolides 
such as erythromycin, peptides such as vancomycin, and aminoglycosides such as 
gentamicin, and spirotetronates such as kijanmicin.
67, 68
 Glycosylation is also important 
for the activity of natural product anticancer agents such as doxorubicin, antiparasitic 
agents such as avermectin, and antifungal agents such as blasticidin-S.
65
 
Carbohydrate moieties of bioactive compounds have been implicated in the 
control of drug pharmacokinetics including absorption, distribution and metabolism.
69
 
Evidence also suggests that sugar components are often involved in interaction between 
drug and cellular target and their presence is important for the bioactivity of many natural 
products.
69, 70
 A growing number of natural products produced by bacteria consist of 
oligosaccharide chains.
71
 These chains are composed of deoxysugars that are further 
modified by methylation, acetylation, and amination.
71
 
Bacterial natural products require NDP-activated sugars for glycosylation, and 
most often these sugars are transferred by a dedicated glycosyltransferase to a 
nucleophilic receptor (hydroxyl or amino group) on the aglycone scaffold.
65
 The resulting 
N- and O-linkages are quite common in bacterial natural products and O-glycosylation in 
particular has been extensively studied.
72
 C-glycosylation is rarely found in bacterial 
natural products, and is of particular interest from the pharmaceutical viewpoint since 
these bonds are stable towards glycosidase degradation.
71
 This rare type of glycosylation 
has been identified in the antibiotics medermycin, granaticin, and the anticancer agent 
urdamycin.
65
  C-glycosylation is more commonly found in aryl-C-glycosides, which are 
biologically important natural products including pluramycins, anguicylines, 
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benzoisochromanequinones (BIQ) and salmochelin siderophores.
73, 74
 In pluramycins, 
anguicylines and BIQs, C-glycosidic linkages are located ortho to a hydroxyl group, 
while C-glucosylation on salmochelins occurs at 2,3-dihydroxybenzoyl rings at position 
5, para to a phenol hydroxyl group.
73, 75
  
 
1.1.3.1 Natural Product Glycosyltransferases: Classification, Folds and 
Mechanisms  
Glycosyltransferases catalyze the transfer of a sugar moiety from an activated 
donor to an acceptor molecule, which is termed the aglycone in natural products.
71
 
Glycosyltransferases are classified using a system based on substrate specificity, type of 
reaction, and amino acid sequence similarity of GTs.
71
 However, despite their apparent 
diversity in functions, they demonstrate great structural similarity.
71, 76
  Actinomycetes, 
which produce the majority of glycosylated bacterial secondary metabolites have 
glycosyltransferases that, for the most part, belong to the GT-1 family (CAZy 
classification).
71
 Glycosyltransferases from strains producing polyketide antibiotics are 
more similar to each other than enzymes from strains producing glycopeptides or polyene 
antibiotics. In particular, glycosyltransferases from the macrolide pathways are shown to 
be quite closely related.
71
 Phylogenetic analysis of glycosyltransferases also demonstrates 
relationships between enzymes that act on the same region of similar aglycones, 
regardless of the identity of the NDP-sugar substrate.
71
 
Two types of folds have been observed via X-ray analysis of glycosyltransferases, 
GT-A and GT-B.
71
 GT-A has two dissimilar domains. The N-terminal domain is involved 
in nucleotide sugar binding, comprising several β-strands that are each flanked by α-
helices as in an α/β/α sandwich topology which resembles a Rossmann fold. The C-
terminal domain, which contains the acceptor-binding site, consists largely of mixed β-
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sheets.
77, 78
 The NDP-binding region of GT-A enzymes generally contains a DXD motif 
that is involved in metal binding and anchoring the diphosphate moiety of the NDP-
sugar.
78
 Members of the GT-B superfamily are also bi-lobal enzymes that have folds 
consisting of two β/α/β Rossmann-like domains; with the active site lying in the cleft 
between the domains.
79
 In contrast to GT-A family enzymes, in GT-B family enzymes, 
the N-terminal domain provides the acceptor (aglycone) binding site, while the C-
terminal of the enzyme is associated with either the NDP-sugar or the donor substrate. 
79
 
GT-B family enzymes are more disparate than the GT-A family proteins, sharing less 
than 10% sequence identity, although structures that have been solved demonstrate 
similarity.
78
  It should be noted here that the fold or superfamily of the enzyme does not 
dictate the mechanism of the enzyme or the resulting stereochemical outcome of the 
product. 
80
 Indeed, non-glycosyltransferase enzymes are also known to adopt the GT-B 
fold, an example of which is UDP-GlcNAc 2-epimerase.
81
   
The majority of natural product glycosyltransferases are members of the GT-B 
family.
78
 The members of the GT-B superfamily seem to display a greater degree of 
diversity in the glycosyltransferase catalytic mechanisms between and among family 
members, as compared to what has been observed for inverting GT-A enzymes.
79
 The 
greater mechanistic diversity is perhaps a reflection of the greater diversity of chemistries 
catalyzed by this superfamily of enzymes, and perhaps also by the physical separation of 
the two domains.  Thus, the mechanisms of these enzymes cannot be definitively 
predicted, although a general mechanism can be described.  
Briefly, the SN2 inverting mechanism involves the direct attack of the anomeric 
center, displacing the NDP activating group. In this mechanism, the active site 
nucleophile is proposed to stabilize and position the aglycone in the active site for the 
direct attack, while the NDP group is again displaced with the assistance of a metal ion.
79
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As the NDP group is displaced, an active site base abstracts a proton from the aglycone 
hydroxyl.
79
 The resulting hydroxyl ion can attack the opposing face of the sugar, finally 
transferring the sugar to the aglycone and inverting the stereochemistry of the bond. 
Thus, the nucleophilic acceptor attacks the anomeric carbon from the opposite side of the 
sugar ring as the NDP leaving group in a synchronous, concerted manner with highly 
dissociative oxocarbenium-like character. 
82
  
 
1.5 Mechanisms of Inverting and Retaining Glycosyltransferases 
 
Meanwhile, the SN1 retaining mechanism is proposed to pass through a short-
lived oxocarbenium transition state, which is facilitated by the lone pair electrons from 
the endocyclic oxygen. As the NDP group is displaced with the assistance of a metal ion, 
the terminal phosphate abstracts a proton from the aglycone hydroxyl.
79
 The NDP group 
displacement occurs without the stabilization of an active site nucleophile, a transient 
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oxocarbenium ion forms. The formation of the oxocarbenium ion enables the direct 
attack of the anomeric carbon by the aglycone hydroxyl ion, on the same face as the 
leaving group, thus retaining the stereochemistry of the original NDP group. 
83
 These 
mechanisms are shown in figure 1.2.  
 
1.6 Proposed C-Glycosylation Mechanisms 
 
 
 
 
 
 
 
 
 
The mechanism of C-glycosylation is not as well studied as O-glycosylation, 
although there are two current mechanistic proposals. Due to the similarity of O- and C-
glycosyltransferases, a Fries-type rearrangement was proposed.
73
 The mechanistic 
rearrangement would begin with O-glycosylation of a hydroxylated aglycone, after which 
an intramolecular rearrangement would transfer the O-linkage to a C-linkage ortho to the 
original hydroxyl group of the aromatic ring.
73
 The second proposed mechanism is a 
direct alkylation, via a Friedel-Crafts type mechanism, requiring an activated glycoside 
donor and an aryl acceptor that is activated through its inherently electron-rich nature.
73
 
Both mechanisms are shown in Figure 1.3. 
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Synthetic preparation of aryl-C-glycosides by Friedel-Crafts type reaction 
resemble natural aryl-C-glycosylation with ortho- and/or para-substituted products 
predominating.
73
 For example, in salmochelin, selective glucosylation occurs exclusively 
at position 5, which is para to the phenol hydroxyl at position 2 of the 2,3-
dihydroxybenzoyl group.
75
 In many other C-glycosylated natural products the addition of 
sugars is ortho to the phenol hydroxyl, again mirroring the Friedel-Crafts type of 
coupling.
73
 
The simplicity of a direct nucleophilic attack of an activated glycoside by an 
electron-rich aromatic ring makes this an attractive and feasible mechanism. Supporting 
this model, the UrdGT2 glycosyltransferase form the urdamycin biosynthetic pathway 
was found to catalyze both O and C-glycosylation in a heterologous system using S. 
fradiae.
84
 This study was the first to demonstrate that a natural product GT could 
synthesize both C- and O-glycosidic linkages.
84
 These results support the direct C-
glycosylation mechanism, because in this case, initial O-glycosylation of the aglycone 
followed by O-C rearrangement is not favored.
78
  Moreover, the recently solved X-ray 
crystal structure of UrdGT2 revealed that the anomeric carbon of the NDP-sugar 
substrate binds in close proximity to C-9 of the aglycone substrate, and is properly 
positioned for a direct addition to the aromatic ring.
85
 Asp137 was proposed to be the 
base responsible for deprotonation of the aglycone phenolate group via a tightly bound 
active site water molecule.
78
  
 
1.1.4 PROKARYOTIC GLYCOSYLATION SUMMARY 
As shown above, prokaryotic glycosylation is incredibly varied and includes the 
modification of proteins, lipids and small molecules. These compounds and 
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macromolecules have diverse biological activities, and may be essential for prokaryotic 
viability. These glycosylation events may be superfluous, however, most provide at least 
some benefit to the organism. Glycosylation includes N- and O-linkages on proteins, 
lipids and small molecules. Rarely, C-linkages may occur on small molecules. It is 
interesting to compare these diverse glycosylation events to eukaryotic systems, because 
this comparison can provide information regarding both prokaryotic and eukaryotic 
systems.  
 
1.2 ROLE OF EUKARYOTIC GLYCOSYLATION 
The biological roles of glycosylation in multi-cellular eukaryotes are complex, 
varied and difficult to define in terms of absolute functions. In fact, glycosylation is the 
most complex type of posttranslational modification in eukaryotes.
86
 Although, the roles 
that glycosylation may play in the human body have not yet been fully investigated, 
many theories have been posited regarding the roles of each type of glycosylation.
87
 
However, for every rule there are exceptions that can be found.
87
 It is generally believed 
that carbohydrates in multicellular organisms have broad-reaching roles, ranging from 
intracellular sorting, protein quality control, cellular communication, cellular adhesion, 
immune response, to host-pathogen interactions.
87, 88
 Perhaps the most inclusive 
statement regarding the biological role of oligosaccharides is that they either mediate 
'specific recognition' events or they provide 'modulation' of biological processes.
87
 It 
should be noted that 0.5 to 1% of the transcribed human genome is devoted to the 
production of proteins involved in the synthesis, degradation, and function of 
glycoconjugates, therefore these sugar moieties may play a more significant role in the 
biology of multicellular organisms than was previously thought.
89
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Across eukaryotic species, there are eight amino acids and 13 monosaccharides 
that participate in protein glycosylation, giving rise to 31 different types of glycosidic 
linkages.
90
 When taking into account anomeric configurations of the sugars, this number 
rises to 37.
90
 However, the majority of eukaryotic protein glycosylation can be divided 
into two groups, N-linked and O-linked, comprising five and 27 of 37 types of linkages 
respectively across species.
88, 90, 91
 Among the 31 types of potential glycosidic linkages in 
eukaryotes, the majority of N-glycans are of one type (β-Asn), while twelve types of O-
glycans have been identified.
91
 These two types of protein glycosylation are associated 
with many congenital diseases (congenital defects in glycosylation) in humans, thus they 
are the most well-characterized.
87, 89, 91, 92
   
These two types of glycosylation, which are conserved from yeast to humans, 
share many similarities.
88, 91
 First, in the case of many organisms, glycosylation is 
absolutely required for normal development.
87, 89
 Complete loss of N-glycosylation is 
lethal in both yeast and mammals, while partial loss results in severe multi-systemic 
defects and abnormalities leading to severe or lethal phenotypes.
87, 89
 It appears that 
glycosylation plays a major role in embryonic and postembryonic development, thus it 
has been difficult to study the effects of glycosylation-defective intact multi-cellular 
organisms.
87, 91
 Work by Robbins and co-workers in identification of genes involved in 
asparagine-linked glycosylation (alg genes) allowed studies on N-linked glycosylation in 
yeast.
46
 These studies demonstrated that if such alg mutations were combined with a 
conditional mutation affecting oligosaccharyltransferase activity in the same cell, a lethal 
phenotype resulted. 
93
 
Second, both N-linked and O-linked glycosylation begin in the endoplasmic 
reticulum (ER) of the cell, and progress through the Golgi apparatus.
90, 91
   The reactions 
of N-glycosylation in the ER hardly differ between yeast and animals, however 
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subsequent reactions, taking place in the Golgi cisternae, differ considerably.
91
  The 
biosynthesis of sugar chains linked through O-mannoside also proceeds in mammals in 
the same way as in yeast, as was recently shown.
94-96
  Mucin type O-glycosylation, 
thought to be limited to eukaryotes, begins in the cis-Golgi apparatus across species.
90, 91
 
Current research suggests that many forms of glycosylation are conserved in manner, 
location and pattern.  
 
1.3 SELECTED TYPES OF PROTEIN GLYCOSYLATION, N-GLYCOSYLATION AND 
MUCIN TYPE O-GLYCOSYLATION (O-GALNAC DERIVED GLYCOSYLATION) 
 
1.3.1  N-GLYCOSYLATION 
Asparagine linked glycosylation was first discovered in the 1960s, and the 
oligosaccharide structure was elucidated by the work of Kornfeld and coworkers. An 
excellent review of this work can was published in Annu. Rev. Biochem. In 1985.
97
  N-
linked glycosylation is characterized by β-glycosylamide linkage to asparagine.98 As 
mentioned previously, in all eukaryotes, the N-glycosylation process is conserved through 
the endoplasmic reticulum (ER). This conservation includes the construction of the core 
N-glycan structure on the substrate lipid, which is then transferred en bloc to the protein 
acceptor by a complex of enzymes known as the OST, or oligosaccharyltransferase. 
97
 
In prokaryotic N-glycosylation systems, polyprenols continue to serve as lipid 
carriers and the oligosaccharide is also constructed on the lipid, followed by transfer to 
the protein.
46, 98
 A comparison of the N-linked glycosylation machinery involved in 
eukaryotic systems and the model prokaryotic system found in the Gram-negative 
bacteria C. jejuni, similarities become readily apparent.
98
 Prokaryotes need undecaprenyl 
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as a lipid substrate while dolichol is utilized in higher organisms.
46
 Several proteins 
involved in the biosynthesis of the lipid-linked oligosaccharide (LLO) show sequence 
similarity to eukaryotic and prokaryotic proteins.
46
  This finding is not unexpected when 
the similarity between lipid-linked oligosaccharides (LLO) in eukaryotes and 
lipopolysaccharide (LPS) biosynthesis in bacteria is considered. 
99
  
For example, N-acetylglucosaminyl phosphate transferase (GPT), the protein 
catalyzing the first step in LLO biosynthesis, displays a signal sequence similar to 
bacterial UDP-N-acetylmuramoyl-pentapeptide transferases involved in murein 
biosynthesis, and UDP-GlcNAc:undecaprenol-P GlcNAc-1-P transferases involved in 
lipopolysaccharide biosynthesis.
46
 Both the ALG1 and the ALG2 proteins, the key 
proteins in eukaryotic N-linked-glycosylation have sequence similarity to bacterial 
glycosyltransferases.
46
 Alg1p and Alg2p share a common sequence motif with these 
bacterial glycosyltransferases. This motif is also found in the PIG-A protein, a GlcNAc 
transferase required for the assembly of the GPI-anchor precursor, or the sucrose 
synthase of plants.
100, 101
 The existence of a conserved sequence motif in such diverse 
glycosyltransferases which all utilize nucleotide-activated sugars suggests a common 
evolutionary origin of these enzymes.
46
 
There are some key differences between eukaryotic and prokaryotic systems. In 
prokaryotic systems, these glycosylation events must occur on the bacterial membrane. In 
eukaryotic systems the membrane of the endoplasmic reticulum is the location of these 
glycosylation events, and events occur on both sides (cytosolic and luminal) of the 
membrane.
46, 97
 Thus, in eukaryotes, a flipping of the lipid-linked oligosaccharide across 
the membrane is a necessary step.
46
 In the dolichol pathway assembly of the 
oligosaccharide continues in the lumen of the ER after the flipping reaction, whereas in 
lipopolysaccharide biosynthesis the oligosaccharide is transferred from the carrier 
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undecaprenol to lipid A in the periplasmic space.
102
 The glycans formed in each process 
are different, prokaryotes forming a much shorter non-branched chain, while a longer 
branched chain is formed in eukaryotic systems.
46, 97
 Some of the bacterial 
glycosyltransferases that are similar to eukaryotic proteins involved in N-glycosylation 
use different nucleotide-activated sugars and are involved in the biosynthesis of 
lipopolysaccharides or exopolysaccharides, instead of protein glycosylation.
46
 These 
glycosyltransferases required for the assembly of lipopolysaccharides or 
exopolysaccharides in both Gram-negative and -positive bacteria may represent a distinct 
family of glycosyltransferases.
46
 
A sequence search for Dol-P-man or Dol-P-glc dependent glycosyltransferases 
Alg3, Alg9, Alg6, Alg8, and Alg10, which are involved in luminal biosynthetic reactions, 
found no similarity to any bacterial proteins.
46
 These results led to speculation that the 
first part of the eukaryotic dolichol-linked oligosaccharide biosynthesis, which takes 
place at the cytoplasmic side of the ER membrane, shares a common origin with bacterial 
lipopolysaccharide biosynthesis.
46
 N-linked glycosylation also occurs in archaea, and has 
been shown to follow a similar pathway to that of eukaryotic cells.
5, 60, 103
  Eubacterial 
glycosyltransferases have been shown to share a tripartite sequence motif found in Dol-
PP-glc and Dol-P-man synthases.
46
 Intriguingly, proteins similar in predicted structure 
(membrane proteins with C-terminal hydrophilic domain) and in primary sequence to 
eukaryotic STT3 protein have been detected in all three archaeal genomes sequenced thus 
far.
104
 Taken together, these findings suggest that eukaryotic N-linked protein 
glycosylation may originate from an archaebacterial process, that in turn is derived from 
a similar process in archaea. 
46
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1.3.1.1 N-glycan Overview 
The N-oligosaccharide structure was elucidated by the work of Kornfeld and 
coworkers, and subsequent research has established the biosynthetic pathway of N-glycan 
formation and attachment. 
 
1.7 The Core N-Glycan Structure 
 
As previously mentioned, the glycan is assembled in the ER on the lipid carrier 
dolichol phosphate.
97
 Snider and co-workers used ConA to define the membrane 
orientation of the lipid-linked oligosaccharide intermediates and the enzymes involved in 
their synthesis.
105, 106
 Their data indicate that Man3-5GlcNAc2 species face the cytosol 
whereas the Man6-9GlcNAc2 and Glc1-3Man9GlcNAc2 species face the lumen of the 
ER.
97, 105, 106
 These results suggest that the Man5GlcNAc2 species is assembled on the 
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cytosolic face of the ER leaflet and then translocated to the luminal side, where the 
assembly continues.
97, 105, 106
 
 
1.3.1.2 N-Glycosylation: The Cytosolic Reactions 
Thus, the first steps of LLO biosynthesis occur on the outer membrane, or 
cytosolic face of the ER. Here, sugars are added in a stepwise fashion with the first seven 
sugar moieties (2 N-acetylglucosamine (GlcNAc), and 5 mannose (Man)) derived from 
the nucleotide activated sugars UDP-GlcNAc and GDP-Man.
97
 Biosynthesis of the LLO 
begins on the cytoplasmic side of the ER with the addition of GlcNAc to Dol-P by Alg7. 
The heterodimeric complex Alg13/14 catalyzes the second GlcNAc addition to the 
LLO.
107, 108
 In the third step, the alg1 gene product transfers GDP-Man to Dol-PP-
GlcNAc2Man1.
46
 The fourth cytoplasmic glycosylation step is catalyzed by Alg2, which 
adds two mannose moieties to the growing chain to generate Dol-PP-GlcNAc2-Man3 
109
 
The fifth and final cytoplasmic step is catalyzed by Alg11, which also adds two mannose 
moieties to the growing chain to generate Dol-PP-GlcNAc2-Man5.
109
 The glycan chain is 
flipped such that the glycan is now within the lumen of the ER where subsequent 
additions occur.  
To obtain the NDP-sugar substrates, GlcNAc and Man glucose-6-phosphate (Glc-
6-P) is converted to fructose-6-phosphate (Frc-6-P), catalyzed by 
phospoglucoisomerase.
110
 Fructose-6-phosphate is subsequently converted to 
glucosamine, then acetylated to form N-acetylglucosamine-6-phosphate (GlcNAc-6-P).
46, 
111
 GlcNAc-6-P is converted to N-acetylglucosamine-1-phosphate (GlcNAc-1-P) by the 
enzyme N-acetylglucosamine-phosphomutase and finally to UDP-N-Acetylglucosamine 
(UDP-GlcNAc).
46, 112
 The GDP-mannose biosynthetic pathway is well-characterized.
46
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To generate GDP-mannose, fructose-6-phosphate is isomerized to mannose-6-phosphate 
(Man-6-P) by phosphomannoisomerase (PMI40).
113
 Mannose-6-phosphate is then 
activated by transfer to GDP by GDP-Man pyrophosphorylase to form GDP-mannose 
(GDP-Man).
114, 115
 
 
1.3.1.3 N-Glycosylation Substrates: Lipid-Linked Sugars and the Role of Dolichol-
Phosphate 
The next seven sugars added to the growing glycan chain are derived from lipid 
intermediates in the lumen, dolichol-phosphate-mannose (Dol-P-Man) and dolichol-
phosphate-glucose (Dol-P-Glc).
97
 Dolichol-phosphate (Dol-P) acts as the carrier in the 
assembly of pyrophosphate-linked oligosaccharides and is the acceptor in the synthesis of 
the sugar donors Dol-P-Man and Dol-P-Glc from GDP-Man and UDP-Glc, 
respectively.
46
 Synthesis of Dol-P-linked oligos requires UDP-GlcNAc, UDP-Glc, and 
GDP-Man as direct donors for LLO synthesis in the cytosol, or as indirect donors to 
generate Dol-P sugars that serve as substrates after LLO flipping into the lumen of the 
ER.
46
 
Dol-P is the substrate of a number of enzymes in the N-glycosylation pathway and 
the availability of this lipid is one of the rate-limiting factors in the synthesis of LLOs in 
higher eukaryotic cells.
116-119
 Dol-P is generated by de novo synthesis but it is also a 
product of the Dol-P-Man and Dol-P-Glc dependent glycosyltransferase reactions.
46
  The 
dolichol cycle of recycling from the lumen of the ER to the cytosol and how it occurs 
remains to be understood.
46
 Recycling would explain the regulation of a pathway which 
takes place at both the cytoplasmic and luminal sides of the ER.
46
 Flux through the 
pathway would then be regulated by the availability of dolichol or Dol-P.
46
 Lipid linkage 
may be the method of choice by which cells can “overcome the barrier of diffusion 
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control and to make the multimolecular reaction processes at low concentrations more 
efficient”. 120 The lipid linkages may also facilitate the very rapid rate of LLO 
biosynthesis ensuring the availability of fully assembled LLO that is required for the 
efficient N-linked glycosylation of translocating proteins.
46
 
Other than Dol-P, the requisite donor sugars GlcNAc, Man and Glc must also be 
available for N-glycosylation to proceed. To generate UDP-glucose, glucose-6-phosphate 
is converted to glucose-1-phosphate by phosphoglucomutase (PGM1, PGM2), in 
preparation for nucleotidyl activation.
121, 122
 Glucose-1-P is activated to UDP-glucose by 
UDP-Glc pyrophosphorylase (UGPase). The gene encoding UGPase, UGP1, is an 
essential gene. The generation of the remaining two sugars, GlcNAc and Man, was 
discussed in the previous section. Once the NDP-sugars are biosynthesized, some of these 
sugars are transferred to the dolichol lipid in the membrane of the ER. The alg5 gene 
encodes Dol-P-Glc synthetase, and it is proposed that the Dol-P-Glc is generated on the 
cytoplasmic side of the ER and later flipped into the lumen.
123
 GDP-Man is transferred to 
dolichol to form Dol-P-Man by DPM1, which is an essential gene for cellular viability. 
Dol-P-Man is a substrate used in many cellular glycosylation processes including N-
linked glycosylation, O-linked glycosylation, GPI anchors and, as will be discussed later, 
C-linked glycosylation.
46, 95, 124-126
 Notably, steps in N-glycosylation requiring Dol-P-Man 
are not essential, as alg3 mutants accumulate the Alg3 substrate, Man5GlcNAc2-PP-Dol, 
and this glycan can be transferred to protein in cells devoid of any Dol-P-Man.
127
  
 
1.3.1.4 N-Glycosylation: The Lumenal Reactions 
Using these Dol-P substrates, Man5GlcNAc2-PP-Dol is elongated in the lumen of 
the ER. A total of 4 mannosyltransferases and 3 glucosyltransferases are involved in the 
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completion of the LLO core oligosaccharide, which are responsible for the additions of  4 
mannoses followed by 3 glucoses in a stepwise fashion at the luminal side of the ER 
membrane.
46, 128, 129
 
 
1.8 The N-Glycosylation Pathway 
 
The first step in luminal biosynthesis is catalyzed by the Alg3 enzyme, which 
initiates the Dol-P-monosaccharide-dependent glycosyltransferase reactions at the 
luminal side of the ER (α-1,3-mannosyltransferase).46, 127 The subsequent step is 
catalyzed by Alg9, an α-1,2 mannosyltransferase that adds a mannose residue to the α-1,3 
Man.
97, 128
 The subsequent addition of and α-1,6 linked mannose is postulated to be 
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catalyzed by the Alg12 enzyme, and Alg6 is believed to catalyze the transfer of the first 
glucose to the oligosaccharide (α-1,3).46, 130 Alg8 protein adds the second glucose, and 
Alg10 adds the terminal glucose to the oligosaccharide in α-1,3 and α-1,2 linkages 
respectively, finally yielding Glc3Man9GlcNAc2.
46
 These glycosyltransferases that utilize 
Dol-P-mannose or Dol-P-glucose are highly hydrophobic, basic proteins, with calculated 
molecular mass between 60-75 kDa and are assumed to contain multiple transmembrane 
domains with only small hydrophilic loops.
46
 
The LLO elongation is a highly ordered assembly in which individual sugar 
residues of the protein bound core oligosaccharide fulfill specific functions in the 
processing of glycoproteins in the ER.
131
  These roles may explain the high level of 
conservation and the precision of the assembly pathways of the LLO in eukaryotic cells.
46
 
All alg genes have homologs in higher organisms (around 50% identity), and for each 
step in biosynthesis a single glycosyltransferase exists, with the exception of  alg2 and 
alg11, which each catalyze two steps of the LLO elongation.
93, 109, 123, 127, 130, 132
 These late 
glycosyltransferases in lumen use Dol-P-saccharides and are non-essential for viability as 
mutations in these enzymes result in underglycosylation of secretory proteins in vivo.
46
 
Underglycosylation appears to be due to a decreased affinity of oligosaccharyltransferase 
(OST) towards truncated oligosaccharides. These glycans are still transferred, just with 
reduced efficiency.
46
 
 
1.3.1.5 N-glycosylation: Protein Glycosyltransferase Oligosaccharyltransferase 
Complex 
The oligosaccharyl transferase (OT) complex consists of nine subunits, five of 
which are essential gene products.
133
 The OT catalyzes the N-glycosylation of most 
secretory and membrane bound proteins.
133
 The OT complex transfers the Dol-PP- 
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Glc3Man9GlcNAc2 to the asparagine residue in the protein consensus sequence of NXS/T 
(where X is any amino acid) on a growing polypeptide chain.
62
 Statistical analysis 
indicates that only 65% of all available N-glycosylation sites are utilized.
134
 
Three subcomplexes have been proposed, comprised of: Ost1p-Ost5p, Ost2p-
Swp1p-Wbp1p, and Stt3p-Ost4p-Ost3p, although studies do not completely support this 
proposal.
135
 Maximal rate of N-glycosylation requires presence of all subunits.
135
 Ost1p, 
Ost2p, Wbp1p, Swp1p, and Stt3p are proposed to carry out critical functions.
135
 Subunits 
encoded by non-essential genes (Ost3p, Ost6p, Ost4p, Ost5p) may perform important 
accessory functions.
135
 Each protein component in this complex will be examined in turn. 
 
1.3.1.6 Ost1p/Ribophorin I 
Ribophorin I was found to crosslink with all other OT subunits and Alg 1, an 
enzyme involved in Dol-PP-oligosaccharide biosynthesis and to ribosomes.
133, 136, 137
 
Ribophorin I was also found to crosslink to a subset of membrane protein, irrespective of 
their glycosylation status after integration into the Sec61 translocon.
138
 Ost1p was also 
able to crosslink to glycosylatable substrate-based peptide photoaffinity probe. Thus it 
was proposed that Ost1p bears the peptide-binding site of the OT complex. However, it 
was shown later that this is not the case.
139
 Instead, it is now postulated that the luminal 
domain of ribophorin I may be involved in funneling the newly synthesized peptides into 
the active site of Stt3p for the N-glycosylation reaction.
133, 137
 Ost1p has also been  
reported to be N-glycosylated at four consensus sites.
133
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1.3.1.7 Ost5p 
Ost5p is a 9.5 kDa membrane protein, present in highly purified OST 
preparations.
140
 This protein is not essential for growth, but its depletion results in a 
minor defect in OT activity. Ost5p is not known to interact directly with other OT 
components,  most likely Ost1p and/or Stt3p.
140
 No function is currently proposed for this 
protein.
137
 
 
1.3.1.8 Ost2p 
The Ost2p protein is predicted to possess three transmembrane segments with the 
N-terminus in cytosol and the C-terminus in the lumen.
141
 The protein sequence is highly 
conserved, especially in transmembrane regions, suggesting that functional properties 
reside in these segments. Ost2p has been found to interact strongly with Wbp1p, which is 
implicated in Dol-PP-oligo recognition, and thus may aid Wbp1p in recognition of the 
Dol-pp-oligo.
136, 141
 
 
1.3.1.9 Swp1p 
The Swp1p protein is a product of an essential gene, but the function of this 
protein is yet unclear.
137
 The protein has three transmembrane segments, with the N-
terminus in the lumen and C-terminus in the cytosol.
135
  Swp1p was found to interact and 
crosslink to components of the OST complex as well as the protein translocation 
complex, specifically Wbp1p, Sss1p and Stt3p.
136, 142, 143
  These interactions led to the 
proposal that Swp1p may aid Ost1p in funneling nascent polypeptide chains to the active 
site of the OT complex, as the luminal domain of the protein interacts with Ost1p.
144
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1.3.1.10 Wbp1p/OST48 
The Wbp1p protein is proposed to be responsible for the recognition of the 
substrate dolichol-PP-oligosaccharide.
137
 Investigations using mammalian systems have 
shown that a chemically reactive hexapeptide could be covalently linked to either 
ribophorin I (homolog of Ost1p) or OST48.
145
 Chemical modification of cysteine 
residues suggested that Wbp1p may be involved in recognition of the Dol-P-
oligosaccharide.
146
 Wbp1p has a GIFT domain, which in other proteins is known to bind 
oligosaccharides.
137
 The Lennarz group has shown that the sequence of the luminal half 
of the protein is important for the function of Wbp1p.
144
 They have also reported that the 
luminal domain may possess a divalent metal binding site.
144
 It should also be noted that 
two N-glycan sites on Wbp1p are occupied.
133
 
 
1.3.1.11 Ost4p 
The Ost4p protein is a minimembrane protein of only 36 amino acids, and has 
been found to be encoded by a non-essential gene.
147
 The null strain exhibits a 
temperature sensitive phenotype that results in a severe underglycosylation defect.
147
 The 
protein functions in the binding of Ost3p and Stt3p together in a subcomplex of OT via 
interactions with amino acid residues near the cytosolic leaflet of the ER membrane.
148, 
149
 Ost4p has also been proposed to be responsible for recruiting Ost3p or Ost6p into the 
OT complex.
150
  
 
1.3.1.12 Ost3p and Ost6p 
These proteins are thought to have redundant functions, due to their sequence 
similarity and similar hydropathy plots.
137, 143
 Disruption of either of the genes results in a 
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minor glycosylation defect, while a double mutant yields a severe underglycosylation 
phenotype that affects both membrane and soluble glycoproteins.
143
 This redundancy is 
supported by the finding that two OT isoforms exist in the ER membrane that contain all 
OT subunits except Ost3p and Ost6p.
151
 The two isoforms differ in that they contain 
either Ost3p or Ost6p.
151
 Both proteins have lumenal domains predicted to have a 
thioredoxin-like fold.
152
 The Sbh1p protein, the β subunit of the Ssh1 translocon, exhibits 
a specific interaction between Ost3p, not 6p, while the Sbh2p interacts with Ost6p, not 
3p.
137, 151
 All other OT subunits have an identical interaction pattern with the Sbh1p and 
Sbh2p proteins, which suggests that the two complex isoforms are generated by virtue of 
association with Ost3p or Ost6p and specifically associate with the similar translocon 
complexes.
137
 
 
1.3.1.13 Stt3p 
Three lines of evidence clearly indicate that this protein bears the active site of the 
OT region.
133
 Mutagenesis studies using a labeled acceptor substrate indicate that the 
Stt3p protein bears the peptide recognition site and/or the catalytic site for oligosaccharyl 
transfer.
47, 137, 139, 153
 The protein pglB, a known homolog of Stt3 in C. jejuni has been 
shown to be essential for glycosylation in this species.
41, 154
 As discussed previously, no 
other OT subunits are present in C. jejuni that could account for the N-glycosylation 
activity.
44
 In the mammalian system, Stt3p was the only protein that could be crosslinked 
to the glycosylation consensus sequence of the translocating nascent chain.
155
 Stt3p has 
also been shown to be involved in cell wall biosynthesis in yeast β-1,6-glycan, and to 
interact with protein kinase cascade components via its N-terminal domain, which is 
oriented towards the cytosol.
133
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Stt3p was found to be N-glycosylated at two different sites, and abolishing this 
glycosylation at N535 or N539 resulted in lethal phenotype in yeast, although the loss of 
glycosylation does not prevent Stt3p incorporation into the OT complex.
133
 These N-
glycosylation sites are highly conserved across species, although only N539 was found to 
be N-glycosylated in the wild type enzyme.
133
 Taken together, these data suggest that N-
glycosylation is required for the function of Stt3p, the enzyme responsible for N-
glycosylation.
133
 The function of Stt3p N-glycosylation was proposed based on the 
secondary structure prediction, as these glycosylation sites (N535 and N539) are located on 
a flexible loop that may be possible to interact with the catalytic site.
133
 N-glycan sites 
located less than 12-14 residues from a transmembrane segment of a protein are not 
modified in vitro, which suggests that the active site of the OT is located 30-40 Å from 
the luminal face of the ER.
133
  
Lennarz and co-workers have also proposed that the N539NT glycans may be close 
to the catalytic site W516WDYG via interaction between the glycans and the aromatic 
amino acids W516W, and that this interaction may be important for the function of 
Stt3p.
133
 Lennarz also proposes that N535 may be involved directly in some function of 
Stt3p, which may be lost when N535 is glycosylated.
133
 It should be noted that the C. 
jejuni pglB enzyme has a potential glycosylation site (N534QS) that occurs after predicted 
catalytic site W457WDYG.
133
 
 
1.3.1.14 The Role of N-glycosylation 
The single most important role of N-glycosylation is to promote proper folding of 
newly synthesized peptides in the ER.
62
 It has been proposed that eukaryotic N-
glycosylation evolved to a mechanism in which the protein substrate is presented to the 
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machinery in a flexible form before folding.
48
 This form of glycosylation appears to be a 
eukaryotic adaptation of glycan function that allows cells to produce and secrete larger 
and more complex proteins at higher levels.
62
 This role explains why N-linked 
glycosylation must occur co-translationally in the ER, before the folding process 
begins.
62
 N-linked glycans have a direct effect on the folding process.
156, 157
 Peptide 
studies indicate that although N-linked glycosylation does not induce permanent 
secondary structure, glycans alter the conformational preferences close to the 
gycosylation site, resulting in a more compact conformation.
157
 For example, a truncated 
N-linked glycan GlcNAcβ1-4GlcNAc, the disaccharide chitobiose, tends to induce a 
compact β turn, and a total of one third of N-linked glycans occur in such locations.62, 158, 
159
 A large polar saccharide unit is likely to affect the folding process locally by orienting 
the peptide segment towards the surface of protein domains.
62
 When multiple sites on a 
given protein are modified, protein folding may be compromised even though none of the 
glycans are needed individually for the future function of the protein, thus, glycans 
appear to have a “global” effect as well as a local effect on protein folding.62 
When N-glycosylation is inhibited, the most commonly observed effect is the 
generation of misfolded aggregated proteins that fail to reach a functional state, although 
dependence on N-glycosylation for folding varies on a case-by-case basis.
62
 For example, 
during inhibition, some protein folding becomes temperature sensitive, while other 
proteins are only partially dependent on N-glycosylation, and some are dependent on N-
glycosylation in one cell type but not others.
62
 Also, some glycosylation sites are more 
important than others in a protein, which implies local effects on protein folding.
62
 
Refolding studies carried out in vitro using glycosylated and non-glycosylated versions of 
the same protein confirm that oligosaccharide moieties have a positive effect on the 
folding process.
156, 160
  
 59 
Glycans are usually not essential for maintaining the folded structure, once 
folding is complete.
156, 161, 162
 Although the presence of glycans increases protein stability, 
the effect is rather small. Most glycans can be removed after folding without major 
effects on protein structure/conformation.
62, 156, 157
 Glycans keep the protein in solution 
and thus mimic roles played by molecular chaperones.
163
 This former system would, of 
course, be more efficient for the cell. Instead of having a molecular chaperone for each 
protein, or even each class of difficult proteins, N-glycosylation can be considered as a 
generalized quality control system, which tags the protein as needing special “folding” 
attention. This system localizes potential problematic or difficult proteins to an 
intracellular compartment, where they can be scrutinized by cellular machinery. If they 
pass this molecular scrutiny, they will be sent through the secretory pathway, if they fail, 
these proteins will be refolded or destroyed to prevent them from causing problems in the 
cell. 
 
1.3.1.15 The Calnexin-Calreticulin Cycle 
Calnexin and calreticulin comprise a unique chaperone system found in the ER of 
nearly all eukaryotes.
131, 164, 165
 Glycans are the “admission ticket” to this chaperone 
cycle.
62
 Calnexin (CNX) is a membrane bound protein, while calreticulin (CRT) is a 
soluble chaperone.
131
 These lectins, CNX and CRT, bind transiently to virtually all newly 
synthesized glycoproteins.
166, 167
 Both chaperones interact with the glycans of the 
glycoprotein substrate after they have been trimmed by ER glucosidases I and II to the 
monoglucosylated form (Glc1Man9-6GlcNAc2). However, if there is a glycosylation site 
within the first 50 amino acids, chaperone interaction may begin co-translationally.
62
 
After translation, lectin binding may continue for a period ranging from a few minutes to 
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several hours depending on the rate of folding, and these protein interactions slow down 
the rate of folding, but increase efficiency.
62
 
Both CNX and CRT are asymmetric molecules with a long, curved, hydrophilic 
peptide arm formed by the P-domain.
168-170
  The P domain interacts with the ER 
cochaperone ERp57, or it may form a region that protects the bound substrate molecule 
during folding, but this does not form the lectin binding site.
62
 CNX/CRT forms a 
complex with ERp57, a thiol oxidoreductase of protein disulfide isomerase (PDI), and 
short lived disulfide bonds form between CNX/CRT and substrate glycoproteins.
171
  
These disulfide bonds are transiently formed in oxidation and isomerization reactions, 
and lead directly to the formation of correctly paired disulfide bonds.
172
  
 
1.3.1.16 UGGT Folding Sensor  
Association of glycoproteins with CNX/CRT involves a binding and release cycle 
driven by the opposing actions of two soluble ER enzymes, UDP-glucose:glycoprotein 
glucosyltransferase (UGGT) and glucosidase II.
62
 UGGT is a soluble 170 kDa 
glycoprotein that is ubiquitously expressed in the lumen of most eukaryotic cells.
173-176
 
UGGT is comprised of a large N-terminal folding sensor and a smaller C-terminal 
domain (catalytic).
177
 UGGT adds a glucose residue to high mannose glycans and 
strongly recognizes the core pentasaccharide, Man3GlcNAc2, region of high mannose 
type glycoprotein oligosaccharide, suggesting its capacity to accept a wide range of N-
glycan structures.
178
 UGGT is a folding sensor, and only reglucosylates an incompletely 
folded glycoprotein.
165, 179, 180
 
181
  Previous studies suggest that UGGT senses exposed 
hydrophobic patches of unfolded polypeptides proximal to the glycosylation site.
182-187
 
UGGT favors the presence of a hydrophobic substituent in proximity to the reducing end 
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of high-mannose glycans. As revealed through comparison of various acceptor substrates, 
the activity is of these acceptor substrates is governed by the hydrophobicity and 
orientation of the aglycone.
178
 After glucosylation, the protein is redirected to folding 
chaperones, and the glucose residue is then removed. 
62
 Proteins that are folded properly 
are transferred to the Golgi where they undergo mannose trimming and elongation to one 
of three types of glycan structures as shown in figure 1.10.
97
 If the protein is still not 
folded, when UGGT binds, the protein will be reglucosylated, and redirected to the 
folding chaperones. 
 
1.9 CNX/CRT and UGGT Protein Folding Quality Control Cycle  
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CNX/CRT appear to be essential in vivo because transgenic mice devoid of CRT die on 
embryonic day 18.
188
 The essential nature of this cycle has also been shown through the 
lethal outcome of inherited glucosidase I deficiency involving a neonate born with severe 
generalized hypotonia and dysmorphic features.
189
 These defects are likely the result of a 
shutdown of the CNX/CRT cycle.
62
 
 
1.3.1.17 ERAD- The Fate of Misfolded Proteins 
Mannose trimming at B and C arms of the glycan seems to function as a regulation 
system, in which accumulation of such glycans attenuates the glycoprotein entry into 
CNX/CRT cycle, consequently delivers GP to the ER associated degradation (ERAD) 
process.
190
 When a glycoprotein is not folded properly, ER mannosidase I removes an α-
1,2-linked mannose residue from the α-1,3 branch of the core oligosaccharide, which 
targets the resulting structure Glc0-3Man8GlcNAc2 to ERAD.
62
 If a glycoprotein is not 
folded properly it is targeted to ERAD, in which the misfolded protein identified via an 
unknown mechanism, exported to the cytosol, subsequently ubiquitinated, and finally 
degraded by the 26s proteasome.
191-193
 The mannosidase responsible for the mannose 
trimming activity is quite slow, which may protect proteins against premature 
degradation.
161, 194, 195
   
It is apparent that Man8 structures serve as part of the signal needed for ERAD, 
although mannose trimming alone is not sufficient for ERAD, as correctly folded 
glycoproteins are trimmed of mannose residues before leaving the ER.
62
 The ERAD 
model for degradation is not completely clear. In fact, multiple parallel pathways leading 
to degradation exist, and mannose trimming has been identified as one of the most 
conspicuous sorting criteria.
62
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1.10 The Fate of Properly Folded N-Glycans 
The Fate of Properly Folded N-Glycans 
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1.3.2 MUCIN TYPE O-GLYCOSYLATION 
Mucins are defined as cell surface or secreted glycoproteins with large numbers of 
clustered O-glycans.
196
 Mucin-type O-glycosylation is initiated by the addition of a single 
GalNAc residue to the hydroxyl side chain of the fully folded peptide in the Golgi 
apparatus.
86
 O-glycosylation is mainly a post-translational, post-folding event, thus only 
exposed Ser/Thr are expected to be glycosylated.
86
 This type of glycosylation commonly 
occurs in Ser/Thr rich protein domains, but there is no known glycosylation consensus 
sequence, as observed in the case of N-glycosylation.
86
 O-glycans are typically less 
branched than N-glycans, and commonly have biantennary structures.
196
 It should be 
noted that not all O-glycans are mucin-type. Some proteins contain relatively few 
scattered O-glycans that have either short chains with a few residues, or elongated bi-
antennary structures.
196
 Although, in mammals, mucin type O-linked glycans on secreted 
membrane-bound proteins are the most common type of O-linked glycans that occur.
86
 
Mucin expression is enriched in epithelial cells specialized for mucus production and 
residing at the interface with the external environment. 
196
 
There are 8 basic or “core structures” for mucins, which begin with an α-linked 
attachment of an N-acetylgalactosamine (GalNAc) to the hydroxyl side chain of a Ser or 
Thr.
86
 After the initial GalNAc attachment, glycans can be elongated to more complex 
structures, which can be terminated by the addition of sialic acid or fucosylation.
86, 196
 
This elongation process is highly regulated and highly complex. 
86
 The initial GalNAc 
additions vary due to differences in tissue specific expression of proteins. Site specificity 
has been found to be tissue specific by statistical analysis of large numbers of known 
attachment sites, as there are different GalNAc transferases with overlapping, but 
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different specificities, and these proteins have different tissue-specific expression 
patterns.
197, 198
  
. 
1.3.2.1 The Role of Mucin-type O-glycosylation on Protein Structures 
Mucin-type O-glycosylation is commonly found on β-turns, and structures with 
extended conformation that often have high proline content.
86
 By steric hindrance and 
repulsion between sialic acids, multiple O-linked glycans confer an elongated structure to 
the peptide backbone, essential for the function of mucins, and distort the α helicity of 
peptides.
86, 199
 Mucins may fulfill role as “molecular spacers”, distancing proteins from 
their neighbors.
86
 Mucin type O-glycans are often found in regions of proteins with low 
hydrophobicity and no large side chains, such as tryptophan, or phenylalanine present. 
86
 
O-glycans assist in the maintenance of secondary and tertiary structure of glycoproteins, 
and may play a role in the stabilization of quaternary structure of glycoprotein 
complexes.
86
 Their roles in maintaining the three-dimensional structure of glycoproteins 
are accomplished through intermolecular interactions.
86
 Finally, alternative protein 
splicing confers an additional regulation level for the properties and activity of different 
glycoproteins.
86
 
 
1.3.2.2 The Signal Sequence for Mucin-type O-glycosylation 
There is a primary sequence preference for mucin type O-glycosylation that is due 
to regional specificity.
86
 The sequence preference is different for serine or threonine, as 
threonine appears to be glycosylated more efficiently than serine.
86
 In the 8 positions 
preceding and following the O-glycosylated threonine, many serine, threonine, proline 
and valine residues occur, with proline or other uncharged residues commonly occurring 
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at positions -1 and +3.
86, 196
 In the case of Serine O-glycosylation, a specificity window of 
15 or 39 amino acids was identified and in many cases proline, threonine or serine was 
present at positions -9, -8 and +1, with respect to the glycan.
86
 Cysteine has not been 
found at positions -2 to +2, and tryptophan is never at positions -1 and +1.
86
 Methionine, 
aspartate and asparagine are rarely seen in proximal to mucin-type O-glycosylation sites, 
nor are positively charged residues seen in the immediate vicinity of the attachment site.
86
 
Likewise, a negatively charged residue at position -1 has never been documented.
86
 
Regardless of whether the glycosylation occurs on serine or threonine; alanine, serine and 
threonine are commonly found adjacent to the glycosylated residue. 
86, 196
 These rules for 
O-glycan attachment were established by comparison of different sites on known 
glycoproteins, without reference to the tissue-specificity. 
86
 
 
1.3.2.3  Mucin-type O-glycosylation Core Structures 
The majority of O-glycans produced in vivo are comprised of core structures 1-4 
with the Core 2 subtype most abundant. Most O-glycans contain the Core 1 subtype 
structure, which is formed by the addition of galactose (Gal) in a β1–3 linkage to the 
initial GalNAc moiety (Galβ1–3GalNAcα-Ser/Thr).196 Core 2-type O-glycans are 
generated by addition of GlcNAc to the GalNAc in a β1–6 linkage forming (GlcNAcβ1–
6GalNAcα-Ser/Thr) and contain the Core 1 subtype within the Core 2.196 The Core 2 O-
glycan may be elongated to either a mono- or biantennary form with the presence of 
multiple lactosamine (Galβ1-4GlcNAc) units and terminal linkages of fucose and sialic 
acid.
196
 In myeloid cell types, Core 2 O-glycans appear to function as a scaffold for the 
production of selectin ligands that act in regulating inflammation.
196
  The absence of the 
Core 2 GlcNAcT enzyme which produces Core 2 O-glycans results in a partial deficiency 
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in E-, L-, and P-selectin ligand biosynthesis.
196
 Core 3 O-glycans can serve as building 
blocks for the formation of bi-antennary O-glycans.
196
 Core 3 is found in few tissue types 
and may compete against Core 1 formation as both Core 1 and Core 3 require the same 
substrate.
196
 Core 3 and Core 4 are mostly localized to the intestinal tract.
196
 
.  
1.11 Mucin-type O-Glycan Core Structures 1-8 
 
Core 5 O-glycans (GalNAcα1–3,GalNAcα-Ser/Thr) have been found on 
glycoproteins from several vertebrate species. This structure exists on some human 
adenocarcinomas and on cells comprising the embryonic gut.
196
 Core 6 O-glycan 
formation (GlcNAcβ1-6GalNAcα-Ser/Thr) has been reported on human embryonic gut 
and mucins from ovarian cysts, although it is possible that the Core 6 subtype is a Core 2  
degradation product.
196
 Core 7 O-glycans (GalNAcα1-6GalNAcα-Ser/Thr) were found in 
a study of O-glycans from bovine submaxillary sources.
196
 In addition, linkage of fucose 
(α1–2) to the GalNAcα-Ser/Thr has been observed.196 Further O-glycan diversification 
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continue to grow with the elucidation of more novel core subtypes, although most of 
these new subtypes are found at relatively low levels and are most likely segregated to 
specific tissue or cell types.
196
 After core formation, these chains are elongated by the 
sequential addition of sugars from NDP-sugar donors and exported though the secretory 
pathway. 
 
1.3.2.4 Role of Mucin-type O-glycosylation  
Upon secretion, mucins generally remain at the surface of epithelial cells and are 
capable of providing a gelation function by retaining water and by their entanglement 
through intra- or intermolecular disulfide linkages. 
196
 Thus, mucin type O-glycosylation 
may be crosslinked by disulfide bonding in solution to promote gelation. Lack of mucins 
in the digestive tract may result in gastric ulcers.
196
  Salivary mucins also provide 
lubrication for epithelial surfaces and may modulate the infectious nature of oral 
microbes, thus a lack of salivary gland function may yield abnormal mucosal surfaces 
with chronic low-level inflammation.
196
 Salivary mucins also adhere to tooth enamel, 
thereby protecting against demineralization by organic acids, while others can agglutinate 
certain oral streptococcal strains.
196
  
O-Linked glycosylation modulates the aggregation of glycoproteins, maintains 
protein stability, and confers protease and heat resistance.
86
 Some mucin-type O-glycans 
act as temperature barriers against low temperatures to protect living tissues from 
freezing.
196
 Such “anti-freeze” glycoproteins have been characterized and shown to 
inhibit the formation of “nucleation centers” at temperatures below the freezing point of 
water.
196
  In these anti-freeze proteins, the peptide sequence “Ala-Ala-Thr” is repeated, in 
some cases more than 40 times, with each threonine residue carrying the O-glycan 
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structure Galβ1–3GalNAcα.196  Chemical elimination of these O-glycans has been shown 
to abolish the antifreeze function of these proteins.
196
  
The O-glycan role as “molecular spacer” was previously mentioned. They are 
important, especially for membrane bound receptors where the functional part of the 
receptor is oriented to the extracellular space because of the presence of glycans.
86
 O-
glycans have been reported to function in sperm binding to the egg. The mammalian egg 
coat (the zona pellucida) contains a large number of O-glycans, as well as some N-
glycans. Removal of egg N-glycans by glycosidase treatment does not abolish sperm 
binding, but loss of O-glycans following mild alkali treatment ablates sperm binding.
196
 
Involvement of alterations of O-linked glycosylation in health and disease is 
relevant for further medical research and disease treatment.
86
 For example, O-
glycosylation of collagen plays an important role in arthritis.
86
 Blood coagulation factor 
IXa, a naturally occurring mutation (R94S) is associated with hemophilia B defect. The 
mutation introduces an O-glycosylation site, which in turn is responsible for a strong 
reduction in the activity of factor IXa.
86
 Various pathogens can use these oligosaccharide 
structures found on cell surface O-glycans as receptors for binding and host infection.
196
 
Multimericity of the receptors and ligand multivalency can result in higher affinity 
binding, which is crucial for rotavirus binding to sialic acids.
86
 In some cases, secreted 
mucins contain identical oligosaccharide structures at high densities and are capable of 
binding to pathogens, saturating pathogen receptors.
196
 Thus, O-glycans on secreted 
mucins have been suggested to act as “decoys” in an organism's effort to evade pathogen 
infection, luring the pathogen in question to bind to the mucin rather than the host 
tissues.
196
  
The vertebrate hematopoietic system utilizes O-glycans during both development 
and function.
196
 O-Glycans play important roles in the recognition of other glycoproteins 
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such as selectin, ABO blood group antigens, MHC-complex.
86
  Lymphocyte homing and 
the leukocyte inflammatory response are regulated by glycans that function as selectin 
ligands.
196
 The role of O-glycans in immune response, selectin-mediated trafficking and 
cellular adhesion processes is quite extensive. For example, the involvement of selectin 
ligands in cancer cell metastasis has been proposed from studies revealing reduced 
metastasis in selectin-ligand-deficient systems.
196
 Thus, it appears that specific O-glycan 
linkages have unique roles in various physiologic systems.
196
 
O-Glycans are also essential for intermolecular interactions, and have important 
regulatory roles, including the modulation of the activity of enzymes and signaling 
molecules and in cellular glycoprotein expression and processing.
86
 It is possible that O-
glycan formation is under the control of glycosyltransferases that operate in protein-
specific glycosylation reactions in vivo.
196
  This implies that the function of some 
glycoproteins may be dependent on the O-glycan structure attached.  
  
1.4 SELECTED TYPES OF MONOGLYCOSYLATION, O-GLCNACYLATION, O-
MANNOSYLATION AND C-MANNOSYLATION 
1.4.1 O-GlcNAcylation 
1.4.1.1 O-GlcNAcylation Overview  
It is now known that many proteins within cellular compartments are dynamically 
modified at their serine and threonine hydroxyl groups by the attachment of O-linked N-
acetylglucosamine monosaccharides, which are dynamically attached in a β-linkage to 
proteins. O-GlcNAcylated proteins that have been identified are functionally diverse, 
however they share two common features: (1) they are also phosphorylated and (2) they 
form reversible multimeric complexes with other polypeptides or structures, and these 
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associations are often regulated by phosphorylation.
200
  Thus far, the majority of the 
hundreds of O-GlcNAc-modified proteins detected by two-dimensional gel analyses of 
the nuclear and cytosolic fractions have not been identified. 
201
 
 
1.4.1.2 Discovery of O-GlcNAcylation 
β-O-N-Acetylglucosamine (β-O-GlcNAc) addition to serine and threonine 
residues on proteins was first shown to be a major form of intracellular glycosylation in 
murine lymphocytes in 1984.
202
  In 1986, the O-GlcNAc modification was found to be 
abundant in the cytoplasm and in virtually all subcellular organelles of rat liver, except 
for mitochondria.
203
 These studies also found that the nucleoplasm contains the largest 
number of the O-GlcNAcylated proteins.
203
 Rapidly, during the next two years, several 
different groups showed that nuclear pore proteins, which regulate trafficking of 
molecules into and out of the nucleus, are extensively O-GlcNAcylated.
201, 203
 Since these 
early studies, O-GlcNAc has been reported to occur on a large number of proteins. 
201
 
During the past several years, O-GlcNAc-modified proteins have been shown to be 
almost exclusively restricted to the cytoplasm and nucleus, except extracellular α-linked 
O-GlcNAc saccharides found in slime molds, and are abundant in virtually all eukaryotes 
examined, including protozoa and fungi, as well as in viruses.
204
  
 
1.4.1.3 The Role of the O-GlcNAc Modification 
It should be noted that β-O-GlcNAcylation is much more like phosphorylation 
than other forms of glycosylation, in that this form of protein post-translational 
modification is reversible and even reciprocal to phosphorylation, and dynamic.
200
 
Incredibly, β-O-GlcNAcylation has been shown to play a role in almost every phase of 
 72 
cellular growth and normal cellular processes.
200
 The removal of β-OGT from the cell 
results in cell death, embryonic lethality in murine models and reduced cell viability.
205
 
The cellular processes that β-OGT has been found to be involved in are too numerous to 
describe in detail, thus only a few general areas will be listed here.  
The importance of the nuclear pore O-GlcNAcylated proteins in nuclear transport 
has been shown. Studies from several laboratories suggest a model in which the nuclear 
pore glycoproteins play a part in the initial peripheral binding of transport molecules.
201, 
203
   This is followed by the docking of the transported molecule at the center of the pore 
complex, and its translocation.
201, 203
  Many different chromatin proteins, with a broad 
range of physical associations with chromatin, are O-GlcNAcylated.
203
 RNA polymerase 
II and virtually every RNA polymerase II transcription factor examined to date contains 
O-GlcNAc. 
201, 203, 206
 Functions proposed for O-GlcNAcylation of transcription factors 
include nuclear transport, assembly into multimeric complexes, and regulation of 
phosphorylation.
201
 Recent findings suggest that O-GlcNAc on transcription factors in 
fungi is important to transcription even in lower eukaryotes. 
201, 203
  
Many nuclear oncoproteins and tumor suppressors such as p53, c-Myc, v-Erb-a 
and the SV40-T antigen are O-GlcNAcylated.
201
 Cytoskeletal bridging proteins, and other 
cytoskeletal proteins such as β-amyloid are O-GlcNAcylated, suggesting a role in 
Alzheimer‟s disease.201 Cytokeratins, all three types of neurofilament proteins and 
microtubule associated proteins are modified by O-GlcNAc.
201
 More recent research has 
demonstrated the role of this modification in glucose regulation and metabolic 
homeostasis at the cellular level.
201
 Clearly, this modification is broad reaching and is 
involved in almost every aspect and function of cellular growth and development. 
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1.4.1.4 The O-GlcNAc Glycosyltransferase, β-OGT 
The β-O-GlcNAc glycosyltransferase is highly conserved evolutionarily, with 
more than 85% similarity and >65% identity between the primary sequence of the 
enzyme derived from the nematode, Caenorhabditis elegans, and humans.
204, 207
  
Homologous open reading frames can be found in the public databases as far down the 
evolutionary scale as cyanobacteria.
204
 The N-terminus of the protein has a region of 
multiple (11.5) tetratricopeptide repeats, or 23 anti-parallel α-helices, which create a 
superhelix, while the C-terminal domain contains the enzyme active site.
207
 
Tetratricopeptide repeats are 34 amino acid sequences that are known to mediate protein-
protein interactions, which would enable the glycosyltransferase to achieve broad 
substrate specificity.
208
 Instead of a single enzyme binding site, which would restrict the 
ability of β-OGT to bind to multiple partners, the TPR domain enables binding to many 
substrates without a dedicated binding site for each partner enzyme.
207
  The TPR repeat 
region also modulates dimerization of β-OGT.207 
It should also be noted that β-OGT, like the active component (Stt3p) of OT in N-
glycosylation is apparently self-glycosylated, and in addition is phosphorylated as well.
209
 
Unlike Stt3p, an active site in the enzyme is not known, nor has a potential active site 
been proposed.  
 
1.4.2 O-MANNOSYLATION 
1.4.2.1 O-Mannosylation Overview  
The O-mannose modification is a monosaccharide linkage in which mannose is 
transferred from Dol-P-man to a serine or threonine residue of a protein in an α 
linkage.
210
  This modification occurs in the lumen of the ER and is catalyzed by two 
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protein-O-mannosyltransferase proteins, POMT-1 and POMT-2.
95
 This glycosylation 
event occurs co-translationally.
211
 The initial glycosylation modification may be 
elongated by several additional mannose residues using a battery of mannosyltransferases 
that extend similar structures on N-linked chains in yeast.
210
  
 
1.4.2.2 O-Mannosylation Discovery 
O-αMan was identified in yeast in the 1950s by Margolis and coworkers, where 
O-mannosylated glycoproteins are abundant in the yeast cell wall.
212, 213
 In fungi, all O-
mannosyl glycans are neutral linear glycans consisting of 1-7 mannose units.
212
 Other 
than fungi, O-linked mannose is also found in the skin collagen of a clam worm.
212
  
O-αMan was identified in 1979 as the protein-linked sugar in rat brain 
proteoglycan.
214
 In these studies, the glycan was released by mild base hydrolysis with 
simultaneous reduction of mannose to mannitol, thus the anomeric linkage could not be 
determined.
214
 More recently, O-mannose-based glycans containing four to eight sugars 
have been isolated from total brain glycopeptides and in a tetrasaccharide derived from 
Ser/Thr-rich domains in bovine peripheral nerve α-dystroglycan.215 This structurally 
important protein is found on Schwann cell membranes and forms  a linkage with another 
membrane protein, β-dystroglycan, to laminin in the extracellular matrix.210, 215 The 
oligosaccharide Sia2–3Galβ1–4GlcNAc-β1–2Man-Ser/Thr (figure 1.7) accounts for two 
thirds of the O-glycans of α-dystroglycan and is probably involved in the important α-
dystroglycan-laminin binding, since sialidase prevents the interaction, but removal of N-
glycans does not.
86
 Similar glycans (Siaα2-3Galβ1-4GlcNAcβ1-3Man1-Ser/Thr) have 
been found in rat brain proteoglycans.
216, 217
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1.12 O-Mannose Based Glycan Structure 
 
 
 
 
 
 
 
 
 
 
 
 
A small portion of total rat brain glycopeptide contains O-mannose-linked glycans 
and carries the HNK-1 antigenic epitope, an unusual 3-O-sulfated glucuronic acid at the 
nonreducing end of the glycan chain, which is implicated in neuronal cell adhesion.
217
 In 
addition, dystroglycan isolated from other sources has been shown to contain a 
fucosylated, nonsialylated O-mannose-based structure with the Galβ1–4GlcNAcβ1–
2Man linkage.
210
 Quite recently, Smalheiser et al. have shown that dystroglycan from 
sheep brain carried the Neu5-Acα2-3Galβ1-4GlcNAcβ1-2Man, Galß1-4-GlcNAcβ1-
2Man, and Galβ1-4(Fucα1-3)Glc-NAcβ1-2Man structures.218 To date, α-dystroglycan has 
been found to be O-mannosylated in human, rabbit, sheep and bovine tissue.
212
 Other 
neural proteins besides α-dystroglycan carrying these interesting O-mannose glycans 
have not been identified, but they are believed to be abundant since the estimated ratio of 
mannose-terminated to GalNAc-terminated O-glycans in total brain glycopeptides is 
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approximately 1:3.
210
 Indeed, 30% of protein O-glycosylation in the brain are O-mannose 
linked glycans.
213
 
 
1.4.2.3 The Cellular Role of O-mannosylation 
Thus, in higher organisms, O-mannosylation may be more diverse and complex 
than expected and O-mannose based glycans play an important role in specific cell 
adhesion processes.
210
  O-Mannosylation is an evolutionarily conserved protein 
modification and may be essential for muscle development in both vertebrates and 
invertebrates.
95
 A homolog of POMT1, the „rt‟ mutant in Drosophila causes reduced 
fertility and viability as well as defects of myogenesis.
95
 It is postulated that besides its 
neurological function, O-mannosylation may be required for the integrity of muscle 
structures in mammalian cells.
212
  Dystroglycan complex links the extracellular matrix to 
the cytoskeleton in a wide variety of tissues.
212
 α-Dystroglycan is the cell surface 
component of the dystroglycan complex, and is heavily glycosylated. It is known to bind 
laminin and agrin in the basal lamina of muscle cells and Schwann cells.
212
 Sialylated O-
glycan is involved in the interaction with laminin, and these O-mannosylated glycans 
may mediate the binding to laminin in multiple eukaryotic tissues. Certainly, α-
dystroglycan is an essential component of the dystrophin-glycoprotein complex which 
functions in linking the actin cytoskeleton to extracellular matrix in muscle and nervous 
tissue.
213
 
In mammals, O-mannosylation may also play important roles in the cellular 
recognition step in development. Dystroglycan is required for normal embryonic 
development beyond the egg cylinder stage.
219
 Thus, defective O-mannosylation may 
hinder growth beyond this developmental stage. Infection may also involve α-
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dystroglycan. Two unrelated pathogenic agents, several members of the arenavirus family 
including the Lassa fever virus, and lymphocytic choriomeningitis virus and 
Mycobacterium leprae, the bacterium responsible for leprosy, bind to target cells through 
interactions with a common receptor, α-dystroglycan. These glycans are important for 
infection by disease-causing agents.
212
 These data suggest that the α-dystroglycan glycans 
may possibly contribute to invasion by these causative pathogens, although details of the 
underlying mechanisms remain to be determined.
212
 
Protein-O-mannosylation appears to be required for normal structure and function 
of α-dystroglycan in muscle and brain.95 The absence of POMT-1 results in an autosomal 
recessive disorder characterized by congenital muscular dystrophy, lissencaphaly, and 
eye anomalies termed Walker-Warburg syndrome (WWS) (OMIM # 236670).
220, 221
 In 
severe cases of WWS, children are affected from birth, with likely brain malformation 
and rarely live beyond infancy.
95
 POMT1 mutations cause complete loss of O-mannosyl 
glycans in WWS.
95
 Since these glycans play important roles in adhesion process, a defect 
in the biosynthesis of O-mannosyl glycans has a severe effect on cell migration and cell 
adhesion.
95
 Patients with mutations in POMT1 have normal POMT2.
95
  The fact that  
POMT1 and POMT2 mutations are mutually exclusive suggests that POMT2 may be 
essential for normal development. Thus POMT2 mutations may cause embryonic 
lethality.
95
 POMT1 is highly expressed in fetal brain, testis and skeletal muscle, while 
POMT2 is highly expressed in testis.
96, 222
 However POMT1 and 2 are normally 
expressed in all human tissues.
96, 222
 
In non-mammalian eukaryotic species, other types of O-linked mannosylation 
occur, most notably in yeasts, where its function does not involve neural cell adhesion or 
multi-cellular developmental stages.
86
 Instead, in yeasts and other unicellular eukaryotic 
organisms, O-mannosylation is essential for cell wall rigidity and integrity, and this 
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glycosylation event is vital for protein modification and protein transport.
223
 Note that in 
higher organisms, protein transport is not dependent on O-mannosylation. Candida 
albicans deficiency in POMT leads to defects in multiple cellular functions including 
expression of virulence.
224
 
 
1.4.2.4 Protein-O-Mannosyltransferase (ScPmt1/2, POMT1/2) 
The enzymes responsible for O-mannosylation are two protein-O-
mannosyltransferases, POMT-1 and POMT-2.
95
 POMT-1 and POMT-2 are active only 
when co-expressed, which suggests that a heterodimeric complex is necessary for the 
activity of the enzymes.
95
 This dimerization holds true for the yeast homolog ScPMT1p, 
which requires a heterodimeric complex with ScPMT2p for maximum transferase 
activity.
225
 It has been postulated that dimerization of the two POMTs may form a 
physical pore, which is in turn involved in flipping the Dol-P-Man across the ER 
membrane.
46
 Dimerization may facilitate substrate binding and define specificity, or even 
that the POMT1/2 complexes may provide higher efficiency transfer.
225
  
Protein-O-mannosyltransferases are evolutionarily conserved from yeast to 
humans.
225
 These POMTs are integral membrane proteins localized to the ER and 
predicted to have multiple transmembrane helices.
127, 225, 226
 Yeast homologs are 
postulated to have no less than 7 transmembrane domains, including a large hydrophilic 
ER oriented segment flanked by five N-terminal and two C-terminal spanning 
domains.
225
 The N-terminal faces the cytosol, while the C-terminus faces the lumen.
225
 
Deletion mutagenesis has identified the N-terminal third of the transferase as being 
essential for the formation of a functional ScPMT1p-ScPMT2p complex. Mutation of 
R138 has demonstrated that this residue is critical for dimerization of ScPmt1p/2p and 
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may preserve a local arrangement of the N-terminal region essential for 
mannosyltransferase activity.
225
 Deletion of the central hydrophobic loop (Loop 5), where 
the Mannosyltransferase Inositol and Ryanodine receptor (MIR) domains are located, 
eliminates mannosyltransferase activity but not protein-protein interactions.
225
 Secondary 
structure predictions of loop 5 predict alternating α and β secondary structure.225 
Alignment of all PMT family members revealed that the central loop with MIR domains 
contains three highly conserved peptide motifs which can be considered as signature 
motifs of the PMT family.
225
 Furthermore, point mutations of highly conserved residues 
within these motifs severely diminish transferase activity.
225
 Clearly the invariant 
residues are essential for ScPMT1p function.
225
 These proteins are purported to be 
inverting glycosyltransferases, using general acid/base catalysis, involving residues 
Glu78, Arg64 and Arg138.
225
 
 
1.4.3 C-MANNOSYLATION 
1.4.3.1 C-Mannosylation Overview 
The most recently discovered protein glycosylation event, C-mannosylation, is the 
addition of a mannose residue in an α linkage to the C2 of the indole ring of 
tryptophan.
227
 This glycosylation event is known to be protein catalyzed, and occurs in 
the lumen of the ER in most eukaryotic cells, but not in bacteria, yeasts or plants.
227
 Since 
the discovery of C-mannosylation, 10 proteins have been experimentally identified to be 
C-mannosylated, although 336 proteins in the human proteome have been predicted to 
undergo modification thusly.
227, 228
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1.4.3.2 Discovery of C-mannosylation 
Hofsteenge and co-workers first discovered the C-mannosylation modification on 
RNase2 from human urine in 1994.
229
 At this time, it was unclear if the glycosylation was 
a chemical degradation signal, or a modification generated before the excretion process. 
It was subsequently determined that RNase2 was C-mannosylated upon secretion from 
mammalian cells.
228
 During the next phase of this research, Hofsteenge and coworkers 
examined a variety of cultured cells including bacteria, yeast, insect and mammalian cells 
and established that higher eukaryotes such as mammalian cells and some insect cells 
exhibit C-mannosylation, whereas bacteria and yeast do not.
228
 They also identified the 
C-mannosylation consensus motif WXXW, where the first tryptophan becomes C-
mannosylated.
228
 Replacement of the second tryptophan by other amino acids abolished 
or substantially reduced the level of C-mannosylation.
228
 They went on to determine that 
this modification is protein catalyzed, and occurs in the lumen of the ER using the 
substrate Dol-P-Man as the biosynthetic donor for C-mannosylation.
126
 Hofsteenge and 
coworkers went on to identify C-mannosylation on IL-12b, multiple complement 
proteins, properdin, thrombospondin, and the erythropoietin receptor.
227
 During this time, 
this group also identified another C-mannosylation signal sequence termed a 
thrombospondin repeat or “TSR” (WXXWXXWXXC) in which multiple tryptophan 
residues were found to be C-mannosylated. They were unable to identify the enzymes 
responsible for catalyzing the C-mannosylation glycosylation reaction. Recently, the first 
viral protein, sGP from Zaire ebolavirus was shown to be C-mannosylated, and it was 
predicted that other viral proteins have the potential to possess this unique modification 
as well.
230
 A novel marine natural product was also found to be C-mannosylated.
231
 
Taken together, these data indicate that this glycosylation event may have broad 
applications in both natural products biosynthesis and infectious disease research. 
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1.4.3.3 The Role of C-mannosylation  
Due to the novelty of this protein post-translational modification, and the absence 
of knowledge of the enzyme, the function of this modification is unknown. Several 
theories have been proposed as to the role of C-mannosylation. It has been suggested that 
the function of the mannose residue is structural in nature, and is responsible for the 
orientation of the tryptophan residue in the protein.
232
 In RNase2 for example, the 
mannosylation appears to be in a position in which it can stabilize the loop structure upon 
which it is located, and orient the indole ring of the tryptophan within the protein.
232
 A 
simple function may be to increase the polarity of the hydrophobic residues in the 
aqueous extracellular environment. An interesting proposal involves the complement 
pathway, in which multiple proteins are C-mannosylated.
233
 The biological consequence 
of the complement pathway is to activate mannose binding lectin (MBL), whose function 
is to bind terminal mannose residues in glycoproteins and pathogen membrane glycans.
234
 
It was proposed that perhaps the C-mannosylated residues could have some interaction 
with MBL, yet when this was examined, neither of these known mannose binding lectins, 
MBL or Concanavalin A (ConA), were able to bind C-mannosylated tryptophan.
234, 235
 
Yet another proposal, and perhaps the most practical, is that the C-mannosylation is a 
secretory message, directing soluble proteins for export out of the cell.
228
  This is the 
most likely function of the modification, as the O-mannosylation secretory signal used in 
simple eukaryotic organisms has been co-opted and is now used for α-dystroglycan in 
higher eukaryotes. This would also provide the benefit of protein stability as in vitro 
galactosylation and sialylation of therapeutic glycoproteins have been suggested to 
increase serum half-life, and increasing the amount of glycosylation on proteins that are 
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used as therapeutics has been shown to increase and prolong in vivo activity.
236, 237
 
However, the role of C-mannosylation cannot be fully explored until the C-
mannosyltransferase is identified. 
 
1.4.3.4 C-Mannosyltransferase 
The focus of the second portion of this dissertation project is to find potential  C-
mannosyltransferase candidates, and to identify the C-mannosyltransferase. Taking into 
account what is known regarding the C-mannosylation, and other glycosylation events 
that occur in the ER, we can suggest several characteristics of the enzyme. First, the 
protein must have a Dol-P-man binding site, as is found on the N-terminus of POMT1 
and POMT2.
225
 This protein may also be a multi-pass transmembrane protein, like most 
of the OT complex involved in N-glycosylation as well as POMT1 and POMT2 in O-
mannosylation.
133, 225
 This protein may well be a complex of proteins, again as found in 
both N-glycosylation and O-mannosylation.
133, 225
  Alternatively, this protein may be a 
homodimer, as observed with β-OGT.209 It is also quite possible that, like β-OGT and 
Stt3p, the catalytic protein in the OT complex, the C-mannosyltransferase is C-
mannosylated, thus the WXXW motif may be present in the protein. 
137, 209
 In addition to 
all these factors, the protein must also possess an ER targeting sequence at the N-
terminus, which will be readily apparent upon protein sequence examination. This is a 
challenging task, and when completed will allow assay development to explore the 
protein function and potential cellular roles of the enzyme.   
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1.5 COMPARISON OF EUKARYOTIC AND PROKARYOTIC GLYCOSYLATION SYSTEMS 
In summary, by comparing the similarities and differences between eukaryotic 
and prokaryotic glycosylation systems, an overall understanding of glycosylation can be 
reached. Extensive studies over years through protein identification, mechanistic 
elucidation and functional assignment have provided valuable knowledge of these 
pathways in multiple contexts. Comparison of disparate pathways also demonstrates 
striking similarities and conservation among glycosylation systems that may be extended 
to systems which have not been characterized. Here, each of the O-, N- and C- eukaryotic 
protein glycosylation systems is summarized and compared side by side with the 
prokaryotic systems.  
 
1.13 N-Glycosylation Comparison of Prokaryotic and Eukaryotic Systems 
As  previously discussed, the most common modification of eukaryotic secretory 
proteins is N-glycosylation, which is well-characterized. The nucleotide-activated sugars 
are added sequentially to a dolichol pyrophosphate carrier and then translocated across 
the ER membrane. In prokaryotic N-glycosylation systems, the nucleotide-activated 
sugars are also added sequentially to an undecaprenyl pyrophosphate carrier and then 
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translocated across the cellular membrane. At this point in both the bacterial and 
eukaryotic systems, the glycan is a lipid-linked heptasaccharide containing one branching 
sugar. However, in eukaryotes, the heptasaccharide is processed to a tetradecasaccharide 
(Glc3Man9GlcNAc2) prior to glycosyltransfer while prokaryotic glycans are not 
processed after this stage.  
In the central step of the process, the OT complex transfers an assembled 
oligosaccharide from the lipid carrier to an asparagine residue in the emerging 
polypeptide. In eukaryotes, this process requires a multiprotein complex, while in 
prokaryotes only the Stt3 ortholog is needed. In eukaryotes, the covalently attached 
glycans are modified in the ER and Golgi complex by trimming, further glycosylation, 
sulfation and epimerization. In contrast, there is no evidence of further processing of the 
bacterial heptasaccharide. Interestingly, in archaea, the N-linked glycan synthesis 
proceeds through lipid-linked intermediates using both polyprenyl carriers and dolichol 
phosphate carriers on the extracellular cell surface. Further trimming reactions have also 
been described in archaea.
238
  
The N-linked glycosylation sequence recognized by the OT, Asn-X-Ser/Thr, is 
conserved in eukaryotes, bacteria and archaea. It has been shown that the specificity of 
archaeal OT is not as strict as the eukaryotic and bacterial OTs, because replacement of 
the serine residue in one glycosylation site in H. halobium did not prevent N-
glycosylation of the S-layer. It remains to be determined whether bacterial and archaeal 
glycosylation also show dependence on protein structural domains as is the case in 
eukaryotic systems, in which N-glycosylation is sensitive to the secondary structure of 
the protein. Also, in eukaryotes, the range of sugars that can be linked to Asn through a 
GlcNAc moiety is defined and limited as compared to those of bacteria and archaea.  
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These simple organisms are capable of synthesizing glycoproteins with multiple glycan 
structures and linkage types, resulting in a highly diverse assortment of glycoconjugates.  
In eukaryotes, O-linked glycosylation occurs sequentially at Ser or Thr residues 
located in hydrophobic patches of the target protein. The product of one 
glycosyltransferase becomes the acceptor substrate for the next glycosyltransferase and 
nucleotide-activated sugar. There are no definitive sequons for O-glycosylation, although 
there are shared amino acid patterns among known glycosylation sites in proteins. This is 
similar to the O-linked process in bacteria. The process of O-linked glycosylation occurs 
mainly in the Golgi complex in eukaryotes, although O-mannosylation begins in the ER 
and O-GlcNAcylation occurs in the cytosol and nucleus. In archaea and bacteria, these 
glycosylation steps are much more reminiscent of O-GalNAc or O-Man based 
glycosylation, and occur at the plasma membrane or in the cytoplasm or at the interface 
between the cytoplasm and the surface appendages such as pili and flagella. It should be 
noted that six O-linked β-GlcNAc moieties were identified on the peritrichous flagella of 
Listeria monocytogenes.
239
  
In bacteria, there is no known protein C-glycosylation. This is distinct from N- 
and O-glycosylation events which are common in prokaryotes. However, small molecule 
C-glycosylation in prokaryotes has been reported, and many of these compounds are aryl-
C-glycosides.
73
 The C-glycosylation of the aromatic ring in eukaryotic proteins suggests 
that there may be some similarity between the prokaryotic and eukaryotic C-
glycosylation mechanism, although the enzymes may be divergent, as seen in bacterial 
and eukaryotic OTs involved in protein N-glycosylation.  
It is worth noting that O- and N-glycosylation are conserved from the single-cell 
to the most complex organisms. However, C-mannosylation is found only in higher 
eukaryotes, and the roles of glycosylation change to a certain extent when progressing 
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from lower to higher order organisms. For example, O-glycans in archaea, bacteria and 
eukaryotes (O-GalNAc derived) are generally found on the cell surface and are 
responsible for cellular adhesion, ligand binding, cellular structure and cellular 
interactions. O-Mannosylation, which plays a role in muscle and neural function in higher 
eukaryotes has a similar function as proteins involved in flagellar function in lower 
organisms. The function of N-glycosylation in eukaryotes is to affect protein folding 
while in prokaryotes it seems to be related to protein complex formation. In both cases N-
glycosylation may mediate proper protein functions. These comparisons are not perfect, 
as the function of N-glycosylation in archaea cannot be compared to those in bacteria and 
eukaryotes in the same fashion. Moreover, mono-glycosylation events such as C-
mannosylation and O-GlcNAcylation have no equivalents in the single-celled world.  
If a comparison could be made, one might correlate small molecule glycosylation 
of natural products to C-mannosylation of proteins. Small molecules can be glycosylated 
then exported from the cell. This is analogous to C-mannosylation of proteins to facilitate 
their export from the cell. Natural products are commonly used as targeted warheads to 
destroy bacteria invading the producing organisms. Interestingly, C-mannosylation is 
found on many proteins in the human immune system, and thus may be involved in 
protecting the body from foreign invaders. C-mannosylation is also found on viral 
proteins, suggesting that C-mannosylation may have evolved as a response to pathogens. 
Conversely, pathogens may have evolved this type of glycosylation to better evade the 
human immune system. The full array of C-mannosylated proteins is yet unknown, thus 
these suggestions are merely conjecture based on known data. Further investigation 
would certainly provide additional insight for better assessing the roles of C-
mannosylation. 
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1.6 SUMMARY AND THESIS STATEMENT 
This work involves two very different glycosylation projects. The first project, 
detailed in Chapters 2 and 3, deals with the elucidation of the glycosylation of the novel 
tetronolide natural product, kijanimicin. In Chapter 2, the biosynthesis of the deoxysugar 
TDP-L-digitoxose, from the kijanimicin pathway was investigated in vitro. The genes 
were identified from the cluster, cloned, expressed and the encoded products were 
purified. Activity was demonstrated for each enzyme in the pathway and in Chapter 3 the 
pathway was reconstructed in vivo using Streptomyces lividans. These strains of S. 
lividans were used to examine kijanimicin glycosyltransferase activity. We were able to 
demonstrate the activity of 3 of the 4 digitoxosyltransferases in the biosynthetic pathway, 
and propose a biosynthetic Scheme by which the tetrasaccharide chain is formed. We also 
identified two putative glycosidases with novel folds, and one glycosyltransferase that 
appears to have the unprecedented activity of attaching 2 if not 3 sugars in sequence. 
 In the second portion of this work, as described in Chapters 4 and 5, we 
attempted to identify the eukaryotic C-mannosyltransferase (CMT) enzyme and 
demonstrate its activity in vitro and in vivo. In Chapter 4, our efforts to locate the CMT 
are described. Through in silico analysis, putative C-mannosyltransferase genes were 
identified. These genes were expressed in E. coli and S. cerevisiae. However, gene 
expression was apparently toxic to E. coli. Although expression in S. cerevisiae was 
acceptable, extraction of the desired protein proved to be problematic. Thus, in Chapter 5, 
we describe our efforts to develop a CMT assay for use in vitro by expressing the 
putative CMT in insect cells. This approach was much more promising. We also 
attempted to knock down the putative CMT genes using shRNA. Our results showed that 
the putative CMT genes identified in this study were essential for cellular viability. 
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This work has contributed to the fields of both C-mannosylation and natural 
product glycosylation. We have elucidated the biosynthetic pathway of a novel 
deoxysugar, and identified potentially valuable tools for glycoengineering. These include 
a glycosyltransferase that appears to exhibit novel polymeric activity, and two 
glycosyltransferase proteins that are apparent glycosidases. Our attempts to identify CMT 
led to valuable information for the future development of specific assays for C-
mannosylation. We also identified several promising protein candidates that are 
apparently essential for cellular viability in H. sapiens. 
 
 
 
 
.  
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2 Prokaryotic Glycosylation: Reconstruction of the Digitoxose 
Biosynthetic Pathway in Kijanimicin Biosynthesis   
 
2.1 INTRODUCTION 
Carbohydrates moieties decorate a wide variety of biologically active natural 
products that are used as therapeutic agents against diverse disease states including 
cancer, bacterial and fungal infections.
70
 These natural products are secondary 
metabolites that result from complex multi-step biosynthetic pathways and are produced 
in a variety of organisms.
240
 Although these compounds are diverse in structure and mode 
of action, their glycosylation status has been shown to be critical for the bioactivity of 
multiple classes of antibiotics including macrolides,
 
peptides, and aminoglycosides,
 
as 
well as natural-product
 
anticancer, antiparasitic,
 
and antifungal agents.
65, 70, 72, 240
 Because 
removal of these sugar residues often results in the loss of biological activity of the parent 
compounds, altering native glycosylation patterns may vary the biological activity of 
their parent molecules 
240, 241
  
Addition of non-native carbohydrate biosynthetic pathways to an organism 
producing bioactive natural products, coupled with promiscuous glycosyltransferases has 
allowed the production of many novel products that are differentially glycosylated in 
vivo.
65, 240
 To reconstruct the carbohydrate pathways which generate the sugar moieties in 
vivo, the genes involved must be identified and the relevant respective enzymes must be 
characterized. Also, application of glycosyltransferases to generate novel bioactive 
compounds with an altered carbohydrate pattern requires them to be promiscuous.
65
 
Mounting evidence from efforts devoted to studying this class of enzymes in the last few 
years indicates that many glycosyltransferases involved in the biosynthesis of secondary 
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metabolites, such as polyketide and non-ribosomal peptide antibiotics, have relaxed 
substrate specificity.
241
 Polyketides such as macrolides, polyenes, tetracyclines and 
tetrononic acids, are compounds of great interest due to the diversity of structures and 
biological activities found in this subgroup of natural products.
240,242 
Thus, increasing the 
available catalog of glycosyltransferases with known substrate flexibility would expand 
the biosynthetic possibilities of glycodiversification.  
 
2.1 Kijanimicin A, a Secondary Metabolite Produced by A. kijaniata  
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The novel natural product kijanimicin, (see figure 2.1) was first isolated from 
Actinomadura kijaniata (ATCC 31588) in 1981.
243
 It displays antibiotic activity against 
anaerobes such as Propionibacterium acnes and several strains of Plasmodium in murine 
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models.
243
 The structure of the compound was subsequently determined by chemical 
degradation, X-ray crystallography and spectroscopic studies.
244-246
 Kijanimicin is a 
polyketide, with a unique tetronic acid structure, containing a branched-chain 
tetrasaccharide moiety, consisting of three units of 2,6-dideoxy-α-L-hexopyranose 
(digitoxose) and one unit of 2,6-dideoxy-4-O-methyl-β-L-hexopyranose (4-OMe-
digitoxose) (2), as well as the novel amino sugar kijanose (3).
246 Digitoxose and other 
2,6-dideoxysugars, are ubiquitous in nature and are especially abundant in bacterial 
secondary metabolites, such as macrolides and aminoglycoside antibiotics.
241
  
Besides kijanimicin, L-digitoxose is also found in many other bioactive 
compounds, such as in antibiotics jadomycin, several antifungal polyene macrolides from 
streptomycetes, and the tetrocarcin group of antitumor antibiotics from Micromonospora 
chalcea.
247-249
 L-digitoxose has also recently been identified in new decalactone 
derivatives from the sea sponge Latrunculia corticata.
250
 The D epimer of digitoxose is 
found as a structural component in cardiac glycosides (e.g., digitoxin), pregnane 
glycosides (e.g., cynaphyllosides isolated from the aerial parts of Cynanchum aphyllum) 
and apoptosis inducers (e.g., ammocidin, from Saccharothix sp. AJ9571).
251-253
 D-
digitoxose is also found in saccharomycins, a novel class of heptasaccharide antibiotics, 
which are active against multiple-drug resistant strains of bacteria.
254
 The presence of 
digitoxose in natural products with varied biological functions makes this sugar an 
attractive building block to be used in combinatorial biosynthesis to glycosylate existing 
compounds.  
It has been a longstanding goal in both synthetic chemistry and biology to build 
structural diversity by appending a wide variety of glycosides to a fixed aglycone 
scaffold. In 2002, Rohr and Mendez engineered a plasmid construct for their 
combinatorial biosynthesis work in which genes from the oleandomycin and 
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erythromycin gene clusters were used to generate thymidine diphosphate (TDP)-L-
digitoxose in vivo via an unnatural pathway, involving non-enzymatic tautomerization 
between TDP- L-olivose and TDP- L-digitoxose.
255, 256
 
 
2.2 Combinatorial Biosynthesis of TDP-L-Digitoxose (from Mendez and Rohr) 
 
In 2004, they engineered another plasmid construct that utilized the genes from 
the mithromycin, oleandomycin and erythromycin gene clusters to generate TDP-L-
digitoxose in vivo. The key step of this preparation included the conversion of an 
intermediate with a 3-axial hydroxyl group, to the corresponding equatorial epimer by a 
3,5-epimerase to generate TDP-L-digitoxose.
256
 These biosynthetic pathways can be seen 
in figure 2.2. Although alternative biosynthetic routes exist for the synthesis of TDP-L-
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digitoxose, elucidation of the native pathway would provide more efficient tools for the 
combinatorial endeavors. Therefore, the biosynthetic pathway from TDP-α-D-glucose to 
TDP-L-digitoxose was studied and fully elucidated in this work. 
 
2.1 Synthesis of L-digitoxose by Brimacombe and coworkers 257 
 
Chemical syntheses of both D- and L-digitoxose are known.
257-263
   Brimacombe 
and coworkers performed the synthesis of L-digitoxose using 2,3-O-benzylidene-α-L-
rhamnopyranoside (Scheme 2.1). Synthesis commences by protecting the free hydroxyl 
with 2-methoxyethoxymethyl (MEM) group under standard conditions. Treatment of the 
protected sugar with n-butyllithium generates a methyl-2,6-dideoxy-α-L-erythro-
hexopyranosid-3-ulose intermediate in 41% yield. This intermediate was further reduced 
with sodium borohydride to afford L-digitoxose and other isomers as minor products.
257
 
In 1982, Fronza et al. reported a three step synthesis of L-digitoxose in which  
2,3-isopropylidene-4-deoxy-L-erythrose, the same chiral starting material used by 
Brimacombe and coworkers,  was converted to an allylated carbinol by treatment with 
diallylzinc.
260
 Subsequent exposure of the carbinol to ozonolysis followed by reductive 
workup affords the desired product L-digitoxose. Although the diallylzinc addition 
proceeds in moderate yield, the yield for the ozonolysis was not reported (scheme 2.2).  
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2.2 Synthesis of L-digitoxose by Fronza et al. 
 
Braun and coworkers adopted an approach which could be used to synthesize both 
enantiomers of digitoxose, and synthesized the L form in approximately 4% yield 
(scheme 2.3).
261
 This route uses chiral acetate synthesized from lactate and erythrose as 
the starting material to generate the required chirality. Both antipodes of the starting 
materials could be synthesized from commercially available materials. Aldol addition 
followed by ester hydrolysis gives a -hydroxy acid, which cyclizes upon deprotection of 
the diol to give an intermediate lactone in good yield. This lactone, upon disamylborane 
reduction, gives digitoxose in an overall yield of 4% over 9 steps. 
 
2.3 Synthesis of L-digitoxose by Braun and coworkers 
 
Pederson generates the 2,6-dideoxy-L-ribo-hexose by first treating a L-ribo-
lactone with hydrazine then bromine followed by basic hydrolysis to generate a 6-
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bromosugar with the desired stereochemistry.
263
 As shown in scheme 2.4, the primary 
alcohol is removed via treatment of the diol with hydrobromic acid, followed by 
hydrogenolysis to furnish the 2,6-dideoxylactone (the same intermediate as 
Brimacombe‟s route), which could be isolated and purified as the diacetate. Subjecting 
the crude reaction product to disamylborane reduction generates the final product in 18% 
yield over 5 steps with only the final purification.
263
 
 
2.4 Synthesis of L-digitoxose by Bock et al. 
 
Wang and coworkers successfully synthesized L-digitoxose using ring closing 
metathesis on an allylic lactone, followed by further elaboration using redox chemistry to 
generate L-digitoxose.
262
 An asymmetric enzyme-catalyzed isomerization prior to the 
ring-closing metathesis generates the desired enantiomer (see scheme 2.5). The yield is 
quite low; 6% overall yield over 9 steps.
262
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2.5 Synthesis of L-digitoxose by Wang and coworkers 
 
The advantages of elucidating the biosynthetic pathway of L-digitoxose are 
twofold. First, as illustrated above, the reported yields from chemical synthesis are 
relatively low. For biological applications, the sugar needs to be further activated through 
phosphorylation followed by TMP-morpholidate coupling at the C-1 position. The 
morpholidate coupling results in significant loss of compound, as the reaction affords 
both α and  anomers of the TDP-sugar.264 Clearly, the biosynthetic approach has the 
advantage to be more stereoselective to generate the desired product than a chemical 
synthesis route. The second advantage of the biosynthetic approach is that it would also 
allow us to investigate the functions of the glycosyltransferases of the kijanimicin 
pathway in vitro and in vivo. 
Thus, the first goal of this research project focuses on the determination of the 
enzymes involved in the biosynthesis of TDP-L-digitoxose. Once the pathway of 
digitoxose biosynthesis is established, we can investigate its subsequent attachment to the 
kijanolide aglycone during kijanimicin formation in A. kijaniata. This chapter will 
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describe the cloning and expression of the putative genes and the purification of the gene 
products proposed to be involved in the biosynthesis of TDP-L-digitoxose.  To verify the 
functions of the enzymes involved in the biosynthesis of digitoxose, we have generated  
and characterized the carbohydrate intermediates produced at each step of the 
biosynthetic pathway.  
 
2.3 The Kijanimicin Gene Cluster from A. kijaniata. 
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2.1.2 SEQUENCE ANALYSIS OF THE GENE CLUSTER 
In order to understand the formation of kijanimicin, and more specifically the 
biosynthesis of digitoxose, we endeavored to reconstruct this deoxysugar biosynthetic 
pathway in vitro. We first subjected the gene cluster to in silico analysis to predict genes 
involved in the conversion of glucose-1-phosphate to TDP-L-digitoxose. Sequence 
alignments were undertaken by Dr. Hua Zhang, and the final gene cluster assembly is 
shown in figure 2.3. By comparing open reading frames in the gene cluster to known 
NDP-sugar biosynthetic enzymes candidate genes that may be involved in TDP-L-
digitoxose biosynthesis were identified. 
 The amino acid sequences of KijD5 (298 aa) and KijD4 (375 aa) show homology 
respectively to glucose-1-phosphate thymidylyltransferases and TDP-D-glucose 4,6-
dehydratases from various Streptomyces strains. The highest similarity of KijD5 is found 
with AAK83289.1 (59% identity and 73% similarity), the glucose-1-phosphate 
thymidylyltransferase in spinosyn biosynthesis from Saccharopolyspora spinosa and 
BAA84594.1 (59% identity and 71% similarity), the glucose-1-phosphate 
thymidylyltransferase localized in the avermectin biosynthetic cluster isolated from 
Streptomyces avermitilis.
265, 266
 KijD4 showed high homologies towards AAK83290.1 
(69% identity and 81% similarity), the TDP-D-glucose 4,6-dehydratase in spinosyn 
biosynthesis from S. spinosa and BAA84593 (68% identity and 82% similarity), the 
TDP-D-glucose 4,6-dehydratase localized in the avermectin biosynthetic cluster isolated 
from S. avermitilis.
265, 266
 KijB1 (479 aa) shows the highest similarity to MtmV, TDP-D-
4-keto-6-deoxyglucose-2,3-dehydratase localized in the mithramycin biosynthetic cluster 
from Streptomyces argillaceus (52% identity and 71% similarity).
267
 
  KijB1 and KijD10 (336 aa) possess 49.9% and 55% identities to the products of 
gra-orf27 (CAA09648) and gra-orf26 (CAA09647), in the granaticin biosynthetic 
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cluster, which have been proposed to encode a TDP-D-4-keto-6-deoxyglucose-2,3-
dehydratase and TDP-D-3,4-diketo-2,6-dideoxyglucose-3-ketoreductase, respectively.  
The gene products of the granaticin cluster were biochemically characterized by Draeger 
et al.
268
 Based on their analysis, it was predicted that KijD10 would be a TDP-D-3,4-
diketo-2,6-dideoxyglucose-3-ketoreductase whose product has an equatorial hydroxyl 
group at the C-3 position (Figure 2.4, Compound 8).  
KijD11 (194 aa) exhibits significant homologies to 3,5- and 5-epimerase enzymes that act 
on a TDP-D-4-keto-6-deoxyhexose. The highest homologies occur with TylCII  
(AAD41825) (57% identity and 68% similarity) and the gra-orf25 product (CAA09646, 
granaticin biosynthetic cluster) (52% identity and 68% similarity).
269
 Significantly, the 
similarity of KijB1 to TylCII is a strong indication that this is a protein involved in 
digitoxose biosynthesis. The protein sequence of lipDig3, found in the α-lipomycin 
biosynthetic cluster, another tetronate class natural product, whose aglycon is decorated 
with digitoxose, shows 58% homology to TylCII.
270
 The biosynthetic pathway of 
digitoxose should thus involve C-3 ketoreduction and C-5 epimerization yielding TDP-4-
keto-2,6-dideoxyhexose, which is consistent with the presence of gra-orf26 and gra-orf27 
in the kijanimicin biosynthetic cluster.
268, 271
  Accordingly, KijD10 and KijD11 were 
proposed to mediate conversion of the KijB1 product (TDP-D-3,4-diketo-2,6 
dideoxyglucose) to TDP-L-4-keto-2,6-dideoxyhexose.  
The product of KijC2 (391 aa) displays the highest homology to JadV, the 
(nucleotide diphosphate) NDP-4-keto-6-deoxyhexose-4-reductase found in the jadomycin 
biosynthetic cluster from Streptomyces venezuelae (46% identity and 58% similarity).
247
 
Jadomycin possesses an L-digitoxose unit attached to its anguicycline aglycone and gene 
disruption studies demonstrated that jadV is essential to the biogenesis of the L-
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digitoxose moiety of jadomycin B.
247
 The high similarity between KijC2 and JadV 
further suggests its involvement in the L-digitoxose pathway of kijanimicin biosynthesis.  
 
2.4 TDP-L-Digitoxose Biosynthetic Pathway, adapted from Wang et al. 
 
These sequence alignments led us to propose the TDP-L-digitoxose biosynthetic 
pathway as shown in Figure 2.4. Thus, in this chapter we cloned and heterologously 
expressed the genes kijD5, kijD4, kijB1, kijD10, kijD11 and kijC2, for use in the in vitro 
assays to demonstrate their involvement in the biosynthetic pathway of TDP-L-
digitoxose. 
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2.2 EXPERIMENTAL DETAILS 
 
2.2.1 MATERIALS 
 
2.2.1.1 Bacterial Strains  
Escherichia coli (E. coli) strain DH5α and Actinomadura kijaniata SCC1256 
(ATCC 31588) were purchased from Bethesda Research Laboratories (Gaithersburg, 
MD) and the American Type Culture Collection (Manassas, VA), respectively. The 
overexpression hosts E. coli BL21, BL21(DE3), BL21(DE3)PLysS and BL21 
RosettaII(DE3) were purchased from Novagen (Madison, WI). E. coli XL-1 Blue MRF' 
used for cosmid library preparation was obtained from Stratagene (La Jolla, CA). 
 
2.2.1.2 Biochemicals  
Enzymes and the molecular weight standard used for the molecular cloning 
experiments were products of Invitrogen (Carlsbad, CA) or New England Biolabs 
(Beverly, MA). Restriction digestion enzymes, calf intestinal alkaline phosphatase (CIP), 
100X bovine serum albumin (BSA), T4 ligase, and their respective buffers were products 
of New England Biolabs. Ni-NTA agarose resin was obtained from Qiagen (Valencia, 
CA). Growth media components were acquired from Becton Dickinson (Sparks, MD).  
Rabbit muscle pyruvate kinase was purchased from Sigma as a 400-800 unit/mg 
ammonium sulfate precipitate.  This ammonium sulfate precipitate was dissolved in water 
to a concentration of 2500 units/mL, dialyzed against 50 mM NaH2PO4, 300 mM NaCl, 
pH 8.0, to remove ammonium sulfate, and stored at -80 °C.  Antibiotics and chemicals 
such as isopropyl-β-D-thiogalactopyranoside (IPTG) and dithiothreitol (DTT) were 
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products of Sigma-Aldrich Co. (St. Louis, MO) or Fisher Scientific (Pittsburgh, PA).  
Agarose for DNA electrophoresis was obtained from Fisher Scientific (Pittsburgh, PA).  
Bio-Gel P2 resin and all reagents for sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) were purchased from Bio-Rad (Hercules, CA), with the 
exception of the prestained protein molecular weight marker, which was ordered from 
New England Biolabs.  Antibodies used for Western blotting procedures, monoclonal 
anti-polyhistidine clone His-I H1029 and anti-mouse IgG (alkaline phosphatase 
conjugate) A2429 were purchased from Sigma. For Western blot detection, nitroblue 
tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) were both 
obtained from Promega. 
 
2.2.1.3 Plasmids, Vectors and DNA Manipulation  
Vector pET28b(+) was purchased from Novagen (Madison, WI). Cloning vector 
pANT841 was obtained from Dr. C. E. Hutchinson. Gigapack III Gold packaging extract, 
Plasmids SuperCos 1 and pBluescript II SK(+), used for cosmid library construction and 
cosmid fragment subcloning, respectively, were purchased from Stratagene (La Jolla, 
CA). DNA gel extraction and spin miniprep kits were obtained from Qiagen (Valencia, 
CA). DNA polymerase pfu was purchased from Stratagene. Oligonucleotide primers for 
cloning were prepared by Integrated DNA Technologies (Coralville, IA). The 
digoxigenin (DIG)-labeling and probing kit for colony hybridization assays was 
purchased from Boehringer Mannheim (Mannheim, Germany). 
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2.2.1.4 Instrumentation 
PCR reactions were carried out using an Eppendorf Mastercycler gradient thermal 
cycler from Brinkman-Eppendorf (Westbury, NY). For agarose gel electrophoresis, a 
mini-sub-cell GT from BioRad (Richmond, CA) was used, powered by a Fisher FB-300 
electrophoresis power source. After electrophoresis, DNA bands were visualized using a 
Fisher FBTIV-08 UV transilluminator. Cell disruption was performed with a Fisher 550 
Sonic Dismembrator, equipped with a standard sonicator horn. For SDS-page gel 
electrophoresis, a mini PROTEAN II vertical system from BioRad (Richmond, CA) was 
used, equipped with an FB-300 or EC-1000-90 electrophoresis power source from Fisher, 
or E-C apparatus corporation, respectively. Mini-trans blot assembly apparatus used for 
Western blot, GelAir drying system for acrylamide gel preservation, and the necessary 
accessories and reagents were all products of BioRad. The nitrocellulose Hybond-C or 
Optitran BA-5 85 reinforced nitrocellulose membrane used for Western blot was from 
Amersham Bioscences or Whatman (Dussel, Germany), respectively.  
To obtain pH values, a Corning 240 pH meter equipped with an Accumet 
electrode (Fisher) was used.  Large scale centrifugation procedures were performed using 
an Avanti J-25 unit or a J-E instrument from Beckman (Arlington Heights, IL).  
Microscale centrifugation procedures were carried out using an Eppendorf 5415C from 
Brinkmann Instruments, (Westbury, NY). Ultraviolet-visible spectra were recorded using 
Beckman DU-650 spectrophotometer. Amicon YM-10 filtration products were purchased 
from Millipore (Billerica, MA). HPLC Separations used a Beckman 366 from Beckman 
Instruments (Fullerton, CA) equipped with a CarboPac PA1 HPLC column from Dionex 
(Sunnyvale, CA). ÄKTA FPLC Instrument was from Amersham Pharmacia Biosciences 
(now GE Healthcare). Mono-Q H/R 10/10 and 16/10 FPLC columns were from 
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Pharmacia (Uppsala, Sweden).  DNA and biological compounds were dried using a 
Savant Speedvac SC100, equipped with a Savant refrigerated condensation trap RT100 
and Gel Pump GP100. DNA concentrations were measured using a NanoDrop ND-1000 
UV-Vis instrument from Thermo Fisher Scientific (formerly NanoDrop Technologies 
LLC).  
 NMR spectra were acquired on either a Varian Unity 300 or 500 MHz 
spectrometer. Sequencing of subclones was performed using a capillary-based AB 3700 
DNA analyzer by the Core Facilities in the Institute of Cellular and Molecular Biology of 
the University of Texas at Austin. Mass spectra (low-resolution ESI) were obtained on a 
Finnegan LCQ ion trap mass spectrometer. Spectra were acquired by the Mass 
Spectrometry Core Facility in the Department of Chemistry and Biochemistry of the 
University at Texas at Austin or the College of Pharmacy of the University of Texas at 
Austin.   
 
2.2.2 GENERAL PROCEDURES   
All protein purification operations were carried out at 4 ºC. Protein concentrations 
were determined according to Bradford using bovine serum albumin (BSA) as the 
standard.
272
  The relative molecular mass and purity of enzyme samples were determined 
using SDS-polyacrylamide gel electrophoresis as described by Laemmli.
273
 NMR 
chemical shifts (δ in ppm) are given relative to that of deuterated water (D2O, δ 4.65 for 
1
H NMR) in the case of all NMR assays, with coupling constants reported in Hertz (Hz).    
The general methods and protocols for recombinant DNA manipulations were as 
described by Sambrook et al.
274
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2.2.3 EXPERIMENTAL PROCEDURES 
 
2.2.3.1 Bacterial Strains and Growth Conditions 
Actinomadura kijaniata SCC1256 (ATCC 31588) was maintained at 30 ºC on ISP 
medium 2. For genomic DNA extraction, a seed culture of Actinomadura kijaniata was 
grown in liquid V15 medium (seed media) (1% glucose, 0.2% peptone, 0.2% N-Z amine 
A, 1% beef extract, 0.2% NaNO3, 0.1% K2HPO4, 0.054% MgSO4•7H2O, 0.05% 
CaCl2•2H2O, pH adjusted to 7.2 before autoclaving) for 24-30 h at 30 ºC, diluted into 
V15-P medium (20% w/v sucrose, 3% glucose, 1.5% bactosoytone, 0.3% glycine, 0.04% 
CaCl2•2H2O, 0.1% MgCl2•6H2O, pH adjusted to 7.2.), and grown for 40-48 h at 30 ºC.
275
 
E. coli DH5α was used for routine cloning experiments. E. coli XL-1 Blue MRF' 
was used for cosmid manipulations. E. coli DH5α used for routine cloning experiments 
and BL21, BL21(DE3),  BL21(DE3)pLysS,  and BL21 RosettaII(DE3)  for protein 
purification experiments were maintained on Luria-Bertani (LB) broth or LB-agar plates 
(1% NaCl, 1% tryptone, 0.5% yeast extract, pH 7.5, and in the case of plates, 2% agar). 
Culture media was supplemented with 100 µg/mL ampicillin or 50 µg/mL kanamycin 
with the addition of 35 µg/mL chloramphenicol in the case of BL21 RosettaII(DE3) and 
BL21(DE3)pLysS. To liquid cultures, volume of sterile 80% glycerol equal to 20% of the 
original culture volume was added and gently mixed to homogeneity. The mixture was 
aliquotted into sterile Eppendorf tubes, flash frozen in liquid N2 and stored at -80 ºC until 
use. Glycerol stocks were used in a 1:20 dilution to inoculate fresh media for plasmid 
preparations. 
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2.2.3.2 Preparation of Competent Cells 
The rubidium chloride (RbCl) method was used to make E. coli cells chemically 
competent.
274
 A fresh colony of E. coli of the appropriate strain was used to inoculate 2 
mL of Luria-Bertani (LB) (1% NaCl, 1% yeast extract, 0.5% tryptone, pH 7.5) broth. 
This culture was grown at 37 ºC with 250 RPM shaking. After overnight incubation, 1 
mL of the culture was used to inoculate 100 mL of fresh LB media in a 1:100 dilution. 
The freshly inoculated culture was incubated at 37 ºC with 250 RPM shaking until the 
OD600 of the culture reached 0.4 to 0.5 absorbance units. At this time, the culture was 
transferred to a two chilled sterile 50 mL conical tubes and incubated on ice for 15 min. 
The cultures were centrifuged at 3,000 g for 10 min at 4 ºC. The supernatant was 
discarded and the cell pellets were gently resuspended in 33 mL of  cold RF1 solution 
(100 mM RbCl, 50 mM MnCl2, 30 mM potassium acetate, 10 mM CaCl2 15% glycerol, 
pH 5.8, filter sterilized using 0.22 µm membrane).  The cell suspension was incubated on 
ice for an additional 15 min and centrifuged again at 3,000 g for 10 min at 4 ºC. This RF1 
washing step was repeated and the cells resuspended in 12.5 mL of RF2 solution (10 mM 
RbCl, 10 mM MOPS, 75 mM CaCl2 15% glycerol, pH 6.8, filter sterilized using 0.22 µm 
membrane). The cell suspension was incubated on ice for 10 min, and 50-100 µL of the 
mixture was dispensed into sterile eppendorf tubes. The aliquots were flash frozen in 
liquid N2 and stored at -80 ºC until use. 
 
2.2.3.3 Creation of a Cosmid Library from A. kijaniata 
Cosmid DNA preparations were carried out by Dr. Hua Zhang. Standard genetic 
manipulations were performed as described by Sambrook et al.
274
 Briefly, genomic DNA 
of Actinomadura kijaniata was isolated using a procedure derived from the SuperCos 1 
Cosmid Vector Kit, with the following additional steps at the beginning of the procedure. 
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The cell pellet was washed with 10 mM EDTA followed by 3 h digestion at 30 ºC in 
Solution A (10 mM NaCl, 20 mM Tris•HCl, pH 8.0, 1 mM EDTA) containing lysozyme 
at 2.5 mg/mL final concentration.  For the construction of Actinomadura kijaniata 
SCC1256 genomic library, chromosomal DNA was partially digested with Sau3AI and 
fragments of 20 to 40 kb were ligated into SuperCos 1 that was prepared by linearizing 
with XbaI, CIAP treatment, and subsequent digestion with BamHI. Gigapack III Gold 
packaging extract was used to perform in vitro packaging, which was done according to 
the manufacturer‟s protocol. A 500 bp kijd1 fragment labeled with digoxigenin (DIG) 
was used to probe the library as the starting point for chromosome walking. Cosmids 
pHZ-8, pHZ-14, pHZ-P1, pHZ-P5 and pHZ4-6 were digested with ApaI and BamHI, and 
1-5 kb fragments were subcloned into pBluescript II SK(+). DNA manipulations of 
Actinomadura kijaniata SCC1256 were performed as described by Kieser et al.
276
 DNA 
sequencing data were assembled and analyzed using Vector NTI Suite program (version 
6.0; InforMax, Inc.; Bethesda, MD). Protein sequences were analyzed with the NCBI 
BLAST server. 
 
2.2.3.4 PCR Reactions  
The general protocol for amplification of genes from Gram-positive bacteria is as 
follows. Primers were prepared by dilution with TE buffer (50 mM Tris, 1 mM EDTA, 
pH 8.0) to a concentration of 100 µM.  This stock solution was further diluted to 20 µM 
with sterile water.  Template DNA from the A. kijaniata genome was obtained from 
cosmids constructed by Dr. Hua Zhang. Genes kijB1 and kijC2 were amplified from 
cosmid pHZ4-6, and kijD10 and kijD11 were amplified from cosmid pHZ14. Polymerase 
chain reactions (PCR) consisted of the following: 72 µL of sterile water, 10 µL of 10X 
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pfu polymerase buffer, 10 µL of dimethylsulfoxide (DMSO), 10 µL of a 20 mM  
deoxyribonucleotidyl triphosphosphate (dNTP) solution, 2.5 µL of each primer (5′ and 3′) 
at 20 µM, 1 µL of template DNA, and 2 µL of pfu polymerase (5 units), for a 100 µL 
total reaction volume in an 0.5 mL thin walled PCR tube.  
The PCR reactions were carried out using an Eppendorf thermocycler with the lid 
temperature set at 105 ºC and an initial denaturing step of 2 min at 95 ºC.  The first 3 
program cycles consisted of a 30 s denaturing step at 95 ºC, an annealing step at 5 ºC 
below the lowest annealing temperature for the overlapping region of each primer pair for 
30 s, and an elongation step of 1 min/kb at 72 ºC. The remainder of the program consisted 
of a 30 s denaturing step at 95 ºC, an annealing step at an annealing step with temperature 
5 ºC below the lowest annealing temperature (for the entire primer) of each primer pair 
for 30 s, and an elongation step of 1 min/kb at 72 ºC. This was repeated 27 times, with 
each cycle ending in a 10 min extension at 72 ºC. The temperature was reduced to 4 ºC 
until the product was removed from the thermocycler.  PCR products were stored at 4 ºC 
until purified. 
 
2.2.3.5 PCR Product Purification 
A typical PCR purification consisted of agarose gel electrophoresis employing an 
0.8% TAE-agarose gel with 5 µg/mL ethidium bromide. PCR products were diluted to 
83% with 6X DNA loading dye (0.25% xylene cyanol, 0.25% bromophenol blue, 15% 
Ficoll 400) and electrophoresed at 100 V for 30 min. After electrophoresis, DNA bands 
of the correct base pair length, as estimated from comparison with DNA ladder, were 
excised from the gel with a clean scalpel. DNA was purified from agarose slices using the 
Qiagen gel extraction kit, according to the manufacturer‟s protocols with the following 
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modifications. Instead of heating at 55 ºC to melt the agarose, gel slices were heated at 65 
ºC until the gel was fully dissolved. DNA elution buffer EB was also heated to 65 ºC 
prior to DNA elution, and the volume used for elution was 30 µL.  
 
2.2.3.6 DNA Ligations and Plasmid Transformation 
PCR products for the kijanimicin biosynthetic protein constructs were digested 
with the appropriate restriction enzymes, generally NdeI and HindIII at 37 ºC overnight. 
A typical reaction mixture contained 30 µL of purified PCR product, 1-2 µL of each 
enzyme, 0.4 µL of 100X BSA, 4 µL of 10X NEB buffer 2 and sterile water to a final 
volume of 40 µL. Digested products were cleaned with the Qiagen PCR purification kit, 
following the manufacturer‟s protocols, and ligated to the corresponding sites in the 
pET28 a or b+ plasmid. The pET28 a or b+ plasmid was prepared by digesting with NdeI 
and HindIII at 37 ºC overnight followed by treatment for 1-2 h at 37 ºC with CIP in NEB 
buffer #2. A typical reaction mixture contained 30 µL of purified vector, 2 µL of each 
enzyme, 0.4 µL of 100X BSA, 4 µL of 10X NEB buffer 2 and sterile water to a final 
volume of 40 µL. After overnight digestion, pET28a or b+ was treated for 1-2 h at 37 ºC 
with 0.2 µL of CIP in NEB buffer #2. The digested plasmid was electrophoresed using a 
0.8% TAE-agarose gel, followed by extraction using the Qiagen Gel Extraction kit with 
modified protocols as previously detailed. In some cases, plasmids were extracted using 
the Qiagen gel extraction kit, following the instructions for PCR purification.  
A Nanodrop instrument was used to quantify the plasmid and the insert DNA 
solutions. A typical ligation mixture included 90 fm ends of gel purified PCR product, 30 
fm ends of pET28a or b+, 2 µL of 5X T4 ligase buffer, 3.5 µL of sterile water, and 0.5 
µL of T4 ligase to a final volume of 10 µL. The ligation mixture was incubated at room 
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temperature for 1-2 h, or overnight at 4 ºC. An aliquot of the ligation mixture (5 µL) was  
introduced to competent E. coli DH5α cells (50 µL) and incubated on ice for 30 min. 
After incubation, the cells were transformed by heat shock at 42 ºC for 30 s, and 
incubated on ice for 2 min. LB broth (500 µL) was added to the transformed cells and 
incubated at 37 ºC with 200 RPM shaking for 45 min, and plated on LB-agar plates 
supplemented with 50 µg/mL kanamycin. Positive transformants were selected by 
incubation overnight at 37 ºC.  
 
2.2.3.7 DNA Extraction by Alkaline Lysis  
Colonies appearing after overnight incubation were screened for the presence of 
plasmid containing PCR product using the method of alkaline lysis.
277
 Briefly, 5 mL 
cultures of each positive transformant were grown overnight at 37 ºC in LB media with 
50 µg/mL kanamycin. Cultures were centrifuged at 12,000 g for 30 s, the supernatant was 
removed and the cells were resuspended in 100 µL of cold Resuspension solution (50 
mM glucose, 25 mM Tris•HCl (pH 8.0), 10 mM EDTA (pH 8.0), 100 µg/mL RNase). 
Cells were disrupted with the addition of 200 µL fresh Lysis solution (200 mM NaOH, 
1% SDS), and inverted 5 times to mix. Lysis reactions were quenched with the addition 
of 150 µL of Neutralization solution (3 M potassium acetate, 11.5% acetic acid). 
Reactions were mixed to ensure neutralization and incubated at 4 ºC for 5 min, followed 
by centrifugation for 5 min at 12,000 g to precipitate cellular debris. Supernatants 
containing plasmid DNA were transferred to fresh tubes and the DNA was precipitated 
by the addition of two volumes of 100% ethanol and 1/10 volume of 3 M sodium acetate, 
pH 5.2. Solutions were mixed to ensure homogeneity and centrifuged at 12,000 g for 15 
min at 4 ºC. The supernatants were removed by aspiration, taking care not to disturb the 
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DNA pellet. DNA pellets were washed with 70% ethanol and centrifuged again at 12,000 
g for 5 min. The final ethanol wash was removed and solutions were dried using a 
centrifugal vacuum apparatus for 10 min at room temperature to remove any remaining 
ethanol. Pellets containing plasmid DNA were resuspended in 30 µL of 50 mM Tris•HCl 
(pH 8.5).  
 
2.2.3.8 DNA Analytical Restriction Digestion and Fragment Analysis 
Plasmid DNA obtained from this preparation was subjected to enzymatic 
digestion with NdeI and HindIII. A typical reaction mixture contained 15 µL of DNA, 2 
µL of 10X NEB reaction buffer #2, 0.1 µL of each enzyme (NdeI and HindIII), 0.2 µL of 
100X BSA and 2.6 µL of sterile water. The reactions were incubated for 2 h at 37 ºC, 
after which time 10 µL aliquots were removed and analyzed by gel electrophoresis. 
Samples were diluted 5X in DNA loading dye and electrophoresed for 30 min at 100 V 
using a 0.8% TAE-agarose gel with 5 µg/mL ethidium bromide (gel concentration).  
Electrophoretic results as visualized on agarose gels were used to confirm the 
presence of the DNA insert of the appropriate length. Colonies determined to contain the 
vector and successfully ligated PCR product were grown overnight at 37 ºC with 200 
RPM shaking in LB media supplemented with 50 µg/mL kanamycin. After overnight 
incubation, bacteria were harvested by centrifugation at 12,000 g for 30 s. Plasmid DNA 
was extracted from the bacterial pellet using the Qiagen miniprep kit, following the 
manufacturer‟s protocols with the following adjustments to the protocol: the optional 500 
µL PB wash was always performed to remove additional contaminants, and elution buffer 
EB was heated to 65 ºC before DNA elution. The purified plasmid was sequenced to 
confirm the identity of the PCR product. 
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PHRED sequences obtained from the DNA facility were aligned against the gene 
sequences previously identified for the target genes though gene cluster sequencing. Both 
forward and reverse sequences were compared to the originally obtained gene sequences 
to determine that the sequences were correct with no mutations.   
 
2.2.3.9 SDS-PAGE 
The relative molecular mass and purity of enzyme samples were determined using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) as described by 
Laemmli.
273
 Proteins were electrophoresed using a discontinuous buffer system 25 mM 
Tris•HCl, 192 mM glycine and 0.1% SDS (pH 8.3).273 Gels were 75 mm, and 12% 
acrylamide was used for the separatory gel, while the stacking gel was 4% acrylamide. 
Protein samples were diluted 2X with SDS-Loading dye (62.5 mM Tris•HCl buffer pH 
6.8, containing 10% glycerol, 2% SDS, 5% β-mercaptoethanol, and 0.0025% 
bromophenol blue, and heated to 100 ºC for 5 min followed by a brief centrifugation step. 
The protein gels were electrophoresed using a setting of 30 mA per gel, allowing the 
process to continue until the loading dye ran off the bottom of the gel. Gels were 
removed from glass plates, and stacking gel removed. A corner of each gel was also cut 
to preserve orientation of the gel samples. Gels were stained with Coomassie blue (2.5 
g/L of Coomassie Brilliant Blue G-250 in acetic acid:water:methanol (1:4:5) by volume) 
until gels were dark blue.
278
 Gels were removed from staining solution, rinsed in ddH2O, 
and introduced to destaining solution (ethanol:acetic acid:water in a ratio of 4:5:41 by 
volume).
278
 Protein concentrations were determined according to Bradford using BSA as 
the standard, and the dye reagent from BioRad.
272
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2.2.3.10 Western Blot Procedure 
Western blotting was used to detect the presence of polyhistidine tags on 
heterologously expressed and purified proteins.
279
 SDS-PAGE of elution fractions from 
Ni-NTA chromatography procedures was performed in duplicate for each protein. The 
gels were processed as detailed previously up to the staining step, at which point they 
were assembled into the transfer cassettes. The gels were transblotted onto the 
nitrocellulose membrane at 100 V for 1 h, using a running buffer of 25 mM Tris base, 
192 mM glycine, 20% v/v methanol (pH 8.3).  Cassette assembly and electrophoresis 
were carried out according to the directions provided by BioRad. After transblotting 
electrophoresis, the membrane was carefully removed from the transfer cassette and the 
presence of the prestained marker on the blot was visually assessed to ensure transfer was 
complete. The membrane was transferred to a small plastic box and immersed in 5% non-
fat dry milk in Tris buffered saline and Tween (TBST) (20 mM Tris•HCl, 150 mM NaCl, 
0.5% v/v Tween® 20, pH 7.5). The membrane was blocked in this solution for 1 h, with 
agitation, overnight at 4 ºC or at room temperature for 1 h. After which, the solution was 
removed and the membrane was rinsed thrice in TBST to remove excess blocking 
solution. The membrane was immersed in primary antibody solution (15 mL TBST, 
1:30,000 dilution of monoclonal anti-polyhistidine clone His-1, 1:1000 dilution of 20% 
v/v NaN3), and incubated with agitation overnight at 4 ºC or room temperature for 1 h. 
After incubation, the solution was removed from the membrane and the membrane was 
washed thrice with TBST to remove any excess primary antibody solution remaining on 
the membrane. The membrane was incubated in secondary antibody solution (15 mL 
TBST, 1:30,000 dilution of anti-mouse IgG [Fc specific] alkaline phosphatase conjugate, 
1:1000 dilution of 20% v/v NaN3), and incubated with agitation overnight at 4 ºC or room 
temperature for 1 h. After incubation, the solution was removed from the membrane and 
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the membrane was washed thrice with TBST to remove any excess secondary antibody 
solution remaining on the membrane. To visualize proteins, the membrane was  
immersed in 5 mL color development solution (100 mM Tris•HCl, 100 mM NaCl, 5 mM 
MgCl2, pH 9.5) with the addition of 66 µL NBT and 33 µL BCIP. The membrane was 
incubated in the dark for 2-5 min or until purple bands appeared on the blot. 
Development was stopped by rinsing the membrane with ddH2O. Membranes were dried 
and scanned within 24 h. 
 
2.2.4 GENERATION OF TDP-L-DIGITOXOSE BIOSYNTHETIC PROTEINS 
 
2.2.4.1 TTP3 PROTEIN MIXTURE 
The genes encoding thymidine kinase (TK), thymidylate kinase (TMK), and 
nucleotide diphosphate kinase (NDK) were amplified from the genomic DNA of E. coli 
strain HMS174 and cloned into the pET28b+ vector in tandem such that each gene is 
associated with its own ribosome binding site and His6-tag, by Dr. Yung-nan Liu. The 
PCR products of the TK, TMK and NDK genes, after digestion with the appropriate 
restriction enzymes, NdeI/EcoRI, EcoRI/HindIII or HindIII/XhoI, respectively were 
ligated in-frame and downstream from the His-tag encoding sequence to the NdeI/XhoI 
digested pET28b(+) vector. The resulting plasmid pET/TK/TMK/NDK was used to 
transform the E. coli cloning host DH5α, and kanamycin resistant clones were 
characterized by restriction mapping. The plasmid DNA isolated from the positive clones 
was used to transform E. coli BL21(DE3).  
STEP 1: GROWTH OF E. COLI CELLS. An overnight culture of E. coli BL21(DE3)-
pET/TK/TMK/NDK was grown in LB media supplemented with kanamycin (50 μg/mL) 
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at 37 °C. 2 mL of overnight culture was used to inoculate 1 L of LB supplemented with 
kanamycin (50 μg/mL). Typically, 6 L of culture was incubated at 37 °C until the OD600 
reached 0.4-0.6, followed by the addition of isopropyl-β-D-thiogalactopyranoside (IPTG) 
to a final concentration of 0.3 mM, and the temperature was reduced to 25 ºC. The culture 
was allowed to grow for an additional 18 h at 25 °C, at which time the cells were 
harvested by centrifugation at 4,500 g for 15 min at 4 °C, and stored at -80 °C. 
STEP 2: CRUDE EXTRACT PREPARATION. Cells from 6 L of culture were resuspended 
in 100 mL of Lysis buffer I (50 mM sodium phosphate, 150 mM NaCl, 10 mM 
imidazole, pH 8.0), and disrupted with 5 × 1 min sonication bursts, with 1 min cooling 
intervals between bursts. Cellular debris was removed by centrifugation at 15,000 g for 
25 min, and the soluble supernatant was removed and retained.  
STEP 3: NI-NTA CHROMATOGRAPHY. To the crude extract, 4 mL of prepared Ni-
NTA resin was added and the resulting mixture was incubated for 1 h with gentle shaking 
at 4 °C. The resin slurry was loaded into an empty column (2 × 25 cm). The column was 
washed with 100 mL of Wash buffer I (50 mM sodium phosphate, 150 mM NaCl, 20 mM 
imidazole, pH 8.0), and the TK, TMK and NDK protein mixture was eluted from the 
column using 12 mL of Elution buffer I (50 mM sodium phosphate, 150 mM NaCl, 250 
mM imidazole, pH 8.0). The desired protein fractions were pooled and desalted by 
dialyzing against 1 L of Dialysis buffer I (50 mM potassium phosphate buffer (pH 7.5) 
15% glycerol) with 3 changes. 
 
2.2.4.2 RFBA- (α -D-GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE)  
The α-D-glucose-1-phosphate thymidylyltransferase, RfbA was prepared in the 
following manner.  The rfbA gene was amplified from Salmonella enterica serovar 
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Typhimurium LT2 genomic DNA with an upstream ribosome binding site 
(RBS)/translational spacer element (TSE) using PCR by Dr. Yung-nan Liu.   The PCR-
amplified gene was purified, digested with BamHI and PstI, and ligated into BamHI/PstI 
digested pUC18.  A (His)5-tag was added to the C-terminus of RfbA by PCR 
amplification of the rfbA insert of plasmid rfbA/pUC18 and cloning back into the same 
vector. The rfbA-(His)5/pUC18 plasmid was used to transform the BL21(DE3) cells for 
protein expression. 
STEP 1: GROWTH OF E. COLI CELLS. The resulting construct was used to transform 
E. coli BL-21(DE3). Cultures was grown in LB media in the presence of 100 µg/mL 
ampicillin overnight. Overnight culture (1 mL) was used to inoculate each L of fresh LB 
broth. The cultures were subsequently incubated for 20 h at 37 ºC with 250 RPM shaking.  
Cells were harvested by centrifugation for 15 min at 4,500 g at 4 ˚C and stored overnight 
at -80 ˚C. 
 STEP 2: CRUDE EXTRACT PREPARATION. The protein RfbA is expressed as an N-
terminal His6 tagged protein and purified by affinity chromatography with Ni-NTA resin. 
The cells were resuspended in 2 mL Lysis buffer II (50 mM NaH2PO4, 300 mM NaCl, 10 
mM imidazole with 10% glycerol pH 8.0) per gram cell wet weight. Cells were disrupted 
by 12 × 30 s sonication pulses with 1 min cooling periods between the pulses and crude 
protein extracts were obtained by centrifugation at 10,000 g, 4 ºC for 20 min.  
STEP 3: NI-NTA CHROMATOGRAPHY. Protein was further purified by Ni
2+
 affinity 
chromatography following manufacturer‟s instructions with 10% glycerol in all buffers. 
Briefly, 4 mL of resin was prepared by washing with Lysis buffer II and allowed to bind 
with soluble protein at 4 ºC for 1 h, then loaded onto a 2 × 25 cm column. The column 
was packed by gravity flow and washed with 5 column volumes (CV) of Lysis buffer 
followed by two washes with 10 CV of Wash buffer II (50 mM NaH2PO4, 300 mM NaCl, 
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20 mM imidazole, 10% glycerol, pH 8.0). RfbA protein was eluted with 12 mL of 
Elution buffer II (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, 15% glycerol, 
pH 8.0), which was collected in 1.5 mL fractions, with RfbA most heavily concentrated 
in fractions E3-E5. These fractions were collected and dialyzed against 3 L of Dialysis 
buffer II (50 mM NaH2PO4, 300 mM NaCl, 15% glycerol, pH 8.0). The dialyzed protein 
solution was concentrated using the Amicon filtration system. Protein was flash frozen in 
liquid nitrogen and stored at -80 ºC until use.  
 
2.2.4.3 RFBB (TDP-GLUCOSE 4,6-DEHYDRASE) 
RfbB used in the synthesis was prepared in the following manner.  The rfbB gene 
was amplified from Salmonella enterica serovar Typhimurium LT2 genomic DNA using 
PCR by Dr. Yung-nan Liu.  The PCR-amplified gene was purified, digested with EcoRI 
and BamHI, and ligated into EcoRI/BamHI digested pUC18. An N-terminal His6 tag was 
added to the construct in a manner similar to that previously described for the 
recombinant RfbA construct. 
STEP 1: GROWTH OF E. COLI CELLS. The resulting construct was used to transform 
E. coli BL21(DE3) and grown in LB broth in the presence of 100 µg/mL ampicillin 
overnight at 37 ºC. Overnight culture (1 mL) was used to inoculate each liter of fresh LB 
broth. The cultures were subsequently incubated for 20 h at 37 ºC with 250 RPM shaking.  
Cells were harvested by centrifugation for 15 min at 4,500 g at 4 ˚C and stored overnight 
at -80 ˚C. 
STEP 2: CRUDE EXTRACT PREPARATION. The protein RfbB is expressed as an N-
terminal His6 tagged construct and purified by affinity chromatography using Ni-NTA 
resin. The cells were resuspended in 2 mL Lysis buffer with 10% glycerol pH 8.0 per 
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gram cell wet weight. Cells were disrupted by sonication 12 × 30 s pulses with 1 min 
cooling periods and crude protein extracts were obtained by centrifugation for 20 min at 4 
ºC at 10,000 g.  
STEP 3: NI-NTA CHROMATOGRAPHY. Protein was further purified by Ni
2+
 affinity 
chromatography following manufacturer‟s instructions with 10% glycerol in all buffers. 
Briefly, 6 mL of resin was prepared by washing with Lysis buffer II and allowed to bind 
with soluble protein at 4 ºC for 1 h, then loaded onto a 2 × 25 cm column. The column 
was packed by gravity flow and washed with 5 CV of Lysis buffer followed by two 
washes with 10 CV of Wash buffer II. RfbB protein was eluted with 12 mL of Elution 
buffer II, which was collected in 1.5 mL fractions, with RfbB most heavily concentrated 
in fractions E2-E8. These fractions were collected and dialyzed against 3 L of Dialysis 
buffer II (50 mM NaH2PO4, 300 mM NaCl, 15% glycerol, pH 8.0). The dialyzed protein 
solution was concentrated using the Amicon filtration system. Protein was flash frozen in 
liquid nitrogen and stored at -80 ºC until use. 
 
2.2.4.4 TYLX3 – (2,3-DEHYDRATASE) 
Previous Liu group members have used the KijB1 homolog TylX3 to generate the 
TDP-α-2,6-dideoxy-D-glycero-4-hexulose. Briefly, Dr. Huwai (Raymond) Chen created 
the expression construct by amplifying the tylX3 gene by PCR from template DNA 
obtained from S. fradiae.  The PCR product was purified, digested and ligated into the 
pET28b+ vector to generate an N-terminally-His6 tagged gene construct.  The ligation 
mixture was used to transform E. coli DH5α cells, and colonies positive for the construct 
pHC45 were isolated and grown overnight at 37 ºC with 250 RPM shaking in LB broth 
supplemented with 50 µg/mL kanamycin.  
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STEP 1: GROWTH OF E. COLI CELLS.  The pHC45 plasmid was purified using the 
Qiagen miniprep kit following the manufacturer‟s protocols and used to transform E. coli 
BL-21(DE3). After overnight selection on LB-agar supplemented with 50 µg/mL 
kanamycin, colonies that grew were used to inoculate 25 mL of LB broth supplemented 
with kanamycin at 50 µg/mL, and grown overnight at 37 ºC with 250 RPM shaking. The 
overnight culture was used to inoculate 6 L of fresh LB media (4 mL culture per L broth), 
supplemented with 50 µg/mL kanamycin. The cultures were grown at 37 ºC with 250 
RPM shaking until the OD600 of the culture reached 0.3, at which point the temperature 
was reduced to 24 ºC. The cultures grown for an additional h or until the OD600 reached 
0.4. The cultures were induced with IPTG to a final concentration of 50 µM, and allowed 
to grow for an additional 15 h at 24 ºC. The cells were harvested by centrifugation at 
4,500 g for 20 min at 4 ºC and stored at –80 ºC until protein purification.  
STEP 2: CRUDE EXTRACT PREPARATION. The cells were resuspended in 2 mL Lysis 
buffer III (50 mM NaH2PO4, 300 mM NaCl, 5 mM imidazole, 20% glycerol, 5 mM β-
mercaptoethanol, pH 8.0) per gram of cells (wet weight).  The resuspended cells were 
disrupted by sonication using 5 × 1 min pulses, with 1 min cooling intervals between 
bursts. After sonication, the cellular debris was removed by centrifugation at 35,000 g for 
20 min. The supernatant was decanted and retained for further purification.  
STEP 3: NI-NTA CHROMATOGRAPHY. Protein was further purified by Ni
2+
 affinity 
chromatography following slightly adjusted manufacturer‟s instructions, with 20% 
glycerol and 5 mM β-mercaptoethanol in all buffers. Briefly, 5 mL of resin was prepared 
by washing with Lysis buffer III and allowed to bind with soluble protein at 4 ºC for 2 h 
with gentle shaking. The mixture was centrifuged at 1,000 g and the supernatant 
containing unbound protein was decanted from the pelleted resin. The resulting slurry 
was mixed well and loaded onto a 2 × 25 cm column. The column was packed by gravity 
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flow and washed with 1 CV of Lysis buffer III followed by two washes with 5 CV each 
of Wash buffer IIIa (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 20% glycerol, 
5 mM β-mercaptoethanol, pH 8.0)  and IIIb (50 mM NaH2PO4, 300 mM NaCl, 40 mM 
imidazole, 20% glycerol, 5 mM β-mercaptoethanol, pH 8.0). The TylX3 protein was 
eluted with 20 mL of Elution buffer III (50 mM NaH2PO4, 300 mM NaCl, 250 mM 
imidazole, 20% glycerol, 5 mM β-mercaptoethanol, pH 8.0) and collected in 1.5 mL 
fractions. The pooled fractions were dialyzed against 4 L of Dialysis buffer III (50 mM 
Tris, 20% glycerol, pH 7.5 at 25 ºC). The dialyzed protein solution was concentrated 
using the Amicon stirred cell filtration system. Protein was flash frozen in liquid nitrogen 
and stored at -80 ºC until use.  
 
2.2.4.5 KIJD10   (3-KETOREDUCTASE) 
This gene was amplified by PCR from a cosmid library constructed from A. 
kijaniata using the primers (upstream 5′-TAGGGGAGTTCATATGGAGAATCCGGC-
GAA-3′) and (downstream 5′-GGCTCCTGAAAAGCTTCTAAACCCGGGTCA-3′). The 
PCR fragment was subsequently purified by agarose gel electrophoresis followed by 
Qiagen gel extraction kit and ligated into the vector pANT841. This construct was 
subsequently digested with NdeI and HindIII and the fragment ligated into corresponding 
sites in the vector pET28b to create a protein expression construct with an N-terminal 
His6 tag. The construct was isolated from E. coli DH5α using the Qiagen miniprep kit, 
and submitted for DNA sequencing to ensure there were no mutations from the PCR 
process. 
STEP 1: GROWTH OF E. COLI CELLS.  This construct was used to transform E. coli 
BL21(DE3) pLysS cells which were subsequently grown in 10 mL LB media 
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supplemented with 50 µg/mL kanamycin at 37 ºC with 250 RPM shaking. The cultures 
were transferred to 6 L of fresh LB media and incubated at 37 ºC with 250 RPM shaking 
until the OD600 reached 0.4. The temperature was reduced to 14 ºC and protein expression 
was induced with 1 mM IPTG. Cells were grown for 18 h after induction and 
subsequently harvested by centrifugation for 15 min at 4,500 g and frozen overnight at -
80 ºC. 
STEP 2: CRUDE EXTRACT PREPARATION. The cells were resuspended in 4 mL of 
Lysis buffer II, per gram cell, wet weight. Cells were disrupted by sonication using 24 × 
10 s pulses, with 20 s cooling intervals between bursts. Crude protein extracts were 
obtained by centrifugation at 10,000 g at 4 ºC for 20 min.  
STEP 3: NI-NTA CHROMATOGRAPHY. Protein was further purified by Ni
2+
 affinity 
chromatography following manufacturer‟s protocols with 10% glycerol in all buffers. 
Briefly, 10 mL of resin was prepared by washing with Lysis buffer II and allowed to bind 
with soluble protein at 4 ºC overnight, and loaded onto a 2 × 25 cm column. The column 
was packed by gravity flow and washed with 5 CV of Wash buffer II. KijD10 protein 
was eluted with 15 mL of Elution buffer II and collected in 1.8 mL fractions, with 
KijD10 most heavily concentrated in early fractions E1-E4. These fractions were 
combined and concentrated by filtration using a YM-10 and dialyzed against Dialysis 
Buffer IV (50 mM Tris•HCl, 2 mM EDTA, 1 mM DTT with 10% glycerol, pH 7.5). 
Protein was flash frozen in liquid N2 and stored at -80 ºC until use.  
 
2.2.4.6 KIJD11  (5-EPIMERASE) 
This gene was amplified by PCR from a cosmid library constructed from A. 
kijaniata using the primers (upstream 5′-AGGACATGCATATGAGCGGTATCGA-
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GATCG-3′) and (downstream 5′-GGTGTCGCGGAAGCTTCCGCCCGGCTCAGA-3′). 
The PCR fragment was purified by gel extraction (Qiagen) and ligated into the vector 
pANT841. This construct was subsequently digested with NdeI and HindIII and the 
fragment ligated into pET28a to create a protein expression construct with an N-terminal 
His6 tag. The construct was isolated from E. coli DH5α using the Qiagen miniprep kit, 
and submitted for DNA sequencing to confirm the correct gene sequence. 
 STEP 1: GROWTH OF E. COLI CELLS. This construct was use to transform E. coli 
Bl21(DE3) pLysS cells which were subsequently grown in 10 mL LB media 
supplemented with 50 µg/mL kanamycin and 35 µg/mL chloramphenicol at 37 ºC with 
250 RPM shaking. The cultures were transferred to 6 L of fresh LB media supplemented 
with both 50 µg/mL kanamycin and 35 µg/mL chloramphenicol and incubated at 37 ºC 
with 250 RPM shaking until the OD600 reached 0.5-0.6. The temperature was reduced to 
14 ºC and protein expression was induced with the addition of 1 mM IPTG. Cells were 
incubated for an additional 20 h. Cells were harvested by centrifugation for 15 min at 
4,500 g and frozen overnight at -80 ºC.  
STEP 2: CRUDE EXTRACT PREPARATION. The cells were resuspended in Lysis buffer 
II, using 2 mL buffer per gram cell wet weight, to which 1 mg/mL lysozyme was added. 
This mixture was allowed to incubate on ice for 1 h, stirring every 15 min. Cells were 
disrupted by sonication using 5 × 20 s pulses, with 40 s cooling intervals between bursts. 
Crude protein extracts were obtained by centrifugation at 10,000 g at 4 ºC for 20 min.  
STEP 3: NI-NTA CHROMATOGRAPHY. Protein was purified by Ni
2+
 affinity 
chromatography following manufacturer‟s instructions with 10% glycerol in all buffers. 
Briefly, 5 mL of resin was prepared by washing with Lysis buffer II and allowed to bind 
with soluble protein at 4 ºC for 1 h, then loaded onto a 2 × 25 cm column. The column 
was packed by gravity flow and washed with 5 CV of Lysis buffer II followed by two 
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washes with 10 CV of Wash buffer II. KijD11 protein was eluted with 15 mL of Elution 
buffer I and collected in 1.5 mL fractions, with KijD11 most heavily concentrated in 
fractions E1-E5. These fractions were collected and concentrated by filtration using a 
YM-10 and dialyzed against Dialysis Buffer II (50 mM NaH2PO4, 300 mM NaCl, 15% 
Glycerol pH 8.0) Protein was flash frozen in liquid N2 and stored at -80 ºC until use.  
 
2.2.4.7 KIJC2  (4-KETOREDUCTASE) 
This gene was amplified by PCR from a cosmid library constructed from A. 
kijaniata using the primers (upstream 5′-AGGACATGCATATGAGCGGTATCGA-
GATCG-3′) and (downstream 5′-GGTGTCGCGGAAGCTTCCGCCCGGCTCAGA-3′). 
The PCR product was subsequently purified by using the Qiagen gel extraction kit, 
digested with NdeI and HindIII and ligated into the corresponding sites of the vector 
pET28a to create a protein expression construct with an N-terminal His6 tag. The 
construct was isolated from E. coli DH5α using the Qiagen miniprep kit, and submitted 
for DNA sequencing to confirm the correct gene sequence. 
STEP 1: GROWTH OF E. COLI CELLS. This construct was used to transform E. coli 
BL21 Rosetta II DE3 (Novagen) cells by heat shock and grown in 10 mL LB media 
supplemented with 50 µg/mL kanamycin and 35 µg/mL chloramphenicol at 30 ºC with 
250 RPM shaking. After overnight incubation, 3 mL of culture (per L) was transferred to 
6 L of fresh LB media supplemented with 50 µg/mL kanamycin and 35 µg/mL 
chloramphenicol, and incubated at 30 ºC with 250 RPM shaking for 24 h. Cells were 
harvested by centrifugation for 15 min at 4,500 g and frozen overnight at -80 ºC.  
STEP 2: CRUDE EXTRACT PREPARATION. The cells were resuspended in 2 mL Lysis 
buffer IV (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, 1 mM DTT with 10% 
 124 
glycerol, pH 8.0) per gram cell wet weight, to which 1 mg/mL lysozyme was added. This 
mixture was allowed to incubate on ice for 1 h, stirring every 15 min. Cells were 
disrupted by sonication using 8 × 45 s pulses, with 1 min cooling intervals between 
bursts. Crude protein extracts were obtained by centrifugation at 10,000 g at 4 ºC for 20 
min. 
STEP 3: NI-NTA CHROMATOGRAPHY. Protein was purified by Ni
2+
 affinity 
chromatography following manufacturer‟s instructions with 10% glycerol in Lysis and 
Wash buffers, and 15% glycerol in Elution buffer. 1 mM dithiothreitol (DTT) was 
included in all buffers. Briefly, 6 mL of resin was prepared by washing with Lysis buffer 
IV (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 1 mM DTT, 10% glycerol, pH 
8.0) and allowed to bind with soluble protein at 4 ºC for 2 h, then loaded onto a 2 × 25 
cm column. The column was packed by gravity flow and washed with 5 CV of Lysis 
buffer followed by two washes with 10 CV of Wash buffer IV (50 mM NaH2PO4, 300 
mM NaCl, 20 mM imidazole, 1 mM DTT, 10% glycerol, pH 8.0). KijC2 protein was 
eluted with 15 mL of Elution buffer IV (50 mM NaH2PO4, 300 mM NaCl, 250 mM 
imidazole, 1 mM DTT, 20% glycerol, pH 8.0) and collected in 1.5 mL fractions, with 
KijC2 most heavily concentrated in fractions E4-E7. These fractions were collected and 
concentrated by filtration using a YM-10 and dialyzed against Dialysis Buffer IV (50 
mM NaH2PO4, 300 mM NaCl, 20% glycerol, 1 mM DTT, pH 8.0). Protein was flash 
frozen in liquid N2 and stored at -80 ºC until use.  
 
2.2.5 TDP-L-DIGITOXOSE BIOSYNTHESIS 
 
 125 
2.2.5.1 Enzymatic Synthesis of TDP-D-glucose (2) 
TDP-α-D-glucose was prepared from thymidine and glucose-1-phosphate (1) in a 
two-stage, one-pot reaction.
280
 A reaction mixture containing 76.2 mM 
phosphoenolpyruvate (PEP), 24 mM thymidine, 1.6 mM ATP, 27 mM MgCl2, 25 µM 
thymidine kinase (TK), 25 µM thymidylate kinase (TMK), 25 µM nucleoside 
diphosphate kinase (NDK), and 1000 units of rabbit muscle pyruvate kinase (PK) in 17 
mL of 45 mM Tris•HCl buffer, pH 7.5, was incubated at 37 °C for 4 h, generating 
thymidine triphosphate (TTP).  The enzymes were removed by filtration through an 
Amicon YM-10 membrane at 4 ºC, and glucose-1-phospate (4), MgCl2, and α-D-glucose-
1-phosphate thymidylyltransferase (RfbA) from S. enterica LT2 were added to the filtrate 
to give final concentrations of 28 mM, 50 mM, and 36 µM, respectively.  The mixture 
was incubated for 16 h at 37 °C, centrifuged at 5,000 g for 10 min at 4 ºC to remove 
precipitate, and filtered through an Amicon YM-10 membrane at 4 ºC to remove 
enzymes.  The crude product (5, with a theoretical yield of 228 mg), was stored at 4 °C.   
 
 
2.2.5.2 Purification of TDP-D-glucose (5) by Bio-Gel P2 Chromatography 
 The enzyme-free filtrate from the previous step was loaded onto a Bio-gel P2 
column (25 mm  100 cm) pre-washed with water, and run at a flow rate of 12 mL/h with 
water as the eluent, collecting 8 mL fractions.  Fractions displaying UV absorption at 267 
nm were lyophilized, and the identity and purity of the compounds in each fraction 
analyzed by HPLC using the analytical program and conditions detailed below.  TDP-D-
glucose (5) containing fractions (total weight 170 mg) varied in purity from 25-70%, 
were pooled according to their purities.  
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2.2.5.3 Enzymatic Conversion of TDP-D-glucose (5) to TDP-4-keto-6-deoxy-D-
glucose (6)   
TDP-D-glucose (5, 25 mg) obtained from the previous step was dissolved in 50 
mM Tris buffer, pH 7.5 to give a final concentration of 23 mM. This solution was 
incubated with the 4,6-dehydrase RfbB from S. enterica LT2 (18 µM) at 37 °C for 2 h, or 
for 3-4 hour at 30 ºC, after which RfbB was removed by filtration through an Amicon 
YM-10 membrane at 4 ºC.  A total of 23.75 mg of TDP-4-keto-6-deoxy-D-glucose (6), 
which was greater than 90% pure, was obtained.  The concentration of 6 was determined 
spectrophotometrically at 267 nm, where the molar extinction coefficient (ε) of 6 is 9600 
M
-1
cm
-1
.   
 
2.2.5.4 Enzymatic Conversion of TDP-4-keto-6-deoxy-D-glucose (6) to TDP-4-keto-
2,6-dideoxy-D-glucose (8)   
TDP-4-keto-6-deoxy-D-glucose (6) 23.75 mg, obtained from the previous step 
was collected and added to a mixture containing 160 nM TylX3 (KijB1 substitute), 360 
nM KijD10, 1.2 M substrate equivalents (~51 mg) NADPH, 10% glycerol in 50 mM Tris 
buffer, pH 7.5 for a final reaction volume of 3 mL. This reaction was allowed to incubate 
at room temperature (25 ºC) for 8-12 h. The progress of the reaction was monitored by 
HPLC using the analytical program and conditions detailed below. When the reaction 
was observed to have come to completion, the enzymes were removed by filtration 
through an Amicon YM-10 membrane at 4 ºC. Approximately 20 mg of TDP-4-keto-2,6-
dideoxy-D-glucose (8) was obtained. 
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2.2.5.5 Purification of TDP-4-keto-2,6-deoxy-D-glucose (8) by Bio-Gel (P2) 
Chromatography 
The enzyme-free filtrate from the previous step was loaded onto a Bio-Gel P2 
column (25 mm  100 cm) pre-washed with water, and run at a flow rate of 12 mL/h with 
25 mM NH4HCO3 at ambient pH as the eluent, collecting 8 mL fractions.  Fractions 
observed to have UV absorption at 267 nm were lyophilized to near dryness, and the 
identity and purity of the compounds in each fraction assessed by HPLC using the 
analytical program and conditions detailed below. TDP-4-keto-2,6-dideoxy-D-glucose 
(8) containing fractions generally eluted after 22-24 h with the compound of interest in 2-
3 fractions only. Generally, the two later fractions were of very high purity (> 90%) and 
one early fraction was often contaminated with NADP
+
, a byproduct of the reduction 
reaction. Overall recovery of product (8) varied from 10 to 15 mg. The two high-purity, 
high-concentration fractions were combined and lyophilized to near dryness (generally to 
< 1 mL total volume). NMR spectra: 
1
H NMR (300 MHz, D2O): (a mixture of hydrate 
and keto forms): δ 1.10 (3H, d, J = 6.4, 5-Me of the hydrate form), 1.18 (3H, d, J = 6.4, 
5-Me of the keto form), 1.72-1.78 (1H, m, 2-Hax), 1.82 (3H, s, 5′′-Me), 2.05 (1H, m, 2-
Heq), 2.20-2.30 (2H, m, 2′-H), 3.91 (1H, dd, J = 12.9, 5.9, 3-H), 3.94 (1H, q, J = 6.4, 5-
H), 4.06 (3H, m, 4′-H, 5′-H), 4.51 (1H, m, 3′-H), 5.50 (1H, dd J = 6.6, 4.0, 1-H), 6.24 (1-
H, t, J = 6.9, 1′-H), 7.64 (1H, s, 6′′-H). 31P NMR (121 MHz, D2O): δ -10.6 (d, J = 19.7), -
12.6 (d, J = 19.7). High resolution ESI-MS of 8, calculated for C16H25N2O15P2 (M-H)- 
547.0725, found 547.0691.   
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2.2.5.6 Enzymatic Conversion of TDP-4-keto-2,6-dideoxy-D-glucose (8) to TDP-L-
Digitoxose (10)   
The concentration of the product of the previous step, TDP-4-keto-2,6-dideoxy-
D-glucose (8), was determined spectrophotometrically at 267 nm, where the molar 
extinction coefficient (ε) of TDP is 9600 M-1cm-1. Product (8) was added to a mixture 
containing 100 nM KijD11, 10 µM KijC2, 1.4 M substrate equivalents NADH, 10% 
glycerol and 10 mM MgCl2 in 50 mM Tris buffer, pH 7.5 with the final reaction volume 
adjusted to bring the concentration of 8 to 1 mM. The mixture was divided into 200 µL 
aliquots and allowed to incubate at room temperature (25 ºC) for 12-18 h with gentle 
agitation. The progress of the reaction was monitored by HPLC using the analytical 
program and conditions detailed below. When the reaction was observed to have come to 
completion, the enzymes were removed by filtration through an Amicon YM-10 
membrane at 4 ºC. Approximately 0.1 mg of product TDP-L-digitoxose (10) was 
obtained for every mg TDP-4-keto-2,6-dideoxy-D-glucose (8) substrate used. 
 
2.2.5.7 Purification of TDP-L-Digitoxose (10) using FPLC and Bio-Gel (P2) 
column chromatography   
The enzyme-free filtrate from the previous step was purified using a Fast-Protein 
Liquid Chromatography (FPLC). All FPLC analysis was performed using a Mono Q 
16/10 column with 500 µL of sample for each injection.  The sample was eluted by a 
gradient of water as solvent A and 250 mM NH4HCO3 as solvent B where the gradient 
ran from 0 to 40% B over 5 min, held at 40% for 5 min, running from 40 to 100% B over 
20 min, 60 to 100% B over 2 min, 10 min wash at 100% B, 100 to 5% B over 5 min, and 
reequilibration at 5% B for 15 min.  The flow rate was 4 mL/min and fractions were 
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collected beginning at 50% B.  TDP-L-digitoxose eluted at 55-60% B and fractions were 
immediately flash frozen in liquid nitrogen and stored at -80 ºC.  
Fractions that appeared to contain the compound of interest (10) were analyzed by 
HPLC using the analytical program detailed below, to verify the presence of TDP-L-
digitoxose (10).  The fractions containing 10 were stored at -80 ºC and thawed gently at 4 
ºC. The compound was desalted using a Bio-Gel (P2) column (1 × 12 cm) with the flow 
rate set at 5 mL/min with water as the eluent, collecting 8 mL fractions. Fractions 
collected from this column were spectrophotometrically analyzed at 267 nm to detect the 
presence of TDP. Fractions showing UV absorption at 267 nm were flash frozen in liquid 
N2 and stored at -80 ºC until concentration by lyophilization. Samples (20 µL) of each 
eluate fraction showing UV absorbance at 267 were analyzed by HPLC to determine the 
identity and purity of the compounds in each fraction. The resulting product was 
concentrated by lyophilization and re-purified to remove any remaining salt or glycerol 
by HPLC using a C-18 column (Varian), monitoring at 267 nm, with a flow rate of 1 
mL/min, using water as the eluent.  Low resolution CI-MS of 10, calculated for 
C16H26N2O14P2 (M + H) 532, found 532.  Low resolution ESI of 10, calculated for 
C16H26N2O14P2 (M - 2H) 530, found 265.  Attempts to obtain high resolution MS data 
(FAB, CI, ESI) and 
1
H NMR spectrum were unsuccessful. 
 
2.2.5.8 TDP-L-Digitoxose Acetylation 
Following the procedure reported by Blakeney et al. and previously used in our 
research group as shown in scheme 2.6, compound 10 (approx. 0.5 mg, 90 µmol, 1 eq) 
was acidified with concentrated HCl (approx. 200 µL) to pH 2 and was boiled for 10 min. 
281, 282
 This mixture was neutralized with 12 M potassium hydroxide (KOH) ( pH 7 as 
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judged by pH paper) and lyophilized to dryness. The mixture was redissolved in 0.5 M 
NH4OH (approx. 0.6 mL), which was subsequently mixed with 1 mL dry dimethyl 
formamide (DMF). DMF was dried by pouring over hot 4Å mol sieves. To this was 
added NaBH4 (21 mg, 555 µmol, 6.2 eq). The reaction was stirred at 40 ºC for 90 min 
and quenched with 100 µL of glacial acetic acid (at room temp, ~21 ºC). 1-Methyl-
imidazole (200 µg, 2 µmol, 0.02 eq) and 6 mL of freshly distilled acetic anhydride were 
added to the mixture (at room temperature, 21 ºC) and the reaction was allowed to stir at 
room temperature (21 ºC) for just over 1 h. The reaction was quenched with 5 mL cold 
methanol. The resulting crude reaction mixture was partitioned between water and 
chloroform, and the aqueous layer was extracted with chloroform (2 × 30 mL). Combined 
organic layers were washed with water (2 × 10 mL) and dried (Na2SO4), and 
concentrated. The resulting sample was subjected to GC/MS. Low-resolution GC/EI-MS 
of 12: 318 (the parent peak), 231 (C1-C4 and C3-C6 fragments), 245 (C2-C6 fragment). 
 
 
2.6 Acetylation of TDP-L-digitoxose 
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2.2.5.9 Characterization of the Degradation Product (2S,3S)-2-methyl-3-hydroxy-4-
keto-2,3-dihydropyran (9a) by 
1
H NMR  
To verify the activity of KijD11, a time course assay was conducted and 
monitored by in situ NMR spectroscopy. The protein was prepared by dialyzing a fresh 
preparation of KijD11 against 6 L (12 × 500 mL) of dialysis buffer IIb (50 mM 
NaH2PO4, 300 mM NaCl, pH 8) without glycerol at 4 ºC, exchanging the buffer every 30 
min, and allowing the last exchange to incubate overnight at 4 ºC. After dialysis, the 
protein was removed from the dialysis tubing and centrifuged for 20 min at 10,000 g (4 
ºC) to remove any precipitate. The protein was quantified following the method of 
Bradford.
272
 Compound (8) TDP-4-keto-2,6-dideoxy-D-glucose of high purity was 
lyophilized, and redissolved with 100 µL D2O and an appropriate amount of 50 mM 
potassium phosphate buffer (pH 7.5) to achieve a final concentration of 10 mM in 600 µL 
in an NMR tube. The initial spectrum was acquired, and a special program was applied to 
reduce the water peak.  The tube was then removed and 5 µL of KijD11 was added to a 
final enzyme concentration of 10 nM. The assay was monitored for 3 h with time points 
taken every 5 min throughout this experiment, using the initial reading (prior to enzyme 
addition) as time point 0 (see figure 2.9). At the completion of the reaction, a NOSY 
NMR was also performed. Product (8) 
1
H NMR (500 MHz, D2O): δ 1.33 (3H, d, J = 6.4, 
5-Me), 1.68-1.76 (1H, m, 2-Hax), 1.82 (3H, d, J = 4, 5′′-Me), 2.20-2.30 (2H, m, 2′-H), 
2.24-2.30 (1H, m, 2-Heq), 3.55-3.60 (1H, m, 5-H), 3.86-3.96 (1H, m, 3-H), 4.06 (3H, m, 
4′-H, 5′-H), 5.18 (1H, m, 1-H), (1-H, t, J = 6.8, 1′-H), 7.64 (1H, s, 6′′-H). Degradation 
product (9a) 
1
H NMR (500 MHz, D2O) δ 1.41 (3H, d, J = 6.9, 2-Me), 4.12 (1H, d, J= 
12.4, 3-H), 4.26-4.34 (1H, m, 2-H), 5.37 (1H, d, J = 5.8, 5-H), 7.46 (1H, d, J = 5.8, 6-H).   
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2.2.5.10 Analytical HPLC Program and Conditions 
All HPLC analysis was performed using an analytical Dionex Carbopac PA1 (4 
cm × 250 cm) column, equipped with a guard column (4 cm × 50 cm) with 20 µL of 
sample for each injection.  The sample was eluted by a gradient of water as solvent A and 
500 mM NH4OAc (adjusted to pH 7.0 with aqueous NH3) as solvent B; where the 
gradient ran from 5 to 20% B over 15 min, then 20 to 60% B over 20 min, 60 to 100% B 
over 2 min, 3 min wash at 100% B, 100-5% B over 5 min, and re-equilibration at 5% B 
for 15 min.  The flow rate was 1 mL/min, and the detector was set at 267 nm to observe 
TDP. 
 
2.3 RESULTS AND DISCUSSION 
To reconstruct the TDP-L-digitoxose pathway in vitro, the enzymes proposed to 
be involved in the biosynthetic pathway were cloned and heterologously expressed in E. 
coli. The proteins were purified and used in the subsequent biosynthetic assays.  
 
2.3.1 PROTEIN PURIFICATION 
A total of 9 enzymes were purified from E. coli as His6-tagged proteins using Ni-
NTA chromatography. Native E. coli TDP biosynthetic enzymes thymidine kinase (TK), 
thymidylate kinase (TMK), and nucleotide diphosphate kinase (NDK) were purified 
together, thus specific purification data for each enzyme is unavailable.  After 
purification, the thymidylyltransferase RfbA protein concentration was determined to be 
45.7 mg/mL or 1.404 mM.  RfbA has a molar extinction coefficient (ε) of 30,820 M-1cm-1 
at A280 and a molecular mass of 32.6 kDa.  The approximate amount of RfbA purified by 
this protein procedure was 140 mg; or 23 mg of RfbA per L of LB Broth. The protein 
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concentration of purifed 4,6-dehydratase RfbB concentration was determined to be 80 
mg/mL or 1.93 mM.  RfbB has a molar extinction coefficient (ε) of 65,790 M-1cm-1 at 
A280 and a molecular mass of 41.6 kDa.  The approximate amount of RfbB purified by 
this protein procedure was 480 mg; or 80 mg of RfbB per L of LB Broth. The KijB1 
homolog, TylX3 was originally purified by Dr. H. Chen. The protein concentration 
following Dr. Chen‟s method was determined to be 4 mg/mL or 76 µM.  TylX3 has a 
molar extinction coefficient (ε) of 60,650 M-1cm-1 at A280 and a molecular mass of 52.4 
kDa. The approximate amount of TylX3 purified by this protein procedure was 60 mg; or 
10 mg of TylX3 per L of LB Broth. The putative 3-ketoreductase, KijD10 protein 
concentration was determined to be 5.4 mg/mL or 145 µM using our purification 
methods.  KijD10 has a molar extinction coefficient (ε) of 38,810 M-1cm-1 at A280 and a 
molecular mass of 37.1 kDa.  The approximate amount of KijD10 purified by this protein 
prep was 54 mg; or 9 mg of KijD10 per L of LB Broth. The putative 5-epimerase, 
KijD11, protein concentration was determined to be 35 mg/mL or 1.6 mM.  KijD11 has a 
molar extinction coefficient (ε) of 19,420 M-1cm-1 at A280 and a molecular mass of 19.4 
kDa.  The approximate amount of KijD11 purified by this protein prep was 70 mg; or 12 
mg of KijD11 per L of LB Broth. The final protein, KijC2 was purified to a concentration 
of 28.6 mg/mL or 820 µM.  The putative 4-ketoreductase KijC2 has a molar extinction 
coefficient (ε) of 32,530 M-1cm-1 at A280 and a molecular mass of 34.9 kDa, but is 
observed as a dimer of ~ 70 kDa.  The approximate amount of KijC2 purified by this 
protein prep was 42 mg; or 7 mg of KijC2 per L of LB Broth. Proteins KijB1, KijD10, 
KijD11 and KijC2 are shown below in figure 2.5. 
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2.5 TDP-L-digitoxose Biosynthetic Proteins 
 
 
 
 
 
 
 
 
 
 
 
2.3.2 GENERATION OF TDP-L-DIGITOXOSE 
The first three steps of the biosynthetic pathway of 6-deoxyhexoses have been 
characterized by multiple research groups and therefore there was no pressing need to 
study the first three enzymes of the TDP-L-digitoxose biosynthetic pathway (KijD5, 
KijD4 and KijB1).
283, 284
    For simplicity, we utilized previously characterized enzymes 
from the rhamnose and mycarose pathways in this work. The gene expression and 
solubility of these protein products are known, and the purification methodology had 
previously been developed in our research group. The focus here is on the latter steps of 
the biosynthetic pathway (8-9), as the earlier steps (4-7) have been established during 
studies of previously elucidated pathways. 
285,
 
286,
 
287
 
Native E. coli TDP biosynthetic enzymes thymidine kinase (TK), thymidylate 
kinase (TMK), and nucleotide diphosphate kinase (NDK) were expressed as His6 tagged 
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proteins and used to generate thymidine diphosphate (TDP) from thymidine and ATP in 
situ as shown below in Figure 2.6. 
 
2.6 Biosynthesis of TTP from ATP using TK, TMK and NDK 
 
 
The RfbA protein, a well-characterized protein from the native E. coli rhamnose 
pathway was used instead of the KijD5 protein to couple α-D-glucose-1-phosphate (4) to 
the TDP moiety in situ to generate TDP-α-D-glucose (5) as shown in Scheme 2.7. The 
sugar (5) was purified by size exclusion chromatography to remove unreacted starting 
material (TTP and α-D-glucose-1-phosphate) and other co-substrates used in the reaction 
(pyruvate, ADP, phosphoenolpyruvate). The purity of the product was assessed by 
analytical HPLC. Under the gradient conditions used, the product eluted at 34 min. 
Impurities such as thymidine monophosphate (TMP) and thymidine diphosphate (TDP), 
had HPLC retention times of 25 min and 43 min, respectively. 
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2.7 Biosynthesis of TDP-α-D-glucose from α-D-glucose-1-phosphate (4) and 
TTP 
 
 
 
 
 
At this stage of purification, it is necessary to remove thymidine monophosphate 
(TMP) and thymidine diphosphate (TDP) because previous research had shown that TDP 
is a competitive inhibitor of enzymes involved in the subsequent biosynthetic assays.
288
 
On a more practical note, TDP is used as the chromophore for our spectrophotometric 
quantitation, thus excess TDP skews the concentration calculations.  
 
2.8 Early Reactions in the TDP-L-digitoxose pathway  
With starting material (5) in hand, we chose to employ the RfbB protein, a well-
characterized 4,6-dehydratase from the E. coli rhamnose pathway for the next conversion 
step in lieu of the native KijD4 protein. The RfbB protein has been used previously with 
great success to generate TDP-4-keto-6-deoxy-α-D-glucose (6) from TDP-α-D-glucose 
(5).  This biosynthetic step has been well characterized by multiple research groups and is 
the last common intermediate in many sugar biosynthetic pathways.
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substrate (5) was incubated with enzyme for 3 h at 30 ºC, and the conversion to (6) was > 
95% complete as assessed by analytical HPLC. A new product peak appeared during the 
HPLC elution at 33 min, with concomitant decrease of the substrate peak at 34 min. 
 
2.7 Overlaid HPLC Traces showing TDP-α-D-glucose (5), TDP-4-keto-6-
deoxy-α-D-glucose (6), and TDP-4-keto-2,6-dideoxy-α-D-glucose (8) 
 
 
 
 
 
 
 
 
 
 
 
 
As shown in Scheme 2.9, the KijB1 analog, TylX3, a 2,3-dehydratase from the 
mycarose biosynthetic pathway of S. fradiae was incubated with TDP-4-keto-6-deoxy-α-
D-glucose (6) to generate TDP-3,4-diketo-2,6-dideoxy-α-D-glucose (7). The product of 
this reaction is unstable and has been shown to degrade rapidly to maltol (7a) at room 
temperature, which is a mild condition compared to the 30 ºC environment encountered 
in antibiotic producing strains of Streptomyces.  Thus, a coupled assay to generate a more 
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stable product was carried out with the addition of KijD10 (3-ketoreductase) and NADPH 
to generate the stable intermediate TDP-4-keto-2,6-dideoxy-α-D-glucose (8). 286 
 
2.9 TDP-4-keto-6-deoxy-α-D-glucose (6), conversion to TDP-4-keto-2,6-
dideoxy-α-D-glucose (8) 
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If, as we predict, KijD10 is responsible for the 3-ketoreduction step, we expect to 
see a NADP
+
 peak appears in the HPLC trace and increases over time with concomitant 
increase of a new product peak. We also expect to see a product peak with a retention 
time of 32 min, as observed for the authentic standard, an intermediate generated in the 
spinosyn biosynthetic pathway. 
287
 
To drive the reaction forward, 4 equivalents of KijD10 were added to the reaction 
for every equivalent of TylX3 protein. The reaction was incubated at room temperature to 
prevent excess degradation of the unstable TylX3 intermediate (6) for 3-6 h or until the 
reaction reached >95% completion. This produced a new, more stable product (8), as 
demonstrated by a new HPLC peak with a retention time of 32 min as expected, while the 
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substrate peak (retention time 33 min) decreased in size.(Figure 2.8) These results are in 
agreement with reported HPLC retention time for TDP-4-keto-2,6-dideoxy-D-glucose.
287
 
 
2.8 Conversion of TDP-4-keto-6-deoxy-α-D-glucose (6), to TDP-4-keto-2,6-
dideoxy-α-D-glucose (8) 
 
Incubation mixture containing 10 mM TDP-4-keto-6-deoxy-α-D-glucose (6), 160 nM 
TylX3, 360 nM KijD10, 1.2 mM NADPH in 50 mM Tris•HCl, pH 7.5, 10% glycerol 
after 0 h, 3 h, and 6 h, respectively showing time dependent formation of 8 with 
concomitant decrease of 6. 
 
The KijD10 product was characterized by 
1
H NMR and 
31
P NMR, and found to 
be identical to the previously characterized TDP-4-keto-2,6-dideoxy-α-D-glucose 
generated in the study of the spinosyn pathway from Saccharopolyspora spinosa.
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should be noted that as the KijD10 enzyme is subjected to multiple freeze-thaw cycles, 
the efficiency of conversion drops from >95% in 3 h to 85% over 12 h.  
The product (8) was purified and subsequently incubated with KijD11, the 
putative 5-epimerase at room temperature. A new HPLC peak (9) with a retention time of 
35 min appeared and increased over time, while the substrate peak showed concurrent 
decrease. As the reaction progressed, another peak appeared with the retention time of 
approximately 2 min as the 35 min product peak (9) began to decrease. This reaction was 
repeated for in situ 
1
H-NMR analysis, which showed the production of two compounds; a  
predicted product  (9) and a compound appearing to result from degradation of 9 (9b, 
Figure 2.10). It is likely that the epimerized product, TDP-4-keto-2,6-dideoxy-L-allose 
(9), degrades to a pyran ring and TDP. (See Figure 2.10) 
The structure of the degradation product cannot be fully assigned from this NMR 
spectrum due to the complexity of the reaction mixture. Those signals corresponding to 
the KijD11 product, TDP-4-keto-2,6-dideoxy-L-allose (9), reached maximum intensity at 
~20 min and then diminished.
289
 A third set of signals corresponding to the degradation 
product appeared after a short lag. The 
1
H-NMR and COSY spectra taken at the end of 
reaction allowed the verification of (2S, 3S)-2-methyl-3-hydroxy-4-keto-2,3-
dihydropyran as the degradation product.
290
 As demonstrated by HPLC analysis and 
NMR in situ assay, degradation of the intermediate (9) begins shortly after the reaction 
commences, therefore to generate the desired product a coupled assay was performed. 
Due to the apparent instability of the intermediate, the KijD11 and KijC2 proteins were 
incubated with the TDP-4-keto-2,6-dideoxy-α-D-glucose substrate. A new peak with a 
retention time of 34 min appeared in the HPLC trace (10). (See figure 2.11)  
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2.9 1H NMR Time Course Analysis of the KijD11 Reaction 
TDP-L-digitoxose is a highly unstable compound and degrades during its 
biosynthesis. Attempts at purification using methods normally applied to these sugars, 
such as size exclusion chromatography using Bio-Gel P2 resin failed. When the TDP-L-
digitoxose was applied to the column, absorption profile of the elution fractions indicated 
1
H NMR stack plot of the KijD11 reaction [10 mM (5) and 10 µM KijD11 in 50 mM 
KH2PO4 buffer (pH 7.5)] monitored over 180 min. The signals corresponding to each 
compound are labeled: (O) from 8,(●) from 9, and (□) from 9a (see Experimental 
Procedures for details). 
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that the expected product had degraded to an uncharacterized product, most likely a pyran 
ring. 
 
2.10 Proposed Conversion of TDP-4-keto-2,6-dideoxy-L-allose (9) to a Pyran 
Ring Product (9a) and TDP 
 
Our only option to purify the compound was therefore to employ FPLC using ion 
exchange chromatography, however the high salt concentrations also proved to be 
problematic for the stability of the product, as concentration in the presence of 
bicarbonate appeared to cause additional degradation of the product. Thus, we 
concentrated the sugar to a small volume and applied it to a very short P2 column in 
order to remove as much of the bicarbonate buffer as possible. 
The fractions found to contain the sugar were additionally desalted using isocratic 
elution using an HPLC equipped with a C-18 column, with water as the eluting solvent. 
This step also served to remove remaining glycerol and dithiothreitol in the sample in 
preparation for NMR analysis. 
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2.11 Analytical HPLC Traces of TDP-L-digitoxose (10) Conversion from TDP-
4-keto-2,6-dideoxy-α-D-glucose (8) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The fractions containing sugar were lyophilized again and stored at -80 ºC. 
Unfortunately, the sugar was not stable enough to characterize using NMR, and our 
attempts at high resolution mass spectrometry failed due to the instability of the TDP-
sugar. We were able to obtain low resolution mass spectrometry results using ESI-MS 
and CI (negative mode). The calculated mass for the expected product, TDP-L-
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digitoxose, is 532 and the found mass was in CI was 532, and the found mass was 265 in 
ESI-MS, which corresponds to the -2 charge state. Because the product is too unstable to 
be characterized by NMR, we decided to generate the TDP-sugar, and obtain enough 
material for chemical acetylation in order to characterize the product.  
 
2.12 GC-MS of TDP-L-Digitoxose Acetylation Products 
A large-scale synthesis was carried out from 5 mg of compound (8) following the 
method presented earlier in this chapter. After the synthesis, the product (10) was purified 
using FPLC only, and fractions were combined and subjected to acid hydrolysis 
following the procedure reported by Blakeney et al and previously used in our research 
group. 
281, 282
 After the TDP-moiety was removed from the TDP-L-digitoxose (10), the 
resulting compound, (11) was dried and reduced with sodium borohydride, followed by 
peracetylation using 1-methyl-imidazole and acetic anhydride. The final product, 
tetraacetyldigitoxose (12) was analyzed and allowed us to confirm that these gene 
products together produce TDP-L-digitoxose. 
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2.4 CONCLUSIONS 
Herein, we report the results of our investigations of the function of the genes of 
the TDP-L-digitoxose biosynthetic pathway. We have confirmed the assignments of the 
genes as follows: KijB1 encodes a 2,3-dehydratase, KijD10 encodes the 3-ketoreductase, 
KijD11 encodes a 5-epimerase, and KijC2 encodes the 4-ketoreductase. (See schemes 2.9 
and 2.10) Previously, in vitro assays for testing the activity of the glycosyltransferases 
have been hampered by the unavailability of TDP-L-digitoxose. Our success in 
reconstructing the deoxysugar pathway allows further investigation into the role and 
specificity of each of the glycosyltransferases that build the digitoxose tetrasaccharide 
chain of kijanimicin. We have now identified the genes necessary to generate TDP-L-
digitoxose in vivo and in vitro, thus this portion of the research allows us to investigate 
the activity of the kijanimicin glycosyltransferases that were identified through gene 
cluster sequencing.  
There are no glycosyltransferases known to date that can accept kijanolide as a 
substrate, which provides a new aglycone scaffold for combinatorial biosynthesis, thus 
with the elucidation of this pathway, we have not only confirmed the identity of the 
kijanimicin biosynthetic gene cluster, but we are now also able to investigate the activity 
of these novel glycosyltransferases in the kijanimicin gene cluster. To harness the full 
potential of the combinatorial approach for therapeutic purposes, a glycosyltransferase 
“gene toolbox” must be generated, which should include glycosyltransferases that 
recognize different, structurally diverse antibiotic aglycones.
291
 As reported in a later 
chapter, our research expands this toolbox, by providing four novel glycosyltransferases 
for use in combinatorial biosynthesis that may demonstrate interesting and unique 
substrate flexibility or glycosylation activity. 
, 
 146 
3 Chapter 3:  Prokaryotic Glycosylation Reactions: Reconstruction of 
the Glycosylation Reactions of Kijanimicin Biosynthesis   
 
3.1 INTRODUCTION 
It has been argued that glycosyltransfer reactions are, on quantitative terms, the 
most important biological transformations in Nature, since they account for the 
biosynthesis and hydrolysis of the bulk of biomass.
3
 As a logical extension, one may also 
argue that the most important enzymes are those that are involved in glycosylation 
reactions, including unusual sugar biosynthesis, glycosyltransferases which catalyze the 
transfer of sugar moieties from activated sugar donor molecules to specific acceptor 
molecules to form glycosidic bonds, and glycosidases, which catalyze the removal of 
sugar moieties from glycosylated acceptor molecules. Notably, the biosynthesis of 
disaccharides, oligosaccharides and polysaccharides involves the action of literally 
hundreds of different glycosyltransferases.
4
 The importance of glycosylation to natural 
product biosynthesis is no exception to this argument, and in fact may serve to 
demonstrate the importance of glycosylation as the bioactivity of many natural products 
including clinically important antibiotics and anticancer therapeutics depends on their 
sugar moieties. 
292
 
 The investigation of kijanimicin (1) glycosylation is particularly interesting, due 
to the presence of a branched-chain tetrasaccharide moiety consisting of three units of 
2,6-dideoxy-α-L-hexopyranose (digitoxose) and one unit of 2,6-dideoxy-4-O-methyl-β-
L-hexopyranose (digitoxose) (2), as well as the novel amino sugar kijanose (3) as shown 
in Figure 3.1.
246
 Ubiquitous in nature, 2,6-dideoxysugars such as digitoxose are 
especially abundant in bacterial secondary metabolites, including macrolide, polyene, 
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enediyine, pregnane and aminoglycoside antibiotics, while kijanose is quite rare.
241
 This 
nitro sugar had been found in only a few spirotetronate antibiotics, such as kijanimicin 
(1), lobophorin B, tetrocarcins, and arisostatin A. 
68, 249, 293-295
  The unusual nitrosugar D-
kijanose (3), whose biosynthesis likely involves new chemistry, is still under 
investigation by multiple research groups.
68
 A survey of known spirotetronate natural 
product structures shows diverse glycosylation patterns, particularly in the 
oligosaccharide chain attached to the C-9 position. The structure of the oligosaccharide 
chain at the C-9 position of tetrocarcin has been shown to be an important modulator of 
its Bcl-2 inhibition activity, suggesting that glycodiversification at this position may lead 
to spirotetronate derivatives with high therapeutic value. 
296
  
 
3.1 Tetronolide Natural Products: Highlighting Differential Glycosylation at C-
9 
 
Landomycin A is a hexasaccharide-containing compound which is produced by 
Streptomyces cyanogenus S13622 and exhibits strong antitumor activities, in particular 
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against prostate cancer lines.
71
 These unusual activities can be attributed to the presence 
of the long oligosaccharide chain, since landomycins with shorter sugar side chains as 
landomycin E produced by S. globisporus possesses much weaker antitumor activity.
71
 
Thus, we are interested in identifying the glycosyltransferases responsible for the 
generation of the C-9 glycosylation long chain oligosaccharide. The biosynthesis of TDP-
L-digitoxose was elucidated in chapter 2, thus enabling experimental analysis of 
kijanimicin digitoxosyltransferase activity. The presence of TDP-L-digitoxose in 
biologically active natural products with varied functions makes digitoxose an attractive 
building block to be used in combinatorial biosynthesis to glycosylated secondary 
metabolites, however combinatorial biosynthesis requires not only the NDP-sugar 
donors, but glycosyltransferases that can accept these NDP-sugars as substrates. To 
discover the glycosyltransferases that are responsible for the addition of TDP-L-
digitoxose to the tetronolide aglycone, the biosynthetic gene cluster of kijanimicin was 
examined in silico.  
Using NCBI Blast, open reading frames in the kijanimicin biosynthetic cluster 
were examined and 5 glycosyltransferase genes were identified. Sequence analysis 
demonstrated that KijD9 has 38-40% pairwise identity to other glycosyltransferases in 
the cluster. The remaining four glycosyltransferases KijC1, KijC3, KijC4 and KijA4 
exhibit 50-58% pairwise identity to each other as well as to the chlorothricin 
glycosyltransferases ChlC6 and ChlC7. 
68, 293
 Chlorothricin is another spirotetronate 
natural product decorated with 2 digitoxose moieties. Thus the strong similarity of the 
KijGTs to the ChlGTs suggests that they share similar aglycone and sugar substrates.
293
 
Taken together, these data strongly suggest that KijC1, KijC3, KijC4 and KijA4 are 
digitoxosyltransferases responsible for constructing the C-9 oligosaccharide of 
kijanimicin.
68
  From sequence alignment, it is not possible to predict the order of the 
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glycosylation events, nor which protein is responsible for a specific digitoxosyl 
attachment.  
  
3.1 Proposed Glycosylation Pathway in Kijanimicin Biosynthesis 
 
 
Most GTs involved in natural product biosynthesis catalyze the transfer of one 
sugar to one glycosidic bond.
297
 There exist only a few examples of bifunctional GT 
enzymes responsible for the catalysis of two glycosidic bonds in the literature (e.g., 
LanGT1, LanGT4 and AveBI). 
298, 299
 Thus, we proposed a scheme involving four 
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glycosyltransferases in the sequential transfer of four digitoxosyl moieties in the 
biosynthesis of kijanimicin as shown in Scheme 3.1. 
The order of transfer is unknown and the latter steps, especially the order of 
attachment of the third and fourth sugars, can only be determined experimentally. If the 
β(1-4) linkage is formed before the terminal α(1-3) linkage, the resultant 3-sugar 
compound will be 16b, if the obverse is true, the resulting 3-sugar intermediate 
compound will be 16a.  In any event, the final addition, be it the α(1-3) or β(1-4) linkage, 
the end product should be kijanimicin A (1). 
Returning to focus on the in silico characterization of the kijanimicin 
glycosyltransferases, these proteins share sequence homology and align to 
glycosyltransferases that are members of the GT-B superfamily. Proteins of the GT-B 
superfamily are bi-lobal enzymes that have two β/α/β Rossmann-like domains with the 
active site lying in the cleft between the domains.
79
 Each lobe of the enzyme is associated 
with either the NDP-sugar or the aglycone substrate.
79
 It should be noted that enzymes in 
the same superfamily or having the same folds so not necessarily have similar 
mechanisms or the same stereochemical outcome of the product.
80
 Indeed, non-
glycosyltransferase enzymes are also known to adopt the GT-B fold, an example of 
which is UDP-GlcNAc 2-epimerase. 
81
  Notably, the kijanimicin glycosyltransferases, 
which belong to the GT-B family exhibit interesting stereochemical variance, since they 
are responsible for creating both α and β linkages from a TDP-sugar substrate that 
originally has a β configuration. Thus, three glycosyltransferases in this pathway must 
catalyze an inverting (SN2) reaction and one must catalyze a retaining or (SN1) 
glycosyltransfer reaction.  
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3.2 Inverting and Retaining Glycosyltransfer Reactions for an L-sugar  
 
The members of the GT-B superfamily seem to display a higher degree of 
diversity in the catalytic mechanisms as compared to what has been observed for the 
inverting GT-A enzymes. 
79
 The greater mechanistic diversity is perhaps a reflection of 
the greater diversity of reactions catalyzed by this superfamily of enzymes. This may also 
be a result of  the greater physical separation of the two domains in the enzymes. 
Therefore, the mechanisms of these enzymes cannot be definitively predicted, although a 
general mechanism can be described.  
Briefly, the SN2 inverting mechanism involves the direct attack at the anomeric 
center by the acceptor, displacing the NDP activating group. In this mechanism, the 
active site nucleophile, is proposed to stabilize and position the aglycon in the active site 
for the direct attack, while the NDP group is displaced with the assistance of a metal 
ion.
79
 As the NDP group is displaced a basic residue within the enzyme active site 
abstracts a proton from the aglycone hydroxyl. 
79
 The resulting hydroxyl anion can then 
attack the opposing face of the sugar in a concerted manner, finally transferring the sugar 
to the aglycone with inversion of the stereochemistry of the anomeric center. Thus, the 
nucleophilic acceptor attacks the anomeric carbon from the opposing side of the sugar 
ring as the NDP leaving group in a synchronous, concerted manner with highly 
dissociative oxocarbenium-like character. 
82
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3.3 Mechanisms of Inverting and Retaining Glycosyltransferases 
 
Meanwhile, the SN1 retaining mechanism is proposed to pass through a short-
lived oxocarbenium transition state, which is facilitated by the lone pair electrons from 
the endocyclic oxygen. As the NDP group displacement occurs without the stabilization 
of the active site nucleophile, a transient oxocarbenium ion forms, and a proton is 
abstracted from the aglycone acceptor hydroxyl. The formation of the oxocarbenium ion 
enables the direct attack of the anomeric carbon by the aglycon hydroxyl ion, retaining 
the stereochemistry of the original NDP group. 
83
 These mechanisms are shown in Figure 
3.3. The specific mechanisms of the kijanimicin glycosyltransferases cannot be 
established until their functions are elucidated through experimental analysis, however it 
is unlikely that they are vastly divergent from the mechanisms presented above.  
The focus of this research is to elucidate the order of attachment of digitoxosyl 
moieties to the kijanolide aglycone to generate the tetrasaccharide chain.  The branched 
oligosaccharide chain has been previously synthesized by Thiem and Kopper in 1990 
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using an N-iodosuccinimide procedure employing regioselectively blocked L-
digitoxosides and L-digitoxals. 
300
 The tetrasaccharide chain was later characterized 
extensively by 
1
H-NMR. This work will attempt to isolate and characterize any 
intermediate products that may be generated during these studies.  No previous 
biosynthetic studies have been carried out to investigate the formation of the branched 
tetrasaccharide, despite evidence that modification of the C-9 glycan may have a 
significant effect on the bioactivity of the natural product.  
Our research plan includes the cloning and expression of the five 
glycosyltransferase genes in S. lividans. The kijanimicin aglycone will be isolated and 
used in assays both in vivo and in vitro to build the tetrasaccharide chain one sugar “link” 
at a time. Each of the intermediate products will be isolated and characterized, then used 
as substrates for subsequent reactions until kijanimicin A is constructed. Once the 
digitoxosyltransferases have been identified and their activity confirmed, potential 
glycodiversification experiments can be carried out to alter the C-9 glycosylation pattern 
of kijanimicin. This alteration could yield new natural products with different 
bioactivities suitable for potential clinical applications. 
 
3.2 EXPERIMENTAL DETAILS 
 
3.2.1 MATERIALS 
 
3.2.1.1 Bacterial Strains  
Escherichia coli (E. coli) strain DH5α,  Streptomyces lividans TK-24 strain and 
Actinomadura kijaniata SCC1256 (ATCC 31588) were purchased from Bethesda 
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Research Laboratories (Gaithersburg, MD) and the American Type Culture Collection 
(Manassas, VA), respectively. The overexpression hosts E. coli BL21, BL21(DE3), 
BL21(DE3)PLysS and BL21 RosettaII(DE3) were purchased from Novagen (Madison, 
WI). E. coli XL-1 Blue MRF' used for cosmid library preparation was obtained from 
Stratagene (La Jolla, CA).  
 
3.2.1.2 Biochemicals  
Enzymes including and molecular weight standard used for the molecular cloning 
experiments were products of Invitrogen (Carlsbad, CA) or New England Biolabs 
(Beverly, MA). Restriction digestion enzymes, calf intestinal alkaline phosphatase 
(CIAP), 100X BSA, T4 ligase, and their respective buffers were products of New 
England Biolabs (Beverly, MA). Ni-NTA agarose resin was obtained from Qiagen 
(Valencia, CA). Growth media components were acquired from Becton Dickinson 
(Sparks, MD).  Rabbit muscle pyruvate kinase was purchased from Sigma as a 400-800 
unit/mg ammonium sulfate precipitate.  This ammonium sulfate precipitate was dissolved 
in water to a concentration of 2500 units/mL, dialyzed against 50 mM NaH2PO4, 300 mM 
NaCl, pH 8.0, to remove ammonium sulfate, and stored at -80 °C.  Antibiotics and 
chemicals such as isopropyl-β-D-thiogalactopyranoside (IPTG) and dithiothreitol (DTT) 
were products of Sigma-Aldrich Co. (St. Louis, MO) or Fisher Scientific (Pittsburgh, 
PA).  Agarose for DNA electrophoresis was obtained from Fisher Scientific (Pittsburgh, 
PA).  Bio-Gel P2 resin and all reagents for sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) were purchased from Bio-Rad (Hercules, CA), with the 
exception of the prestained protein molecular weight marker, which was ordered from 
New England Biolabs.  Antibodies used for Western blotting procedures, monoclonal 
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anti-polyhistidine clone His-I H1029 and anti-mouse IgG (alkaline phosphatase 
conjugate) A2429 were purchased from Sigma. For Western blot detection, nitroblue 
tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) were both 
obtained from Promega. 
 
3.2.1.3 Plasmids, Vectors and DNA Manipulation  
Vector pET28b(+) was purchased from Novagen (Madison, WI). Gigapack III 
Gold packaging extract, Plasmids SuperCos 1 and pBluescript II SK(+), used for cosmid 
library construction and cosmid fragment subcloning, respectively, were purchased from 
Stratagene (La Jolla, CA). DNA gel extraction and spin miniprep kits were obtained from 
Qiagen (Valencia, CA). DNA polymerase pfu was purchased from Stratagene. 
Oligonucleotide primers for cloning were prepared by Integrated DNA Technologies 
(Coralville, IA). Plasmid vectors pSET152, pWHM3, pWHM468 and pWHM467 were a 
kindly provided by Dr. C. R. Hutchinson.
301-303
  The pLitmus28 vector was obtained from 
NEB. pET28 a and b+ vectors were purchased from Novagen. 
 
3.2.1.4 Instrumentation 
PCR reactions were carried out using an Eppendorf Mastercycler gradient thermal 
cycler from Brinkman-Eppendorf (Westbury, NY). For agarose gel electrophoresis, a 
mini-sub-cell GT from BioRad (Richmond, CA) was used, powered by a Fisher FB-300 
electrophoresis power source. After electrophoresis, DNA bands were visualized using a 
Fisher FBTIV-08 UV transilluminator. Cell disruption was performed with a Fisher 550 
Sonic dismembrator, equipped with a standard sonicator horn. For SDS-page gel 
electrophoresis, a mini PROTEAN II vertical system from BioRad (Richmond, CA) was 
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used, equipped with an FB-300 or EC-1000-90 electrophoresis power source from Fisher, 
or E-C apparatus corporation, respectively. Mini-trans blot assembly apparatus used for 
Western blot, GelAir drying system for acrylamide gel preservation, and the necessary 
accessories and reagents were all products of BioRad. The nitrocellulose Hybond-C or 
Optitran BA-5 85 reinforced nitrocellulose membrane used for Western blot was from 
Amersham Bioscences or Whatman (Dussel, Germany), respectively.  
To obtain pH values, a Corning 240 pH meter equipped with an Accumet 
electrode (Fisher) was used.  Large scale centrifugation procedures were performed using 
an Avanti J-25 unit or a J-E instrument from Beckman (Arlington Heights, IL).  
Microscale centrifugation procedures were carried out using an Eppendorf 5415C from 
Brinkmann Instruments, (Westbury, NY). Ultraviolet-visible spectra were recorded using 
Beckman DU-650 spectrophotometer. Amicon YM-10 filtration products were purchased 
from Millipore (Billerica, MA). HPLC separations used a Beckman 366 from Beckman 
Instruments (Fullerton, CA) equipped with a CarboPac PA1 HPLC column from Dionex 
(Sunnyvale, CA) or a C-18 from Varian (Lake Forest, CA). Polygram Sil G/UV254 plates, 
0.25 mm; were purchased from Macherey-Nagel Inc. (Easton, PA). DNA and compounds 
were dried using a Savant Speedvac SC100, equipped with a Savant refrigerated 
condensation trap RT100 and Gel Pump GP100. DNA concentrations were measured 
using a NanoDrop ND-1000 UV-Vis instrument from Thermo Fisher Scientific (formerly 
NanoDrop Technologies LLC).  
 NMR spectra were acquired on either a Varian Unity 300 or a 500 MHz 
spectrometer. Sequencing of subclones was performed using a capillary-based AB 3700 
DNA analyzer by the Core Facilities of the Institute of Cellular and Molecular Biology at 
the University of Texas at Austin. Mass spectra (low-resolution ESI) were obtained on a 
Finnegan LCQ ion trap mass spectrometer. High-resolution ESI spectra were obtained 
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using an IonSpec 9.4T FT-ICR mass spectrometer. Spectra were acquired by the Mass 
Spectrometry Core Facility in the Department of Chemistry and Biochemistry of the 
University at Texas at Austin.   
 
3.2.2 GENERAL PROCEDURES   
Protein concentrations were determined according to Bradford 
272
 using bovine serum 
albumin as the standard.  The relative molecular mass and purity of enzyme samples were 
determined using SDS-polyacrylamide gel electrophoresis as described by Laemmli.
273
 
NMR chemical shifts (δ in ppm) are given relative to that of deuterated water (D2O, δ 
4.65 for 
1
H NMR), with coupling constants reported in Hertz (Hz).     
 
3.2.3 EXPERIMENTAL PROCEDURES 
3.2.3.1 Bacterial Strains and Growth Conditions 
Actinomadura kijaniata SCC1256 (ATCC 31588) was maintained at 30 ºC on ISP 
medium 2. For kijanimicin production, spore suspensions of wild-type A. kijaniata were 
grown in seed media (0.3% beef extract, 0.5% tryptose, 0.1% dextrose, 2.4% potato 
starch, 0.2% CaCO3, pH 7.2) and vegetative media (0.5% yeast extract, 1% dextrose, 2% 
soluble starch, 0.5% NZ-amine A, 0.4% CaCO3, 0.024% CoCl2·6H2O).
243
 In both seed 
and vegetative media, A. kijaniata was grown on a rotary shaker at 30°C, 250 RPM.   
S. lividans TK-24 strain was maintained on R1R2 media (10.3% sucrose, 1% 
glucose, 1% MgCl2, 0.5% yeast extract, 2.2% agar, 0.15% L-proline, 0.1% L-asparagine, 
0.01% casamino acids, 0.005% KH2PO4, 0.3% CaCl2, 10% 0.25 M TES buffer, pH 7.2, 
0.2% trace elements).
276
 Trace elements solution is composed of: 0.004% ZnCl2, 0.2% 
FeCl3•6H2O, 0.001% CuCl2•2H2O, 0.001% MnCl2•4H2O, 0.001% Na2B4O7•10H2O, and 
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0.001% (NH4)Mo7O24•10H2O. Liquid cultures of S. lividans TK-24 employed YEME 
media (34% sucrose, 1% glucose, 0.5% bacto-peptone, 0.3% yeast extract, 0.3% malt 
extract).
276
 
Escherichia coli DH5α was used for routine cloning experiments. E. coli BL21, 
BL21(DE3),  BL21(DE3)pLysS,  and BL21 RosettaII(DE3) were cultured in LB-media 
supplemented with 100 µg/mL ampicillin or 50 µg/mL kanamycin with the addition of 35 
µg/mL chloramphenicol in the case of BL21 RosettaII(DE3) and BL21(DE3)pLysS .  To 
liquid cultures, a volume of sterile 80% glycerol equal to 20% of the original culture 
volume was added and gently mixed to homogeneity. The mixture was aliquotted into 
sterile Eppendorf tubes, flash frozen in liquid N2 and stored at -80 ºC until use. Glycerol 
stocks were used in a 1:20 dilution to inoculate fresh media for plasmid preparations. 
Competent cells were prepared as described in chapter 2. 
 
3.2.3.2 DNA Manipulation 
Template DNA used in the following experiments in this chapter was generated 
by Dr. Hua Zhang, following the procedures described in Chapter 2. Routine genetic 
manipulations in E. coli were performed as described by Sambrook et al.
274
  Standard 
genetic manipulations in S. lividans were performed as described by Kiser et al.
276
  
Cosmids used in these experiments were: pHZ-8 and pHZ4-6. The ermE* promoter was 
retrieved as a 279-bp KpnI-BamHI fragment from pWHM79 and ligated into the same 
restriction sites of pWHM3, which generated pWHM3-ermEp.
304
 Subcloning of the DNA 
fragment harboring actIIorf4 and actI promoter was previously reported.
305
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3.2.3.3 PCR Reactions  
The general protocol for amplification of genes from gram-positive bacteria is as 
follows. Primers were prepared by dilution with TE buffer (50 mM Tris, 1 mM EDTA, 
pH 8.0) to a concentration of 100 µM.  This stock solution was further diluted to 20 µM 
with sterile water.  Template DNA from the A. kijaniata genome was obtained from 
cosmids constructed by Dr. Hua Zhang. Glycosyltransferase genes kijc1, kijc3, kijc4, and 
kija4 were amplified from cosmid pHZ4-6, while kijd9 was amplified from cosmid pHZ-
8. Polymerase chain reactions (PCR) consisted of the following: 72 µL of sterile water, 
10 µL of 10X pfu polymerase buffer, 10 µL of dimethylsulfoxide (DMSO), 10 µL of a 20 
mM deoxyribonucleotidyl triphosphosphate (dNTP) solution, 2.5 µL of each primer (5′ 
and 3′) at 20 µM, 1 µL of template DNA, and 2 µL of pfu polymerase (5 units), for a 100 
µL total reaction volume in an 0.5 mL thin walled PCR tube.  
The PCR reactions were carried out using an Eppendorf thermocycler with the lid 
temperature set at 105 ºC and an initial denaturing step of 2 min at 95 ºC.  The first 3 
program cycles consisted of a 30 s denaturing step at 95 ºC, an annealing step at 5 ºC 
below the lowest annealing temperature for the overlapping region of each primer pair for 
30 s, and an elongation step of 1 min/kb at 72 ºC. The remainder of the program consisted 
of a 30 s denaturing step at 95 ºC, an annealing step at an annealing step with temperature 
5 ºC below the lowest annealing temperature (for the entire primer) of each primer pair 
for 30 s, and an elongation step of 1 min/kb at 72 ºC. This cycle was repeated 27 times, 
with program ending in a 10 min extension at 72 ºC. The temperature was reduced to 4 ºC 
until the product was removed from the thermocycler.  PCR products were stored at 4 ºC 
until purified. 
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3.2.3.4 PCR Product Purification 
A typical PCR purification consisted of agarose gel electrophoresis employing an 
0.8% TAE-agarose gel with 5 µg/mL ethidium bromide. PCR products were diluted to 
83% with 6X DNA loading dye (0.25% xylene cyanol, 0.25% bromophenol blue, 15% 
Ficoll 400) and electrophoresed at 100 V for 30 min. After electrophoresis, DNA bands 
of the correct base pair length, as estimated from comparison with DNA ladder, were 
excised from the gel with a clean scalpel. DNA was purified from agarose slices using the 
Qiagen gel extraction kit, following the manufacturer‟s protocols with the following 
modifications. Instead of heating at 55 ºC to melt the agarose, gel slices were heated at 65 
ºC until the gel was fully dissolved. DNA elution buffer EB was also heated to 65 ºC 
prior to DNA elution.  
 
3.2.3.5 DNA Ligations and Plasmid Transformation 
PCR products for the kijanimicin biosynthetic protein constructs were digested 
with the appropriate restriction enzymes, generally NdeI and HindIII at 37 ºC overnight. 
A typical reaction mixture contained 30 µL of purified PCR product, 1-2 µL of  each 
enzyme, 0.4 µL of 100X bovine serum albumin (BSA), 4 µL of 10X NEB buffer 2 and 
sterile water to a final volume of 40 µL. Digested products were cleaned with the Qiagen 
PCR purification kit, following the manufacturer‟s protocols, and ligated to the 
corresponding sites in the pET28 a or b+ plasmid. The pET28 a or b+ plasmid was 
prepared by digesting with NdeI and HindIII at 37 ºC overnight followed by treatment for 
1-2 h at 37 ºC with calf intestinal alkaline phosphatase (CIP) in NEB buffer #2. A typical 
reaction mixture contained 30 µL of purified vector, 2 µL of each enzyme, 0.4 µL of 
100X BSA, 4 µL of 10X NEB buffer 2 and sterile water to a final volume of 40 µL. After 
overnight digestion, pET28a or b+ was treated for 1-2 h at 37 ºC with 0.2 µL of CIP in 
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NEB buffer #2. The digested plasmid was electrophoresed using a 0.8% TAE-agarose 
gel, followed by extraction using the Qiagen gel extraction kit with modified protocols as 
previously described. In some cases, plasmids were extracted using the Qiagen gel 
extraction kit, following the instructions for PCR purification.  
A Nanodrop instrument was used to quantify the plasmid and insert DNA 
solutions. A typical ligation mixture included 90 fm ends of gel purified PCR product, 30 
fm ends of pET28a or b+, 2 µL of 5X T4 ligase buffer, 3.5 µL of sterile water, and 0.5 
µL of T4 ligase to a final volume of 10 µL. The ligation mixture was incubated at room 
temperature for 1-2 h, or overnight at 4 ºC. An aliquot of the ligation mixture (5 µL) was 
introduced to competent E. coli DH5α cells (50 µL) and incubated on ice for 30 min. 
After incubation, the cells were transformed by heat shock at 42 ºC for 30 s, and 
incubated on ice for 2 min. LB broth (500 µL) was added to the transformed cells and 
incubated at 37 ºC with 200 RPM shaking for 45 min. After incubation, transformation 
reactions were plated on LB-agar plates supplemented with 50 µg/mL kanamycin. 
Positive transformants were selected after incubation overnight at 37 ºC.  
 
3.2.3.6 DNA Extraction by Alkaline Lysis  
Colonies appearing after overnight incubation were screened for the presence of 
plasmid containing PCR product using the method of alkaline lysis.
277
 Briefly, 5 mL 
cultures of each positive transformant were grown overnight at 37 ºC in LB media 
supplemented with 50 µg/mL kanamycin. Cultures were centrifuged at 12,000 g for 30 s, 
the supernatant was removed and the cells were resuspended in 100 µL of cold 
Resuspension solution (50 mM glucose, 25 mM Tris•HCl (pH 8.0), 10 mM EDTA (pH 
8.0), 100 µg/mL RNase). Cells were disrupted with the addition of 200 µL fresh Lysis 
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solution (200 mM NaOH, 1% SDS), and inverted five times to mix. Lysis reactions were 
quenched with the addition of 150 µL of Neutralization solution (3 M potassium acetate, 
11.5% acetic acid). Reactions were mixed to ensure neutralization and incubated at 4 ºC 
for 5 min, followed by centrifugation for 5 min at 12,000 g to precipitate cellular debris. 
Supernatants containing plasmid DNA were transferred to fresh tubes and the DNA was 
precipitated by the addition of two volumes of 100% ethanol and 1/10 volume of 3 M 
sodium acetate pH 5.2. Solutions were mixed to ensure homogeneity and centrifuged at 
12,000 g for 15 min at 4 ºC. The supernatants were removed by aspiration, taking care 
not to disturb the DNA pellet. DNA pellets were washed with 70% ethanol and 
centrifuged again at 12,000 g for 5 min. The final ethanol wash was removed and 
solutions were dried using a centrifugal vacuum apparatus for 10 min at room 
temperature to remove any remaining ethanol. Pellets containing plasmid DNA were 
resuspended in 30 µL of 50 mM Tris•HCl (pH 8.5).  
 
3.2.3.7 DNA Analytical Restriction Digestion and Fragment Analysis 
Plasmid DNA obtained from this preparation was subjected to enzymatic 
digestion with NdeI and HindIII. A typical reaction mixture contained 15 µL of DNA, 2 
µL of 10X NEB reaction buffer #2, 0.1 µL of each enzyme (NdeI and HindIII), 0.2 µL of 
100X BSA and 2.6 µL of sterile water. The reactions were incubated for 2 h at 37 ºC, 
after which time 10 µL aliquots were removed and analyzed by gel electrophoresis. 
Samples were diluted 5X in DNA loading dye and electrophoresed for 30 min at 100 V 
using a 0.8% TAE-agarose gel with 5 µg/mL ethidium bromide (gel concentration).  
Electrophoretic results as visualized on agarose gels were used to confirm the 
presence of the DNA insert of the appropriate length. Colonies determined to contain the 
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vector and successfully ligated PCR product were grown overnight at 37 ºC with 200 
RPM shaking in LB media supplemented with 50 µg/mL kanamycin. After overnight 
incubation, bacteria were harvested by centrifugation at 12,000 g for 30 s. Plasmid DNA 
was extracted from the bacterial pellet using the Qiagen miniprep kit, following the 
manufacturer‟s protocols with the following adjustments to the protocol: the optional 500 
µL PB wash was always performed to remove additional contaminants, and elution buffer 
EB was heated to 65 ºC before DNA elution. The purified plasmid was sequenced to 
confirm the identity of the PCR product. 
PHRED sequences obtained from the DNA facility were aligned against the gene 
sequences previously identified for the target genes though gene cluster sequencing. Both 
forward and reverse sequences were compared to the originally obtained gene sequences 
to determine that the sequences were correct with no mutations.   
 
3.2.3.8 Preparation of Plasmids for S. lividans TK-24 Heterologous Expression 
Once the DNA sequence was confirmed to be the desired glycosyltransferase, the 
gene was digested with the appropriate enzymes, gel purified using the Qiagen gel 
purification kit following the manufacturer‟s instructions with adjustments as listed 
previously.  Expression vectors (pWHM3-ermE
*
, pWHM3-actIp, pWHM467-ermE
*
, or 
pWHM467-actIp) were prepared by enzymatic digestion with the XbaI and HindIII 
enzymes overnight at 37 ºC, followed by the addition of 0.2 µL (2 units) of calf intestinal 
alkaline phosphatase (CIP). After CIP addition, the reaction was incubated for an hour at 
37 ºC before purification.  To purify digested DNA, the Qiagen gel purification kit was 
used according to manufacturer‟s instructions for purifying PCR products.  
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Both vector and gene insert were quantified using a Nanodrop. Ligations were 
performed at room temperature for 1-2 h or overnight at 4 ºC, with a typical reaction 
mixture consisting of 90 fmol ends of the gene to be inserted, 30 fmol ends of vector 
pWHM3, 2 µL of 5X T4 ligase buffer, 0.5 µL of T4 ligase and sterile water to a final 
volume of 10 µL. An aliquot (5 µL) of the ligation reaction was transferred to 50 µL of 
chemically competent E. coli DH5α and incubated on ice for 30 min. The transformation 
procedure is identical to that previously listed, with the following adjustments.  
Ampicillin was the selective antibiotic to be used, thus the transformation was not 
incubated for 30-45 min after the heat shock, instead, it was plated directly onto LB-agar 
plates supplemented with 100 µg/mL ampicillin (amp100).  
After overnight incubation at 37 ºC, colonies appearing on the selection plates 
were screened for successful ligation using the alkaline lysis procedure and enzymatic 
digestion according to the method described above with the following adjustments. The 
enzymes used for digestion were XbaI and HindIII. Positive colonies were again 
amplified and gene-containing plasmids purified for transformation into S. lividans TK-
24. 
 
3.2.4 PREPARATION OF S. LIVIDANS TK-24 PROTOPLASTS 
A starter culture of S. lividans was grown in YEME media at 30 ºC with 200 RPM 
shaking. To inoculate the media, a square of agar was cut from an R1R2 agar plate of S. 
lividans with a red-hot steel needle and introduced to 10-20 mL media in a glass culture 
tube with sterile glass beads. This culture was grown until mycelia were clearly seen in 
the media. This small-scale culture was transferred to 50-100 mL of YEME media with 
0.5% glycine, and allowed to grow for 48 h at 30 ºC, with 200 RPM shaking. After two 
 165 
days of growth, very little mycelia was seen in the culture, and the media was somewhat 
cloudy.  
Protoplast buffer (20 mL) (12.875% sucrose, 0.25% MgCl2, 0.03% K2SO4, 0.25% 
trace elements, 0.0625% KH2PO4, 4.6% CaCl2, 1.25% 0.25 M TES buffer pH 7.2) and 1 
mg/mL lysozyme were added to the solution and mixed gently. The solution was 
incubated for 30 min at 30 ºC without shaking. After this time, the solution was mixed by 
swirling gently, and again incubated at 30 ºC without shaking for an additional 15-20 
min. The culture was removed from the incubator and filtered in a sterile environment 
through a syringe packed with sterilized cotton to remove the mycelia from the culture. 
The filtrate containing protoplasts was centrifuged at 5000 g for 30 min. In a sterile 
environment, the supernatant was decanted, and the pellet containing protoplasts was 
resuspended in protoplast buffer and divided into 200 µL aliquots. These aliquots were 
frozen slowly at -80 ºC.  
 
3.2.5 PROTOPLAST TRANSFORMATION OF S. LIVIDANS TK-24 
Aliquots (200 µL) containing protoplasted S. lividans were removed from the -80 
ºC freezer and thawed under hot running water. After thawing, the protoplasts were 
pelleted at 6700 g for 30 s and the supernatant was decanted. The protoplast pellets were 
resuspended in the remaining protoplast buffer (50-100 µL). The plasmid to be 
transformed (1 µg) was added to the protoplasts in situ, and allowed to equilibrate for 
several min. To this mixture was added 250 µL of a sterile PEG-T solution (25% 
polyethylene glycol (PEG) 1450, 75% T-Buffer (2.5% sucrose, 0.25% MgCl2, 1.47% 
CaCl2, 0.04% K2SO4, 0.2% trace elements, 0.58% maleic acid, pH 8.0 with 1 M Tris base, 
0.1% KH2PO4, 7.36% CaCl2, 2% 0.25 M TES buffer pH 7.2). T-buffer (1 mL) was added 
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to each of the transformations and 250 µL of each transformation was aliquotted onto 
five freshly made R1R2 agar plates. The mixture was tapped to distribute evenly on each 
plate and plates were incubated overnight at 30 ºC. After overnight recovery, antibiotic 
(generally thiostrepton 50 mg/mL in DMSO) mixed with 10.3% sucrose solution was 
overlaid onto each plate. Positive transformants were selected after 5 days of incubation 
at 30 ºC. Distinctive white and red colonies appearing on R1R2 plates were selected and 
plated onto fresh R1R2 agar supplemented with the appropriate selective antibiotic and 
incubated at 30 ºC until plates were confluent (5-7 days).  
 
3.2.6 SDS-PAGE 
The relative molecular mass and purity of enzyme samples were determined using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) as described by 
Laemmli.
273
 Proteins were electrophoresed using a discontinuous buffer system 25 mM 
Tris•HCl, 192 mM glycine and 0.1% SDS (pH 8.3).273 Gels were 75 mm, and 12% 
acrylamide was used for the separatory gel, while the stacking gel was 4% acrylamide. 
Protein samples were diluted 2X with SDS-Loading dye (62.5 mM Tris•HCl buffer pH 
6.8, containing 10% glycerol, 2% SDS, 5% β-mercaptoethanol, and 0.0025% 
bromophenol blue, and heated to 100 ºC for 5 min. Samples were centrifuged briefly to 
return samples to the bottom of the tubes. The protein gels were electrophoresed using a 
setting of 30 mA per gel, allowing the gel to run until the loading dye ran off the bottom 
of the gel. Gels were removed from glass plates, and stacking gel removed. A corner of 
each gel was also cut to preserve orientation of the gel samples. Gels were stained with 
Coomassie blue (2.5 g/L of Coomassie Brilliant Blue G-250 in acetic 
acid:water:methanol (1:4:5) by volume) until gels were dark blue. 
278
 Gels were removed 
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from staining solution, rinsed in ddH2O, and introduced to destaining solution 
(ethanol:acetic acid:water in a ratio of 4:5:41 by volume). 
278
 Protein concentrations were 
determined according to Bradford using BSA as the standard, and the dye reagent from 
BioRad. 
272
 
 
3.2.7 WESTERN BLOT PROCEDURE 
Western blotting was used to detect the presence of polyhistidine tags on 
heterologously expressed and purified proteins. 
279
 SDS-PAGE of elution fractions from 
Ni-NTA chromatography procedures was performed in duplicate for each protein. The 
gels were processed as detailed previously up to the staining step, at which point they 
were assembled into the transfer cassettes. The gels were transblotted onto the 
nitrocellulose membrane at 100 V for 1 h, using a running buffer of 25 mM Tris base, 
192 mM glycine, 20% v/v methanol (pH 8.3).  Cassette assembly and electrophoresis 
were carried out according to the directions provided by BioRad. After transblotting 
electrophoresis, the membrane was carefully removed from the transfer cassette and the 
presence of the prestained marker on the blot was visually assessed to ensure transfer was 
complete. The membrane was transferred to a small plastic box and immersed in 5% non-
fat dry milk in Tris buffered saline and Tween (TBST) (20 mM Tris•HCl, 150 mM NaCl, 
0.5% v/v Tween® 20, pH 7.5). The membrane was blocked in this solution for 1 h, with 
agitation, overnight at 4 ºC or at room temperature for 1 h. After which, the solution was 
removed and the membrane was rinsed thrice in TBST to remove excess blocking 
solution. The membrane was immersed in primary antibody solution (15 mL TBST, 
1:30,000 dilution of monoclonal anti-polyhistidine clone His-1, 1:1000 dilution of 20% 
v/v NaN3), and incubated with agitation overnight at 4 ºC or room temperature for 1 h. 
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After incubation, the solution was removed from the membrane and the membrane was 
washed thrice with TBST to remove any excess primary antibody solution remaining on 
the membrane. The membrane was incubated in secondary antibody solution (15 mL 
TBST, 1:30,000 dilution of anti-mouse IgG [Fc specific] alkaline phosphatase conjugate, 
1:1000 dilution of 20% v/v NaN3), and incubated with agitation overnight at 4 ºC or room 
temperature for 1 h. After incubation, the solution was removed from the membrane and 
the membrane was washed thrice with TBST to remove any excess secondary antibody 
solution remaining on the membrane. To visualize proteins, the membrane was immersed 
in 5 mL color development solution (100 mM Tris•HCl, 100 mM NaCl, 5 mM MgCl2, 
pH 9.5) with the addition of 66 µL NBT and 33 µL BCIP. The membrane was incubated 
in the dark for 2-5 min or until purple bands appeared on the blot. Development was 
stopped by rinsing the membrane with ddH2O. Membranes were dried and scanned 
within 24 h to preserve coloration. 
 
3.2.8 KIJANIMICIN PRODUCTION  
To obtain kijanimicin, kijanosyl-kijanolide and kijanolide, A. kijaniata was 
cultured by the method of Waitz and extracted with ethyl acetate followed by 
fractionation on silica gel column.
243,68  
A. kijaniata mycelial glycerol stocks were grown 
in seed media (2.4% potato starch, 0.5% tryptose, 0.3% beef extract, 0.2% CaCO3, 0.1% 
glucose, with the solution pH adjusted to 7.2 prior to sterilization). This culture was 
grown at 30 ºC with 200 RPM shaking for 48 h. Cultures in seed media (10-20 mL) were 
used to inoculate 1 L of vegetative media (0.5% yeast extract, 1% dextrose, 2% soluble 
starch, 0.5% NZ-amine A, 0.4% CaCO3, 0.024% CoCl2·6H2O).  This culture was allowed 
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to grow for 5-7 days at 30 ºC with 250 RPM shaking. After this time, cultures were a 
deep forest green, due to high mycelial growth.  
 
3.2.9 KIJANIMICIN EXTRACTION 
To obtain kijanimicins A, B, C and other minor products such as ECK-1, the 
media containing tetronolide products was separated from A. kijaniata mycelia by 
centrifugation at 6700 g for 20 min at 4 ºC. The supernatant was decanted and filtered to 
remove any unpelleted mycelia. The pellets were combined and washed with sterile water 
to remove any remaining broth. The mycelial pellets were washed with 10.3% sucrose 
solution twice and retained at -20 ºC for use as future inoculum. The media was extracted 
with 2 volumes of ethyl acetate and the solvent was removed through rotary evaporation.  
 
3.2.10 KIJANIMICIN PURIFICATION 
STEP 1: SILICA GEL CHROMATOGRAPHY. The crude extract was resuspended in 
chloroform and loaded onto a silica gel column (4 × 30 cm) prepared in chloroform. The 
crude mixture was separated using a chloroform-methanol gradient with 2% acetic acid. 
kijanimicin A, the major product, eluted at 10% methanol + 2% acetic acid, kijanimicin B 
(17) and kijanimicin C (18) eluting just prior to kijanimicin A and ECK-1 (19) at higher 
methanol concentrations. Fractions were collected (15 mL) and neutralized with 82.5 µL 
of 8 N ammonium hydroxide just after elution and assessed for purity by TLC using a 
mobile phase of 10% methanol in chloroform. TLC plates were developed in vanillin 
stain (1.5 g vanillin, 3 mL H2SO4, in 200 mL methanol), and plates were heated to 
visualize spots. Kijanimicin compounds appeared as black spots on a pinkish to yellow-
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ivory background. Fractions were combined based on TLC purity and were in some cases 
further purified by HPLC. 
STEP 2: HPLC PURIFICATION USING C-18 COLUMN. HPLC purification of 
kijanimicins was accomplished using a gradient of 20 mM ammonium acetate pH 5.5 as 
eluent A and acetonitrile as eluent B on a C-18 column. The gradient began in 5% eluent 
A and remained at 5% for 5 min, after which time, the gradient was increased to 30% B 
over 10 min, followed by the elution stage, an increase to 70% B over 35 min. After 
which time, the gradient was increased to 100% B over 2 min, held at 100% B for 5 min 
and returned to 5% B over 4 min and held at 5% B for 8 min to equilibrate the column. 
The flow rate was 1 mL/min when using an analytical scale column (250 × 5 mm), and 5 
mL/min using a semi-preparatory scale column (250 × 10 mm). The UV detector was set 
at 240 nm to detect kijanimicin compounds.  Under these conditions, kijanimicin A (1), 
the major product, eluted at 33 min, kijanimicin B (17) eluted at 41.1 min, and 
kijanimicin C (18) at 47.4 min. The minor product O-β-D-kijanosyl-(1→17)-kijanolide 
(13) eluted at 27.5 min and ECK-1 (19) at 29.8 min.  Peaks were collected and submitted 
for Mass Spectrometry. Dr Hyung Jin Kwon performed the 
1
H and 
13
C NMR analysis to 
further characterize the products.    
 
3.2.11 KIJANIMICIN HYDROLYSIS 
To afford O-β-D-kijanosyl-(1→17)-kijanolide (13), mild acid hydrolysis 
following the method of Mallams as shown in Scheme 3.2. 
245
 Briefly, purified 
kijanimicin A (1) (approx. 400 mg, 304 µmol, 1 eq) was introduced to 400 mL of 0.5 N 
HCl in methanol and stirred for 16-20 h at room temperature. After incubation, the 
reaction was neutralized with 8 N NH4OH (to pH 7 as judged by pH paper). 
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3.2 Kijanimicin Hydrolysis 
 
The resulting crude reaction mixture was dried and resuspended in chloroform. 
The resulting products were concentrated, and the sample was subjected silica gel 
chromatography employing a methanol gradient from 1-20% to isolate the O-β-D-
kijanosyl-(1→17)-kijanolide product 13. Column fractions observed to contain kij-kij 
(13) were concentrated and subjected to HPLC, following the same procedure described 
in the previous section. Peaks eluting at 27.5 min were collected from the HPLC, 
concentrated and submitted to MS to confirm the presence of O-β-D-kijanosyl-(1→17)-
kijanolide (13) (calculated m/e [M-H]
-
 for C42H57N2O12, 781.3912, observed 781.3925). 
Dr Hyung Jin Kwon performed 
1
H and 
13
C NMR analysis to further characterize product 
13. For the sake of simplicity, protons on the kijanose ring are denoted by “A”. 1H NMR 
(500 MHz, CDCl3) of O--D-kijanosyl-(117)-kijanolide (13): 6.01 (1H, ddd, J= 10.2, 
11-H), 5.49 (1H, s, 21-H), 5.42 (1H, ddd, J= 10.0, 4.8, 2.4, 12-H), 5.18 (1H, d, J= 9.8, 
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15-H), 5.13 (1H, d, J= 10.9, 19-H), 5.07 (1H, d, J= 10.0, A-4-NHCOOCH3), 4.44 (1H, 
dd, J= 9.8, 2.1, A-1-H), 4.36 (1H, d, J= 9.8, A-4-H), 4.21 (2H, s, 22-CH2OH), 4.19 (1H, 
m, 17-H), 3.70 (3H, s, A-4-NHCOOCH3), 3.64 (1-H, dd, J= 9.5, 6.6, 9-H), 3.60 (1-H, dd, 
J= 10.9, 2.0 20-H), 3.48 (1H, d, J= 6.0 13-H), 3.47 (1H, s A-5-H), 2.77 (1-H, d, J= 15.4, 
A-2-H), 2.66 (1H, dd, J= 7.8, 7.4, 23-H), 2.38 (1H, dd, J= 14.3, 7.8, 24-H), 2.32 (1H, dd, 
J= 16.2, 9.7, 16-H), 2.25 (1H, br m 16-H), 2.23 (1H br m 8-H), 2.07 (1H, dd, J= 10.3, 
2.1, 10-H), 1.98 (1H, s 5-H), 1.83 (1H, d, J= 14.6, 24-H), 1.62 (3H, s, 4-CH3), 1.60 (1H, 
m, A-2-H), 1.60 (1H, s 6-H), 1.57 (3H, s, A-3-CH3), 1.38 (3H, br s, 18-CH3), 1.35 (1H, br 
s, 14-CH3), 1.31 (3H, d, J= 7.4, 23-CH3), 1.14 (3H, d, J= 6.4, A-6-H), 1.03 (3H, d, J= 
7.1, 8-CH3), 0.62 (3H, d, J= 5.7, 6-CH3); 
13
C NMR (125 MHz, CDCL3): 206.5 (C3), 
201.5 (C26), 167.1 (C1), 157.3 (A-4-NHCOOCH3), 141.4 (C22), 137.1 (C18), 135.8 
(C14), 126.6 (C12), 125.4 (C11), 123.4 (C15), 121.5 (C19), 119.3 (C21), 101.9 (C2), 
97.1 (A-C1), 91.0 (A-C3), (C9), 83.2 (C25), 78.5 (C17), 76.1 (C9), 69.0 (A-C5), 65.0 
(C32), 53.7 (A-C4), 53.2 (C13), 52.7 (A-4-NHCOOCH3), 51.0 (C4), 42.8 (C5), 41.7 
(C7), 40.4 (C20), 38.2 (C8), 35.8 (A-C2), 35.4 (C24), 34.7 (C8), 31.3 (C23), 31.1 (C6), 
31.0 (C16), 22.3 (6-CH3), 20.2 (23-CH3), 17.0 (A-C6), 15.1 (4-CH3) 15.0 (18-CH3), 13.7 
(14-CH3), 13.0 (8-CH3). 
 
3.2.12 CONSTRUCTION OF THE TDP-L-DIGITOXOSE BIOSYNTHETIC PLASMID 
This plasmid was constructed by Dr. Hyung-jin Kwon of our research group. 
Briefly, a 2.1-kb fragment comprising kijD4 and kijD5 was amplified from the cosmid 
HZ-14 by PCR using the forward primer 5′-TCTTAGAATTAATTAAGAAGCCTTTTGT-
AC-3′ with an engineered PacI restriction site (italicized and underlined) and the reverse 
primer 5′-GCGCCGCCATGCATTCGAGCAGGACGCGAC-3′ with the engineered NsiI 
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restriction site (italicized and underlined) and subcloned into the PacI-NsiI sites of 
pWHM468 to generate p1-86A.  A 1.7-kb fragment comprising kijD10 and kijD11 was 
amplified from the cosmid HZ-14 by PCR using the forward primer 5′-
CATGACGGCTGCAGGTGGGCGCGCGCCATG-3′ with an engineered PstI restriction 
site and the reverse primer 5′-GCATGACAAGATCTCTTGCGTTTGTGCCGA-3′ with 
the engineered BglII restriction site (as indicated by italicized and underlined bases) and 
subcloned into the PstI-BglII sites of pLitmus28 to generate p1-86C.  A 1.8-kb fragment 
comprising kijC2 was amplified from the cosmid HZ 4-6 by PCR using the forward 
primer 5′-CCTCAATGTTAATTAAGGACGCCCGTGCCC-3′ with an engineered PacI 
restriction site, and the reverse primer of 5′-GTGGACACCGCCATGCATTCTCCTCTT-
TCC-3′ with the engineered NsiI site (as indicated by italicized and underlined bases) and 
subcloned into the PacI-NsiI sites of pWHM468 to generate p1-86B.   
A 1.2-kb fragment comprising kijB1 was amplified from the cosmid HZ 4-6 by 
PCR using the forward primer 5′-AGCCCTGGTCTGCAGACCGGGGCCGGACAC-3′ 
with an engineered PstI restriction site and the reverse primer 5′-CTCGAATTCGAGATC-
TCGGGCATCGCCGTC-3‟ with the engineered EcoRI and BglII restriction sites (as 
indicated by italicized and underlined bases), and subcloned into the PstI-EcoRI sites of 
pUC18 to generate p1-86D.   
The XbaI-NsiI fragment of 1-86A and the PstI-BglII fragment of 1-86D were 
subcloned into the corresponding XbaI-BglII sites of pLitmus28, generating p1-94A. The 
XbaI-NsiI fragment of 1-86B and the PstI-BglII fragment of 1-86C were similarly ligated 
into the XbaI-BglII sites of pLitmus28, generating pHJK-1-94B.  The XbaI-PacI 
fragment containing the actI promoter from pWHM467, the PacI-SpeI fragment of 1-94A 
(kijD5-kijD4-kijB1), and the XbaI-BglII fragment of 1-94B (kijC2-kijD11-kijD10) were 
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ligated into the XbaI-BglII restriction sites of 1-107A, which is a pSET152-derivative that 
harbors an engineered BglII site in the polycloning site, to yield p1-114A, or pDIG. 
 
3.2.13 EXPRESSION CONSTRUCTS FOR GLYCOSYLTRANSFERASES (IN VIVO) 
 
3.2.13.1 Generation of the kijC3 Expression Construct (In Vitro and In Vivo) 
A 1.2-kb fragment comprising kijC3 was amplified from the cosmid HZ4-6 by 
PCR using the forward primer 5′-GTCCTCCCACCGAAGGAGCTCATATGCGCG-3′ 
with an engineered NdeI site as indicated above by italicized bases and the reverse primer 
5′-TCATGGTCTGGAATTCCGGTCGAACGGGCG-3′ with an engineered EcoRI site, as 
indicated by italicized bases.  The PCR product was subcloned into the corresponding 
NdeI-EcoRI sites of pET28a to generate p1-61A. The kijC3 containing insert of pHJK-1-
61A was isolated by restriction digest as an XbaI-HindIII fragment, which includes the 
ribosomal binding site of pET28a, and ligated into the corresponding restriction sites of 
pWHM3-ermE* to yield p1-73A for the expression of the kijC3 gene.  
 
3.2.13.2 Generation of the kijC4 Expression Construct (In Vitro and In Vivo) 
A 1.2-kb fragment comprising kijC4 was amplified from the cosmid HZ4-6 by 
PCR using the forward primer 5′-CCCGCCGTCCGCAGAGGTAGCATATGCGCA-3′ 
with an engineered NdeI site as indicated by italics, and the reverse primer with an 
engineered EcoRI restriction site 5′-GTGGGAGGACGAATTCCCGGTGGCCCGTCA-
3′. The PCR product was subcloned into the corresponding NdeI-EcoRI sites of pET28a 
to generate p1-61B. The kijC4 containing insert of pHJK-1-61B was isolated by 
restriction digest as a XbaI-HindIII fragment, which includes the ribosomal binding site 
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of pET28a, and ligated into the corresponding restriction sites of pWHM3-ermE* to yield 
p1-73B, for the expression of the kijC4 gene.   
 
3.2.13.3 Generation of the kijD9 Expression Construct:  
A 1.2-kb fragment comprising kijD9 was amplified from the cosmid HZ14 by 
PCR using the forward primer 5′-GACGGGGGCGCGCGAATTCTACTTCCCCTG-3′ 
with an engineered EcoRI site as indicated by italicized bases, and the reverse primer 5′-
CGTGCCGTCCTCGGATGCATGTGCTACCCC-3′, with the engineered NsiI site as 
indicated by italicized bases. This PCR product was subcloned into the corresponding 
EcoRI-NsiI sites of pLitmus28 to yield p1-77B. The kijD9 containing insert of 1-77B was 
reisolated as XbaI-NsiI fragment and ligated into the corresponding XbaI-HindIII sites of 
pWHM3-ermE* in conjunction with the PstI-HindIII fragment of kijD4-kijD5 from 1-
86A, to generate p1-125B. The insert of p1-77B was recovered as an XbaI-NsiI fragment 
and subcloned into the XbaI-HindIII sites of pWHM3-ermE* in conjunction with the 
NsiI-HindIII fragment of actIIorf4, to generate p1-125C.   Strains containing this plasmid 
were used as controls for all in vivo feeding experiments. 
 
3.2.13.4 Generation of the kijC1 Expression Construct:  
The 6-kb PstI fragment from the cosmid HZ4-6 was subcloned into the 
corresponding PstI site of pLitmus28, to yield p1-115B. Restriction digestion-analysis 
indicated that an XbaI site is present in the polycloning site located upstream to the kijC1 
gene. Since a PstI site is located 1-kb-upstream of the start codon of kijC1, the kijC1 
containing insert of pHJK-1-115B was recovered as a 3-kb XbaI-SacI fragment, which 
also contains truncated kijB1 upstream and truncated kijC2 downstream. This fragment 
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was subcloned into the corresponding sites of pGEM7zf, yielding p1-126A. The kijC1 
containing insert of p1-126A was rescued as an XbaI-NsiI fragment and subcloned into 
the XbaI-HindIII restriction sites of pWHM3-ermE* in conjunction with the NsiI-HindIII 
fragment of actIIorf4, to generate p2-11C.  
 
3.2.13.5 Generation of the kijA4 Expression Construct: 
A 4.7-kb NcoI fragment from the cosmid HZ4-6 was ligated into the 
corresponding NcoI site of pLitmus28. The restriction digestion-analysis identified two 
clones, p1-141A and p1-141B. The XbaI site of the polycloning site is located upstream 
of the kijA4 gene in p1-141B. It should also be noted that the plasmid p1-141B harbors 
kijA3, in addition to kijA4. The kijA3 and A4 containing insert in p1-141B was recovered 
as an XbaI-HindIII digested fragment and ligated into the corresponding restriction sites 
of pWHM3-ermE* to generate p2-11B.   
 
3.2.13.6 Generation of the Expression Construct for kijD9, kijC3, kijC4, & kijC1:   
The kijC1 containing insert of pHJK-1-115B was recovered as a 3-kb XbaI-SacI 
fragment, within which the upstream kijB1 and downstream kijC2 genes were both 
truncated, and subcloned into the corresponding restriction sites of pUC18, yielding p1-
126C. The XbaI-EcoRI fragment from p1-126C and the kijD9 containing EcoRI-NsiI 
fragment from p1-77B were ligated into the XbaI-NsiI sites of pLitmus28 to generate p1-
128A. The kijC1-kijD9 containing insert of p1-128A was recovered as an XbaI-NsiI 
fragment and ligated into the corresponding restriction sites of pWHM467, which yielded 
p1-139A. The 2.5-kb XbaI-EcoRI fragment containing kijC3 and kijC4 from p1-77C was 
ligated into the corresponding restriction sites of pWHM468 to generate p1-139B, from 
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which the gene containing insert was isolated as a 2.5-kb PacI-EcoRI fragment and 
ligated into the corresponding restriction sites of pWHM467 to generate p1-142B. The 
gene-containing insert of p1-139A was isolated as a PacI-NsiI fragment and ligated into 
p1-142B, previously digested with PacI and NsiI to generate p2-11A.     
 
3.2.14 KIJANIMICIN GLYCOSYLTRANSFERASES C1, C3, C4 AND A4: IN VIVO 
CONSTRUCTION OF THE TETRASACCHARIDE BRANCHED CHAIN  
STEP 1: PREPARATION OF PDIG PROTOPLASTS. The pDIG plasmid containing the 
entire digitoxose biosynthetic pathway was transformed into S. lividans TK-24 
protoplasts according to the procedure described previously. After selection on R1R2 
plates supplemented with 50 µg/mL apramycin, a plate with confluent mycelial growth, 
expressing the secondary metabolites (as observed by pigment in agar plates) common to 
this strain, was used to inoculate a 10-20 mL culture of YEME media supplemented with 
50 µg/mL apramycin as described previously (section 3.2.4). The culture was grown at 
30 ºC with 250 RPM shaking for 48-72 h, when visible mycelia could be observed in the 
culture. At this time, 10 to 15 mL of the small-scale culture was used to inoculate 50-100 
mL of fresh YEME, supplemented with 50 µg/mL apramycin and 0.5% glycine. This 
culture was grown at 30 ºC for 3 d with 250 RPM shaking and pDIG protoplasts were 
prepared from this culture following the procedure described in section 3.2.4.  
STEP 2: TRANSFORMATION OF GLYCOSYLTRANSFERASE EXPRESSION PLASMIDS INTO 
PDIG PROTOPLASTS. A plasmid containing a kij glycosyltransferase gene under the 
control of the ermE
*
 promoter was transformed into S. lividans TK-24 pDIG protoplasts 
according to the procedure described previously (section 3.2.4 and 3.2.5). After selection, 
a plate with confluent mycelial growth, expressing the secondary metabolites (as seen by 
visible pigment) common to this strain, was used to inoculate a 20 mL culture of YEME 
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media supplemented with 50 µg/mL thiostrepton and 50 µg/mL apramycin using the 
procedure described previously (section 3.2.5). The culture was grown in a sterile culture 
tube with glass beads at 30 ºC with 250 RPM shaking for 48-72 h, at which point mycelia 
were observed in the culture.  
STEP 3: PREPARATION OF PDIG-GT STRAINS FOR FEEDING EXPERIMENTS. At this 
time, the small-scale cultures were used to inoculate fresh R1R2 media (with and without 
sucrose), supplemented with 50 µg/mL thiostrepton and 50 µg/mL apramycin. Plates 
were inoculated with 1 mL of culture and grown at 30 ºC for 3-5 d, or until secondary 
metabolites (pigment) could be observed in the agar.  
STEP 4: FEEDING EXPERIMENTS USING PDIG-GT STRAINS. After 3-4 d, the plates 
were observed to have strong mycelial growth and had turned a reddish-purple color from 
secreted secondary metabolites. At this stage of growth, O-β-D-kijanosyl-(1→17)-
kijanolide (13), kijanimicin A (1), kijanimicin B (17), or kijanimicin C (18) in cold 
10.3% sucrose solution (5 µg/mL agar, 200 µg/plate) was spread onto the plates and 
allowed to dry. The plates were returned to the incubator and grown at 30 ºC for an 
additional 3-5 d.  
STEP 5: HARVESTING AGAR FROM FEEDING EXPERIMENTS USING PDIG-GT STRAINS. 
After the final incubation, the agar was removed from the plastic dishes and transferred to 
2 L wide mouthed Erlenmeyer flasks. Ethyl acetate to cover the plates was added to each 
flask and the agar was extracted overnight. After 16-18 h, the organic extracts were dried 
over Na2SO4. The organic extracts were then transferred to 1L round-bottomed flasks and 
the solvent was removed by rotary evaporation. The wine-colored residue was 
resuspended in CHCl3 and transferred to clean glass sample bottles. 
STEP 6: FEEDING EXPERIMENT SAMPLE PREPARATION: SILICA GEL 
CHROMATOGRAPHY. The crude mixture was separated using a chloroform-methanol step 
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gradient in the presence of 2% acetic acid. The column was flushed with CH3Cl until the 
first yellow pigment eluted and the gradient started at that time. Kijanimicin A (1) eluted 
at 10% methanol + 2% acetic acid, whereas kijanosyl-kijanolide (kij-kij) (13), kij B (17) 
and kij C (18) eluted prior to kij A. Generally, methanol steps included 1%, 2%, 5% and 
10% and each step included 2% acetic acid. Fractions were collected (15 mL) until the 
purple pigment band eluted from the column. Fractions were immediately neutralized 
with 82.5 µL of 8 N ammonium hydroxide. Aliquots (1 mL) of each fraction were 
transferred to Eppendorf tubes and the solvent was removed using a speedvac. The 
concentrated samples were assessed for the presence of kijanimicin compounds by TLC 
using a mobile phase of 10% methanol in chloroform. TLC plates were developed in 
vanillin stain (1.5 g vanillin, 3 mL H2SO4, in 200 mL methanol), and plates were heated 
to visualize spots. Kijanimicin compounds appeared as black spots on a pinkish to 
yellow-ivory background. Fractions were combined based on TLC results and analyzed 
using HPLC. 
STEP 7: HPLC ANALYSIS OF FEEDING EXPERIMENT SAMPLES USING C-18 COLUMN. 
HPLC analysis of kijanimicins from feeding experiments was accomplished using several 
different HPLC programs, although all samples were processed using a gradient of 20 
mM ammonium acetate pH 5.5 as eluent A and acetonitrile as eluent B on a C-18 
column. For analytical separations the flow rate was 1 mL/min, while for preparatory 
separations the flow rate was 5 mL/min. In all cases, the detector was set to 240 nm. For 
the initial glycosyltransferase activity test, the gradient began in 10% eluent A and 
remained at 10% for 10 min, after which time, the gradient was increased to 95% B over 
20 min. After which time, the gradient was held at 95% B for 10 min and returned to 10% 
B to equilibrate the column. Under these conditions, O-β-D-kijanosyl-(1→17)-kijanolide 
(13) eluted at 22 min O-β-D-kijanosyl-(1→17)-O-α-L-digitoxosyl-(1→9)-kijanolide (1-
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SC) (14) at 22.5 min, and O-β-D-kijanosyl-(1→17)-O-α-L-digitoxosyl-(1→9)-O-α-L-
digitoxosyl-(1→3)-kijanolide (2-SC) (15) at approximately 22.5 min. To assess the 
production of 15, and afford resolution between 13, 14 and 15 the following program was 
used. The gradient began in 5% eluent A and remained at 5% for 10 min, after which 
time, the gradient was increased to 30% B over 20 min, followed by the elution stage, an 
increase to 40% B over 30 min. After which time, the gradient was increased to 100% B 
over 2 min, held at 100% B for 5 min and returned to 5% B over 4 min and held at 5% B 
for 8 min to equilibrate the column. Under these conditions, O-β-D-kijanosyl-(1→17)-
kijanolide  (13) eluted at 48 min O-β-D-kijanosyl-(1→17)-O-α-L-digitoxosyl-(1→9)-
kijanolide (1-SC) (14) at 52 min, and O-β-D-kijanosyl-(1→17)-O-α-L-digitoxosyl-
(1→9)-O-α-L-digitoxosyl-(1→3)-kijanolide (2-SC) (15) at approximately 53 min. For the 
glycosyltransferase activity test using (18) as the substrate, the gradient began in 10% 
eluent A and remained at 10% for 10 min, after which time, the gradient was increased to 
80% B over 20 min. After which time, the gradient was held at 95% B for 10 min and 
returned to 10% B to equilibrate the column. Under these conditions, kijanimicin C (18) 
eluted at 28.5 min, and 32-deoxy-O-β-D-kijanosyl-(1→17)-kijanolide (20) eluted at 29 
min. All other experiments employed a gradient that began in 5% eluent A and remained 
at 5% for 5 min, after which time, the gradient was increased to 30% B over 10 min, 
followed by the elution stage, an increase to 70% B over 35 min. After which time, the 
gradient was increased to 100% B over 2 min, held at 100% B for 5 min and returned to 
5% B over 4 min and held at 5% B for 8 min to equilibrate the column. Under these 
conditions using an analytical scale column, kijanimicin A (1), the major product, eluted 
at 33 min, kijanimicin B (17) eluted at 41.1 min, kijanimicin C (18) at 47.4 min, O-β-D-
kijanosyl-(1→17)-kijanolide (13) at 27.5 min and ECK-1 (19) at 29.8 min.  
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3.2.15 KIJANIMICIN GLYCOSYLTRANSFERASE C4: IN VIVO GENERATION OF 
COMPOUND 15 
Using the previously constructed S. lividans strain containing the pDIG and KijC4 
plasmids, the following feeding experiments were carried out. 
STEP 1: FEEDING EXPERIMENTS USING PDIG-GTC4 STRAINS. After 3-4 d, the plates 
were observed to have strong mycelial growth and had turned a reddish-purple color from 
secreted secondary metabolites. At this stage of growth, O-β-D-kijanosyl-(1→17)-
kijanolide (13) in cold 10.3% sucrose solution (5 µg/mL agar, 200 µg/plate) was spread 
onto the plates and allowed to dry. The plates were returned to the incubator and grown at 
30 ºC for an additional 3-5 d.  
STEP 2: HARVESTING AGAR FROM FEEDING EXPERIMENTS USING PDIG-GT STRAINS. 
After the final incubation, the agar was removed from plastic dishes and transferred to 2 
L wide mouthed Erlenmeyer flasks. Ethyl acetate to cover the plates was added to each 
flask and the agar was extracted overnight. After 16-18 h, the organic extracts were dried 
over Na2SO4, and the solvent was removed by rotary evaporation. The wine-colored 
residue was resuspended in CHCl3 and transferred to clean glass sample bottles. 
STEP 3: FEEDING EXPERIMENT SAMPLE PREPARATION: SILICA GEL 
CHROMATOGRAPHY. The crude mixture was separated using a chloroform-methanol step 
gradient in the presence of 2% acetic acid. Generally, methanol steps included 1%, 2%, 
5% and 10% and each step included 2% acetic acid. O-β-D-kijanosyl-(1→17)-kijanolide 
(kij-kij) (13), O-β-D-kijanosyl-(1→17)-O-α-L-digitoxosyl-(1→9)-kijanolide (1-SC) (14),  
O-β-D-kijanosyl-(1→17)-O-α-L-digitoxosyl-(1→9)-O-α-L-digitoxosyl-(1→3)-kijanolide 
(2-SC) (15), eluted within the first 10-20 fractions (1-2% methanol). Fractions were 
collected (15 mL) until the purple pigment band eluted from the column. Fractions were 
immediately neutralized with 82.5 µL of 8 N ammonium hydroxide. Aliquots (1 mL) of 
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each fraction were transferred to Eppendorf tubes and the solvent was removed using a 
speedvac. The concentrated samples were assessed for the presence of kijanimicin 
compounds by TLC using a mobile phase of 1:2 hexanes: ethyl acetate with 2% acetic 
acid. TLC plates were subjected to development twice in the same solvent system before 
visualization. TLC plates were developed in vanillin stain (1.5 g vanillin, 3 mL H2SO4, in 
200 mL methanol), and plates were heated to visualize spots. Kijanimicin compounds 
appeared as black spots on a pinkish to yellow-ivory background. Compounds 13, 14 and 
15 had approximate Rf values of 0.31, 0.11 and 0.06, respectively. Fractions were 
combined based on TLC results and the organic solvent was removed under vacuum.  
The remaining aqueous solvent was removed using the speedvac until samples were dry. 
The dry samples were resuspended in methanol and further purified using HPLC. 
STEP 4: HPLC PURIFICATION OF COMPOUND 15 USING C-18 COLUMN. HPLC 
purification of (15) from feeding experiments was accomplished using several different 
HPLC programs, although all samples were processed using a gradient of 20 mM 
ammonium acetate pH 5.5 as eluent A and acetonitrile as eluent B on a semi-preparative 
scale C-18 column, with a flow rate of 5 mL/min and the detector was set to 240 nm. To 
afford resolution between 13, 14 and 15, the gradient began in 5% eluent A and remained 
at 5% for 10 min, after which time, the gradient was increased to 30% B over 20 min, 
followed by the elution stage, an increase to 40% B over 30 min. After which time, the 
gradient was increased to 100% B over 2 min, held at 100% B for 5 min and returned to 
5% B over 4 min and held at 5% B for 8 min to equilibrate the column. Under these 
conditions, O-β-D-kijanosyl-(1→17)-kijanolide  (13) at 42 min O-β-D-kijanosyl-(1→17)-
O-α-L-digitoxosyl-(1→9)-kijanolide (1-SC) (14) at 46 min,  O-β-D-kijanosyl-(1→17)-O-
α-L-digitoxosyl-(1→9)-O-α-L-digitoxosyl-(1→3)-kijanolide (2-SC) (15) at 
approximately 50 min. 
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3.2.16 KIJANIMICIN SUSCEPTIBILITY OF S. LIVIDANS  
 S. lividans TK-24 was cultured on agar plates, prepared using R1R2 media and 40 
µg of each compound, kijanimicin A (1), kijanimicin B (17), kijanimicin C (18), and O-
-D-kijanosyl-(117)-kijanolide (13) were applied in a Φ of 0.1 cm. The plate was 
incubated at 30 ºC for 2-3 d, and growth inhibition radius for each compound was 
measured. 
 
3.2.17 EXPRESSION CONSTRUCTS FOR GLYCOSYLTRANSFERASES (IN VITRO) 
 
Generation of the kijC3 and kijC4 expression constructs (1-73A and 1-73B 
respectively) were described in sections 3.2.13.1 and 3.2.13.2. 
 
3.2.17.1 Generation of the KijD9 In Vitro Expression Construct:  
A 1.2-kb fragment comprising kijD9 was amplified from the cosmid HZ-14 by 
PCR using the forward primer 5′-GATCGATCATATGCGGGTTCTGTTCACC-3′ with 
an engineered NdeI site as indicated by italicized bases, and the reverse primer 5′-
TATTAAGCTTCTACCCCCGGACCAGAGC-3′ with the engineered HindIII site as 
indicated by italicized bases. Protocols for PCR, cloning, digestion and transformation 
were followed as described above. The plasmid generated by this protocol is 
pWHM3(ermE*)-kijd9, which produces an N-terminal His6 tagged KijD9 protein.  
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3.2.17.2 Generation of the KijA4 In Vitro Expression Construct:  
A 1.2-kb fragment comprising kijA4 was amplified from the cosmid HZ-14 by 
PCR using the forward primer 5′-CACGATCCATATGCTGTTGCGAATCCTGTTCAC-
CG-3′ with an engineered NdeI site as indicated by italicized bases, and the reverse 
primer 5′-CATGAAGCTTGGCCGGTGCGGTCAC-3′ with the engineered HindIII site as 
indicated by italicized bases. Protocols for PCR, cloning, digestion and transformation 
were followed as described above.  The plasmid generated by this protocol is 
pWHM3(ermE*)-kija4, which produces an N-terminal His6 tagged KijA4 protein.  
 
3.2.17.3 Generation of the KijC1 In Vitro Expression Construct:  
A 1.2-kb fragment comprising kijC1 was amplified from the cosmid HZ-14 by 
PCR using the forward primer 5′-CTCCGTTCATATGCGCGTTCTGTTCACCCTG-3′ 
with an engineered NdeI site as indicated by italicized bases, and the reverse primer 5′-
GAACAAGCTTTCAGACCAGCCGCTCCAG-3′ with the engineered HindIII site as 
indicated by italicized bases. Protocols for PCR, cloning, digestion and transformation 
were followed as described above.  The plasmid generated by this protocol is 
pWHM467(ermE*)-kijc1, which produces an N-terminal His6 tagged KijC1 protein. 
 
3.2.17.4 General Procedure for the Growth of Cells Expressing Kijanimicin 
Glycosyltransferases  
A plasmid containing a kij glycosyltransferase gene under the control of the 
ermE* promoter was transformed into S. lividans TK-24 protoplasts according to the 
procedure described previously. After selection, a plate with confluent mycelial growth, 
expressing the secondary metabolites (as seen by visible pigment) common to this strain, 
was used to inoculate a 20 mL culture of YEME media supplemented with 50 µg/mL 
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thiostrepton as previously described in section 3.2.4. The culture was grown in a sterile 
culture tube with glass beads at 30 ºC with 250 RPM shaking for 48-72 h, when mycelia 
was observed in the culture. At this time, 10 to 15 mL of the small-scale culture was used 
to inoculate 1 L of fresh YEME, supplemented with 50 µg/mL thiostrepton. This culture 
was grown at 30 ºC for 3 days with 250 RPM shaking.  
After three days, the culture was observed to have strong mycelial growth and had 
turned a pink/purple color from excreted secondary metabolites. At this stage of growth, 
the mycelial pellet was harvested by centrifugation at 6700 g, 4 ºC for 20 min.  After the 
initial centrifugation, the pellet was washed with water and re-pelleted under the same 
conditions to remove any remaining media. The mycelia were stored at -80 ºC until 
protein extraction or processed immediately. 
 
3.2.17.5 Purification of the Kijanimicin Glycosyltransferase Proteins from S. 
lividans.  
STEP 1: CRUDE EXTRACT PREPARATION. The mycelia were resuspended in 20 mL of 
Lysis Buffer II (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole with 10% glycerol, 
pH 8.0) and 1 mg/mL lysozyme was added to the mixture. The solution was stirred every 
15 min for 1 h and sonicated for a total pulse time of 3 min, using a program of 10 s 
bursts with 30 s cooling intervals to complete the lysis of the bacterial cell wall. After 
sonication, the solution was clarified by centrifugation at 4 ºC for 20 min at 10,000 g.  
STEP 2: AMMONIUM SULFATE PRECIPITATION. The supernatant was decanted into a 
chilled 40 mL centrifuge tube on ice and a small stir bar was added. Ammonium sulfate 
(to 70%) was added slowly over 30 min while the supernatant was stirred slowly on ice. 
After the ammonium sulfate was added, the solution was transferred to an orbitron 
mixing device at 4 ºC and allowed to mix for 30 min to 1 h. After the solution was mixed, 
 186 
the ammonium sulfate precipitated solution was centrifuged at 18,000 g for 30 min at 4 
ºC to isolate the proteins. The supernatant was carefully decanted and the pellet 
containing the protein of interest was resuspended in 5-10 mL of Lysis buffer II, and 
dialyzed against 3 L of Dialysis buffer IIa (50 mM NaH2PO4, 300 mM NaCl, 10 mM 
imidazole with 10% glycerol, pH 8.0), at 4 ºC, for 3 h with changes of 1 L at the end of 
each h.  
STEP 3: NI-NTA CHROMATOGRAPHY. After dialysis, the protein mixture was 
introduced to 2 mL of Ni-NTA resin prepared by washing three times in Lysis buffer II, 
and bound overnight at 4 ºC on the orbitron mixer. After Ni-NTA binding, the slurry was 
introduced into a 1 × 25 cm open column and allowed to flow through by gravity. The 
column was washed twice with 25 mL of Wash Buffer II  and the protein was eluted with 
12 mL of Elution Buffer II. Elution fractions (1 mL) were collected and analyzed by 
SDS-PAGE and Western Blot. Fractions that appeared to contain the protein of interest as 
detected by Coomassie staining were combined, dialyzed against 3 L of Dialysis buffer 
II, at 4 ºC, for 3 h with changes of 1 L at the end of each h. After dialysis, the protein was 
concentrated under N2 gas at 4 ºC using an Amicon stirred cell system equipped with a 
YM-10 membrane. The protein was dispensed into aliquots, flash frozen in liquid N2 and 
stored at -80 ºC until use. 
 
3.2.17.6 Purification of KijA4 and KijC1 from E. coli.  
STEP 1: GROWTH OF E. COLI CELLS. An overnight culture of E. coli BL21(DE3)-
pET-kijA4 or E. coli BL21 Rosetta II (DE3)-pET-kijC1 was grown in LB medium 
supplemented with kanamycin (50 μg/mL) (and chloramphenicol (35 µg/mL) for kijC1) 
at 37 °C. An aliquot (2 mL) of overnight culture was used to inoculate 1 L of LB 
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supplemented with kanamycin (50 μg/mL). To express kijC1, typically, 3 L of culture 
was incubated at 30 °C. The culture was allowed to grow for an additional 18 h at 30 °C, 
at which point the cells were harvested by centrifugation at 4,500 g for 15 min at 4 °C, 
and stored at -80 °C. To express kijA4, typically, 3 L of culture was incubated at 30 °C 
with 250 RPM shaking until the OD600 of the culture reached 0.3, at which point the 
temperature was reduced to 24 ºC. The cultures were allowed to grow for an additional 
hour and the OD600 reached 0.4. The cultures were induced with IPTG to a final 
concentration of 50 M, and allowed to grow for an additional 15 h at 18 or 22 ºC. The 
cells were harvested by centrifugation at 4,500 g for 20 min at 4 ºC and stored at –80 ºC 
until protein purification.  
STEP 2: CRUDE EXTRACT PREPARATION. The cells were resuspended in 20 mL of 
Lysis Buffer II and 1 mg/mL lysozyme was added to the mixture. The solution was 
stirred every 15 min for 1 h and sonicated for a total pulse time of 2 min, using a program 
of 10 s bursts with 30 s cooling intervals to complete the lysis of the bacterial cell wall. 
After sonication, the solution was clarified by centrifugation at 4 ºC for 20 min at 10,000 
g.  
STEP 3: NI-NTA CHROMATOGRAPHY. The supernatant was introduced to 2 mL of 
Ni-NTA resin prepared by washing three times in Lysis buffer II, and bound overnight at 
4 ºC on the orbitron mixer. After Ni-NTA binding, the slurry was introduced into a 1 × 
25 cm open column and allowed to flow through by gravity. The column was washed 
twice with 25 mL of Wash Buffer II and the protein was eluted with 12 mL of Elution 
Buffer II. Elution fractions (1 mL) were collected and analyzed by SDS-PAGE and 
Western Blot.  
Fractions that appeared to contain the protein of interest as detected by Coomassie 
staining were combined, dialyzed against 3 L of Dialysis buffer II, at 4 ºC, for 3 h with 
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changes of 1 L at the end of each h. After dialysis, the protein was concentrated under N2 
gas at 4 ºC using an Amicon stirred cell system equipped with a YM-10 membrane. The 
protein was dispensed into aliquots, flash frozen in liquid N2 and stored at -80 ºC until 
use. Culture and induction conditions were optimized for each enzyme to obtain 
maximum amounts of soluble protein. The gene products were purified by Ni-NTA 
affinity chromatography to near homogeneity.  
 
3.2.18 KIJANIMICIN GLYCOSYLTRANSFERASES C1, C3, C4 AND A4: IN VITRO 
CONSTRUCTION OF THE TETRASACCHARIDE BRANCHED CHAIN  
Kijanimicin glycosyltransferases KijC4, KijC3, KijC1, KijA4 and KijD9 were 
purified from S. lividans in the previous section were utilized in activity assays. 
Kijanolide, obtained through mild acid hydrolysis as described in section 3.2.11 was also 
employed. 
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 TDP-L-digitoxose was biosynthesized according to procedures described in 
Chapter 2. Each glycosyltransferase protein was incubated with the crude TDP-L-
digitoxose and kijanolide substrates to generate the product in vitro and reactions were 
monitored by TLC and analytical HPLC. Reactions were carried out in triplicate and 
conditions were varied in each trial to test the glycosyltransferase activity. 
3.2.18.1 ATTEMPT I 
In this set of reactions, the pH varied between 7.5 to 9. Reactions consisted of the 
following: 0.1 mM crude TDP-L-digitoxose (10), 100 µM KijC4,10 mM MgCl2, 1.2 mM 
kij-kij (in MeOH) (13), 1 mg/mL BSA, and 50 mM Tris (pH 7.5-9.0) in a final reaction 
volume of 180 µL. Aliquots (30 µL) were removed from the reaction at various time 
points (0 h, 30 min, 1 h, 2 h, 4 h, overnight) and flash frozen. Samples were thawed and 
proteins were removed using a YM-10 centrifugal filter (20 min 14,000 g, 4 ºC). The 
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flow through was retained and subjected to HPLC equipped with a C-18 column, 
following the HPLC procedure previously described. 
3.2.18.2 ATTEMPT II 
In this set of reactions, TDP-L-digitoxose was generated in situ using the 4-
ketoreductase from the mycarose pathway, TylC2, which was previously purified by Dr. 
Haruko Takahashi.
306
 Reactions consisted of the following: 1 mM TDP-4-keto-2,6-
dideoxy-D-glucose, 10 nM KijD11, 10µM TylC2, 100 µM KijC4, 10 mM MgCl2, 1.2 
mM kij-kij (13) (in MeOH), 1 mg/mL BSA, 1.4 mM NADPH and 50 mM Tris (pH 9.0) 
in a final reaction volume of 180 µL. Aliquots (30 µL) were removed from the reaction at 
various time points (0 h, 30 min, 1 h, 2 h, 4 h, overnight) and flash frozen. Samples were 
thawed and proteins were removed using a YM-10 centrifugal filter (20 min 14,000 g, 4 
ºC). The flow through was retained and subjected to HPLC equipped with a C-18 
column, following the HPLC procedure previously described. 
3.2.18.3 ATTEMPT III 
In this set of reactions, TDP-L-digitoxose was generated in situ using the 4-
ketoreductase from the digitoxose pathway, KijC2. Reactions consisted of the following: 
1 mM TDP-4-keto-2,6-dideoxy-D-glucose, 10 nM KijD11, 10µM KijC2, 100 µM KijC4 
(or other kijanimicin GT), 10 mM MgCl2, 1.2 mM kij-kij (13) (in MeOH), 1 mg/mL 
BSA, 10% glycerol, 1.4 mM NADH and 50 mM Tris (pH 9.0) in a final reaction volume 
of 200 µL. Aliquots (40 µL) were removed from the reaction at various time points (0 h, 
2 h, 4 h, 8h, overnight) and flash frozen. Samples were thawed and proteins were 
removed using a YM-10 centrifugal filter (20 min 14,000 g, 4 ºC). The flow through was 
retained and subjected to HPLC equipped with a C-18 column, following the HPLC 
procedure previously described. 
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3.2.18.4 ATTEMPT IV 
In this set of reactions, TDP-L-digitoxose was generated in situ using the 4-
ketoreductase from the digitoxose pathway, KijC2. The substrates were varied as well, 
using both 13 and 15 for the next reaction steps. Reactions consisted of the following: 2 
mM TDP-4-keto-2,6-dideoxy-D-glucose, 20 nM KijD11, 20 µM KijC2, 30 µM KijGT, 
10 mM MgCl2, 1.2 mM 2SC (15) or 1.2 mM kij-kij (13) (in MeOH), 10% glycerol, 1.4 
mM NADH and 50 mM Tris (pH 9.0) in a final reaction volume of 200 µL. Aliquots (40 
µL) were removed from the reaction at various time points (0 h, 2 h, 4 h, 8h, overnight) 
and flash frozen. Samples were thawed and proteins were removed using a YM-10 
centrifugal filter (20 min 14,000 g, 4 ºC). The flow through was retained and subjected to 
HPLC equipped with a C-18 column, following the HPLC procedure previously 
described. 
3.2.18.5 ATTEMPT V 
In this set of reactions, TDP-L-digitoxose was generated in situ using the 4-
ketoreductase from the digitoxose pathway, KijC2. The substrates were varied as well, 
using both 13, 14 and 15 for the aglycone acceptor. Reactions consisted of the following: 
2 mM TDP-4-keto-2,6-dideoxy-D-glucose, 20 nM KijD11, 20 µM KijC2, 25 µM KijGT, 
10 mM MgCl2, 1.2 mM 2SC (15) 1.2 mM 1SC (14) or 1.2 mM kij-kij (13) (in DMSO), 
10% glycerol, 2.4 mM NADH and 25 mM Tris (pH 8.0) in a final reaction volume of 200 
µL. Aliquots (50 µL) were removed from the reaction at various time points (0 h, 8 h, 16 
h and 24) and quenched in 250 µL methanol. Samples were centrifuged, the supernatant 
transferred to fresh tubes and concentrated using a speedvac. Samples were resuspended 
in 100 µL methanol and subjected to HPLC equipped with a C-18 column, following the 
HPLC procedure previously described. 
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3.2.19 REVERSE GLYCOSYLTRANSFERASE REACTIONS 
KijC1, KijA4 and KijC4 were examined for their ability to catalyze the formation 
of TDP-L-digitoxose or kijanimicin A biosynthetic intermediates from TDP and 
kijanimicin A. Reaction conditions were as follows #1) 1 mM kijanimicin A (1), 10 mM 
TDP, 10 mM MgCl2, 10 µM GT, 50 mM Tris pH 9 in a final volume of 180 µL.  
Reaction #2: 1 mM kijanimicin (1), 100 µM TDP, 10 mM MgCl2, ~10 µM GT, 10 µM 
KijC4, 10 µM kij-kij (13),  50 mM Tris pH 7.5 in a final volume of 180 µL. Reaction #3: 
1 mM kijanimicin (1), 1 mM kij-kij (13), 100 µM TDP, 10 mM MgCl2, ~10 µM GT, 1 
mg/mL BSA in 50 mM Tris pH 7.5 in a final volume of 180 µL. Reaction #4: 10 mM 
kijanimicin (1), 10 mM TDP, 10 mM MgCl2, ~10 µM GT, 1 mg/mL BSA, 50 mM Tris 
pH 7.5 in a final volume of 100 µL. Total final concentration of methanol was less than 
5% in each reaction. All reactions were incubated overnight, 1-3 were incubated at room 
temperature and reaction 4 was heated to 30 ºC. Reactions were quenched by the addition 
of 2 volumes of methanol to precipitate proteins. Proteins were removed from the 
reactions by centrifugation (20 min 16,100 g, 4 ºC). Supernatant was retained and 
subjected to HPLC equipped with a C-18 column, following the HPLC procedure 
previously described. 
 
3.3 RESULTS AND DISCUSSION 
 
3.3.1 KIJANIMICIN PRODUCTION AND ISOLATION 
To obtain kijanimicin (1) and other kijanolide compounds (17-19), A. kijaniata 
was cultured by the method of Waitz and the secreted secondary metabolites were 
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extracted with ethyl acetate followed by fractionation on silica gel column.
 243,68  
Cultures 
of wild-type A. kijaniata were grown using the procedure of Waitz et al.
 
with several 
modifications. 
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  The major modification was that the cultures were grown aerobically. 
The culture media was harvested and the kijanimicin compounds were isolated from the 
media by extraction with ethyl acetate followed by purification using flash 
chromatography and HPLC.  
Flash chromatography employed a chloroform-methanol gradient in the presence 
of 2% acetic acid. Fractions were collected and immediately neutralized with ammonium 
hydroxide. TLC assessment used a mobile phase of 10% methanol in chloroform, or less 
frequently hexanes: ethyl acetate (1:2). TLC plates were developed in vanillin stain, and 
plates were heated to visualize spots. Kijanimicin compounds appeared as black spots on 
a pinkish to yellow ivory background. Kijanimicin A (1), the major product, eluted at 
10% methanol + 2% acetic acid, and kijanimicin B (17) and C (18) eluted just prior to 
kijanimicin A. Fractions were combined based on purity as assessed by TLC and were in 
some cases further purified by HPLC. Under the previously reported HPLC conditions, 
kijanimicin A (1), the major product, eluted at 33 min, kijanimicin B (17) eluted at 41.1 
min, kijanimicin C (18) at 47.4 min, O--D-kijanosyl-(117)-kijanolide (13) at 27.5 
min, and ECK-1 (19) at 29.8 min. 
HPLC purified compounds were subjected to analysis by MS and NMR. 
Kijanimicin A (1) was analyzed by positive FT-MALDI-TOF MS to yield m/e 1339.675 
(calculated m/e for [M+Na]
+
 of C67H100N2O24 is 1339.656). The identity of kijanimicin 
was further verified by 
1
H and 
13
C-NMR analysis, and the spectral data were consistent 
with previously reported spectra for kijanimicin.
246
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3.4 A. kijaniata Secondary Metabolites, Kijanimicins (A, B and C) and Minor 
Products ECK-1 and O-β-D-(1-17)-kijanosyl-kijanolide 
 
High resolution MS (negative FAB mass spectroscopy) for kijanimicins B (17) 
and C (18) yielded 1025.5248 (calculated m/e C54H77N2O17, [M-H]
-
 1025.5222) and 
1299.6645 (calculated m/e for C67H99N2O23, [M-H]
-
 1299.6639), respectively. Through 
NMR analysis, the structures of these two compounds were firmly designated as 
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kijanimicin B (17) and kijanimicin C (18). The isolation yields of kijanimicin B (17) and 
kijanimicin C (18) were 5 mg and 2 mg per liter of media, respectively.  
Other minor compounds were also detected in the HPLC separation. One of these 
was predicted to be desmethyl kijanimicin B, which gave m/e [M-H]-, 1285 using low 
resolution FAB mass analysis. Using a semi-preparative HPLC column (and the gradient 
profile described in section 3.2.10) with a flow rate of 5 mL/min, kijanimicin C (18), the 
proposed desmethyl kijanimicin B, and kijanimicin B (17) eluted at 36, 39, and 42 min 
respectively. However, O-β-D-kijanosyl-(1→17)-kijanolide (16a or 16b), which 
possesses three digitoxose moieties was not found in any of the extraction samples or 
fractions, although we searched diligently for its presence. This indicated that the three-
digitoxose containing compound is not accumulated at detectable levels in A. kijaniata.  
These results are somewhat surprising if the digitoxose moieties are added 
sequentially as we originally proposed. If the sugars are indeed added sequentially, we 
expect to observe compounds carrying 1, 2, 3, and 4 digitoxose sugars. There are three 
possible interpretations of this data. One possibility is that the export of the 3-sugar 
compound is somehow impeded, and the cellular export machinery can only export the 2- 
and 4-sugar compounds. This possibility was quickly discarded, as the addition of one 
sugar is such a small change of the overall structure of the product.  A more likely 
scenario is that the protein(s) responsible for the latter steps of digitoxose attachment are 
very fast, much faster than the protein(s) responsible for the initial 2-sugar attachment. 
Another possibility is that there is only one protein responsible for the last two sugar 
transfers and there is little protein-substrate dissociation between the successive transfers 
of the third and fourth sugar. In a sequential transfer scenario catalyzed by a single 
enzyme, there would be no need for the growing natural product to dissociate from the 
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active site, thus the addition of the third sugar would be followed immediately by the 
addition of the fourth and final digitoxose sugar. 
To differentiate between the latter two possibilities and to determine the catalytic 
roles of these glycosyltransferases in sugar attachments, glycosyltransferase assays were 
carried out to determine the order of attachment of the sugars and which protein is 
responsible each specific transfer. To carry out these assays, both a source of TDP-L-
digitoxose and the kijanolide aglycone are required.  In the previous Chapter, the TDP-L-
digitoxose biosynthetic pathway was elucidated and thus was applied to prepare the TDP-
sugar donor in vivo and in vitro. A synthetic approach to obtain kijanolide was ruled out 
due to the complexity of the structure.  Thus, we chose to use chemical hydrolysis of the 
kijanimicin product obtained through bacterial production to prepare the desired 
kijanolide and its derivatives. 
 
3.3.2 KIJANIMICIN AGLYCONE GENERATION AND PURIFICATION     
To generate O-β-D-kijanosyl-(1→17)-kijanolide (13) for use in the glycosylation 
experiments, we obtained kijanimicin A (1) in good yield and removed the 
tetrasaccharide branched chain by mild acid hydrolysis. After neutralization and flash 
chromatography, O-β-D-kijanosyl-(1→17)-kijanolide (13) was isolated and identified by 
high resolution using negative FAB MS, which yielded 781.3925 (calculated for m/e [M-
H]
-
 for C42H57N2O12, 781.3912), and further verified by 
1
H and 
13
C-NMR analysis. From 
this reaction, 140 mg (35% yield) of O-β-D-kijanosyl-(1→17)-kijanolide (13), was 
obtained. This aglycone was used in both in vitro and in vivo biosynthetic assays.  
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3.3.3 KIJANIMICIN GLYCOSYLTRANSFERASES C1, C3, C4 AND A4: IN VIVO 
CONSTRUCTION OF THE TETRASACCHARIDE BRANCHED CHAIN  
With the kijanolide aglycone in hand, in vivo assays were attempted using S. 
lividans. A plasmid, pDIG, was constructed to generate TDP-L-digitoxose in S. lividans 
TK-24 strain. Each of the putative glycosyltransferase genes kijA4, kijC1, kijC3, kijC4 
and kijD9 was cloned into the pWHM467-ermE* vector derivative and the genes were 
constitutively expressed in the digitoxose producing strain of S. lividans. Each of these S. 
lividans strains contained the pDIG plasmid, as well as one or more of the kijanimicin 
glycosyltransferase genes.  
O--D-Kijanosyl-(117)-kijanolide (13) prepared as described in the previous 
section, was fed in a sucrose solution to multiple plates containing strains of S. lividans 
expressing the genes in the TDP-L-digitoxose biosynthetic pathway and one or more of 
the kijanimicin glycosyltransferases. 
245
 As a control, KijD9, the glycosyltransferase 
proposed to catalyze kijanose attachment was used, as it should not have activity towards 
the digitoxose substrate. Each strain was assayed for bioconversion of the kijanolide 
aglycone to the expected glycosylated products. Extraction and analysis of the 
glycosylated products by HPLC, MS and NMR demonstrated that glycosyltransferase 
KijC4 catalyzed the attachment of the first digitoxose to the aglycone (13) generating a 
new compound 14, as shown in Figure 3.5.  
Product 14 was isolated and subjected to MS and NMR analysis. These 
experiments were repeated and slightly different HPLC conditions were used to optimize 
the separation between compounds 13 and 14 (Figure 3.6). 
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3.5 KijC4 Catalyzes the First L-digitoxose Attachment to the Kijanolide 
Aglycon (13) 
 
 
What was unexpected and surprising is that the protein KijC4 appears to also 
catalyze a second digitoxose addition, albeit at very low efficiency. These reactions were 
repeated several times, and the outcomes were reproducible. Interestingly, KijC4 not only 
transfers the first 2 digitoxose moieties to the kijanolide aglycone, by appears to be 
 
HPLC traces of S. lividans extracts showing the bioconversion of 13 to 14. Bacterial 
strains containing glycosyltransferases KijC4, KijC3, KijC1, KijA4 and KijD9 were fed  
5 µg/mL agar (13) and grown for 72-128 h. Plates were extracted and kijanimicin 
compounds recovered by flash chromatography, concentrated and analyzed by HPLC. 
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capable of catalyzing the transfer of a third digitoxose. The one- (14) and two-sugar (15) 
containing products shown in figure 3.6 were analyzed by MS and 
1
H-NMR.   
 
3.6 KijC4 Catalyzes the Successive Transfer of Two TDP-L-digitoxose 
Moieties in vivo 
 
 
 
 
 
 
 HPLC traces of S. lividans extracts showing the bioconversion of 13 (aglycone) to 14 
(one digitoxose) and 15 (two digitoxose). Bacterial strains containing GTs KijC4, C3, 
D9, and a construct expressing multiple GTs (D9, C4, C3 and C1) were fed 5 µg/mL agar 
(13) and grown for 72-128 h. Plates were extracted and kijanimicin compounds recovered 
by flash chromatography, concentrated and analyzed by HPLC. 
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3.3 Successive Glycosyltransferase Reactions Catalyzed by KijC4 
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The new compound (14) was found to have an (m/e), [M-H]; 911.458, calculated 
for C48H68N2O15: (m/e), [M-H] 911.454, while compound (15) was found to have an 
(m/e), [M-H]; 1041.518, calculated for C54H78N2O18: (m/e), [M-H] 1041.517. Further 
characterization by NMR confirmed the structures for the 1- and 2-sugar compounds as 
shown in Scheme 3.3.  As mentioned previously, a 3-sugar compound (16a or 16b) was 
isolated at very low yields. It was postulated that KijC4 is responsible for the attachment 
of the first two digitoxosyl moieties and also catalyzes the coupling of a third digitoxose 
in the absence of the real glycosyltransferase involved in the transfer of the third 
digitoxose moiety, which at this stage we reasoned could be either KijC3, KijC1 or 
KijA4. 
Examining compound 15, it was noted that this compound was very similar to 
kijanimicin C (18), differing only in the presence or absence of the hydroxyl group at the 
C-32 position. The feeding experiments were repeated in an attempt to identify the 
glycosyltransferases responsible for the subsequent digitoxose attachments. For these 
feeding experiments, kijanimicin C (18) was fed to plates containing strains of S. lividans 
containing pDIG and plasmids with each kijanimicin glycosyltransferase. We expected to 
observe the formation of 16a or 16b in one of these experiments with KijC1, KijC3 or 
KijA4, which would reveal the identity of the glycosyltransferase catalyzing the third 
digitoxose attachment.  
When results from these experiments were analyzed, it was discovered that the 
putative glycosyltransferases KijC1 and KijA4 have apparent glycosidase activity 
towards kijanimicin C, and do not demonstrate glycosyltransferase activity, as shown in 
Figure 3.7.  Note that a different HPLC program was utilized in this set of experiments to 
ensure separation between the expected 2-, 3-, and potential 4-sugar compounds.  
 
 201 
 
3.7 KijC1 and KijA4 Demonstrate Glycosidase Activity Toward Kijanimicin C 
(18) 
 
 
The substrate, kijanimicin C (18) with (m/e), [M-H] 1025.525 had previously 
been characterized by 
1
H and 
13
C-NMR. In strains producing the KijC1 and KijA4 
proteins, a new peak (20) was formed. We postulated that the new peaks could be 16a 
and/or 16b, leaving KijC3 as a non-functional glycosyltransferase. Upon analysis by MS 
 
HPLC traces of S. lividans extracts showing the bioconversion of 18 (kijanimicin C) to  
20 (32-deoxykijanolide). Bacterial strains containing glycosyltransferases KijC4, KijC3, 
KijC1, KijA4 and KijD9 were fed 5 µg/mL agar (18) and grown for 72-128 h. Plates 
were extracted and kijanimicin compounds recovered by flash chromatography, 
concentrated and analyzed by HPLC. Authentic standard for (18) shown in the bottom 
trace. 
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and NMR, it was found that the new peak was not derived from the formation of 3-sugar 
compound (16a or 16b) as we expected, but resulted from the formation of a new 
compound, O--D-kijanosyl-(117)-32-deoxykijanolide (20).  
 
3.4 KijA4 and KijC1 Catalyzed Reactions 
 
 
These results were quite disparate from what was expected. In the originally 
proposed pathway, each of 5 glycosyltransferases catalyzes the transfer of 1 of the 5 
sugars to the kijanolide aglycone. Moreover, we reasoned that KijD9, due to its 
divergence from all other glycosyltransferases in the pathway is responsible for the 
coupling of the kijanose moiety to the kijanolide aglycone. The other four proteins 
(KijA4, KijC1, KijC3 and KijC4) are responsible for the transfer of each of the four 
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remaining digitoxose moieties to the kijanosyl-kijanolide (13). However, the above 
observation called for a revision of our previously proposed pathway. 
To examine the glycosidase function of KijA4 and KijC1, strains containing 
genes for kijC1 and kijA4 expression were fed kijanimicin A (1) or kijanimicin B (13) 
and processed as previously described. If these proteins were truly glycosidases, KijA4 
and KijC1 would remove digitoxose moieties from all kijanimicins A, B and C.  
 
3.8 Glycosidase Activity of KijC1 and KijA4 Toward Kijanimicins A and B 
HPLC traces of S. lividans extracts showing the bioconversion of kijanimicin A (1) and 
kijanimicin B (17) to kijanosyl-kijanolide (13) and 32-deoxykijanolide (20), respectively. 
Bacterial strains containing putative GTs KijC1 and KijA4 were fed 5 µg/mL agar (1 or 
17) and grown for 72-128 h. Plates were extracted and kijanimicin compounds recovered 
by flash chromatography, concentrated and analyzed by HPLC. Authentic standards for 
(1, 17, 13 and 20) are shown in the bottom two traces. 
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The feeding experiments clearly showed that KijC1 and KijA4 remove the 
branched chain 4-digitoxose structure from Kijanimicin A (1) and Kijanimicin B (17). 
These reactions yielded compounds O--D-kijanosyl-(117)-kijanolide (13) and O--D-
kijanosyl-(117)-32-deoxykijanolide (20), which were clearly visible on the HPLC 
traces, as seen in Figure 3.8. Thus, the results clearly demonstrate that KijA4 and KijC1 
are in fact glycosidases and not glycosyltransferases as previously proposed. The results 
of the in vivo experiments with KijC4, KijC1 and KijA4 prompted a reevaluation of the 
proposed biosynthetic pathway, as shown in Scheme 3.5. 
In the revised biosynthetic pathway, KijC4 transfers the first 3 L-digitoxose 
moieties to kijanolide in a successive fashion, and the transfer of remaining digitoxose 
moiety is catalyzed by KijC3. In this pathway, KijC4 functions as a processive 
glycosyltransferase, while KijC1 and KijA4 function as glycosidases. It should be noted 
that 3 of the digitoxosyl moieties have an α(1-3) linkage, while the branching digitoxose 
has a β(1-4) linkage. This fact is consistent with the proposed role of KijC4 which 
catalyzes the first 3 sugar additions, (for an unknown reason the 3-sugar intermediate 
evaded isolation). Logically, the 3 α(1-3) linkages could be catalyzed by a single 
processive enzyme, while the remaining β(1-4) linkage formation is catalyzed by a 
different glycosyltransferase. The formation of both α and β glycosidic bonds mediated 
by a single enzyme would require that enzyme to have the ability to catalyze both an 
inverting and a retaining reaction in one active site. There is no precedent for a 
glycosyltransferase enzyme with such ability to catalyze both SN1 and SN2 type reactions 
in one active site.  Thus, it is much more likely that one enzyme (KijC4) catalyzes the α 
(inverting) glycosyltransfer reactions in a processive manner while a different enzyme 
(KijC3) catalyzes the β (retaining) glycosyltransfer. 
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3.5 Revised Kijanimicin Glycosylation Proposed Pathway 
 
These two proteins have 53% pairwise identity, yet must catalyze completely 
different reactions, an inverting SN2 and retaining SN1. It is intriguing to discover 
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glycosyltransferases in a single gene cluster sharing such high sequence identity while 
employing completely different mechanisms. 
Glycosyltransferases responsible for multiple additions are known. For example, 
heterologous expression of the landomycin cluster in a S. fradiae mutant led to the 
production of landomycin A demonstrating that four LanGTs are responsible for the 
formation and attachment of six sugars.
307
 However, the glycosyltransferases LanGT4 
and LanGT1 that are responsible for the attachment of two sugars each, do not act in a 
processive fashion.
71
 In this case, LanGT1 is responsible for the addition of the second 
and fifth sugars, while LanGT4 catalyzes the addition of the third and sixth sugars. The 
intermediate fourth sugar is added by LanGT3, while the initial glycosyltransfer is 
catalyzed by LanGT2.
71
 Thus, although these glycosyltransferases are known to catalyze 
the addition of multiple sugars, they do not catalyze multiple sequential additions in a 
processive fashion, as KijC4 appears to do. 
Processive glycosyltransferases such as PglH in C. jejuni have a single active site 
and catalyze successive reactions by slipping the product through its active site. 
308
 This 
glycosyltransferase is interesting to examine as kinetic studies by the Imperiali group 
have suggested a counting mechanism by which the protein adds three UDP-GalNAc 
residues to the growing glycan chain to complete the final product. 
308
 This model may 
provide insights into the mechanism of the KijC4 glycosyltransferase. PglH has increased 
binding affinity as the length of the glycan chain increases, which in turn slows the rate 
of the glycosyltransferase reaction. 
308
  Thus, the initial glycosyltransfer reactions are 
quite slow due to low binding affinity for the substrate, and the latter reactions are slow 
due to the low catalytic rate of the enzyme. 
308
 Under high substrate (aglycone) 
conditions, the 1-sugar intermediate products dissociated at a high rate from the enzyme, 
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while 2- and 3-sugar compounds were retained longer by PglH. 
308
 In this glycosylation 
pathway, the product is removed from the cell thus preventing product inhibition. 
308
  
Again, it is interesting to note that the 3-sugar compound could not be found in 
the feeding experiments or the extract from the original A. kijaniata culture, although in 
the PglH system, all intermediates were observed in vitro. Perhaps a high affinity for 
KijC4 towards the 3-sugar compound can explain this apparent absence in the 
experimental results. In A. kijaniata cultures, the 3-sugar compound (16a) was not 
observed, perhaps due to the presence of KijC3 in the system. If KijC3 is a fast enzyme, 
there would be no detectable accumulation of its substrate (16a). In some cases, we were 
able to recover a compound with the same (m/e) as the predicted 3-sugar compound, but 
were never able to characterize it by NMR.  
With the new proposal, feeding experiments involving KijC3 were undertaken, in 
an attempt to generate the full-length product kijanimicin A (1) from kijanimicin C (18) 
and the two sugar compound 15. If KijC3 is responsible for the addition of the latter 2 
digitoxosyl moieties, kijanimicin A (1) should be produced. If KijC3 is responsible for 
only the β(1-4) addition, the starting material should be recovered, and no new products 
seen in the HPLC traces. Briefly, compound 15 (2SC) or kijanimicin C (18) was fed to 
strains of S. lividans containing the pDIG and kijC3 expression plasmids. The results 
were as we expected, no new compound was added, thus encouraging the belief that the 
substrate of KijC3 is a 3-sugar intermediate. No new compounds were observed in the 
HPLC traces or by TLC analysis of the crude extracts. In some cases, compound 15 or 
kijanimicin C (18) could not be recovered from the plate extracts and disappeared 
completely from HPLC traces. In other cases, the original compounds were recovered, 
and as expected, additional glycosylation was not observed.  
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3.3.4 S. LIVIDANS SUSCEPTIBILITY TO KIJANIMICINS 
The inability to achieve more than 2 digitoxose additions using the heterologous 
expression system in S. lividans prevented further in vivo work in this platform. We 
reasoned that perhaps the failure to detect the formation of the 3-sugar or 4-sugar (kij A) 
compound could be due to toxicity. If kijanimicin A (1) is toxic to S. lividans, then the 
generation of the compound would cause cell death and thus, no significant amounts of 
product would ever be accumulated in the feeding experiment extractions. Thus, the 
susceptibility of the host bacteria to kijanimicin compounds was tested. By growing S. 
lividans on an agar plate and applying 40 µg of each compound (kijanimicin A (1), B 
(17), C (18) and kij-kij (13)) to the plate, significant zones of growth inhibition were 
observed, as seen in Figure 3.9. Clearly, the more digitoxosyl moieties are added to the 
kijanolide aglycone, the more toxic the compound becomes. Thus, in vivo experiments 
could not be continued successfully in this host, because the generation of compound 15 
(2-SC) is detrimental to the host. 
This may also explain why the 3-sugar intermediate had not been observed in S. 
lividans feeding experiments. Perhaps strains producing significant quantities of the 
compound were killed due to toxicity. Thus, it is likely that KijC4 does in fact attach the 
first 3 digitoxosyl moieties in an α(1-3) linkage, but due to toxicity, only the products 
carrying the first 2 sugars can be observed. Obviously, without the 3-sugar compound in 
hand, we cannot examine its toxicity, although the effect can be inferred from the results 
of kijanimicins B (17) and C (18), which are 4- and 2-sugar compounds respectively, that 
the 3-sugar compound could indeed possess an inherent level of toxicity towards the 
heterologous host. However, the lack of accumulation of the 3-sugar compound (16a) 
may also be attributed to product inhibition or high binding affinity towards KijC4.  
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3.9 S. lividans Susceptibility to Kijanimicins A, B, C and Kijanosyl-Kijanolide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4 KIJANIMICIN GLYCOSYLTRANSFERASES C1, C3, C4 AND A4: IN VITRO 
CONSTRUCTION OF THE TETRASACCHARIDE BRANCHED CHAIN  
To continue these experiments, a shift to an in vitro platform was attempted due 
to the toxicity of kijanimicins towards the host S. lividans. A concern regarding in vitro 
work was the instability of TDP-L-digitoxose previously observed in the biosynthetic 
studies carried out in Chapter 2.  
 
S. lividans growth inhibition due to kijanimicin compounds. Mycelia was plated on agar 
plates and compounds were applied in a radius of 0.1 cm. After incubation at 30 ºC, 
zones of growth inhibition were measured. Growth inhibition was found to correlate with 
the presence of the C-32 hydroxy group and the number of L-digitoxose moieties present. 
Kijanimicin A (1) 
(1) 
Kijanimicin B (17) Kijanimicin C (18) 
(14) 
O--D-Kijanosyl-(117)-kijanolide (13)  
, 2.5 cm 
, 2.0 cm , 1.7 cm 
, 0.5 cm 
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To prepare the kijanimicin glycosyltransferases, each of the putative biosynthetic 
genes (kijA4, kijC1, kijC3, kijC4 and kijD9) was amplified by PCR and cloned into the 
pET28b vector to generate N-terminal His6-tagged proteins. Glycosyltransferase genes 
kijD9, kijA4, kijC1, kijC3 and kijC4 were also introduced into a pWHM467-ermE* vector 
and overexpressed in S. lividans. Glycosyltransferase genes kijA4 and kijC1 were 
subsequently overexpressed in E. coli using the pET28b constructs. Culture conditions 
were optimized for each enzyme to obtain maximum amounts of soluble protein. The 
gene products were purified by Ni-NTA affinity chromatography, to near homogeneity. 
Purification of these proteins from S. lividans afforded very clean proteins, with little to 
no contaminants, as shown in Figures 3.10-3.14. KijA4 and KijC1 from E. coli 
preparations were not as pure. When the remaining glycosyltransferases (KijC4, KijC3, 
and KijD9) were expressed in E. coli, expression and solubility problems were 
encountered. 
For these assays, several substrates were employed. Kijanimicins A (1), B (17) 
and C (18) were obtained through organic extractions of A. kijaniata culture media and 
subsequent purification as described in sections 3.2.9 and 3.2.10.
6
 Compound 15 was 
obtained following the procedures in section 3.2.15. To obtain the kijanolide substrate 13, 
the L-digitoxose tetrasaccharide chain was removed by mild acid hydrolysis of 
kijanimicin A.
245
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3.10 KijC4 Protein Purification from S. lividans 
  
 
 
 
 
 
 
 
 
 
 
 
3.11 KijC3 Protein Purification from S. lividans 
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3.12 KijC1 Protein Purification from S. lividans 
 
 
 
 
 
 
 
 
 
  
 
3.13 KijA4 Protein Purification from S. lividans 
 
 
 
 
 
 
 
 
 
 
 
 
 
187 kDa 
 
 
83  
 
62 
 
47 
 
 
 
32 
 
 
 
25 
 
 
 
6.5 
Min 
15 
14 
13  
KijD9, 
C3, 
C4, & 
C1 
KijC4 
KijC3 
KijD9 
1.6 
1.4 
1.2 
1.0 
0.8 
0.6 
0.4 
KijC1 Protein 
 
Elutions from NiNTA 
Column 
187 kDa 
 
83  
62 
 
47 
 
32 
 
 
25 
 
 
Min 
15 
14 
13  
KijD9, 
C3, 
C4, & 
C1 
KijC4 
KijC3 
KijA4 Protein 
 
Elutions from NiNTA 
Column 
 213 
3.14 KijD9 Protein Purification from S. lividans 
 
 
 
 
 
 
 
 
 
 
Many experiments were performed to elucidate the function of these 
glycosyltransferases. Briefly, each glycosyltransferase protein was incubated with crude 
TDP-L-digitoxose and kijanolide substrate 13 to generate the product in vitro. After room 
temperature incubation, the proteins were removed and the samples were analyzed with 
an HPLC equipped with a C-18 column monitoring at 240 nm, using the previously 
described elution program. The results were disappointing, and no new product was seen 
in these assays. Assay conditions were altered, using different pH and protein 
concentrations, the experiments were repeated to no avail. Due to the instability of the 
digitoxose substrate, it is possible that these reactions were doomed to failure as the 
digitoxose degrades rapidly at room temperature.    
To overcome the inherent instability of the TDP-L-digitoxose sugar, assays were 
designed such that the sugar would be biosynthesized in situ. Glycosyltransferases were 
incubated with kijanolide (13), (14) or (15) substrates in reactions with TDP-4-keto-2,6-
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dideoxy-D-glucose, KijD11 and KijC2. These reactions were monitored by TLC and 
analytical scale HPLC, employing the conditions described above.  
 
3.15 Kijanimicin Glycosyltransferase C4 Activity Towards  O--D-kijanosyl-
(117)-kijanolide (13) 
 
Of all the proteins tested, only KijC4 demonstrated activity towards the kijanolide 
substrate (13), as shown in Figure 3.15. These reactions were repeated and the results 
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GTC4 in vitro reactions demonstrating the conversion of 13 to a new peak. Reactions 
consisted of the following: 1 mM TDP-4-keto-2,6-dideoxy-D-glucose, 10 nM KijD11, 
10µM KijC2, 30 µM KijC4 10 mM MgCl2, 1.2 mM kij-kij (13) (in MeOH), 10% 
glycerol, 1.4 mM NADH and 50 mM Tris (pH 9.0) in a final reaction volume of 200 µL. 
Aliquots (40 µL) were removed from the reaction at various time points (0 h, 2 h, 4 h, 8h, 
overnight) and flash frozen. HPLC analysis employed a C-18 column, using the eluents 
and gradient program previously described. 
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confirmed, a new peak appears and increases over time when (13) is incubated in the 
presence of KijC4, but not in the presence of other glycosyltransferases (KijD9, KijC3, 
KijC1, KijA4), which supports the previous in vivo results suggesting that KijC4 is in fact 
responsible for the first glycosylation steps, however we were unable to obtain MS data 
for the expected product. This reaction was repeated, in an attempt to observe two 
digitoxose additions. We attempted multiple conditions, and for the aglycone used the 
previously characterized compounds 14 and 15 as substrates, as well as freshly generated 
14. Attachment of the second digitoxose was not observed under any of the conditions 
that we attempted. Reasoning that the instability of the TDP-L-digitoxose (10) substrate 
was a limiting factor in these assays, another method for obtaining the sugar was 
undertaken. 
 
3.4.2 REVERSE GLYCOSYLTRANSFERASE REACTIONS 
The Thorson group, among others, has discovered that in the presence of excess 
NDP, some glycosyltransferases will catalyze a reverse reaction and transfer the sugar 
from glycosylated product to NDP, thus creating the NDP-activated sugar and 
aglycone.
299, 309, 310
 Our reactions were designed following the method of Thorson, in 
which an excess of TDP is incubated with glycosyltransferase and glycosylated 
product.
299, 309, 310
 Under these conditions we hoped that the kijanimicin 
glycosyltransferases would catalyze the reverse reaction, transferring the digitoxose sugar 
from the glycosylated product kijanimicin A (1) to TDP, generating a TDP-L-digitoxose 
(10) and an aglycone with one (or more) fewer appended sugar. Thorson and co-workers 
also demonstrated that reverse reactions including a second glycosyltransferase with 
substrate specificity for the NDP-activated sugar and target aglycone can be used to 
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generate a new glycosylated natural product using the NDP-activated sugar generated in 
situ. 
299, 309, 310
  
Previous feeding experiments indicated that KijA4 and KijC1 were not 
glycosyltransferases, but instead are novel glycosidases. In vivo, these proteins remove 
the digitoxosyl branched sugar chain from kijanimicins A, B and C. The reversibility of 
glycosidases has never been demonstrated. We were interested to know if these proteins 
were capable of catalyzing reverse reactions to generate TDP-L-digitoxose (10).  Due to 
the difficulty we encountered with the production and purification of the TDP-L-
digitoxose, and its inherent instability, the ability to generate the TDP-activated sugar in 
situ would allow us to conduct extensive glycosyltransferase assays in vitro.  We also 
examined the ability of KijC4 to catalyze the reverse glycosyltransferase reactions. 
KijC1 and KijA4 from E. coli and KijC1, KijA4 and KijC4 from S. lividans 
preparations were incubated with kijanimicin A overnight in the presence of TDP to 
determine if they could catalyze the reverse reaction as seen in vivo. After incubation, the 
samples were divided and analyzed using the Carbopac PA-1 and C-18 HPLC columns to 
assess both the formation of TDP-L-digitoxose (10), and the reduction of kijanimicin A 
(1), respectively. In these experiments, the reverse reactions were not observed, nor did 
we observe a decrease in the amount of kijanimicin A (1). These results indicated that 
most likely the KijC1 and A4 proteins are not active in vitro, while KijC4 does not 
appear to catalyze the reverse reaction with the kijanimicin A substrate. It is may be that 
the addition of the β-linked sugar in kijanimicin A precludes the possibility of the reverse 
reaction of KijC4. In terms of the failure of KijA4 and KijC1 to catalyze the reverse 
reaction, it is unclear whether the purification conditions or reaction conditions resulted 
in protein inactivity, although the possibility exists that the proteins were folded 
incorrectly during heterologous expression. There is no way to examine folded state of 
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the proteins and compare it to the native proteins, as we were unable to manipulate the 
DNA of A. kijaniata. Thus, isolation of the natively folded protein is not possible at this 
stage.  
These results call into question the glycosidase activity observed in the S. lividans 
feeding experiments. If the glycosyltransferase proteins are folded incorrectly in the 
heterologous host, perhaps the glycosidase activity is merely the result of misfolding. It is 
tempting to retain the original biosynthetic proposal that each glycosyltransferase (C4, 
C3, C1, and A4) is responsible for the attachment of only one digitoxosyl moiety. 
However, the processive activity of glycosyltransferase KijC4 must be accounted for in 
some fashion. The in vivo results clearly indicate that KijC4 is a processive 
glycosyltransferase responsible for the attachment of the first 2 digitoxosyl moieties in an 
α(1-3) linkage.  
What, then is the function of having two glycosyltransferases that function as 
glycosidases? It is possible that these glycosidases are involved in self-resistance to 
kijanimicins. As the bioassay shown in Figure 3.9 clearly demonstrates, toxicity increases 
with the addition of more digitoxosyl moieties to the tetrasaccharide branched chain. 
Thus, an obvious mechanism of self-resistance employed by A. kijaniata to avoid this 
toxicity would be the removal of the digitoxosyl moieties from the kijanimicin 
biosynthetic products. Glycosylation or glycosidation as a self-resistance mechanism is 
not common, but it is not unknown, either. One clear example of a resistance mechanism 
based on glycosylation is in the pikromycin/methymycin/neomethymycin biosynthetic 
pathways of S. venezuelae, and involves DesG.
311
 This glycosyltransferase attaches a 
glucose moiety to the natural products.
311
 DesG thus “glucosylates” the natural products 
in the cell, protecting the host from an excess of the natural products in the cell.
311
 
Similar phenomena has also been observed in the oleandomycin producing strains in 
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which OleD catalyzes the glucosylation of oleandomycin as part of a self-resistance 
mechanism.
312
  
 
3.5 CONCLUSIONS 
Herein, we report the results of our investigations of the glycosyltransferase genes 
of the kijanimicin biosynthetic pathway, and revisit the production of TDP-L-digitoxose 
both in vitro and in vivo.  The TDP-L-digitoxose biosynthetic pathway was reconstructed 
in vivo. A plasmid (pDIG) containing all genes necessary for TDP-L-digitoxose 
biosynthesis was constructed and introduced to S. lividans. Each putative 
glycosyltransferase gene was co-expressed in the stain containing the pDIG plasmid. 
These strains were fed various kijanolides and the results show that KijC4 is clearly 
responsible for the first two digitoxosyl α(1-3) attachments. Furthermore it is also likely 
responsible for the third digitoxosyl α(1-3) attachment in a processive manner. The 
successful addition of digitoxosyl moieties to appropriate aglycones demonstrated in vivo 
further confirms that these deoxysugar genes identified and characterized in Chapter 2 are 
indeed responsible for the biosynthesis of TDP-L-digitoxose. The putative 
glycosyltransferases KijC1 and KijA4 were found to have glycosidase activity in vivo 
towards kijanimicins A, B and C, leading to the proposal of their involvement in self-
resistance. The KijC3 glycosyltransferase is hypothesized to catalyze the remaining β(1-
4) linkage. Unfortunately, this hypothesis cannot be examined at the present time due to a 
lack of the proposed substrate. Finally, we reevaluated the proposed glycosylation 
scheme for kijanimicin and developed a new biosynthetic proposal for kijanimicin 
glycosylation as shown in Figure 3.5. If the 3-sugar compound becomes available in the 
future, the function of KijC3 needs be examined. Investigation of the glycosyltransferase 
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ability to accept a linear aglycone substrate can also be examined if the linear aglycone is 
synthesized. 
 
 220 
4 Eukaryotic Glycosylation Studies: Identification of  H. sapiens 
Candidates for the C-mannosyltransferase and their expression in E. 
coli and S. cerevisiae 
 
4.1 INTRODUCTION 
C-mannosylation is a novel protein posttranslational modification discovered on 
RNase 2 in 1994 by Hofsteenge et al.
229
 Subsequent studies revealed that the recognition 
sequence for this type of protein modification is a W-X-X-W motif, with C-
mannosylation occurring on the first tryptophan residue.
313
 Replacement of the second 
tryptophan by other amino acids eliminated or substantially reduced the level of C-
mannosylation.
314
 Accumulated evidence showed that this modification is enzyme 
catalyzed and occurs in Caenorhabditis elegans, amphibians, birds and mammals, but not 
Escherichia coli, insects, or yeast.
314, 315
 The presence of C-mannosylation in fungal 
species other than Saccharomyces has not been investigated. More recent studies have 
found that marine organisms such as mollusks produce C-mannosylated natural products, 
although it is not clear if these small molecules are produced by the mollusks themselves, 
or by marine microorganisms that may colonize them.
316
 
In vitro assays demonstrated that this modification occurs in the lumen of the 
endoplasmic reticulum (ER) leading to the hypothesis that many C-mannosylated 
proteins are secretory or transmembrane in nature. 
315
 Over twelve thousand proteins in 
the mammalian genome contain this W-X-X-W recognition sequences. Limiting this set 
by cellular localization, 336 of these proteins have been proposed to be potentially C-
mannosylated.
314
 These proteins have diverse functions, from channels, receptors and 
transporters to immunoglobulins and enzymes. Many more proteins that carry this motif 
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are of “unknown function” or are “hypothetical” proteins. More recent research in this 
area focused on immune system proteins from the complement pathway, which have 
been found to be C-mannosylated.
317
 Thus far, 24 modification sites have been 
experimentally determined on seven proteins including properdin, IL-12b, RNase2, C6, 
C7, C8a/C8b, and C9, as shown in Table 4.1. 
317,318
 
 
4.1 Known C-Mannosylation Modifications on Human Proteins 
 
Gene Name Position Signal Subsequence Protein Description 
C7 506-509 GGWSCWSSWSPCVQG Complement component C7 
precursor 
C8A 44-47 CQLSNWSEWTDCFPC Complement component C8 alpha 
chain precursor (Complement 
component 8 α subunit) 
C8A 542-545 KADGSWSCWSSWSVC Complement component C8 alpha 
chain precursor (Complement 
component 8 α subunit) 
C8A 545-548 GSWSCWSSWSVCRAG Complement component C8 alpha 
chain precursor (Complement 
component 8 α subunit) 
C8B 70-73 CELSSWSSWTTCDPC Complement component C8 beta 
chain precursor (Complement 
component 8 β subunit) 
C8B 548-551 PIDGKWNCWSNWSSC Complement component C8 beta 
chain precursor (Complement 
component 8 β subunit) 
C8B 551-554 GKWNCWSNWSSCSGR Complement component C8 beta 
chain precursor (Complement 
component 8 β subunit) 
C9 48-51 CRMSPWSEWSQCDPC Complement component C9 
precursor 
RNASE2 
(EDN, 
RNS2) 
34-37 PPQFTWAQWFETQHI Nonsecretory ribonuclease 
precursor (EC 3.1.27.5) 
(Ribonuclease US) (Eosinophil-
derived neurotoxin) (RNase UpI-2) 
(Ribonuclease 2) (RNase 2) 
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IL12B 
(NKSF2) 
319-322 YYSSSWSEWASVPCS Interleukin-12 beta chain precursor 
(IL-12B) (Cytotoxic lymphocyte 
maturation factor 40 kDa subunit) 
(CLMF p40) (NK cell stimulatory 
factor chain 2) (NKSF2). 
PFC 80-83 CRSPRWSLWSTWAPC Properdin precursor (Factor P) 
PFC 83-86 PRWSLWSTWAPCSVT Properdin precursor (Factor P) 
PFC 139-142 PEMGGWSGWGPWEPC Properdin precursor (Factor P) 
PFC 142-145 GGWSGWGPWEPCSVT Properdin precursor (Factor P) 
PFC 196-199 PTHGAWATWGPWTPC Properdin precursor (Factor P) 
PFC 199-202 GAWATWGPWTPCSAS Properdin precursor (Factor P) 
PFC 260-263 PVAGGWGPWGPVSPC Properdin precursor (Factor P) 
PFC 318-321 PVDGEWDSWGEWSPC Properdin precursor (Factor P) 
PFC 321-324 GEWDSWGEWSPCIRR Properdin precursor (Factor P) 
PFC 382-385 PLKGSWSEWSTWGLC Properdin precursor (Factor P) 
PFC 385-388 GSWSEWSTWGLCMPP Properdin precursor (Factor P) 
C6 29-32 CDHYAWTQWTSCSKT Complement component C6 
precursor 
C6 568-571 AVDGQWGCWSSWSTC Complement component C6 
precursor 
C6 571-574 GQWGCWSSWSTCDAT Complement component C6 
precursor 
 
Cytokine receptors may also be C-mannosylated. MBL (mannose binding lectins), 
proteins which activate complement and bind to the outer membranes of some pathogens, 
have a potential C-mannosylation site, thus implicating the importance of this protein 
modification for the entire immune pathway. However MBL-C, a major mannose-binding 
lectin purified from mouse serum, does not bind N-biotinylated C-Man-Trp, based on an 
ELISA assay.
235
 Concanavalin A, a lectin that binds p-O-mannose residues, also failed to 
bind C-Man-Trp.
235
 These results imply that C-Man-Trp is not recognized by canonical 
lectins that bind to O-linked mannose, but may be recognized by other specific proteins 
associated with unknown biological functions.  
The biological role of C-mannosylation has not been experimentally determined. 
The proposed roles of C-mannosylation include protein stability, control of protein 
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secretion, stabilization or orientation of tryptophan residues, and protein interaction in the 
extracellular matrix. For example, in the case of RNase2, mannose appears to interact 
with loop residues that stabilize the N-terminus of the protein and orient the indole ring 
of the modified tryptophan towards the RNase2 active site. For example, protein 
modeling of RNase2 suggests that the mannose moiety likely occupies a cavity adjacent 
to an N-terminal loop that is located just outside the active site of this protein. 
232, 319
    It 
has also been suggested that the hydrophilic nature of C-mannosylation orients the C-
mannosylated tryptophan toward the surface of the modified protein, which may play 
structural or functional roles.
227
  For example, properdin serves the function of a protein 
scaffold, stabilizing the C3 convertase (C3bBb) and protecting the protein from rapid 
inactivation.
317
 In this case, the C-mannosylated residue is located on the surface of 
properdin. C-Mannosylation is not necessarily required for enzymatic activity (as in the 
case of RNase2), but mutation of either tryptophan in the C-mannosylation signal motif 
in the IL-2 receptor abolishes ligand binding.
227
 It has previously been demonstrated that 
mutations of the 
232
WSAWS
236
 motif in the erythropoietin receptor (EPOR) can result in 
strong inhibition of receptor surface expression due to defective intracellular transport.
320
 
However, C-mannosylation did not assist in the expression of EPOR on the cell surface 
or intracellular transport.
321
 Clearly, much more work remains to be done to understand 
the potential roles of this novel modification and the cellular processes in which it may be 
involved. 
The discovery of protein C-mannosylation is a significant contribution to the 
protein glycosylation field, as post-translational modifications are usually essential for 
the function of a given protein.
227
 The ability to reproduce the correct glycosylation 
pattern is important for studying the functions of recombinant glycoproteins, which 
constitute over one-third of all approved therapeutic proteins.
322
 To achieve the necessary 
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human-like glycosylation level, these proteins are generally produced using mammalian 
cell lines.
322
   However, isolation of the desired glycoproteins from mammalian cell 
culture is lengthy, cumbersome and it is difficult to ensure homogeneity of the final 
product glycoforms. Thus, reconstructing human glycosylation pathways in cells that 
allow more control over the purity of the final product are highly desirable, since the 
extent and type of glycosylation have been found to have a marked impact on the 
therapeutic properties of many commercial therapeutic proteins.
322
 It has been shown that 
hyperglycosylation of therapeutic proteins would increase long-term stability of these 
proteins in vivo, by increasing their serum half-life and cellular uptake. Cerezyme®, 
which is used in enzyme replacement therapy for the treatment of Gaucher‟s disease, is 
prepared recombinantly based on the human gene sequence. The requisite N-glycans are 
modified to expose α-mannosyl residues for enhanced liver (kupffer cell) and 
macrophage uptake.
323, 324
 Natively glycosylated protein has a clearance rate of 21 min, 
while modified (terminal α-mannosyl) has a clearance rate of 3.2 min, demonstrating 
increased cellular uptake.
324
  If it is true that many proteins in human serum are C-
mannosylated, it is possible that therapeutic proteins produced as recombinants could be 
more efficacious if they were also C-mannosylated. Even if the target protein lacks native 
C-mannosylation, the addition of one or more mannose residues could increase 
therapeutic efficacy, as seen with erythropoietin (EPO).
325
  C-mannosylation levels also 
appear to increase in specific tissues or cell types under hyperglycemic conditions, 
suggesting a pathological role for C-mannosylation abundance in the development of 
diabetic complications.
326
  
Clearly the questions that remain to be answered outnumber known facts 
regarding the functions and roles of C-mannosylation. It has been reported that insect 
cells do not exhibit C-mannosylation, however, a secondary modification sequence, 
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termed a thrombospondin repeat sequence (WXXWXXWXXC), has also been identified, 
and is apparently recognized and C-mannosylated by both Spodoptera frugiperda Sf-9 
and Trichoplusia ni Hi-5 insect cell lines, contradicting earlier reports.
228, 317
 A bovine 
lens protein was also found to be C-mannosylated at an amino acid sequence that does 
not correspond to either the canonical or thrombospondin repeat sequences, leading to the 
proposal that there exist multiple classes of C-mannosyltransferase enzymes.
327
 The first 
step in answering these myriad questions is to identify the enzyme(s) responsible for this 
unique glycosylation event. 
In this chapter, we attempted to identify the putative C-mannosyltransferases by 
pull-down assays. We also attempted to identify the putative C-mannosyltransferases by 
analysis in silico, using protein O-mannosyltransferase as a BLAST query to isolate 
potential enzyme candidates. These candidates were cloned and we attempted to express 
the genes in E. coli and S. cerevisiae to test their enzymatic functions. 
 
4.2 EXPERIMENTAL DETAILS 
 
4.2.1 MATERIALS  
 
4.2.1.1 Bacterial and Yeast Strains   
E. coli strain DH5α was obtained from Bethesda Research Laboratories 
(Gaithersburg, MD). The overexpression hosts E. coli BL21, BL21(DE3), 
BL21(DE3)PLysS and BL21 RosettaII(DE3) were purchased from Novagen (Madison, 
WI). Saccharomyces cerevisiae yeast strain INVSc1 was acquired from Invitrogen 
(Carlsbad, CA). 
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4.2.1.2 Biochemicals 
Enzymes and molecular weight standards used for the molecular cloning 
experiments were products of Invitrogen (Carlsbad, CA) or New England Biolabs 
(Beverly, MA).  Agarose for DNA electrophoresis was purchased from Fisher Scientific 
(Pittsburgh, PA). Restriction digestion enzymes, calf intestinal alkaline phosphatase 
(CIAP), 100X bovine serum albumin (BSA), T4 ligase, and their respective buffers were 
products of New England Biolabs (Beverly, MA). Ni-NTA agarose and kits for DNA gel 
extraction and spin miniprep were obtained from Qiagen (Valencia, CA). The growth 
media components for bacteria and yeast were acquired from Becton Dickinson (Sparks, 
MD).  Complete supplemental media lacking uracil and histidine (csm -ura-his) was a 
product of Bio-101 Systems/MP Biomedical, (Solon, OH). Antibiotics, amino acids, 
nucleosides and chemicals such as isopropyl-β-D-thiogalactopyranoside (IPTG) and 
dithiothreitol (DTT) were products of Sigma-Aldrich Chemicals, Co. (St. Louis, MO) or 
Fisher Scientific (Pittsburgh, PA). All reagents for SDS-PAGE were purchased from Bio-
Rad (Hercules, CA), with the exception of the prestained protein molecular weight 
marker, which was ordered from New England Biolabs. Amicon YM-10 filtration 
products were acquired from Millipore (Billerica, MA). Y-Per yeast protein extraction 
reagent was obtained from Pierce (now a part of Fisher Thermo Scientific). Longlife 
Zymolyase was purchased from G-Biosciences (St. Louis, MO). Antibodies used for His6 
Western blotting procedures, monoclonal anti-polyhistidine clone His-I H1029, FLAG 
(M2 monoclonal), and anti-mouse IgG (alkaline phosphatase conjugate) A2429 were 
purchased from Sigma. Monoclonal antibodies for myc epitope, and the protein 
interleukin-12 were purchased from Invitrogen. Anti-sGP (MAI-21630) antibody from 
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Pierce was a kind gift of the Croyle Lab at the University of Texas at Austin. For Western 
blot detection, nitroblue tetrazolium (NBT) and 5-bromo-4-chloro-3-indolyl-phosphate 
(BCIP) were obtained from Promega. Porcine sequencing grade modified trypsin 
(V511A) was also obtained from Promega. Synthetic peptides were prepared by the Core 
Facilities of the Institute of Cellular and Molecular Biology at the University of Texas at 
Austin. 
 
4.2.1.3 Plasmids Vectors and DNA Manipulation 
Vectors pET24, pET28b(+), and pET32 vectors were purchased from Novagen 
(Madison, WI). Yeast expression vector pYES, pCR-Blunt and the pBad/Thio-Topo 
vectors were from Invitrogen (Carlsbad, CA), and yeast epitope tagging vector pESC-His 
was obtained from Stratagene (La Jolla, CA).  Glycerol stocks of E. coli containing genes 
for the proteins TMTC2, TMTC3, and IL-12b on TOPO-4 plasmids were obtained from 
OPEN Biosystems (now a part of Thermo Fisher Scientific).  DNA gel extraction and 
spin miniprep kits were obtained from Qiagen (Valencia, CA). DNA polymerase pfu was 
purchased from Stratagene. KOD DNA polymerase was purchased from Novagen 
(Madison, WI). Oligonucleotide primers for cloning were prepared by Invitrogen 
(Carlsbad, CA) or Integrated DNA Technologies (Coralville, IA).  
 
4.2.1.4 Instrumentation  
PCR reactions were carried out using an Eppendorf Mastercycler gradient thermal 
cycler from Brinkman-Eppendorf (Westbury, NY). For agarose gel electrophoresis, a 
mini-sub-cell GT from BioRad (Richmond, CA), powered by a Fisher FB-300 
electrophoresis power source was used. After electrophoresis, DNA bands were 
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visualized using a Fisher FBTIV-08 UV transilluminator. Cell disruption was performed 
with a Fisher 550 Sonic Dismembrator equipped with a standard sonicator horn. 
Homogenization of cells was accomplished with a glass 20 mL Potter-Elvejhem 
homogenizer equipped with both loose (high-clearance) and tight-fitting (low clearance) 
pestles, which was purchased from Wheaton, (Millville, NJ). Thick-walled 4 mL 
polycarbonate centrifuge tubes (13 × 51 mm) were purchased from Beckman.  
For SDS-page gel electrophoresis, a mini PROTEAN II vertical system from 
BioRad (Richmond, CA), equipped with a FB-300 (Fisher) or an EC-1000-90 (E-C 
apparatus corporation) electrophoresis power source was used. Mini-trans blot assembly 
apparatus used for Western blot, GelAir drying system for acrylamide gel preservation, 
and the necessary accessories and reagents were all products of BioRad. The 
nitrocellulose Hybond-C or Optitran BA-5 85 reinforced nitrocellulose membrane used 
for Western blot analysis was from Amersham Bioscences or Whatman (Dussel, 
Germany), respectively. 
A Corning 240 pH meter equipped with an Accumet electrode (Fisher) was used 
to measure pH.  Large scale centrifugation was performed using an Avanti J-25 unit or a 
J-E instrument from Beckman (Arlington Heights, IL).  Microscale centrifugation was 
carried out using an Eppendorf 5415C from Brinkmann Instruments (Westbury, NY). 
Ultraviolet-visible spectra were recorded using a Beckman DU-650 spectrophotometer. 
In the case of Bradford assays, a Synergy HT plate reader by Biotek Instruments, 
equipped with a PC using KC4 software was used. HPLC separations were carried out 
using a Beckman 366 HPLC from Beckman Instruments (Fullerton, CA) equipped with 
an analytical C18 HPLC column from Varian (Lake Forest, CA). The ÄKTA FPLC was 
from Amersham Pharmacia Biosciences (now GE Healthcare). Sephadex 200 gel 
filtration FPLC columns were from Pharmacia (Uppsala, Sweden).  DNA and biological 
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samples were dried using a Savant Speedvac SC100 equipped with a Savant refrigerated 
condensation trap RT100 and Gel Pump GP100. DNA concentrations were measured 
using a NanoDrop ND-1000 UV-Vis instrument from Thermo Fisher Scientific (formerly 
NanoDrop Technologies LLC). Ultracentrifuge Model TL-100, equipped with a Ti-100.4 
rotor (both from Beckman) was used for microsomal preparations.  
 Sequencing of subclones was performed using a capillary-based AB 3700 DNA 
analyzer by the Core Facilities of the Institute of Cellular and Molecular Biology of the 
University of Texas at Austin. Mass spectra were obtained by the Mass Spectrometry 
Core Facility in the Department of Chemistry and Biochemistry using a Waters QTOF 
Premier mass spectrometer operating in electrospray mode, or MALDI-MS using a 
CHCA matrix by the College of Pharmacy of the University of Texas at Austin.   
 
4.2.2 GENERAL PROCEDURES   
The general methods and protocols for recombinant DNA manipulations were as 
described by Sambrook et al.
274
 Protein concentrations were determined according to 
Bradford 
272
 using bovine serum albumin (BSA) as the standard.  All protein purification 
operations were carried out at 4 ºC. The relative molecular mass and purity of enzyme 
samples were determined using SDS-polyacrylamide gel electrophoresis as described by 
Laemmli.
273
   
 
4.2.3 EXPERIMENTAL PROCEDURES      
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4.2.3.1 Bacterial Strains and Growth Conditions 
E. coli DH5α used for routine cloning experiments was maintained on Luria-
Bertani (LB) broth or LB-agar plates. (1% NaCl, 1% tryptone, 0.5% yeast extract, pH 
7.5, and in the case of plates, 2% agar). E. coli BL-21(DE3) and Rosetta strains used for 
routine gene expression experiments were maintained in Luria-Bertani (LB) broth or on 
LB-agar plates, supplemented with appropriate antibiotics (100 µg/mL ampicillin, 50 
µg/mL kanamycin, and/or 35 µg/mL chloramphenicol). To liquid cultures, a volume of 
sterile 80% glycerol equal to 20% of the original culture volume was added and gently 
mixed to homogeneity. The mixture was aliquotted into sterile Eppendorf tubes, flash 
frozen in liquid N2 and stored at -80 ºC until use. Glycerol stocks were used in a 1:20 
dilution to inoculate fresh media for plasmid preparations. Competent cells were prepared 
as described in Chapter 2. 
 
4.2.3.2 Eukaryotic Strains and Growth Conditions 
S. cerevisiae InvSC1 was maintained on YPD-agar plates or cultured in YPD 
liquid media (1% yeast extract, 2% peptone, 2% dextrose, and in the case of plates, 2% 
agar). Yeast transformants were grown in SC dropout media (0.67% yeast nitrogen base 
without amino acids, 2% dextrose, 0.075% complete supplemental media without 
histidine or uracil, with the addition of 0.005% uracil or 0.01% histidine for metabolic 
selection, and in the case of plates 2% agar) Yeast strains were prepared for long term 
storage at -80 ºC by culturing overnight at 30 ºC with 200 RPM shaking in the 
appropriate media. Once the cultures reached OD600 > 1.0, a volume of sterile 80% 
glycerol equal to 20% of the original culture volume was added and gently mixed to 
homogeneity. The mixture was aliquotted into sterile Eppendorf tubes, flash frozen in 
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liquid N2 and stored at -80 ºC until use. Glycerol stocks were used in a 1:20 dilution to 
inoculate fresh media for expression experiments.  
 
4.2.3.3 PCR Reactions  
Primers were prepared by dilution with TE buffer (50 mM Tris•HCl, pH 7.5, 1 
mM EDTA, pH 8.0) to a concentration of 100 µM.  This stock solution was further 
diluted to 10 or 20 µM with sterile water for KOD or pfu reactions respectively. pCR4-
TOPO plasmid vectors containing each gene were obtained as E. coli DH5α glycerol 
stocks from OPEN Biosystems. Template DNA for TMTC2, TMTC3 and IL-12b genes 
was prepared by purifying the plasmid DNA from the E. coli DH5α strains using the 
Qiagen miniprep kit following the manufacturer‟s protocol. Polymerase chain reactions 
(PCR) primers and reaction programs vary for each gene and will be discussed in the 
appropriate sections of this chapter.  
 
4.2.3.4 PCR Product Purification 
Typically, PCR products were purified by agarose gel electrophoresis employing 
a 0.8% TAE-agarose gel with 5 µg/mL ethidium bromide. The samples were diluted to 
80% with 6X DNA loading dye (0.25% xylene cyanol, 0.25% bromophenol blue, 15% 
Ficoll 400) and electrophoresed at 100 V for 30 min. The DNA bands were visualized 
using an ultraviolet illumination source. DNA bands of the correct base pair length were 
excised from the gel with a scalpel and purified using the Qiagen gel extraction kit, 
according the manufacturer‟s protocols with the following modifications. Instead of 
heating at 55 ºC to melt the agarose, gel slices were heated at 65 ºC until the gel was fully 
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dissolved. DNA elution buffer EB was also heated to 65 ºC prior to DNA elution, and the 
elution volume was 30 µL.  
 
4.2.3.5 Shuttle Vector Cloning into pGEM-T easy 
PCR products were ligated into shuttle or expression vectors specific to each 
gene, as described in later sections of this chapter. For ligations into the pGEM-T easy 
vector, the DNA was first A-tailed. Briefly, 20 µL of purified DNA from the previous 
step was transferred to a 0.2 µL thin-walled PCR tube. To this was added 2.5 µL of 10X 
Taq polymerase buffer, 2 µL of a dNTP solution and 0.5 µL of Taq polymerase. The 
reaction was incubated without cycling for 10-30 min at 72 ºC. The A-tailed product was 
purified using the Qiagen gel purification kit following the modifications for purification 
of PCR products, and ligated into the shuttle vector pGEM-T easy. A typical ligation 
mixture included 2.5-3.0 µL of purified A-tailed PCR product, 0.2-0.5 µL of the pGEM-
T easy vector, 2-2.5 µL of 5X T4 ligase buffer, and 0.5 µL of T4 ligase, for a total 
reaction volume of 6 µL.  
The ligation mixture was incubated at room temperature or overnight at 4 ºC. The 
ligation mixture (3 µL) was mixed with competent E. coli DH5α (50 µL) and incubated 
on ice for 30 min. After incubation, the cells were transformed by heat shock at 42 ºC for 
30 s, followed by incubation for 2 min on ice. LB broth (500 µL) was added to the 
transformed cells and the cells were pelleted by centrifugation at 12,000 g for 10 s, 
discarding the supernatant. Cells were resuspended in 50 µL fresh LB media and plated 
on LB-agar supplemented with 100 µg/mL ampicillin, 100 µL of 10 mM IPTG and 100 
µM of 2% X-Gal in DMF. Positive transformants were selected by overnight incubation 
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at 37 ºC. Plates were subsequently incubated for 8-12 h at 4 ºC to allow development of 
the blue color. White colonies were selected for all future screening steps. 
  
4.2.3.6 Shuttle Vector Cloning into pCR-Blunt 
For cloning of PCR products into the shuttle vector pCR-Blunt, a typical ligation 
mixture included 3.5 µL of gel purified PCR product, 0.5 µL of  pCR-Blunt vector, 2 µL 
of 5X T4 ligase buffer solution, 3.5 µL of sterile water, and 0.5 µL of T4 ligase, for a 
total reaction volume of 10 µL. The ligation mixture was incubated at room temperature 
for 30 min-1 h, or overnight at 4 ºC. The ligation mixture (3-5 µL) was mixed with 
competent E. coli DH5α (50 µL) and incubated on ice for 30 min. After incubation, the 
cells were transformed by heat shock at 42 ºC for 30 s, followed by incubation for 2 min 
on ice. LB broth (500 µL) was added to the transformed cells and incubated for 30-45 
min at 37 ºC, with 200 RPM shaking. The cells were plated on LB-agar plates containing 
50 µg/mL kanamycin. Positive transformants were selected by incubation overnight at 37 
ºC.  
 
4.2.3.7 DNA Extraction by Alkaline Lysis  
Colonies appearing after overnight incubation were screened for the presence of 
plasmid containing PCR product using a modified alkaline lysis procedure.
277
 Briefly, 2-5 
mL cultures of each positive transformant were grown overnight at 37 ºC in LB media in 
the presence of selective antibiotic. Culture volume was dependent on the copy number 
of the plasmid. Cultures were centrifuged at 12,000 g for 30 s, the supernatant was 
removed and the cells were resuspended in 100 µL of cold resuspension solution (50 mM 
glucose, 25 mM Tris•HCl, pH 8.0, 10 mM EDTA, 100 µg/mL RNase). Cells were 
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disrupted with the addition of 200 µL fresh lysis solution (200 mM NaOH, 1% SDS), and 
inverted five times to mix. The lysis reaction was quenched with the addition of 150 µL 
of neutralization solution (3 M potassium acetate, 11.5% acetic acid). Reactions were 
mixed to ensure neutralization and incubated at 4 ºC for 5 min, followed by 
centrifugation for 5 min at 16,100 g at 4 ºC to precipitate cellular debris. Each 
supernatant containing plasmid DNA was transferred to a fresh tube and the DNA was 
precipitated by the addition of 2.5 volumes of 100% ethanol or one volume of 
isopropanol and 1/10 volume of 3 M sodium acetate, pH 5.2. Each solution was mixed to 
ensure homogeneity and centrifuged at 16,100 g for 15 min at 4 ºC. The supernatant from 
each sample was removed by aspiration, taking care not to disturb the DNA pellet. Each 
DNA pellet was washed with 70% ethanol and centrifuged again at 16,100 g for 5 min. 
The final ethanol wash was removed and each pellet was dried using a centrifugal 
vacuum apparatus for 2 min at room temperature to remove any remaining ethanol. Each 
pellet containing plasmid DNA was resuspended in 30 µL of 50 mM Tris•HCl (pH 8.5).  
 
4.2.3.8 DNA Analytical Restriction Digestion and Fragment Analysis 
Plasmid DNA obtained from the alkaline lysis preparation was subjected to 
enzymatic digestion with the appropriate restriction enzymes. A typical reaction mixture 
contained 5 µL of DNA, 2 µL of 10X NEB reaction buffer, 0.2 µL of each enzyme, and 
13 µL of sterile water, for a final volume of 20 µL. In the case of shuttle vectors pGEM-T 
easy or pCR-Blunt, a typical reaction mixture contained 3 µL of DNA, 4 µL of 10X 
EcoRI buffer, 0.5 µL of EcoRI, and 13 µL of sterile water, for a final volume of 20 µL. 
Each reaction was incubated for 2 h at 37 ºC, after which time 10 µL aliquots were 
removed and analyzed by gel electrophoresis.  
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Samples were electrophoresed for 30 min at 100 V using a 0.8% TAE-agarose gel 
with 5 µg/mL ethidium bromide. For digestion products greater than 2 kB, the duration of 
the electrophoretic separation was increased to allow greater resolution of digested vector 
and the resulting DNA fragments. Electrophoretic results as visualized on agarose gels 
were used to determine the presence of the DNA insert of the appropriate length.  
Colonies containing the vector with the ligated PCR product were grown at 37 ºC 
in LB media supplemented with selective antibiotic. After overnight incubation, cells 
were harvested by centrifugation at 12,000 g for 30 s. Plasmid DNA was extracted from 
the pelleted bacteria using the Qiagen miniprep kit, according to the manufacturer‟s 
protocols with the following adjustments. The optional 500 µL PB wash was always 
performed to remove additional contaminants, and elution buffer EB was heated to 65 ºC 
before DNA elution.  
 
4.2.3.9 DNA Sequence Analysis  
The purified plasmid was sequenced to confirm the identity of the PCR product. 
For these genes, sequencing reactions using external and internal primers were submitted 
to ensure full sequence coverage. Specific primers used for each sequencing reaction are 
provided in later sections of this chapter. PHRED sequences obtained from the DNA 
facility were aligned against the known gene sequence. Contigs consisting of results from 
DNA sequencing reactions were assembled using the Vector NTI software program and 
compared to the original gene sequence. Both forward and reverse sequences were 
examined to determine that the correct gene sequence was obtained. When necessary, 
point mutations in the amplified sequences were compared to known Single Nucleotide 
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Polymorphisms (SNPs) to determine if any of these is a result of mutations in the DNA 
template.  
 
4.2.3.10 Secondary Cloning into Expression Vectors 
When shuttle vectors were used, the PCR insert was isolated after sequencing and 
ligated into a plasmid expression vector. The general protocol used to generate 
expression constructs is described below.  
STEP 1: GROWTH OF E. COLI CELLS. One colony of E. coli DH5α containing the 
expression vector or the gene of interest in a shuttle vector was used to inoculate 5 mL of 
LB media supplemented with the appropriate selective antibiotic. Cultures were grown 
overnight at 37 ºC with 200 RPM shaking and the plasmids were isolated using the 
Qiagen miniprep kit following the manufacturer‟s protocols with additions and alterations 
as previously detailed.  
STEP 2: SHUTTLE VECTOR DIGESTION. Plasmid DNA obtained from this preparation 
was subjected to enzymatic digestion overnight with the appropriate enzymes. A typical 
preparatory digestion reaction contained: 30 µL of DNA, 4 µL of NEB 10X buffer, 2 µL 
of each enzyme and 2 µL of sterile water (or 1.6 µL of sterile water and 0.4 µL of 100X 
BSA) for a final reaction volume of 40 µL. For yeast expression constructs (tmtc2- and 
tmtc3-pCR-Blunt and il-12b-pGEM-T easy), a typical reaction mixture consisted of 10 
µL DNA, 5 µL of 10X NEB buffer, 35 µL of sterile water and 1 µL of each enzyme. 
Reactions were incubated overnight at 37 ºC. Digestion reactions were subjected to 
agarose gel electrophoresis for 30-40 min at 100 V using a 0.8% TAE-agarose gel with 5 
µg/mL ethidium bromide to separate the gene of interest from the shuttle vector. For 
digestion products greater than 2 kB, the duration of the electrophoretic separation was 
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increased to allow greater resolution of digested vector and the resulting DNA fragment. 
The gel band containing the insert of appropriate size was excised with a clean, sharp 
scalpel and purified using the Qiagen gel purification kit, following the manufacturer‟s 
protocols with the additions and alterations as previously described.  
STEP 3: EXPRESSION VECTOR PURIFICATION AND DIGESTION. Expression vectors 
were prepared by enzymatic digestion with the appropriate enzymes overnight at 37 ºC, 
followed by the addition of 0.1 µL calf intestinal alkaline phosphatase (CIP). The 
reaction was incubated for 1 h at 37 ºC. When NEB buffer 2 was not used in the digestion 
reaction, 0.25 volumes of 1 M Tris, pH 8 was added to the reaction. To purify digested 
DNA, the Qiagen gel purification kit was employed according to manufacturer‟s 
instructions for purifying PCR products.  
STEP 4: DNA LIGATION AND TRANSFORMATION INTO E. COLI. A Nanodrop instrument 
was used to determine the concentration of both vector and gene insert solutions. 
Ligations were performed at room temperature for 1-2 h or overnight at 4 ºC, with a 
typical reaction mixture consisting of 90 fmol ends of gene to be inserted, 30 fmol ends 
of vector, 2 µL of 5X ligation buffer, 0.5 µL of T4 ligase, and sterile water to a final 
volume of 10 µL. A total of 5 µL of the ligation reaction was incubated with 50 µL of 
competent E. coli DH5α on ice for 30 min. The transformation procedure is identical to 
that previously described, except when ampicillin was used as the selective antibiotic, the 
recovery incubation was omitted and the transformation was plated directly onto LB-agar 
plates in the presence of 100 µg/mL ampicillin.  
STEP 5: LIGATION AND SELECTION ANALYSIS. After overnight incubation at 37 ºC, 
colonies appearing on the selection plates were screened for successful ligation by 
alkaline lysis and enzymatic digestion following the method described above with the 
following adjustments.
277
 Digestion was carried out using the restriction enzymes specific 
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for each construct, as indicated in the following chapter. A typical reaction mixture 
contained 5 µL of DNA, 2 µL of 10X NEB reaction buffer, 0.2 µL of each enzyme, and 
13 µL of sterile water, for a final volume of 20 µL. Each reaction was incubated for 2 h at 
37 ºC, after which time 10 µL aliquots were removed and analyzed by gel 
electrophoresis. Samples were electrophoresed for 30 min at 100 V using a 0.8% TAE-
agarose gel with 5 µg/mL ethidium bromide. For digestion products greater than 2 kB, 
the duration of the electrophoretic separation was increased to allow greater resolution of 
digested vector and the resulting DNA fragment.  
Electrophoretic results, as visualized on agarose gels, were used to determine the 
presence of the DNA insert of the appropriate length. Colonies containing the vector with 
the successfully ligated gene of interest were grown at 37 ºC in LB media supplemented 
with the appropriate selective antibiotic. After overnight incubation, cells were harvested 
by centrifugation at 12,000 g for 30 s. Plasmid DNA was extracted from the pelleted 
bacteria using the Qiagen miniprep kit, following the manufacturer‟s protocols with the 
adjustments as described previously. The newly isolated gene-containing plasmids were 
used to transform E. coli BL-21, BL-21*, BL-21(DE3), BL-21(DE3)pLysS and BL-21 
RosettaII (DE3) heterologous expression hosts or S. cerevisiae competent cells. 
 
4.2.3.11 SDS-PAGE 
The relative molecular mass and purity of enzyme samples were determined using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) as described by 
Laemmli.
273
 Proteins were electrophoresed using a discontinuous buffer system 
containing 25 mM Tris•HCl, 192 mM glycine and 0.1% SDS (pH 8.3).273 Gels were cast 
using 75 mm plates, and in most cases 6 or 8% acrylamide was used for the separatory 
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gel, while the stacking gel was 4% acrylamide. Protein samples were diluted 2X with 
SDS-loading dye (62.5 mM Tris•HCl buffer pH 6.8, containing 10% glycerol, 2% SDS, 
5% β-mercaptoethanol, and 0.0025% bromophenol blue), and heated to 100 ºC for 5 min. 
Samples were centrifuged briefly to collect protein at the bottom of the tubes. The protein 
gels were electrophoresed using a setting of 30 mA per gel, allowing the gel to run until 
the loading dye eluted from the bottom of the gel. Gels were removed from the glass 
plates, and the stacking gel was removed and discarded. A corner of each gel was 
removed to preserve orientation of the gel samples. Gels were stained with Coomassie 
blue (2.5 g/L of Coomassie Brilliant Blue G-250 in acetic acid:water:methanol (1:4:5) by 
volume) until gels were dark blue.
278
 Gels were removed from staining solution, rinsed in 
ddH2O, and introduced to destaining solution (ethanol:acetic acid:water in a ratio of 
4:5:41 by volume).
278
 Protein concentrations were determined according to Bradford 
using BSA as the standard, and the dye reagent from BioRad. 
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4.2.3.12 Western Blot Procedure 
Western blotting was used to detect the presence of IL-12b or FLAG and c-myc 
epitopes, or polyhistidine tags on heterologously expressed and purified proteins.
279
 SDS-
PAGE procedures were performed in duplicate for each protein sample. The gels were 
processed as described previously until the staining step, at which point gels were 
assembled into the transfer cassettes. The gels were transblotted onto the nitrocellulose 
membrane at 100 V for 1 h, using a running buffer of 25 mM Tris base, 192 mM glycine, 
20% v/v methanol (pH 8.3).  Cassette assembly and electrophoresis were carried out 
according to the directions provided by BioRad. After transblotting electrophoresis, the 
membrane was carefully removed from the transfer cassette and the presence of the 
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prestained marker on the blot was visually assessed to ensure transfer was complete. The 
membrane was transferred to a small plastic box and immersed in 5% non-fat dry milk in 
Tris buffered saline and Tween (TBST) solution (20 mM Tris•HCl, 150 mM NaCl, 0.5% 
v/v Tween® 20, pH 7.5). The membrane was blocked in this solution for 1 h, with 
agitation, overnight at 4 ºC or at room temperature for 1 h. The solution was removed and 
the membrane was rinsed thrice in TBST to remove excess blocking solution. The 
membrane was immersed in primary antibody solution (15 mL TBST, 1:30,000 dilution 
of monoclonal anti-polyhistidine clone His-1, or a 1:5000 dilution of α-IL-12b, α-myc, or 
α-FLAG. All antibody solutions contained a 1:1000 dilution of 20% v/v NaN3.) and 
incubated with agitation overnight at 4 ºC or room temperature for 1 h. After incubation, 
the solution was removed from the membrane and the membrane was washed thrice with 
TBST to remove any excess primary antibody solution remaining on the membrane. The 
membrane was subsequently incubated in the secondary antibody solution (15 mL TBST, 
1:30,000 dilution of anti-mouse IgG [Fc specific] alkaline phosphatase conjugate, 1:1000 
dilution of 20% v/v NaN3), and incubated with agitation overnight at 4 ºC or room 
temperature for 1 h. After incubation, the solution was removed and the membrane was 
washed thrice with TBST to remove any excess secondary antibody solution remaining 
on the membrane. To visualize proteins, the membrane was immersed in 5 mL color 
development solution (100 mM Tris•HCl, 100 mM NaCl, 5 mM MgCl2, pH 9.5) with the 
addition of 66 µL NBT and 33 µL BCIP. The membrane was incubated in the dark for 2-
5 min or until purple bands appeared on the blot. Development was stopped by rinsing 
the membrane with ddH2O. Membranes were dried and scanned within 24 h. 
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4.2.3.13 In-Gel Tryptic Digestion of Proteins 
Proteins were digested in acrylamide gels following the method of Shevchenko.
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Briefly, major protein bands were excised from Coomassie stained gel with a fresh razor 
blade. Gel slices were transferred to sterile eppendorf tubes and were destained overnight 
at room temperature with slight agitation in fresh destaining solution. After most of the 
dye was removed from the gel bands, destaining solution was removed and replaced with 
500 µL of fresh destaining solution, and destaining continued for another 2 to 3 h. The 
destaining solution was removed and discarded, and the gel slices were dehydrated in 300 
µL of HPLC grade acetonitrile. This step was repeated as necessary until the gel slices 
were an opaque white color. The acetonitrile was removed and discarded. The gel slices 
were subjected to evaporation using vacuum centrifugation for 2-3 min to remove any 
remaining acetonitrile and treated with fresh 10 mM DTT (100 µL) for 1 h at room 
temperature to reduce the proteins in the gel. The sample was centrifuged briefly and the 
DTT solution was removed. The gel slices were incubated at room temperature for 1 h 
with fresh 50 mM iodoacetamide solution (100 µL). The sample was briefly centrifuged 
and the iodoacetamide solution was removed. The gel slices were washed for 10 min with 
100 mM ammonium bicarbonate (200 µL), the sample was centrifuged briefly and the 
ammonium bicarbonate solution was removed. Gel slices were dehydrated in HPLC 
grade acetonitrile (300 µL). This step was repeated as necessary until the gel slices turned 
white, after which the acetonitrile was left on the gel slices for 5 min. The acetonitrile 
was removed and discarded. This step was repeated for two washes of 5 min each, and 
the gel was rehydrated in 100 mM ammonium bicarbonate (200 µL) for 10 min. The 
sample was centrifuged briefly and the ammonium bicarbonate solution was removed. 
Gel slices were dehydrated in HPLC grade acetonitrile (300 µL). This step was repeated 
twice as above, for a total of two 5 min washes. The gel slices were dried by evaporation 
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using the vacuum centrifuge for 2-3 min to remove any remaining acetonitrile. Trypsin 
solution (20 ng/µL) was prepared by adding 1 mL of 50 mM ammonium bicarbonate to 
20 µg enzyme on ice. Trypsin solution (50- 100 µL) was added to cover the gel slices 
completely, and this mixture was incubated on ice for 10-15 min, until the gel pieces 
appeared swollen. Ammonium bicarbonate (20 µL of a 50 mM solution) was added to the 
solution and the digestion was incubated overnight at 37 ºC. The next morning, the 
extract was centrifuged to collect condensate and the digestion solution was removed 
with a gel-loading pipette tip, ensuring exclusion of any gel pieces. Protein was further 
extracted from the gel slices by adding 50% acetonitrile/50% water with 5% formic acid 
(75 µL) and incubating at room temperature for 10 min. The sample was centrifuged and 
the resulting solution transferred to a clean eppendorf tube. This step was repeated for a 
total organic extraction volume of 150 µL.  
 
4.2.4 FIRST ATTEMPT TO IDENTIFY C-MANNOSYLTRANSFERASE: MICROSOMAL 
CROSSLINKING ASSAYS 
4.2.4.1 Preparation of Rat Liver Microsomes 
Microsomes were prepared by sucrose gradient centrifugation according to the 
method of Graham.
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 Adult female rats were sacrificed by decapitation and bled through 
the neck to exsanguinate. Livers were immediately removed and transferred to a chilled, 
pre-weighed beaker containing homogenization medium (250 mM sucrose, 5 mM 
Tris•HCl pH 7.4, 1 mM MgCl2) Livers were weighed and rinsed twice in homogenization 
buffer to remove excess fluids. All remaining steps were carried out between 0-4 ºC. 
Tissue was chopped finely and mixed with homogenization media (0.25 g liver/mL). 
Tissues were homogenized in a Potter-Elvehjem homogenizer and the cell debris pelleted 
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by centrifugation at 1,000 g for 10 min at 4 ºC. Further cellular debris was removed by 
centrifugation (4 ºC) at 3,000 g for 10 min and 10,000 g for 20 min. The resulting 
supernatant was layered on top of a density barrier comprised of 1.5 mL of Solution I (0.6 
M sucrose, 15 mM CsCl, 5 mM Tris•HCl, pH 8.0) and 3 mL of Solution II (1.3 M 
sucrose, 15 mM CsCl, 5 mM Tris•HCl, pH 8.0). The discontinuous gradient was 
centrifuged for 90 min at 100,000 g using a Beckman Ti-70.1 rotor. The pellet, which 
contains the rough microsomes, was washed with 50 mM potassium phosphate buffer, pH 
7.5 and resuspended in 2 mL of 20 mM HEPES-NaOH pH 7.2, containing 110 mM 
potassium acetate and 2 mM magnesium acetate (KMH buffer) and the protease inhibitor 
cocktail (leupeptin, 2.4 µg/mL; antipain, 4 µg/mL; lima bean trypsin inhibitor, 40 µg/mL; 
benzamidine, 20 µg/mL; AEBSF HCl, 10 µg/mL; aprotinin, 2 µg/mL; chymotrypsin, 10 
µg/mL; pepstatin A, 5 µg/mL). Microsomes were aliquotted, flash frozen in liquid 
nitrogen, and stored at -80 ºC. The protein concentration was determined by the method 
of Bradford.
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4.2.4.2 5-Hydroxytryptophan Crosslinking Assay 
In an attempt to isolate the C-mannosyltransferase, an assay was designed to 
crosslink the CMT to an engineered substrate. A small peptide substrate N-
KPPQFAW*AQWFE-C (designed after Doucey) was prepared by solid phase 
synthesis.
315
 An intrinsic crosslinker was engineered by substituting the tryptophan at the 
position of mannosylation with 5-hydroxytryptophan, as indicated by W* above. The 
peptide (1 µmol and 5 µmol), linked to agarose beads, was incubated with 200 µL of 
microsomal protein in the presence of 0.6 molar equivalents of sodium periodate. To 
increase protein solubility and to permeabilize microsomes, 0.2% Triton-X 100 was 
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added to the reaction. Each reaction was brought to 1 mL final volume with KMH buffer 
and incubated for 4 h at room temperature. Sodium borohydride was added in excess to 
quench the reaction. The supernatant was removed and the beads washed 3 times with 
KMH buffer to remove protein that was not crosslinked. Beads were resuspended in 100 
µL of KMH buffer and 20 µL of the resulting solution was removed and added to an 
equal volume of 2X SDS loading buffer in the presence of β-mercaptoethanol. These 
samples were boiled for 30 min and 20 µL of each sample was electrophoresed on a 
denaturing SDS-PAGE gel. The gel was stained with Coomassie blue stain to visualize 
protein bands.   
 
4.2.4.3 CMT Crosslinked Protein In-Gel Digestion 
The major protein bands were excised from the Coomassie stained gel with a 
fresh razor blade. The gel slices were processed according to the method of Shevchenko, 
as described previously.
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 The samples were concentrated to 25 µL using the vacuum 
centrifuge and submitted for MS analysis. 
 
4.2.5 SECOND ATTEMPT TO IDENTIFY C-MANNOSYLTRANSFERASE: IN SILICO GENE 
ANALYSIS 
Using gi 34190043 (H. sapiens protein O-mannosyltransferase 1, POMT-1) as our 
query, this protein sequence was subjected to pblast analysis using the NCBI “Blast” 
website. Among all protein sequences in the database, 23 proteins were identified as 
having some homology to POMT-1. These protein sequences were analyzed manually by 
comparison to POMT-1, and that protein TMTC2 was identified as a possible C-
mannosyltransferase.  
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4.2.6 CLONING OF TMTC2 FOR E. COLI EXPRESSION  
4.2.6.1 PCR Reactions  
The tmtc2 gene was amplified using the pCR-TOPO4 vector as template DNA. 
Primers were designed for direct cloning into the pBad/Thio-Topo vector. The primer 
sequences (5′ start primer, 5′-ATGATTGCAGAGTTGGTGAGCAGCGCTCTG-3′, and 
3′ halt primer, 5′-GGTCTTAGAAGTCTTTAAGCCTTGTTTTTCCATGATGTTCCAC-
AG-3′) were designed to remove the stop codon from the amplified gene such that a C-
terminal V5 epitope and a His6-tag were introduced upon gene expression.  
The primers were obtained as lyophilized powder and were prepared as described 
previously. The PCR reactions consisted of the following: 72 µL of sterile water, 10 µL 
of 10X pfu buffer, 10 µL of a 20 mM dNTP solution, 2.5 µL of each primer (5′ and 3′) at 
20 µM, 1 µL of template DNA, 1.8 µL of pfu polymerase, and 0.2 µL of Taq polymerase 
for a 100 µL total reaction volume in an 0.5 mL thin walled PCR tube. The PCR 
reactions were carried out using an Eppendorf thermocycler with the lid temperature set 
at 105 ºC and an initial denaturing step of 2 min at 95 ºC.  The program consisted of a 30 
s denaturing step at 95 ºC, an annealing step at 58.8 ºC for 30 s, and an elongation step of 
3 min (1 min/kb) at 72 ºC. This cycle was repeated thirty times, followed by a 10 min 
extension at 72 ºC. The temperature was reduced to 4 ºC until the product was removed 
from the thermocycler.  PCR products were stored at 4 ºC until purified. 
 
4.2.6.2 pBAD-TMTC2 Cloning 
The PCR products were purified by agarose gel electrophoresis as described in 
section 4.2.3.4 and ligated into the pBad/Thio-Topo vector. A typical ligation mixture 
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included 4 µL of gel purified PCR product, 1 µL of NaCl solution, and 1 µL of TOPO 
vector. The ligation mixture was incubated at room temperature for 30 min. The ligation 
mixture (2 µL) was mixed with competent E. coli DH5α (50 µL) and transformed 
following the procedure described in section 4.2.3.5.  Positive transformants were 
selected after incubation overnight at 37 ºC on LB-agar plates supplemented with 100 
µg/mL ampicillin.  
Colonies appearing after overnight incubation were screened for the presence of 
plasmid containing the PCR product using a modified alkaline lysis procedure as 
described in section 4.2.3.7.
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 Plasmid DNA obtained from this preparation was 
subjected to enzymatic digestion with NcoI and PmeI followed by agarose gel 
electrophoresis.  
Colonies containing the vector with the ligated PCR product were grown 
overnight at 37 ºC in LB media supplemented with 100 µg/mL ampicillin. Plasmid DNA 
was extracted from the bacterial pellet using the Qiagen miniprep kit, following the 
manufacturer‟s protocols with the adjustments described previously in section 
4.2.3.7.The purified plasmid was sequenced to confirm the identity of the PCR product. 
For the TMTC2 gene, five sequencing reactions, using two external primers (Trx forward 
and pBAD reverse) from the cloning vector and three internal primers were submitted to 
ensure full sequence coverage. Sequencing was analyzed as described in section 4.2.3.9 
and colonies containing the gene of interest having the correct sequence were cultured as 
described above. Plasmid pBAD-TMTC2 was isolated using the Qiagen kit with the 
adjusted protocol as previously described and used to transform E. coli heterologous 
expression hosts. 
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4.2.6.3 pET-TMTC2 Cloning 
To create the pET32a construct, a 5 mL culture of E. coli DH5α cells containing 
pCR-TOPO4-TMTC2 was grown overnight at 37 ºC in LB media supplemented with 50 
µg/mL kanamycin. After overnight growth, the plasmid was isolated using the Qiagen 
miniprep kit following the manufacturer‟s protocols with adjustments as previously 
described. Plasmid DNA obtained from this preparation was subjected to enzymatic 
digestion overnight with NcoI and PmeI following the standard procedure provided in 
section 4.2.3.10. After electrophoresis, the DNA band of the correct size was extracted 
from the gel following the methods described earlier in this chapter. Expression vectors 
were prepared by enzymatic digestion with the appropriate enzymes (NcoI and EcoRV), 
and purified according to the protocols described in section 4.2.3.10. Ligations followed 
the procedures given earlier in the chapter and the transformation procedure is identical 
to that previously described (see section 4.2.3.10), and the transformation was plated 
directly onto LB-agar plates containing 100 µg/mL ampicillin.  
After overnight incubation at 37 ºC, colonies appearing on the selection plates 
were screened for successful ligation by alkaline lysis and enzymatic digestion according 
to the methods described above with the following adjustments. Digestion was carried 
out using the restriction enzymes NcoI and XhoI, Positive colonies were amplified and 
gene-containing plasmids purified for transformation into E. coli BL-21(DE3). This 
construct was created such that the tmtc2 gene would be expressed as an N-terminal 
thioredoxin fusion protein with a His6-tag. 
 
4.2.7 E. coli Transformations and Attempts to Express the tmtc2 Gene 
STEP 1: GROWTH OF E. COLI CELLS. Plasmid constructs pET-TMTC2 and pBad-
TMTC2 were used to transform competent E. coli BL-21(DE3) Rosetta II cells following 
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the previously described protocol. Selection was performed by plating the recombinants 
on LB-agar supplemented with 100 µg/mL ampicillin and incubated overnight at 37 ºC. 
Small-scale cultures were inoculated from colonies grown on the selective plate. Cultures 
of LB broth (20 mL) supplemented with 100 µg/mL ampicillin were inoculated with 
single colonies and grown overnight with 200 RPM shaking. These starter cultures were 
used to inoculate cultures grown in different media at various temperatures with different 
growth times. Media used include Luria-Bertani (LB), Terrific Broth (TB) (1.2% 
tryptone, 2.4% yeast extract, 0.4% glycerol, and 100 mL of  KPi buffer (0.17 M KH2PO4/ 
0.72 M K2HPO4)) and M9ZB media (0.5% NaCl, 0.1% NH4Cl, 0.3% KH2PO4, 0.6% 
Na2HPO4, 1% N-Z-Amine A, 0.4% glucose, 1 mM MgSO4).
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 Cultures were induced at 
varying OD600 as indicated in the table below and the inducer varied based on the 
construct used. Each of the cultures was centrifuged  at 4 ºC to pellet the cells. The cell 
pellets were stored at -80 °C for protein purification. A total of 56 trials were conducted 
to determine the best expression conditions for TMTC2 in E. coli, (Table 4.2).  
 
4.2 Expression conditions for TMTC2 in E. coli 
 
Media Construct 
Growth 
Temp (ºC) 
Induction 
Temp (ºC) Time (h) OD600 
Induction  
(mM IPTG/%L-Ara) Preparation 
LB pET32a 37 18 3 N/A 0 mM I 
TB pET32a 37 18 3 N/A 0 mM I 
LB pET32a 37 18 3 0.8 1.0 mM I 
TB pET32a 37 18 3 0.8 1.0 mM I 
LB pET32a 37 18 12 N/A 0 mM I 
TB pET32a 37 18 12 N/A 0 mM I 
LB pET32a 37 18 12 0.8 1.0 mM I 
TB pET32a 37 18 12 0.8 1.0 mM I 
LB pET32a 30 16 3 N/A 0 mM II 
TB pET32a 30 16 3 N/A 0 mM II 
LB pET32a 30 16 3 0.8 1.0 mM II 
TB pET32a 30 16 3 0.8 1.0 mM II 
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LB pET32a 30 16 12 N/A 0 mM II 
TB pET32a 30 16 12 N/A 0 mM II 
LB pET32a 30 16 12 0.8 1.0 mM II 
TB pET32a 30 16 12 0.8 1.0 mM II 
LB pET32a 37 14 3 N/A 0 mM I 
LB pET32a 37 14 12 N/A 0 mM I 
LB pET32a 37 14 3 1 1.0 mM I 
LB pET32a 37 14 12 1 1.0 mM I 
LB TrxTOPO 37 16 12 0.6-0.7 0 I 
LB TrxTOPO 37 16 12 0.6-0.7 0.000002% I 
LB TrxTOPO 37 16 12 0.6-0.7 0.00002% I 
LB TrxTOPO 37 16 12 0.6-0.7 0.0002% I 
LB TrxTOPO 37 16 12 0.6-0.7 0.002% I 
LB TrxTOPO 37 16 12 0.6-0.7 0.2% I 
LB TrxTOPO 37 16 12 0.6-0.7 2% I 
LB TrxTOPO 30 16 12 0.8 2% I 
TB TrxTOPO 30 16 12 0.9 2% I 
M9ZB TrxTOPO 30 16 12 0.9 2% I 
LB TrxTOPO 30 16 12 0.8 0% I 
TB TrxTOPO 30 16 12 0.9 0% I 
M9ZB TrxTOPO 30 16 12 0.9 0% I 
LB TrxTOPO 30 16 3 0.6-0.7 2% I 
TB TrxTOPO 30 16 3 0.9 2% I 
M9ZB TrxTOPO 30 16 3 0.9 2% I 
LB TrxTOPO 30 16 3 0.8 0% I 
TB TrxTOPO 30 16 3 0.6-0.7 0% I 
M9ZB TrxTOPO 30 16 3 0.9 0% I 
LB TrxTOPO 30 16 12 0.8 2% II 
TB TrxTOPO 30 16 12 0.9 2% II 
M9ZB TrxTOPO 30 16 12 0.9 2% II 
LB TrxTOPO 30 16 12 0.8 0% II 
TB TrxTOPO 30 16 12 0.9 0% II 
M9ZB TrxTOPO 30 16 12 0.9 0% II 
LB TrxTOPO 30 16 3 0.8 2% II 
TB TrxTOPO 30 16 3 0.9 2% II 
M9ZB TrxTOPO 30 16 3 0.9 2% II 
LB TrxTOPO 30 16 3 0.8 0% II 
TB TrxTOPO 30 16 3 0.9 0% II 
M9ZB TrxTOPO 30 16 3 0.9 0% II 
LB TrxTOPO 37 37 3 ~1 2% II 
M9ZB TrxTOPO 37 37 3 ~1 2% II 
LB TrxTOPO 37 37 3 ~1 0% II 
M9ZB TrxTOPO 37 37 3 ~1 0% II 
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4.2.8 E. COLI PROTEIN PURIFICATION METHODS FOR TMTC2- ISOLATING 
TRANSMEMBRANE PROTEIN 
STEP 2A: CRUDE EXTRACT PREPARATION. Preparation I follows a method reported 
by the Imperiali group.
109
 Cells were harvested by centrifugation at 4,500 g for 15 min at 
4 ºC and frozen overnight at -80 ºC.  
STEP 3A: METHOD I. All subsequent procedures were carried out at 4 ºC or on ice. 
Cells were resuspended in 1/20 volume of 50 mM Tris-acetate, pH 8.0, 1 mM EDTA 
buffer and lysed by sonication. Cells were centrifuged at 5,700 g. The supernatant 
fractions from these centrifuged samples were subjected to ultracentrifugation at 142,400 
g for 1 h. The resulting pellet was resuspended in Tris-acetate buffer with 30% w/v 
glycerol and stored at -20 ºC.  
STEP 2B: CRUDE EXTRACT PREPARATION. The preparation II procedure was reported 
by the Schutzbach group. 
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 Volumes given in this protocol are specific for a 1 L 
preparation.  Cultures were harvested by centrifugation at 6,700 g at 4 ºC for 15 min. 
 STEP 3B: METHOD II. All subsequent procedures were carried out at 4 ºC or on 
ice. Cells were washed with 300 mL of water followed by a wash using 100 mL of buffer 
B (25 mM sodium phosphate, pH 8.0, 5 mM MgCl2, and 0.2% β-mercaptoethanol). The 
cell pellet was frozen and stored at -80 ºC overnight. The pellet was thawed, resuspended 
in 10 mL of buffer B, and the cells were ruptured by sonication at a power setting of 4.5 
for 3 × 30 s with a 1 min interval to allow cooling. The particulate (pellet) fraction 
obtained by centrifugation at 39,000 g for 20 min, was washed twice with 25 mL of 
buffer B and resuspended in 5 mL of the same buffer. The suspension was diluted with 
17.5 mL of buffer C, (10 mM sodium phosphate, pH 8.0, containing 0.5 mM EDTA, 10% 
glycerol, 0.1% Nonidet P-40, and 1.0 mM dithiothreitol). Nonidet P-40 (2.5 mL of a 10% 
solution) was added, and the mixture was centrifuged at 39,000 g for 20 min. The 
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supernatant was removed and retained as “fraction C”. Additional enzyme was 
solubilized by the addition of 20 mL of buffer D (0.1 M Tris acetate, pH 7.5, containing 
10% (v/v) glycerol, 0.2% β-mercaptoethanol, and 0.1% (w/v) sodium dodecyl sulfate) to 
the precipitate from the previous step. The precipitate was dispersed by vigorous 
trituration followed by the addition of 2.5 mL of 10% Nonidet P-40. The solution was 
centrifuged as above, and the supernatant was removed and retained as “fraction D”. This 
procedure was repeated once more to yield a third solubilized fraction, which was 
combined with “fraction D” The pellet was retained as “insoluble fraction”. All fractions 
were stored at -20 ºC. 
STEP 4: SDS-PAGE AND WESTERN BLOTTING.  Membrane fractions from Method I 
and Fractions C and D from Method II were analyzed using SDS-PAGE denaturing 
conditions as described in section 4.2.3.11, and electrophoresis was performed in 
duplicate. One gel was subjected to Coomassie staining, and the other was transferred to 
a nitrocellulose membrane for Western blotting. Membranes were probed using Anti-V5 
and Anti-thioredoxin primary antibodies for pBad-TMTC2 constructs. Anti-thioredoxin 
and Anti-His primary antibodies were used to detect full-length transcript for pET-
TMTC2 constructs.  
 
4.2.9 CLONING OF IL-12B FOR E. COLI EXPRESSION  
 
4.2.9.1 PCR Reactions and Product Purification 
The IL-12b gene was amplified using the IL-12b-pCR-TOPO4 vector as template 
DNA.  Primers for il-12b expression were designed for cloning into the pET-32a vector. 
The primer sequences incorporated NdeI and HindIII restriction sites in start and halt 
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primers respectively, (5′ start primer, 5′- GTCGATCCATATGTGTCACCAGC-AGTTG-
3′, and 3′ the halt primer, 5′-ATCGAAGCTTCTAACTGCAGGGCAC-3′) and were 
designed to generate a construct such that an N-terminal thioredoxin and His6-tag would 
be introduced upon gene expression.  
Template and DNA primers were obtained and prepared for PCR as described 
previously.  The PCR reactions consisted of the following: 32.8 µL of sterile water, 5 µL 
of 10X KOD buffer, 5 µL of a 2.0 mM dNTP solution, 3.0 µL of a 25 mM MgSO4 
solution, 1.5 µL of a 10 µM solution of each primer (5′ and 3′), 0.2 µL of template DNA, 
and 1.0 µL of KOD polymerase, for a 50 µL total reaction volume in an 0.2 mL thin-
walled PCR tube. PCR was carried out using an Eppendorf thermocycler with the lid 
temperature set at 105 ºC and an initial denaturing step of 2 min at 95 ºC.  The program 
consisted of a 30 s denaturing step at 95 ºC, an annealing step at 55.9 ºC for 10 s, an 
elongation step of 20 s (20  s/kb) at 70 ºC. This cycle was repeated thirty times, and the 
program ended with a 10 min extension at 70 ºC. The temperature was reduced to 4 ºC 
until the product was removed from the thermocycler.  PCR products were stored at 4 ºC 
until purified. 
The PCR products were purified by agarose gel electrophoresis as described in 
section 4.2.3.4, with the elution volume reduced to 20 µL. 
 
4.2.9.2 IL-12b Shuttle Vector Cloning 
PCR products were A-tailed and ligated into the shuttle vector pGEM- T easy for 
blue-white screening as specified in section 4.2.3.5. After this procedure, the purified 
plasmid was sequenced to confirm that the sequence of the PCR product is correct. For 
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the il-12b gene, two sequencing reactions using the M13 external primers were 
performed to ensure full sequence coverage. 
 
4.2.9.3 Cloning of il-12b into pET32a Plasmid for E. coli Expression 
  The pET32-il-12b expression construct was generated following protocols 
detailed in section 4.2.3.10. Specific details are as follows. All liquid and solid media was 
supplemented with 100 µg/mL ampicillin for selection. Restriction enzymes used for 
digestion were NdeI and HindIII enzymes. Culture volumes for pET vector amplification 
or isolation were 10 mL. Cultures and plate were incubated for 8-10 h only. The plasmid 
generated via this method was pET32a/IL-12b for expression of IL-12b in E. coli as an 
N-terminal thioredoxin (Trx) fusion protein. Positive colonies were amplified and gene-
containing plasmids purified for transformation into E. coli BL-21 and BL-21*. 
 
4.2.10 E. COLI TRANSFORMATIONS AND IL-12B GENE EXPRESSION TRIALS 
The pET32a/IL-12b plasmid construct was transformed into competent E. coli 
BL-21 and BL-21* cells following the protocol described previously and selected by 
plating on LB-ampicillin plates (100 µg/mL) after overnight incubation at 37 ºC.  
Colonies that grew were used to inoculate small-scale (20 mL) cultures and trials were 
conducted to determine the best expression conditions for IL-12b in E. coli according to 
the table below. 
STEP 1: GROWTH OF E. COLI CELLS.  Cultures of LB broth (6 × 20 mL) 
supplemented with 100 µg/mL ampicillin were inoculated with single colonies and grown 
overnight with 200 RPM shaking. Two cultures were grown at 30 °C, two at 37 °C, and 
two at 15 ºC. 
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4.3 Expression conditions for IL-12b in E. coli 
 
Media Cell Line 
Growth 
Temp ºC 
Expression 
Temp ºC Time (h) OD600 
Induction  
(mM IPTG) Preparation 
LB BL-21 37 N/A 12  N/A 0 mM Crude soluble  
LB BL-21 30 N/A  16  N/A 0 mM Crude soluble 
LB BL-21 15 N/A 30  N/A 0 mM Crude soluble 
LB BL-21* 37 N/A 12  N/A 0 mM Crude soluble 
LB BL-21* 30 N/A  16  N/A 0 mM Crude soluble 
LB BL-21* 15 N/A 30  N/A 0 mM Crude soluble 
LB BL-21* 37 N/A 12  0.5 0.1 mM Crude soluble 
LB BL-21* 37 N/A  12  0.5 0.5  mM Crude soluble 
LB BL-21* 37 N/A 12  0.5 1.0 mM Crude soluble 
. 
One culture at each temperature contained the plasmid in the BL-21 expression 
host, and the other contained the plasmid in BL-21*. Cultures grown at 37 °C were 
harvested after 12 h growth while the 30 °C cultures were allowed to grow 16 h before 
harvesting.  The 15 °C cultures were incubated for 30 h and then harvested. Each of the 
cultures was centrifuged at 4,500 g for 15 min to pellet the cells. The cell pellets were 
stored at -80 °C for protein purification.  
STEP 2: CRUDE EXTRACT PREPARATION. All steps were performed at 4 ºC or on ice. 
To assess gene expression level and protein solubility, crude protein extracts were 
prepared by sonication and centrifugation. Briefly, cells were resuspended in 1 mL of 
Lysis buffer II (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole with 10% glycerol 
pH 8.0). Cells were disrupted by 15 × 2 s sonication pulses with 5 s cooling periods 
between the pulses. Aliquots of whole cell sample (50 µL) were removed from each 
sample and retained for later analysis. Crude protein extracts were obtained by 
centrifugation at 10,000 g, at 4 ºC for 20 min.  
STEP 3: CRUDE EXTRACT ANALYSIS. Whole cell, pellet, and supernatant samples 
representing each of the three temperatures and the two types of protein expression cells 
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were analyzed using SDS-PAGE and Western blot following the procedures specified 
earlier in this chapter. The Anti-thioredoxin primary and anti-mouse secondary antibodies 
were used for the Western blotting procedure.  
 
4.2.11 LARGE SCALE IL-12B GENE EXPRESSION IN E. COLI 
STEP 1: GROWTH OF E. COLI CELLS.  A culture containing 20 mL LB media, 
supplemented with 100 µg/mL ampicillin was inoculated with Bl-21* cells carrying the 
pET32a/IL-12b construct. This culture was grown at 37 °C with shaking. After overnight 
incubation, the culture was used to inoculate 6 L of LB media (3 mL/ L), supplemented 
with 100 µg/mL ampicillin. Cultures were incubated at 37 °C with shaking overnight. 
The cells were harvested by centrifugation at 4,500 g for 15 min and stored at -80 °C.  
STEP 2: CRUDE EXTRACT PREPARATION. All steps were carried out at 4 ºC or on  
ice. Cells were resuspended in 2 mL Lysis buffer II (50 mM NaH2PO4, 300 mM NaCl, 10 
mM imidazole with 10% glycerol, pH 8.0) per gram cell wet weight. Lysozyme, 1 
mg/mL, was added to the cell suspension and incubated for 1 h with stirring every 15 
min. Cells were disrupted by 10 × 18 s sonication pulses with 20 s cooling periods 
between pulses. Crude protein extracts were obtained by centrifugation at 10,000 g, at 4 
ºC for 20 min.  
STEP 3: NI-NTA CHROMATOGRAPHY. Protein was purified by Ni
2+
 affinity 
chromatography following manufacturer‟s instructions with 10% glycerol in all buffers. 
Briefly, 5 mL of resin was prepared by washing with Lysis buffer II and allowed to bind 
with soluble protein at 4 ºC for 1 h, loaded onto a 2  25 cm column. The column was 
packed by gravity flow and washed with 5 column volumes (CV) of Lysis buffer II 
followed by two washes with 10 CV of Wash buffer II (50 mM NaH2PO4, 300 mM NaCl, 
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20 mM imidazole, 10% glycerol, pH 8.0). IL-12b protein was eluted with 12 mL of 
Elution buffer II (50 mM NaH2PO4, 300 mM NaCl, 250 mM imidazole, 15% glycerol, 
pH 8.0), which was collected in 1 mL fractions. Whole cell, pellet, flow through, wash, 
and elution samples were analyzed by SDS-PAGE and Western blotting according to the 
protocols described earlier in this chapter. Fractions containing IL-12b as determined by 
SDS-PAGE and Western blot, were collected and dialyzed against 3 L of Dialysis buffer 
II (50 mM NaH2PO4, 300 mM NaCl, 15% glycerol, pH 8.0). The dialyzed protein 
solution was concentrated using the Amicon filtration system. Protein was flash frozen in 
liquid nitrogen and stored at -80 ºC until use.  
 
4.2.11.1 In-Gel Tryptic Digestion of IL-12b 
The major protein bands were excised from the Coomassie stained gel with a 
fresh razor blade. The gel slices were processed according to the method of Shevchenko, 
as specified in section 4.2.3.13.
328
 Samples were submitted to the ICMB Protein Mass 
Spectrometry Facility for MALDI TOF/TOF protein identification. 
 
4.2.12 CLONING OF TMTC2 AND TMTC3 FOR S. CEREVISIAE  
 
4.2.12.1 PCR Reactions and Product Purification 
The potential CMT genes tmtc2 and tmtc3 genes were amplified using constructs 
obtained from OPEN Biosystems as template DNA. TMTC2 primers were designed 
incorporating the restriction enzyme recognition sites for EcoRI and ClaI in the primer 
sequences (5′ start primer, 5′-CCAAGAATTCAATAATGATTGCAGAGTTGGTGAGC-
AGCG-3′, and 3′ halt primer, 5′-GTTGTTATCGATCCGGTCTTAGAAGTCTTTAAGC-
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CTTGTTTTTCC-3′). TMTC3 primers were designed incorporating the restriction 
enzyme recognition sites for ApaI and SalI in the primer sequences (5′ start primer 5′-
TAAGGGCCCAATATGGCTAATATTAACCTAAAAGAAATAACC-3′ and 3′ halt 
primer 5′-CCATGTCGACTTCACCATTTAAAATACGTTCAATC-3′). These primers 
were designed for the pESC-His S. cerevisiae dual expression vector, incorporating  
Kozak sequences before the translation initiation codons and removing the stop codons 
from the amplified genes such that a C-terminal FLAG- or myc-epitope-tag is introduced 
upon expression, respectively.
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   The primers and template were prepared as previously 
specified. The PCR reactions consisted of the following: 140 µL of sterile water, 20 µL 
of 10X KOD buffer, 16 µL of a 2 mM dNTP solution, 12 µL of a 25 mM MgSO4 
solution, 10 µL of dimethyl sulfoxide (DMSO), 1.0 µL of each primer (5′ and 3′) at 10 
µM, and 1 µL of template DNA, for a total volume of 200 µL. The mixture was divided 
into two 0.5 mL thin-walled PCR tubes and 2 µL KOD polymerase was added to each 
reaction. PCR reactions were carried out using an Eppendorf thermocycler with the lid 
temperature set at 105 ºC and an initial polymerase activation step of 2 min at 95 ºC.  The 
program consisted of a 20 s denaturing step at 95 ºC, an annealing step at 43.6 ºC for 10 
s, and an elongation step at 70 ºC for 90 s. This cycle was repeated thirty times, and the 
program ended with a 10 min extension at 70 ºC. The temperature was reduced to 4 ºC 
until the product was removed from the thermocycler.  PCR products were stored at 4 ºC 
until purified.   
 
4.2.12.2 TMTC2 and TMTC3 S. cerevisiae Construct Shuttle Vector Cloning 
PCR products were blunt end ligated into the pCR-Blunt vector following the procedures 
specified in section 4.2.3.6 with the following specifications. All media was 
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supplemented with 50 µg/mL kanamycin. LB-agar plates were used for solid culture, and 
2X YT media was used for liquid cultures (1.6% tryptone, 1% yeast extract, 0.5% NaCl, 
pH 7.0). Liquid culture volume was 3 mL and incubation time was 12-16 h. For these 
genes, five sequencing reactions, using two external primers (M13 forward and reverse) 
from the cloning vector and three internal primers were submitted to ensure full sequence 
coverage. Sequences for internal primers used for tmtc2 are as follows: 
GGGAATTCCATATGGATGGGAAACAAACCACC, GGGAATTCCATATGCTCAA-
GACTGCGATCAGG, and CCGCTCGAGTTTCTCCAGTCACAAACTGTT. 
Sequences for internal primers used for tmtc3 are as follows: 
TTGCCTTGACAGTGTTTTTAGTGGC, CCTCCAAGACTGGTTTAATGGCG, and 
CCTGATCCGAGCAAATGAGTCCCG. Sequences were analyzed as described in 
previous sections. 
 
4.2.12.3 TMTC2 and TMTC3 S. cerevisiae Construct Expression Vector Cloning 
The pESC-His Dual TMTC2, pESC-His Dual TMTC3 and pESC-His Dual 
TMTC2/3 expression constructs were generated following protocols detailed in section 
4.2.3.10. Specific details are as follows. All liquid and solid media was supplemented 
with 100 µg/mL ampicillin for selection. LB-agar was used for solid cultures and 2X YT 
media was used for liquid cultures. Restriction enzymes used for digestion were EcoRI 
and ClaI for tmtc2 and ApaI and SalI for tmtc3. During CIP treatment of pESC-His Dual 
vectors, 0.1 µL CIP and 0.25 volumes of 1 M Tris, pH 8 were added to reactions.  
Ligations were performed at 4 ºC overnight, according to the procedure described in 
section 4.2.3.10 with the following adjustments to the protocol. For the transformation, 
100 µL of competent E. coli DH5α was used. Culture volumes for pESC vector 
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amplification or isolation were 3 mL. Following alkaline lysis, cultures were incubated 
for 6 h only. Plasmids generated via this method included pESC-His-TMTC2, where 
TMTC2 is under the control of the pGal10 promoter, C-terminally tagged with the FLAG 
epitope, and pESC-His-TMTC3, where TMTC3 is under the control of the pGal1 
promoter, C-terminally tagged with the c-myc epitope.  
To generate pESC-His-TMTC2/3, the latter plasmid pESC-His-TMTC3 was 
digested with EcoRI and ClaI and prepared as described above. The digested, CIP treated 
vector was gel purified and subjected to ligation with tmtc2, also digested with these 
enzymes. Ligation, alkaline lysis, electrophoresis and final plasmid preparation were 
repeated as above to construct this plasmid. After construction, the pESC-His dual 
expression vector containing both TMTC2 and TMTC3 was submitted to DNA 
sequencing to ensure that both genes were present in the vector. 
 
4.2.13 CLONING OF IL-12B WITH SECRETION SEQUENCE FOR S. CEREVISIAE  
 
4.2.13.1 PCR Leader Sequence Design 
To target IL-12b for secretion from S. cerevisiae, primers were designed to 
incorporate a signal secretion sequence at the 5′ end of the il-12b gene using TBC 
methodology.
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 The sequence to be added to the 5′ end of the gene was a three-part 
sequence beginning with a leader sequence (L), followed by a prepro sequence (P), and 
ending with a spacer (S) between the prepro sequence and the gene. 
334, 335
 The protein 
sequence is: (L) MKLKTVRSAVLSSLFASQVLG (P) 
QPIDDTESQTTSVNLMADDTESAFATQTNSG GLDVVGLISMAKR (S) EEGEPK.  
Back translation of the protein sequence yielded the DNA sequence to be added as: 5′-
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ATGAAATTGAAAACTGTTAGATCTGCTGTTTTGTCTTCTTTGTTTGCTTCTCAA
GTTTTGGGTCAACCAATAGACGATACTGAATCTCAAACTACTTCTGTTAATTT
GATGGCTGATGATACAGAATCAGCTTTTGCTACTCAGACTAATTCTGGTGGTT
TGGATGTTGTTGGTTTGATTTCTATGGCTAAAAGAGAAGAAGGTGAACCAAA
A-3′.  
Primers used to construct this DNA sequence were designed using Helix web 
analysis found at the website: http://helixweb.nih.gov/dnaworks. The above DNA 
sequence was entered into the program, along with the first 30 nucleotides of il-12b  
(ATGTGTCACCAGCAGTTGGTCATCTCTTGG) to generate primers for overlap 
extension PCR, to synthesize the sequence in situ. Helixweb analysis generated 8 primers 
of 60 bases with overlapping regions of approximately 20 nt each, with melting 
temperatures of 62 ºC. Finally, the restriction site (SacI) and Kozak sequence were added 
to the 5′ sequence of the ultimate 5′ primer. The 3′ primer, including the XhoI restriction 
site, was designed to match the length, GC content, and melting temperature of the final 
5′ primer. The 3′ primer was used to amplify the entire il-12b gene in the final PCR step. 
The final primer sequences are summarized in Table 4.4 below. 
 
4.4 IL-12b S. cerevisiae Primers  
Primer # Sequence 
5′ / 1 5′-GGAGCTCATTATGAAATTGAAAACTGTTAGATCTGC-3′ 
2 5′-CAAAACTTGAGAAGCAAACAAAGAAGACAAAACAGCAGATCTAACAGTTTTCAATTTCAT-3′ 
3 5′-TTCTTTGTTTGCTTCTCAAGTTTTGGGTCAACCAATAGACGATACTGAATCTCAAACTAC-3′ 
4 5′-CTGATTCTGTATCATCAGCCATCAAATTAACAGAAGTAGTTTGAGATTCAGTATCGTCTA-3′ 
5 5′-GATGGCTGATGATACAGAATCAGCTTTTGCTACTCAGACTAATTCTGGTGGTTTGGATGT-3′ 
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6 5′-CACCTTCTTCTCTTTTAGCCATAGAAATCAAACCAACAACATCCAAACCACCAGAATTAG-3′ 
7 5′-CTATGGCTAAAAGAGAAGAAGGTGAACCAAAAATGTGTCACCAGCAGTTGGTCATCTCTT-3′ 
8 5′-CCAAGAGATGACCAACTGCTGGTGACA-3′ 
3′ 5′-ATACTCGAGCCTCCAAATTTTCATCCTGGATC-3′ 
 
4.2.13.2 Overlap Extension PCR Reactions to Generate the IL-12b Leader Sequence  
STEP 1: GENERATION OF THE LPS SEQUENCE. The primers were obtained as 
lyophilized powder and were prepared by dilution with TE buffer to a concentration of 
100 µM.  This stock solution was further diluted to 10 µM with sterile water. A second 
dilution was made to 3 µM, and 1.25 µL of each primer 1-8 were combined with 5 µL of 
10X buffer, 5 µL of 2.0 mM dNTP, 3 µL of 25 mM MgSO4, 1 µL of KOD polymerase, 
and sterile water to a volume of 50 µL. The reaction was heated to 95 ºC for 2 min with 
the lid temperature set to 105 ºC. After the initial denaturing step, the reaction was heated 
for 15 s at 94 ºC, followed by an annealing step at 57 ºC for 30 s. The temperature was 
raised to 68 ºC for 15 s and the cycle was repeated 25 times.  
STEP 2: AMPLIFICATION OF THE LPS SEQUENCE. The PCR reaction from the last 
step was used as the template for the next reaction. To this reaction was added: 2.5 µL of 
10 mM primers 1 and 8 only, 5 µL 10X buffer, 10 µL of 2.0 mM dNTP, 3 µL of 25 mM 
MgSO4, 2 µL of KOD polymerase and sterile water to a volume of 100 µL. The PCR 
cycle described above was repeated, and the reaction was stored at 4 ºC until purification. 
STEP 3: GEL PURIFICATION OF THE LPS SEQUENCE. The PCR products were purified 
by agarose gel electrophoresis as described previously and visualized using a UV 
illumination source. DNA bands of the correct base pair length (approximately 300 bp) 
were excised from the gel and purified using the Qiagen gel extraction kit, following the 
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manufacturer‟s protocols with the modifications as described previously, except that an 
elution volume of 20 µL was used.  
STEP 4: GENERATION OF THE LPS-IL-12B SEQUENCE. Each primer, (1.25 µL of 5′ 
and 3′) at 3 µM were combined with 5 µL of 10X buffer, 5 µL of 2.0 mM dNTP, 3 µL of 
25 mM MgSO4, 20 µL of the purified DNA from the previous step, 0.1 µL of IL-12b 
template DNA, 1 µL of KOD polymerase, and sterile water to a volume of 50 µL. The 
reaction was heated to 95 ºC for 2 min with the lid temperature set to 105 ºC. After the 
initial denaturing step, the reaction was heated for 15 s at 94 ºC, followed by an annealing 
step at 57 ºC for 30 s. The temperature was raised to 68 ºC for 1 min and the cycle was 
repeated 25 times.  
STEP 5: AMPLIFICATION OF THE LPS-IL-12B SEQUENCE. The PCR reaction from the 
last step was gel purified and used as the template for the next reaction. Again, the elution 
volume of the gel purified product was reduced to 20 µL. The primers, (0.5 µL of 10 
mM) 5′ and 3′ only, 2.5 µL of 10X buffer, 10 µL of 2.0 mM dNTP, 1.5 µL of 25 mM 
MgSO4, 10 µL of DNA template, 0.5 µL of KOD polymerase for a volume of 25 µL. The 
reaction was heated to 95 ºC for 2 min with the lid temperature set to 105 ºC. The 
reaction was heated to 95 ºC for 2 min with the lid temperature set to 105 ºC. After the 
initial denaturing step, the reaction was heated for 15 s at 94 ºC, followed by an annealing 
step at 57 ºC for 30 s. The temperature was raised to 68 ºC for 1 min and the cycle was 
repeated 25 times. The cycle terminated in a 10 min final extension at 70 ºC and the 
reaction was stored at 4 ºC until purification. 
STEP 6: GEL PURIFICATION OF THE LPS-IL-12B SEQUENCE. The PCR products were 
purified by agarose gel electrophoresis employing an 0.8% TAE-agarose gel with 5 
µg/mL ethidium bromide as specified in section 4.2.3.4, except that the elution volume 
was reduced to 20 µL. 
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PCR products were A-tailed and ligated into the shuttle vector pGEM-T easy for 
blue-white screening following the procedures described earlier in this chapter. The 
purified plasmid was sequenced to confirm the identity of the PCR product. For these 
genes, two sequencing reactions, using two external primers (M13 forward and reverse) 
from the cloning vector were submitted to ensure full sequence coverage, and DNA 
sequences were evaluated as described previously. 
STEP 7: CLONING OF LPS-IL-12B INTO PYES. Once the DNA sequence was 
confirmed to be the desired gene, il-12b, it was isolated and ligated into the pYES 
plasmid. The pYES-sc-il12b expression construct was generated following protocols 
detailed in section 4.2.3.10. Specific details are as follows. All liquid and solid media was 
supplemented with 100 µg/mL ampicillin for selection. Restriction enzymes used for 
digestion were SacI and XhoI, and a typical reaction mixture consisted of 10 µL of DNA, 
5 µL of 10X NEBuffer, 35 µL of sterile water and 1 µL of each enzyme. Ligations were 
performed at 4 ºC overnight and 100 µL of chemically competent E. coli DH5α was used 
for transformation reactions. Culture volumes for pYES vector amplification or isolation 
were 10 mL. Cultures and plates were incubated for 8-10 h only. The plasmid generated 
via this method was pYES-sc-il12b for expression of il-12b in S. cerevisiae with an N-
terminal secretion sequence for expression of IL-12b in yeast cells, and secretion of the 
protein into the media. Positive colonies were amplified and gene-containing plasmids 
purified for transformation into S. cerevisiae.  
 
4.2.14 S. CEREVISIAE TRANSFORMATIONS AND PROTEIN EXPRESSION 
To transform the InvSC1 yeast strain, a fresh YPD-agar plate was streaked with 
glycerol stock prepared as described previously. After overnight incubation at 30 ºC, a 
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liquid culture of 20 mL YPD media was inoculated using sterile transfer technique. This 
liquid culture was incubated overnight at 30 ºC with 200 RPM shaking. The OD600 was 
measured and the appropriate amount of the culture was transferred to 50 mL fresh YPD 
media to obtain a culture with an OD600 of 0.4. This culture was allowed to grow for 2-4 
h at 30 ºC with 200 RPM shaking. The culture was subsequently transferred into sterile 
50 mL conical tubes and centrifuged at 2,500 g for 5 min to pellet the yeast cells. The 
supernatant was decanted and the cells were resuspended in 40 mL of 1X TE buffer (10 
mM Tris∙HCl, pH 7.5, 1 mM EDTA, pH 8.0). The cells were centrifuged again at 2,500 g 
for 5 min and resuspended in 2 mL 1XLiAc/0.5XTE buffer (100 mM lithium acetate 5 
mM Tris∙HCl, (pH 7.5), 0.5 mM EDTA, (pH 8.0)). The cell suspension was incubated at 
room temperature for 10 min and 100 µL aliquots were dispensed into sterile eppendorf 
tubes for transformation.  
The plasmid used to transform the yeast cells (1 µg) was mixed with 100 µg 
salmon sperm DNA and introduced to the yeast strain. The transformation mix (700 µL) 
(40% PEG 3350, 60% 1XLiAc/0.5XTE buffer) was introduced to the cells, and mixed 
well. The transformation mixture was incubated at 30 ºC for 30 min, and 88 µL of 
dimethyl sulfoxide (DMSO) was added to the mixture. After mixing well, the 
transformation mixture was heat shocked at 42 ºC for 7 min. Cells were pelleted by 
centrifugation at 2,500 g for 30 s, and the supernatant was removed by aspiration. 
Transformants were washed with 1X TE buffer and centrifuged again to pellet the cells. 
Cells were resuspended in 50 µL 1X TE buffer and plated on SC-dropout media. When 
the pYES cloning vector was used, uracil was omitted from media, while histidine was 
omitted from yeast transformed with the pESC-His vector. For strains transformed with 
both vectors, InvSC1 was grown on media without histidine or uracil. Plates were 
incubated at 30 ºC for 2-3 days until colonies appeared on the plates. Positive 
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transformants were used to inoculate 10-20 mL of SC dropout media. Cultures were 
grown overnight at 30 ºC with 200 RPM shaking. After growth, an aliquot of 80% sterile 
glycerol equal to 25% of the culture volume was introduced into the culture and mixed 
thoroughly. The fresh glycerol stocks were aliquotted into 1 mL volumes and frozen at -
80 ºC until needed.  
 
4.2.15 PROTEIN EXPRESSION IN S. CEREVISIAE 
Protein expression was carried out following the manufacturer‟s suggested 
protocols.  Briefly, 200 µL of a glycerol stock was used to inoculate a 20 mL culture of 
SC dropout media, which was then incubated at 30 ºC with 200 RPM shaking overnight. 
SC-his was used for TMTC2, TMTC3 and TMTC2/3 expression. SC-ura media was used 
for IL-12b expression, and for strains containing both plasmids, double dropout SC-ura-
his media was used for culturing. After overnight incubation, the OD600 of each culture 
was taken, and an aliquot of each culture was transferred into a sterile tube such that 
when resuspended in fresh induction media the OD600 of the dilution would be 0.4. The 
aliquots were centrifuged at 2,500 g for 5 min to pellet the cells. The media was 
discarded by decanting and the pellets were washed with 1X TE buffer or 100 mM 
potassium phosphate buffer, pH 7.4. Cells were repelleted by centrifugation as above and 
the wash discarded. SC induction media (0.67% yeast nitrogen base, 2% galactose, 
0.075% complete supplemental media amino acid mixture, without uracil and histidine, 
0.05% uracil, and/or 0.1% histidine) was used to resuspend the cells to an OD600 of 0.4. 
Cells were grown for 14 h, with 1/7
th
 culture volume taken as aliquots at 0, 4, 6, 8, 10, 12 
and 14 h after induction. These aliquots were centrifuged to pellet the cells at 2,500 g for 
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5 min. The supernatants were discarded and cell pellets stored at -80 ºC until screened for 
the presence of target proteins.  
 
4.2.16 PROTEIN EXTRACTION FROM S. CEREVISIAE 
The cell pellets obtained in the previous step were processed using several 
methods to determine the optimal extraction process for these proteins. The first methods 
tried were the total protein extraction protocol (Yaffe-Schatz), the membrane protein 
extraction protocol (Schutzbach), and total protein extraction using the Y-Per protein 
extraction reagent.
331, 336
  
METHOD I: YAFFE-SCHATZ TOTAL PROTEIN EXTRACTION. The total protein 
extraction protocol (Yaffe-Schatz) was applied to 1 mL of yeast cells grown in SC 
induction media. The cells were chilled for 10 min on ice, followed by the addition of 
150 µL YS-lysis solution (2M NaOH, 8% β-mercaptoethanol (v/v)). After addition, the 
cells were mixed well by inversion and incubated for an additional 10 min on ice. 
trichloroacetic acid (150 µL of a 50% solution) was added and the cells were again 
incubated on ice for 10 min. The lysed cells were pelleted by centrifugation for 2 min at 
maximum speed (16,100 g) in a tabletop centrifuge at 4 ºC. The supernatant was 
aspirated and the protein-containing pellet was washed with ice-cold acetone. After an 
additional 2 min centrifugation step, the wash was removed by aspiration and the pellet 
was resuspended in 100 µL 2X SDS sample buffer. In pellets where the sample buffer 
turned yellow, indicating the pH of the solution was too acidic, 10 µL of 1 M Tris, pH 8.0 
was added and mixed well. An aliquot (10 µL) of this sample was loaded onto an SDS-
PAGE for separation and assessment of protein expression through Coomassie staining 
and Western blotting. 
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METHOD II: MEMBRANE PROTEIN EXTRACTION. The membrane protein extraction 
protocol was adapted from Schutzbach et al. (1993).
331
  Cell pellets were washed with 
3/10 culture volume water, followed by a 1/10 volume wash with buffer B (25 mM 
sodium phosphate, pH 8.0, 5 mM MgCl2 and 0.2% β-mercaptoethanol (v/v)). Cell pellets 
were frozen at -80 ºC overnight and resuspended the following day in 1/100 culture 
volume of Buffer B. The suspension was sonicated to break the cells for 1 min per 10 mL 
culture, with 10 s pulses followed by 30 s cooling intervals. Sonication does not always 
break yeast cells, thus, homogenization using a Potter-Elvejhem-type homogenizer 
equipped with a tight-fitting (low-clearance) pestle was also used with 20-30 strokes per 
aliquot. Cell breakage was assessed either by microscopy, or measuring the OD600 of the 
homogenized culture. When the OD600 was reduced to less than 20% of the original 
optical density, the culture was taken to be fully homogenized. The disrupted suspension 
was centrifuged at 39,000 g for 20 min at 4 ºC to obtain a pellet enriched with membrane 
proteins. The pellet was washed twice with 1/40 volumes of Buffer B. The pellet was 
resuspended in 1/200 volumes of Buffer B, which was diluted in 1/60 volumes of Buffer 
C (10 mM sodium phosphate, pH 8.0, 0.5 mM EDTA, 10% glycerol, 0.1% Nonidet P-40, 
and 1 mM dithiothreitol), and further diluted with 1/400 culture volumes of 10% P-40. 
The mixture was again centrifuged at 39,000 g for 20 min at 4 ºC to obtain a pellet. The 
supernatant was retained and the pellet solubilized in 1/50 culture volume of Buffer D 
(100 mM Tris-acetate, pH 7.5, 10% glycerol, 0.2% β-mercaptoethanol, and 0.1% sodium 
dodecyl sulfate (SDS)). This mixture was again sonicated for 1 min per 100 mL culture 
volume to solubilize the pellet more thoroughly, and 1/400 culture volume of 10% 
Nonidet P-40 was added. The mixture was centrifuged again as above, and the 
supernatant was retained. The process of resuspension in Buffer D, sonication, and 
addition of Nonidet P-40, followed by centrifugation was repeated and solubilized 
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fractions combined and 10 µL of these fractions were loaded onto an SDS-PAGE for 
assessment of protein production by Coomassie staining and Western blot analysis. 
METHOD III: TOTAL PROTEIN EXTRACTION EMPLOYING Y-PER. Y-Per reagent from 
Pierce was applied to S. cerevisiae cultures according to the manufacturer‟s protocols. 
Briefly, cells were pelleted at 3,000 g for 5 min at 4 ºC. Cells were frozen at -80 ºC until 
ready to prepare. At this time, cells were weighed and the appropriate amount of Y-Per 
reagent was added according to the wet weight of the cells, (100 mg cells = 250-500 µL). 
The mixture was triturated until homogenous and incubated for 20 min at room 
temperature. After incubation, cell debris was pelleted at 14,000 g for 20 min at 4 ºC. The 
supernatant was removed and analyzed by SDS-PAGE and Western blotting. 
 
4.2.17 SMALL-SCALE MICROSOMAL PREPARATION 
Small scale microsomal preparations, purified following the method of the Aebi 
lab, were used to assess TMTC2, TMTC3 and TMTC2/3 production in yeast.
337
 S. 
cerevisiae cells were grown as stated in section 4.2.3.2. Cells were centrifuged at 5,000 g 
for 5 min at 4 ºC and pellets were washed with 100 mM potassium phosphate buffer (pH 
7.4). Cells were resuspended in spheroplasting buffer 2 (1 M sorbitol, 5 mM MgCl2, 10 
mM DTT, 50 mM HEPES pH 7.4) to a calculated cell density of 200 OD600 per mL. To 
this was added 50 µL of Zymolyase enzyme (75 units) and the solution was incubated at 
30 ºC with 200 RPM shaking for 1-2 h. The solutions were centrifuged at 5,000 g for 10 
min at 4 ºC. The supernatant was removed by aspiration and spheroplasts were lysed by 
the addition of 20 volumes of Spheroplast lysis buffer (10 mM HEPES, pH 7.4, 2 mM 
MgCl2, 1 mM PMSF) and incubated on ice for 30 min. After incubation, spheroplasts 
were homogenized using 12-25 strokes of a Potter-Elvejhem homogenizer. Sucrose 
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solution (2 M) was added to the homogenate to bring the final sucrose concentration to 
0.25 M. The homogenate was mixed well and centrifuged at 2,500 g for 10 min to 
remove cell debris and any unbroken spheroplasts. The supernatant was subjected to 
ultracentrifugation at 150,000 g (avg) for 20 min at 4 ºC, using a Beckman TL-100 
centrifuge equipped with a Ti-100.4 rotor. Microsomes were resuspended in 50 mM 
Tris•HCl pH 7.4, flash frozen and stored at -80 ºC until analysis.   
 
4.2.18 LARGE-SCALE PREPARATION OF YEAST MICROSOMES 
4.2.18.1 Preparation of Spheroplasts 
Several protocols were used to extract endoplasmic reticulum as microsomal 
fractions from S. cerevisiae. The spheroplasting protocol employed was based on the 
procedure reported by Shimoni and Scheikman.
338
 S. cerevisiae cells expressing TMTC2, 
TMTC3 or TMTC2 and 3 were grown as reported in section 4.2.3.2. These cells were 
harvested at the appropriate time points for maximum gene expression (as assessed by 
previous time course assays). After growth, cells were transferred to 50 mL conical tubes 
and washed with 100 mM potassium phosphate buffer, pH 7.5. The cells were incubated 
on ice for 10 min and pelleted again at 4,000 g for 5 min. The supernatant was decanted 
and the cells were resuspended to 100 OD600 units per mL in MP buffer (100 mM 
Tris∙HCl, pH 9.4, 10 mM DTT) and incubated at room temperature for 10 min. Cells 
were centrifuged to re-pellet at 18,600 g for 30 s and resuspended to 100 OD600 units per 
mL in lyticase buffer (0.7 M sorbitol, 10 mM Tris∙HCl (pH 7.4), 1 mM DTT, and 20 mM 
sodium azide). At this point, a small aliquot (10 µL) was removed and retained separately 
for subsequent OD600 comparison. Zymolyase enzyme was added to the cells at ~15 
units/OD600 cells. The samples were incubated for approximately 100 min at 30 ºC with 
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200 RPM shaking. After this time, the OD600 was measured to be 26% of the original 
value, as compared to the untreated aliquot. Samples were chilled on ice for 2 min and 
centrifuged at 5,200 g for 10 min. The supernatant was carefully removed and the pellet 
was resuspended in 2X JR lysis buffer (0.4 M sorbitol, 100 mM potassium acetate, 40 
mM HEPES buffer (pH 7.4), 4 mM EDTA (pH 8.0)) to an OD600 of 250 units/mL. The 
samples were centrifuged at 18,600 g for 5 min at 4 ºC. The supernatant was removed by 
aspiration, and the pellet was resuspended in 2X JR lysis buffer to an OD600 of ~1000 
units/mL, and samples were flash frozen in liquid N2 and stored overnight at -80 ºC.  
 
4.2.18.2 Microsomal preparation from spheroplasts  
4.2.18.3 METHOD I 
Microsomes were prepared using the spheroplasts prepared in the previous step. 
Following the method of Sanyal et al., the remaining steps were carried out quickly and 
on ice, or if possible at 4 ºC.
339
 Spheroplasts were thawed on ice and an equal volume of 
sterile water was added to the sample, with 1 mM each of DTT and phenylmethylsulfonyl 
fluoride (PMSF). Spheroplasts were disrupted with 10-20 strokes of a hand-held Dounce 
or Potter-Elvehjem homogenizer. Breakage was examined using a microscope. If upon 
observation, spheroplasts were not broken, homogenization was repeated until broken 
spheroplasts constituted a majority in the sample. Broken cell suspensions were 
centrifuged at 1,900 g at 4 ºC for 10 min. The supernatant was further clarified by 
centrifugation at 15,100 g at 4 ºC for 10 min. The supernatant was further clarified by 
centrifugation at 48,500 g for 30 min at 4 ºC to pellet microsomes. The pellet was 
resuspended gently in microsome buffer (20 mM HEPES-NaOH, pH 7.4, 100 mM NaCl). 
 271 
The microsomal samples were aliquoted, flash frozen in liquid N2 and stored at -80 ºC 
until use. 
4.2.18.4 METHOD II  
Following the method of Shimoni and Schenkman,
338
 using the previously 
prepared spheroplasts, the remaining steps were carried out quickly at 4 ºC. Lysed 
spheroplasts were thawed on ice and an equal volume of sterile water was added to the 
sample, with 1 mM each of DTT and phenylmethylsulfonyl fluoride (PMSF). 
Spheroplasts were disrupted with 10-20 strokes of a hand-held Dounce or Potter-
Elvehjem homogenizer. Cell breakage was examined using a microscope. If cells were 
not broken upon observation, homogenization was repeated until the majority of cells 
were observed to be broken. Broken cell suspensions were centrifuged at 1,900 g for 10 
min at 4 ºC to pellet cell debris. The supernatant was retained and centrifuged at 27,200 g 
at 4 ºC. The pellet was resuspended gently in buffer B88 (20 mM HEPES, pH 6.8, 250 
mM sorbitol, 150 mM potassium acetate, 5 mM magnesium acetate) to a calculated  
OD600 of 2500 units/mL using a Potter-Elvejhem homogenizer or trituration with a 
micropipette. The suspension was layered on top of a 1.2/1.5 M sucrose 2 step gradient in 
4 mL thick-walled polycarbonate centrifuge tubes. To establish this gradient, 1 mL of a 
1.5 M sucrose solution is dispensed into the centrifuge tube. To establish the 1.2 M step, 
1 mL of the solution was gently layered on the top of the 1.5 mL solution by running the 
solution slowly and carefully down the side of the centrifuge tube. Subsequently, 500 to 
750 µL of the microsomal sample was added to the sucrose gradient following the 
methodology used to add the 1.2 M layer. These tubes were carefully balanced to within 
0.01 g and centrifuged at 150,000 g (avg) at 4 ºC for 1 h. After centrifugation, the 1.2 M 
layer and remaining solution was aspirated from the top of the tube, taking care not to 
 272 
disturb the microsomal band located at the 1.2-1.5 M interface. This layer was removed 
with a Pasteur pipette and diluted with 4-5 volumes of B88 solution. The resulting 
mixture was centrifuged at 27,200 g at 4 ºC for 10 min. The supernatant, which contains 
sucrose from the ultracentrifugation step was removed and the pellet resuspended in a 
small volume of B88 buffer. The volume used was approximately equal to the volume of 
the resulting pellet in the previous step. This pellet was homogenized using a small 
Potter-Elvejhem homogenizer. The OD280 of a 1:100 dilution of the samples with 2% 
SDS (w/v) were measured. The samples were subsequently diluted to an approximate of 
40 calculated OD280, which corresponds to ~ 8 mg/mL total protein. The microsomal 
samples were aliquotted, flash frozen in liquid nitrogen, and stored at -80 ºC until use. 
 
4.2.18.5 S. cerevisiae Microsomal In Vitro C-Mannosylation Assays 
Reactions were carried out using the method of Doucey.
315
 The peptide N-AC-
KPPQFAWAQWFE-NH2, as designed based on the RNase2 sequence, replacing Thr-6 
with Ala to prevent possible O-glycosylation, and used as the mannosyl acceptor 
substrate.
126
 The peptide was incubated in the presence of microsomes from rat liver, 
yeast and insect cells, followed by HPLC purification using reversed phase HPLC 
equipped with a C-18 column (acetonitrile/TFA gradient).  
The reaction mixture contained in a final volume of 240 μL: 0.9 mM of peptide (~ 
400 µg), 145 μg of S. cerevisiae microsomal protein, 20 mM HEPES-NaOH, pH 7.2, 110 
mM potassium acetate, 2 mM magnesium acetate, protease inhibitor cocktail (leupeptin, 
2.4 µg/mL; antipain, 4 µg/mL; lima bean trypsin inhibitor, 40 µg/mL; benzamidine, 20 
µg/mL; AEBSF HCl, 10 µg/mL; aprotinin, 2 µg/mL; chymotrypsin, 10 µg/mL; pepstatin 
A, 5 µg/mL; 2 mM EDTA) and 0.2% v/v Triton X-100. The Triton X-100/protein ratio 
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(wt/wt) was kept constant at 0.34 (total Triton X-100 concentration, 3 mM). The mixture 
was incubated at 37 °C overnight.  
After overnight incubation, the samples were filtered through a YM-10 
centrifugal filter at 14,000 g for 20 min at room temperature. The peptide was purified 
from each sample using HPLC, with a reverse phase C-18 column. Buffer A was water 
with 0.1 % TFA, and buffer B was 90% acetonitrile, with 0.1 % TFA. The gradient was 
linear, increasing buffer B at 1%/min, and samples were monitored at 280 nm 
(tryptophan abs). Peaks were collected and lyophilized to concentrate fractions. The 
concentrated fractions were submitted for MALDI-MS analysis. 
 
4.3 RESULTS AND DISCUSSION 
To isolate the C-mannosyltransferase, attempts were made to crosslink a substrate 
peptide to the enzyme. Purified microsomes from rat liver were allowed to react with the 
substrate peptide containing a selectively oxidizable 5-hydroxytryptophan residue in the 
presence of sodium periodate, which is expected to oxidize 5-hydroxytryptophan such 
that the 5-keto group of 5-HT can crosslink to any reactive amino acid such as the α-
amino or ε-amino of Lys, imidazole of His, or thiol of Cys in the enzyme active site.340-342  
The linkage could then be chemically reduced in the presence of sodium borohydride and 
form an irreversible covalent linkage. The bead-linked peptide could be centrifuged to 
collect the proteins cross-linked to the peptide and washed to remove any unlinked 
proteins. The peptide was released from the agarose beads by boiling and the proteins 
crosslinked to the peptides could be separated on 12% denaturing acrylamide gel.  
Strong bands were excised from the gel, trypsin digested (in-gel) and submitted 
for mass spectrometry analysis. A significant hit from the MS results was the R. 
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norvegicus (rat) dolichyl-diphosphooligosaccharide-protein glycosyltransferase 
(P25235)  63 kDa subunit precursor (EC 2.4.1.119). While this was not the protein we 
had expected to isolate, we began to examine what was known about C-mannosylation 
and whether this information would assist us in identifying the protein in silico.  Previous 
research has shown that the C-mannosyltransferase protein is targeted to the endoplasmic 
reticulum and thus has a distinct ER signal sequence.
315
 In addition, the CMT uses 
dolichol phosphate mannose as the substrate.
315
 
 
4.1 CMT Crosslinking Gel 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Glycosyltransferases using dolichol-phosphate as a substrate have a multispan 
transmembrane topology.
343
 Interestingly, the family of dolichol-phosphate mannose 
protein O-mannosyltransferases (POMT), is highly conserved from yeast to humans.
91
 
Studies of the POMT structure and function have identified two domains critical for 
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mannosyltransferase activity.
225
 The first domain, the protein mannosyltransferase (PMT) 
domain, is found in all dolichol-phosphate mannose protein transferases and is thought to 
be the binding site for the glycolipid. 
225
 The second domain is the mannosyltransferase, 
inositol and ryanodine receptor (MIR) domain, which has been postulated to be the ligand 
binding/transfer domains found in the three proteins for which they are named.
344
 Human 
POMTs have a defined structure consisting of 9 transmembrane domains. 
225,
 
345
  The 
PMT domain and three (MIR) domains are located on hydrophilic loops between the 1
st
 
and 2
nd
 and 8
th
 and 9
th
 transmembrane domains, respectively. These domains are believed 
to come together to catalyze the mannosyltransferase reaction. 
225
 
Sequence alignment cannot distinguish between C-glycosyltransferases and O-
glycosyltransferases in prokaryotes. A recent paper demonstrated that the prokaryotic 
urdamycin C-glycosyltransferase (UrdGT2) displays the unusual ability to generate both 
C–C and C–O glycosidic bonds. 84 It is possible that this sequence similarity may carry 
over into eukaryotic glycosyltransferases. The C-mannosyltransferase (CMT), since it has 
a similar function to the POMT, should show some sequence similarity to POMTs. To 
identify the human CMT gene or genes, we searched for “hypothetical” or “predicted” 
proteins in the human genome that contained the conserved PMT domain.  
H. sapiens protein O-mannosyltransferase 1 POMT-1 (gi 34190043) was 
subjected to pblast using the NCBI “Blast” website. Using all possible protein builds in 
the database, 23 proteins were identified as having some homology to POMT-1. Of the 
proteins identified, the majority (22) of these proteins were identified as POMT-1 splice 
variants, POMT-2, or fragments of either of these two proteins by manual sequence 
alignment using the NCBI website protein alignment tool.  Discarding all splice variants 
or fragments of POMT1 or POMT2 left one protein, annotated TMTC2 (transmembrane 
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and tetratricopeptide repeat containing #2), which has a non-canonical PMT domain and 
does not correspond to the known POMT domain architecture (PMT, MIR domains). 
This protein was present in four builds used for protein analysis and was found 
under the following gi numbers: gi|62739786|gb|AAH93852.1| hypothetical protein 
LOC160335, gi|22749211|ref|NP_689801.1| hypothetical protein LOC160335 [Homo 
sapiens], gi|62740007|gb|AAH93854.1| hypothetical protein LOC160335 [Homo 
sapiens], and gi|21740314|emb|CAD39165.1| hypothetical protein [Homo sapiens].  As 
shown in figure 4.2, the TMTC2 protein contains a non-canonical PMT domain. 
 
4.2  TMTC2 PMT Alignment with Canonical PMT Sequence 
 
 
 
 
 
 
This protein is also lacking the MIR domains found in POMTs. The C-terminus of 
the protein contains multiple TPR (tetratricopeptide) repeats. The TPR is a coiled coil 
structure that creates an amphipathic channel, which is believed to function as a protein-
protein interaction domain that binds the α-helices of multiple proteins. 208 This is 
noteworthy because the protein responsible for mono β-O-GlycNAcylation (β-OGT) of 
many cytosolic proteins also has a TPR binding motif. 
207
 Clearly, this protein which 
exhibits low homology to POMT-1 is a promising candidate worthy of further 
investigation.  
 
                      10        20        30        40        50        60       
              ....*....|....*....|....*....|....*....|....*....|....*....| 
TMTC2      43 WTHIFYND---FWGTLLTHSGSHKSYRP--LCTLSFRLNHAIGGLNPWSYHLVNVLLhAA 
consensus  36 ANALFFMDvhpPLGKMLIALGGYLAGKPplFYFISSGSFLYFGNVPYFSMRLFSALL-GS 
                      80        90        100       110       120       130       
              ....*....|....*....|....*....|....*....|....*....|....*....| 
TMTC2      97 VTGLFTSFSKILLGDGYWT-FMAGLMFASHPIH-TEAVAGIVgraDVGASLFFLLSLLCY 
consensus  95 LTVPLVYLLLLKLGFSRLAaLLAALLVALDNSFvTLSRYILL---DSPLLFFTTLAMYCL 
                     160        170       180       190       200 
              ....*....|....*....|....*....|....*....|....*....| 
TMTC2     155 IKHCSTRGySARTWGWFLGSGLCAGCSMLWKeqGVTVLAVSAVYDVFVFH 205 
consensus 152 LKFEKAPF-SRKWWLWLLLTGIALGLAVSTK--GVGLFTVLPVGLLFIWL 198 
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Indeed, further analysis of this protein revealed that β-OGT is a close paralog of 
TMTC2. In other words, TMTC2 has homology to POMTs and also shows high 
similarity to but a function different than β-OGT. Thus, the TMTC2 protein is likely to 
have glycosyltransferase activity, although TMTC2 most likely has a divergent function 
from the other two proteins. Upon closer examination, the N-terminal portion of the PMT 
domain of TMTC2 is truncated. Interestingly, this region has been determined to be 
important for protein binding in other PMT domain-containing proteins. POMT1 and 2 
are thought to complex with each other in the ER using the N-terminal region of the 
protein.
225
 It has been proposed that the POMT1/2 complex flips Dol-P-man from the 
cytoplasmic face of the ER to the lumen so that the mannose residue is accessible to the 
MIR catalytic domains.
225
  
Investigating the TMTC2 protein using other databases (Uniprot, DBGET, 
Interpro, Pfam, Prosite), revealed several important factors. Using the LIFEdb database, 
the subcellular location of the protein was confirmed to be the endoplasmic reticulum.
346
 
Protein analysis in silico also afforded the identification of another domain in place of the 
three MIR domains. This newly identified domain, DUF1736, is a “domain of unknown 
function” that spans about 100 amino acids and is in the location of the proposed catalytic 
domain in POMT1/2. The secondary structure of TMTC2 was analyzed and compared to 
the known structure of the yeast POMT protein using the PHYRE structure prediction 
server. With very few exceptions, the secondary structure for the entire protein is 
predicted to be α-helical (no β-sheets) with a large unstructured hydrophilic loop 
(luminal) in the middle of the DUF domain that corresponds to the positioning and 
proposed random coil structure of the active site in the POMT proteins. Membrane 
topology predicts this loop to be in the lumen of the ER. 
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NCBI CDART, the conserved domain architecture recognition tool, was then used 
and 14 proteins were identified with structure identical to TMTC2 protein architecture. 
The results indicated that TMTC2 homologs exist in: Rattus norvegicus, Mus  musculus, 
Macaque  macaca fascicularis, Canis familiaris,  Xenopus laevis, Bos taurus, Gallus 
gallus, Danio rerio, Tetraodon nigroviridans, Caenorhabditis elegans, Caenorhabditis 
briggsae, Drosophila melanogaster, Drosophila pseudoobscura, Apis mellifera, 
Anopheles gambiae, Tribolium castaneum, Strongylocentrotus purpuratus, 
Blastopirellula marina, Trichodesmium sp., and Synechocystis sp.. Notably, no fungal, 
bacterial strains or plant species have this gene. In contrast, higher order eukaryotes; 
mammalian, avian, amphibian and annelid model organisms all contain this gene. Using 
the Uniprot server to align protein homologs against TMTC2, it was determined that the 
proteins in the marine organisms do not contain a canonical DUF 1736 domain, although 
it has been reported that some marine organisms produce C-mannosylated natural 
products.
316
 In contrast, the TMTC2 homologs in insects (honeybee, Drosophila and 
Anopheles) contain the DUF 1736 domain and TPR repeats but do not have the canonical 
PMT domain. It is possible that the PMT domain in insects is different than that of the 
canonical PMT sequence for higher organisms. It should be noted here that the 
Drosophila rotated abdomen protein, which is a predicted POMT, does not have an 
apparent PMT domain. 
Overall, the presence of the PMT domain in TMTC2 suggests that TMTC2 most 
likely uses Dol-P-Man as the substrate and it has the ability to bind to many different 
protein substrates due to the presence of the TPR region, which contains 10 TPR repeats. 
On the basis of these analyses, we decided to carry out more experiments to investigate 
TMTC2 as a potential C-mannosyltransferase.  
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The gene TMTC2 was obtained from OPEN Biosystems and used to create 
constructs for expression in E. coli. The gene tmtc2 was expressed in E. coli under 56 
different conditions. Similar work was performed by the Imperiali group, who expressed 
the alg2 and alg11 genes as thioredoxin fusion transmembrane proteins in E. coli.
109
 
Membrane fractions were difficult to load in acrylamide gels, even after solubilization 
with 8 M urea or upon the addition of 10% Nonidet. Samples often ran as „smears‟ in the 
gels as indicated by Coomassie staining. No distinct band corresponding to the desired 
molecular weight of TMTC2 was observed in these gels. However, in the Western blot, 
positive signals appeared as faint smears, which were observed under multiple induction 
conditions. Thus, there was a low level of tmtc2 expression. The low level expression is 
likely due to the observation of premature cell death. This is not surprising as work done 
by Bruno and Miroux suggested that expression of transmembrane proteins in E. coli 
caused cell death.
347
 
4.3 TMTC2 Production in E. coli  
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4.3.2 IL-12B EXPRESSION IN E. COLI 
Results from the previous small-scale experiments demonstrated that the best expression 
and solubility conditions were 37 °C in Bl-21* cells with 1 mM IPTG induction, although 
our previous Western Blot indicated that IL-12b protein had low expression under these 
conditions. Large-scale preparations using these conditions yielded IL-12b as indicated 
by Western blot. Protein concentration was not determined as the protein was only 50% 
pure using this procedure.  IL-12b has a molar extinction coefficient (ε) of 66970 M-1cm-1 
at A280 and a molecular weight of 37.3 kDa.  The Il-12b protein purified by this procedure 
was of low quality and could not be used in in vitro assays. 
 
4.3.3 IL-12b Expression in S. cerevisiae 
Attempts were then made to express the protein in S. cerevisiae. Yeast is an 
excellent platform for C-mannosylation work, as it is a eukaryotic system and thus 
naturally produces the substrate dolichol phosphate mannose (Dol-P-man), and there is 
no endogenous C-mannosyltransferase.
228
 The expression level of tmtc2 and tmtc3 in 
yeast cells was much higher. Our experimental design entailed the coexpression of the 
TMTC2 proteins (TMTC2, TMTC3, and TMTC2/3) with IL-12b, a protein known to be 
naturally C-mannosylated in vivo.
348
 Modified IL-12b should be secreted into the yeast 
culture media, where it can be harvested and analyzed for protein modifications. 
Unfortunately, S. cerevisiae does not appear to secrete IL-12b well. Protein targeting is 
also a concern in this system. If the ER targeting signal intrinsic to the TMTC2 and 
TMTC3 proteins is not recognized by the S. cerevisiae translocation machinery and 
correctly translocated into the endoplasmic reticulum, then the proteins will not have 
access to their native substrate (Dol-P-man) and will not demonstrate activity. Due to 
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these difficulties, we chose to express tmtc2, tmtc3 and tmtc2/3 in yeast strains and purify 
the ER fractions as microsomes for use in in vitro assays.  
Purification of all three proteins (TMTC2, TMTC3 and IL-12b) was attempted 
and it was clear that these proteins did not express well in S. cerevisiae. However, we 
were able to achieve expression of tmtc2 and tmtc3 in yeast, as shown in the Western 
blots below in Figures 4.4 and 4.5, respectively. 
 
4.4 TMTC2 Production in S. cerevisiae (Time Course Assay) 
 
  
Cell samples were taken at 0h, 2h, 4h, 6h, 8h and 10h and processed according to 
the Yaffe-Schatz method for total protein isolation. The best expression results for 
TMTC2 were achieved 8-10 h post-induction in S. cerevisiae. 
Samples were taken at 0h, 2h, 4h, 6h, 8h and 10h and the total protein was 
extracted using the Yaffe-Schatz method. For TMTC3, the best protein production was 
achieved 10 h post-induction in S. cerevisiae, as shown below. 
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4.5 TMTC3 Production in S. cerevisiae (Time Course Assay) 
 
 
 
 
4.6 TMTC2 + IL-12b Production in S. cerevisiae  
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Cell samples were taken at 0h, 2h, 4h, 6h, 8h and 10h post induction. The best 
expression results for the TMTC2 protein under these conditions were achieved 10 h 
post-induction in S. cerevisiae. IL-12b could not be seen on the Western blot, thus we 
abandoned our in vivo assay design, and turned instead to designing an assay to test these 
enzymes in vitro. 
Hofsteenge established an in vitro C-mannosylation system using microsomes as 
the source of enzyme on the basis of the observation in vivo, that the first 12 residues of 
RNase 2 are sufficient for modification.
314
  Reactions were carried out after the method 
of Doucey.
315
 The peptide substrates, N-KPPQFAWAQWFE-C were reacted with 
microsomal fractions from S. cerevisiae containing TMTC2 only, TMTC3 only, 
TMTC2/3, or no protein. The reaction mixture contained reaction buffer (20 mM 
HEPES-NaOH pH 7.2, 110 mM potassium acetate, 2 mM magnesium acetate), protease 
inhibitor cocktail, 2 mM EDTA and 0.2% Triton X-100. The Triton X-100 to protein 
ratio (wt/wt) was kept constant at 0.34 (total Triton X-100 concentration 3 mM). The 
mixtures were incubated at 37 °C overnight. Peptides were removed from the reaction by 
size exclusion filtration and HPLC equipped with a reverse phase C-18 column, using a 
linear gradient of water/acetonitrile (0.1%) TFA. HPLC Peaks with absorbance at 214 
and 280 were collected and concentrated. These samples were submitted for MS analysis.  
Mass spectrometry results were negative as no C-mannosylation was found. 
These peptide samples submitted were still mixtures, despite HPLC purification, and thus 
it was not possible to identify the peptide substrate in control samples.  
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4.4 CONCLUSIONS 
In this chapter, we identified proteins TMTC2 and TMTC3 as putative C-
mannosyltransferases. However, we were unable to demonstrate the activity of the 
proteins TMTC2 and TMTC3 in bacterial platforms. Bacterial expression of these genes 
failed under more than 50 conditions, which differed in media composition, temperature, 
cell lines and induction conditions. Transmembrane proteins are difficult to produce in E. 
coli and other bacteria as the overproduction of these proteins is theorized to overload the 
translocation system that is so essential for cellular metabolism.
347, 349
 Thus, attempts 
were made to produce the TMTC2 and TMTC3 proteins in S. cerevisiae. 
Expression of the genes tmtc2 and tmtc3 were achieved in S. cerevisiae. However, 
co-expression of the target gene il-12b was unsuccessful, which nullified the original 
assay design. In vitro assays using yeast microsomes were also carried out. Synthetic 
peptides were made and tested with microsomes containing TMTC2 and TMTC3. MS 
analysis failed to show C-mannosylation of the peptides. We examined the myriad 
reasons for these results. It is quite possible that the proteins in question. TMTC2 and 
TMTC3, are not targeted to the ER in yeast, and thus are not present in the microsomes 
harvested from the cells. This would also invalidate any in vivo assays we could perform 
in S. cerevisiae. It is also possible that protein misfolding has occurred, and even if 
directed to the proper intracellular organelle, the protein(s) may be non-functional. The 
O-GlcNAc transferase β-OGT has a tetratricopeptide repeat region and has been shown to 
be active when expressed in insect cells.
209
 ß-ogt expression has never been reported in 
yeast or bacteria. Is it possible that bacteria or yeast do not have the capacity to properly 
fold a massive tetratricopeptide repeat region, as found in β-OGT, TMTC2 and TMTC3?   
It is also possible that the protein is not functional under cellular conditions in S. 
cerevisiae. Perhaps the high level of glycosylation undertaken by S. cerevisiae interferes 
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with the C-mannosylation process. One of the previously attractive features of this 
system is the level of high-mannan glycans that S. cerevisiae produces. Clearly, there is 
an abundance of the substrate, dolichol-P-mannose that is readily available in the yeast 
secretory pathway. However, perhaps this abundance of glycosylation works directly 
against our assay design. It is possible that the high glycan levels deplete the cell of the 
substrate Dol-P-Man, lowering the available substrate levels such that the potential C-
mannosyltransferases TMTC2 and TMTC3 cannot act.  
For these reasons, attempts to characterize the putative CMT, TMTC2 using 
bacteria and yeast were abandoned and attention was shifted to studies in higher 
eukaryotic cells, specifically insect and mammalian cells, as will be discussed in the next 
chapter. 
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5  Eukaryotic Glycosylation Studies: Characterization of Potential 
Candidates for the H. sapiens C-mannosyltransferase, Expression in 
Insect and Human Cell Lines 
 
5.1 INTRODUCTION 
Protein glycosylation is a posttranslational modification that is conserved from 
archaea and eubacteria to eukaryotes.
90
 Protein glycosylation is more complex in higher 
organisms, and there is considerable variation in the functions of the added glycans.
88, 87, 
91
 Similar to lower organisms, N-glycosylation assists in protein folding from yeast to 
humans, while O-glycosylation increases protein solubility and generates binding sites on 
cellular surfaces.
91
 In humans and other higher eukaryotes, protein glycosylation and 
other posttranslational modifications are perhaps the most complex.
88
 Complex 
glycosylation events underlie multiple biological processes, such as cellular growth and 
development, cell signaling, and protein folding and activation.
87, 350
 Some glycosylation 
events are trivial and their losses have negligible effect on the biological viability of the 
organism; however, others are absolutely required for cell survival.
91,87
 Such complexities 
in glycosylation are not yet fully understood and remain an active area of investigation.  
It is interesting to note that 0.5-1% of the entire human genome is devoted to the 
production of proteins involved in the synthesis, degradation, and function of 
glycoconjugates.
351
  Therefore, it is likely that glycosylation in humans is a much more 
involved and extensive process than is currently appreciated. Medical science has 
observed that loss of essential glycosylation events leads to congenital disorders of 
glycosylation (CDGs).
89
   When proteins responsible for the glycosylation events falter or 
fail, there can be disastrous consequences for the developing organism. For example, 
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complete loss of N-glycosylation is lethal, while a partial loss can lead to severe 
multisystemic defects. 
89, 352
  Thus far, at least 12 N-glycosylation CDGs are known, and 
another 3 CDGs are proposed to interrupt both N- and O-glycosylation.
352
 Identified 
defects in O-glycosylation include O-fucosylation, O-xylosylation, O-GalNAcylation and 
O-mannosylation. 
352
 These CDGs result in a range of defects affecting musculoskeletal 
development as well as the nervous system. 
89, 352
 Since  O-mannosylation accounts for 
up to 30% of O-glycosylation in the human brain, severe defects in O-mannosylation lead 
to a neuronal migration disorder characterized by no psychomotor development and is 
usually fatal within one year.
213, 352
 O-mannose linkages have also been identified in α-
dystroglycan, which links the actin cytoskeleton to extracellular matrix in muscle and 
nervous tissue.
213
  This finding, and the rotated abdomen mutation identified in D. 
melanogaster by Bridges and Morgan led to further research linking the loss of O-
mannosylation to congenital muscular dystrophies. 
213, 353
  These are only a few examples 
of the severe consequences of glycosylation loss, although many CDGs remain to be 
identified.   
Defects in glycosylation that result in lethality are not classified as CDGs. Thus 
there is another important glycosylation defect, the complete loss of β-O-GlcNAcylation, 
which causes loss of stem cell viability, somatic cell viability and embryonic lethality in 
mice.
205, 354
 Further examination of O-GlcNAcylation has revealed multiple roles for this 
glycosylation event in the cell.  Studies have demonstrated the dynamic interplay 
between protein phosphorylation and β-O-GlcNAcylation with ramifications in cell cycle 
regulation.
355
 The addition and removal of O-GlcNAc are key to histone remodeling, 
transcription, proliferation, apoptosis, and proteasomal degradation, as well as the 
regulation of nutritive pathways in humans (insulin signaling cascade) and plants 
(gibberellin).
356
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In contrast to glycosylation at nitrogen and oxygen, very little is known about 
glycosylation at carbon. Considering the biological importance of protein glycosylation, 
the physiological role of C-mannosyl transfer and the pathological consequences of its 
absence are of particular interest. This novel protein posttranslational modification was 
identified in 1994; however, the function, purpose, and mechanism of the addition 
remains poorly understood.
229, 234
 To obtain further information regarding this unique 
means of protein glycosylation, it is necessary to identify and characterize candidate 
proteins representing potential C-mannosyltransferases. 
To identify potential candidates for the C-mannosyltransferase, we examined 
what is known about the protein(s) and its (their) activity. Previous research had shown 
that the protein is located in the endoplasmic reticulum and uses dolichol phosphate 
mannose as a substrate.
126
 Therefore, we reasoned that our target protein should have a 
PMT (Protein Mannosyl Transferase) domain that binds to dolichol-phosphate-mannose 
(Dol-P-Man). This implied that we could identify potential candidate proteins in silico by 
comparing proteins of undetermined function in the NCBI protein database to amino acid 
sequences of known PMT domains. We used gi 34190043 (H. sapiens protein O-
mannosyltransferase 1, or POMT-1) as the query, and subjected the relevant amino acid 
sequence to pblast using the NCBI “Blast” website.357 Using all possible protein builds in 
the database, 22 proteins were identified as having some homology to POMT-1. Twenty 
one (95%) of these proteins were identified as POMT-1 splice variants, POMT-2, or 
fragments of either of these two proteins.  
The remaining protein, known as TMTC2, that was identified during this database 
search did not correspond to the known POMT domain architecture. POMT proteins are 
known to consist of a series of distinct domains. POMTs have at the N-terminus of the 
protein a PMT followed by a series of three MIR (Mannosyltransferase, Inositol, 
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Ryanodine receptor) domains.
225
 In contrast, TMTC2 has at the N-terminus a non-
canonical PMT domain followed by a DUF (Domain of Unknown Function), whereas a 
series of tetratricopeptide (TPR) repeats is found at the C-terminus. Clearly, this protein 
exhibiting low homology to POMT-1 is a likely candidate for further investigation. Thus, 
we focused our efforts on TMTC2 and a close relative, TMTC3. The protein TMTC3 was 
not identified as a CMT candidate during the BLAST search most likely due to its non-
canonical PMT domain, which exhibits lower homology to the canonical PMT domain 
than does the putative PMT domain of TMTC2. 
Previously, in Chapter 4 we had attempted to express tmtc2 in E. coli and found 
that the production of this protein was toxic to cells, causing cell death within 3 h of 
induction. We tried over 50 conditions and were unable to achieve expression of the 
protein; thus, we turned our attention to the S. cerevisiae system. S. cerevisiae is an 
excellent platform for the study of putative C-mannosyltransferases due to the inherent 
lack of an endogenous C-mannosylation pathway.
227
 We were able to achieve expression 
of the genes tmtc2 and tmtc3 in this platform, and an in vivo assay was designed where 
tmtc2 and tmtc3 would be co-expressed with a gene whose product is known to be C-
mannosylated. The gene il-12b was selected to be this target as the IL-12b protein is 
shown to be C-mannosylated in vivo.
358
 Furthermore, as C-mannosylation occurs in the 
endoplasmic reticulum, the IL-12b protein, which passes through the endoplasmic 
reticulum, should be available for the putative C-mannosyltransferase. The success of this 
assay depends on the expressed IL-12b protein needs to be targeted to the yeast secretory 
pathway in amounts detectable following purification from the culture media.
126
 While 
production of both TMTC2 and TMTC3 in S. cerevisiae was successful, we were not able 
to achieve co-expression of the il-12b gene. Further efforts to apply this assay to insect 
cells will be discussed in this chapter.  
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As an alternative to IL-12b, we also considered sGP from Zaire ebolavirus as a 
target protein for our in vivo C-mannosylation assays. One reason for selecting sGP is 
that it binds to the Fc gamma receptor III on neutrophils, but has no known activity 
towards any other cell type.
359
 Therefore, the production of this protein is expected to be 
essentially benign towards insect and human cells in culture. This is in contrast to IL-12b, 
which has been shown to have anti-tumor activity and may present difficulties in 
generating sufficient quantities of protein in mammalian culture cells.
360
   
sGP is a secreted glycoprotein found in the serum of individuals infected with 
Ebola hemorrhagic fever (EHF) and was found to be C-mannosylated in 2007.
230
 The 
sGP protein is encoded by the fourth viral gene of Ebola virus, which is responsible for 
the production of pre-sGP, and preGP1,2.
230
 To generate sGP, transcriptional editing at the 
RNA level introduces an additional adenine residue that alters the last 28 amino acids of 
the protein C-terminus and introduces a stop codon to truncate the protein.
361
 The edited 
RNA transcript is then translated to pre-sGP and directed into the secretory pathway 
where it undergoes multiple co- and post-translational modifications.
362
 The resulting 
homodimeric protein is N-glycosylated at 5 of the 6 possible sites, carries 2 external and 
2 internal disulfide bonds, and is C-mannosylated at W288, which is the 53rd residue 
from the C-terminus.
230, 361, 362
   
This chapter describes our efforts to develop both in vitro and in vivo assays to 
detect C-mannosylation. Herein, we detail efforts to generate TMTC2 and TMTC3 in S. 
frugiperda insect cells for use in microsomal assays. We also attempt to silence the tmtc2 
and tmtc3 genes in human cells with an endogenous C-mannosylation pathway for use in 
microsomal and in vivo assays as further evidence of the function of these gene products 
as CMTs.  
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5.2 EXPERIMENTAL DETAILS 
 
5.2.1 MATERIALS 
 
5.2.1.1 Bacterial Strains and Cell Culture lines 
 
Escherichia coli strain DH5α was purchased from Bethesda Research 
Laboratories (Gaithersburg, MD).  S. frugiperda Sf9 and Sf21 cell lines were a kind gift 
of Dr. Tanya Paull. H. sapiens HEK 293-T cell line was a kind gift of Dr. Maria Croyle. 
5.2.1.2 Biochemicals  
Enzymes and molecular weight standards used for the molecular cloning 
experiments were products of Invitrogen (Carlsbad, CA) or New England Biolabs 
(Beverly, MA).  Agarose for DNA electrophoresis was obtained from Fisher Scientific 
(Pittsburgh, PA). Restriction digestion enzymes, calf intestinal alkaline phosphatase 
(CIP), 100X BSA, T4 ligase, and their respective buffers were products of New England 
Biolabs (Beverly, MA). Ni-NTA agarose and kits for DNA gel extraction, spin miniprep, 
and maxiprep were obtained from Qiagen (Valencia, CA).  The growth media 
components for bacteria and yeast were acquired from Becton Dickinson (Sparks, MD).  
Antibiotics and chemicals such as isopropyl-β-D-thiogalactopyranoside (IPTG) and 
dithiothreitol (DTT) were products of Sigma-Aldrich Chemicals, Co. (St. Louis, MO) or 
Fisher Scientific (Pittsburgh, PA). All reagents for SDS-PAGE were purchased from Bio-
Rad (Hercules, CA), with the exception of the prestained protein molecular weight 
markers, which were ordered from New England Biolabs. Oligonucleotide primers for 
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cloning were prepared by Invitrogen (Carlsbad, CA). Antibodies used for His6 Western 
blotting procedures, monoclonal anti-polyhistidine clone His-I H1029 FLAG (M2 
monoclonal), and anti-mouse IgG (alkaline phosphatase conjugate) A2429 were 
purchased from Sigma. Antibodies for the myc epitope and the protein interleukin-12 
were purchased from Invitrogen. Anti-sGP (MAI-21630) antibody from Pierce was a 
kind gift of the Croyle Lab. For Western blot detection, nitroblue tetrazolium (NBT) and 
5-bromo-4-chloro-3-indolyl-phosphate (BCIP) were both obtained from Promega. 
Porcine sequencing grade modified trypsin (catalog number V511A, 20 µg) was also 
obtained from Promega. Cell culture media D-MEM and penicillin-streptomycin, were 
from Sigma. Fetal Bovine Serum was from Gibco, and 200 mM L-glutamine from 
Hyclone. Tissue culture dishes (60  15 mm and 150  25 mm) were obtained from 
Falcon (Fisher) and tissue culture flasks T-75 and T-175 were from Grenier Bio-One 
(Frichenhausen, Germany). SF-900 II SFM is a protein-free insect culture medium from 
Invitrogen (Carlsbad, CA).  N-Aza-tetraacetyl-mannose was synthesized in house by 
Chia-I Lin, a graduate student in the Liu lab. Synthetic peptides with and without biotin 
label were prepared by the Core Facilities of the Institute of Cellular and Molecular 
Biology at the University of Texas at Austin. 
 
5.2.1.3 Plasmids, Vectors and DNA Manipulation  
PEF1/Myc-His(b) from Invitrogen (Carlsbad, Ca.) was a gift of the Zhang Lab. 
Plasmids containing genes for TMTC2, TMTC3 and IL-12b were obtained as glycerol 
stocks of E. coli obtained from OPEN Biosystems (now a part of Thermo Fisher 
Scientific).  Plasmid containing sGP was a kind gift of the Croyle Lab. DNA gel 
extraction and spin miniprep kits were obtained from Qiagen (Valencia, CA). Pfu DNA 
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polymerase was purchased from Stratagene. Oligonucleotide primers for cloning were 
prepared by Integrated DNA Technologies (Coralville, IA) or Invitrogen (Carlsbad, CA). 
KOD DNA polymerase was purchased from Novagen (Madison, WI). HuSH plasmids 
for silencing TMTC2 and TMTC3 were purchased from Origene (Rockville, MD). 
 
5.2.1.4 Instrumentation  
PCR reactions were carried out using an Eppendorf Mastercycler gradient thermal 
cycler from Brinkman-Eppendorf (Westbury, NY). For agarose gel electrophoresis, a 
mini-sub-cell GT from BioRad (Richmond, CA) was used, powered by a Fisher FB-300 
electrophoresis power source. After electrophoresis, DNA bands were visualized using a 
Fisher FBTIV-08 UV transilluminator. Cell disruption was performed with a Fisher 550 
Sonic Dismembrator, equipped with a standard sonicator horn. Homogenization of cells 
was accomplished with a glass 20 mL Potter-Elvejhem homogenizer equipped with both 
loose (high-clearance) and tight-fitting (low-clearance) pestles, which was purchased 
from Wheaton, (Millville, NJ). For SDS-PAGE gel electrophoresis, a mini PROTEAN II 
vertical system from BioRad (Richmond, CA) was used, equipped with an FB-300 or 
EC-1000-90 electrophoresis power source from Fisher, or E-C apparatus corporation, 
respectively. A mini-trans blot assembly apparatus used for Western blot, GelAir drying 
system for acrylamide gel preservation, and the necessary accessories and reagents were 
all products of BioRad. Nitrocellulose Hybond-C or Optitran BA-5 85 reinforced 
nitrocellulose membranes used for Western blot were from Amersham Bioscences or 
Whatman (Dussel, Germany), respectively.  
To obtain pH values, a Corning 240 pH meter equipped with an Accumet 
electrode (Fisher) was used.  Large scale centrifugation procedures were performed using 
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an Avanti J-25 unit or a J-E instrument from Beckman (Arlington Heights, IL).  
Microscale centrifugation procedures were carried out using an Eppendorf 5415C from 
Brinkmann Instruments, (Westbury, NY). Ultraviolet-visible spectra were recorded using 
Beckman DU-650 spectrophotometer, or in the case of Bradford Assays, Synergy HT 
plate reader by Biotek Instruments, equipped with a PC using KC4 software. Amicon 
YM-10 filtration products were purchased from Millipore (Billerica, MA). HPLC 
Separations used a Beckman 366 from Beckman Instruments (Fullerton, CA) equipped 
with an analytical C18 HPLC column from Varian (Lake Forest, CA). The ÄKTA FPLC 
Instrument was from Amersham Pharmacia Biosciences (Now GE Healthcare). Sephadex 
200 gel filtration FPLC columns were from Pharmacia (Uppsala, Sweden).  DNA and 
compounds were dried using a Savant Speedvac SC100 equipped with a Savant 
refrigerated condensation trap RT100 and Gel Pump GP100. DNA concentrations were 
measured using a NanoDrop ND-1000 UV-Vis instrument from Thermo Fisher Scientific 
(formerly NanoDrop Technologies LLC). Thick-walled polycarbonate centrifuge tubes (4 
mL, 13 × 51 mm) (Model # 349622) were purchased from Beckman. For microsomal 
preparations, Ultracentrifuge Model TL-100 was used, equipped with a Ti-100.4 rotor 
both from Beckman. Insect cell lines were cultured in either an Isotemp Incubator Model 
#304, or a Percival Scientific incubator, model # 1-30BLL, equipped with an OS-15 
Orbital Shaker (Fisher). Human cell lines were cultured in an Isotemp Incubator (Fisher) 
equipped with regulated CO2 flow.  
 NMR spectra were acquired on either a Varian Unity 300 or 500 MHz 
spectrometer. Sequencing of subclones was performed using a capillary-based AB 3700 
DNA analyzer by the Core Facilities of the Institute of Cellular and Molecular Biology at 
the University of Texas at Austin. Mass spectra were obtained by the Mass Spectrometry 
Core Facility in the Department of Chemistry and Biochemistry at the University of 
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Texas at Austin using a Waters QTOF Premier mass spectrometer operating in 
electrospray mode, or MALDI-MS using a CHCA matrix by or the College of Pharmacy 
at the University of Texas at Austin.   
 
5.2.2 GENERAL PROCEDURES   
The general methods and protocols for recombinant DNA manipulations were as 
described by Sambrook et al.
274
 All protein purification operations were carried out at 4 
ºC. Protein concentrations were determined according to Bradford  using bovine serum 
albumin (BSA) as the standard.
272
  The relative molecular mass and purity of enzyme 
samples were determined using SDS-polyacrylamide gel electrophoresis as described by 
Laemmli.
273
   
 
5.2.3 EXPERIMENTAL PROCEDURES       
 
5.2.3.1 Prokaryotic Strains and Growth Conditions 
Escherichia coli DH5α used for routine cloning experiments was maintained on 
Luria-Bertani (LB) broth or LB agar, (1% NaCl, 1% tryptone, 0.5% yeast extract, pH 7.5, 
and in the case of plates, 2% agar). To liquid cultures, a volume of sterile 80% glycerol 
equal to 20% of the original culture volume was added and gently mixed to homogeneity. 
The mixture was then aliquoted into sterile Eppendorf tubes, flash frozen in liquid N2 and 
stored at -80ºC until use. Glycerol stocks were then used in a 1:20 dilution to inoculate 
fresh media for plasmid preparations. E. coli DH10-Bac used for generation of bacmid 
stocks was maintained on Luria-Bertani (LB) broth or LB agar, supplemented with 50 
µg/mL kanamycin, 10 µg/mL tetracycline, and 7 µg/mL gentamycin. 
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5.2.3.2 Eukaryotic Strains and Growth Conditions 
S. frugiperda Sf9 cell lines were grown as adherent monolayers or as suspension 
cultures. Cells were maintained in Sf-900 II SFM media supplemented with 100 µg/mL 
penicillin-streptomycin solution, 10% fetal bovine serum (FBS) and 20 mM L-glutamate 
(Sf-900 II SFMs). For transfections, Grace‟s Insect Media was used to prepare reagents, 
and cells were grown in Sf-900-II SFM, supplemented with 20 mM L-glutamate and 100 
µg/mL penicillin/streptomycin (Sf-900 II SFMu). For procedures in which proteins were 
harvested from the media, Cells were grown in Sf-900 II SFM media supplemented with 
100 µg/mL penicillin-streptomycin solution, 10% Fetal Bovine Serum (FBS) (Sf-900 II 
SFMp). Cells were cultured at 27 ºC in a humidified environment using T-75 cm
2
 tissue 
culture flasks. For protein expression, cells were cultured in 1 L Bellco long-necked 
conical culture flasks with 250 RPM shaking at 27 ºC. Sf-21 cell lines were maintained in 
Sf-900 II SFM media with no supplementation. Sf-21 cells were cultured in tissue culture 
dishes (150  25 mm) or T-75 cm2 tissue culture flasks in a 27 ºC humidified 
environment. General procedures for insect cell culture followed the methods of Lynn et 
al. 
363
 
H. sapiens HEK 293-T were grown as adherent monolayers. Cells were cultured 
in Dulbecco‟s Modified Eagle Media (D-MEM)s containing 4500 µg/each of glucose, 
pyridoxine-HCl, and NaHCO3, supplemented with: 50 µg/mL penicillin-streptomycin, 
10% fetal bovine serum (FBS) and 20 mM L-glutamate. For plasmid transfections, D-
MEMt containing 4500 µg/L each of glucose, pyridoxine-HCl and NaHCO3, 
supplemented with: 100 µg/mL penicillin-streptomycin, and 20 mM L-glutamate was 
used. For procedures involving protein harvest from the media, D-MEM containing 4500 
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µg glucose/L, pyridoxine-HCl, NaHCO3, supplemented with: 100 µg/mL penicillin-
streptomycin, 10% fetal bovine serum (FBS) and no L-glutamate was used to culture 
cells. For tetraacetyl aza mannose feeding procedures, D-MEMm containing 1000 µg/L 
each of glucose, pyridoxine-HCl, and NaHCO3, supplemented with: 100 µg/mL 
penicillin-streptomycin, 20 mM L-glutamate, 30 µM N-Aza-tetraacetyl-mannose was 
used. Cells were cultured in T-75 cm
2
 tissue culture flasks at 37 ºC under a 5% CO2 
environment. After plasmid transfection, blasticidin (bsd) was added to the culture media 
at a final concentration of 50 µg/mL for selection of cells carrying the protein expression 
construct. After initial selection, the bsd concentration was reduced to 10 µg/mL (final 
concentration). For silencing plasmids, puromycin (pur) was used at a final concentration 
of 1 µg/mL for selection of cells carrying the stably integrated silencing construct. 
 
5.2.3.3 PCR Reactions  
Primers were prepared by dilution with TE buffer (50 mM Tris•HCl, pH 7.5, 1 
mM EDTA, pH 8.0) to a concentration of 100 µM.  This stock solution was further 
diluted to 10 or 20 µM with sterile water. pCR4-TOPO plasmid vectors containing each 
gene were obtained as E. coli DH5α glycerol stocks from OPEN Biosystems. Template 
DNA for tmtc2, tmtc3 and il-12b genes was prepared by purifying the plasmid DNA from 
the E. coli DH5α strains using the Qiagen miniprep kit following the manufacturer‟s 
protocol. Polymerase chain reactions (PCR) primers and reaction programs vary for each 
gene and will be discussed in the appropriate sections of this chapter.  
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5.2.3.4 PCR Product Purification 
Typically, PCR products were purified by agarose gel electrophoresis employing 
a 0.8% TAE-agarose gel with 5 µg/mL ethidium bromide (EtBr). The samples were 
diluted to 80% with 6X DNA loading dye (0.25% xylene cyanol, 0.25% bromophenol 
blue, 15% Ficoll 400) and electrophoresed at 100 V for 30 min. The DNA bands were 
visualized using an ultraviolet illumination source. DNA bands of the correct base pair 
length were excised from the gel with a scalpel and purified using the Qiagen gel 
extraction kit, following the manufacturer‟s protocols. However, gel slices were heated at 
65 ºC, rather than 55 ºC as per instructions, until the gel was fully melted. DNA elution 
buffer (EB) was also heated to 65 ºC during extraction, and the elution volume was 30 
µL.  
 
5.2.3.5 Shuttle Vector Cloning into pGEM-T easy 
PCR products were ligated into shuttle or expression vectors specific to each gene 
as described in later sections of this chapter. For ligations into the pGEM-T easy vector, 
the DNA was first A-tailed. Briefly, 20 µL of purified DNA from the previous step was 
transferred to a 0.2 µL thin-walled PCR tube. To this was added 2.5 µL of 10X Taq 
polymerase buffer, 2 µL of a dNTP solution and 0.5 µL of Taq polymerase. The reaction 
was incubated without cycling for 10-30 min at 72 ºC. The A-tailed product was purified 
using the Qiagen gel purification kit following the modifications for purification of PCR 
products, and ligated into the shuttle vector pGEM-T easy. A typical ligation mixture 
included 2.5-3.0 µL of purified A-tailed PCR product, 0.2-0.5 µL of the pGEM-T easy 
vector, 2-2.5 µL of 5X T4 ligase buffer, and 0.5 µL of T4 ligase, for a total reaction 
volume of 6 µL. The ligation mixture was incubated at room temperature overnight at 4 
ºC. The ligation mixture (3 µL) was then mixed with competent E. coli DH5α (50 µL) 
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and incubated on ice for 30 min. After incubation, the cells were transformed by heat 
shock at 42 ºC for 30 s, followed by incubation for 2 min on ice. LB broth (500 µL) was 
added to the transformed cells and the cells were pelleted by centrifugation at 12,000 g 
for 10 s, discarding the supernatant. Cells were resuspended in 50 µL fresh LB media and 
plated on LB-agar supplemented with 100 µg/mL ampicillin, 100 µL of 10 mM IPTG 
and 100 µM of 2% X-Gal in dimethyl formamide (DMF). Positive transformants were 
selected after overnight incubation at 37 ºC. Plates were subsequently incubated for 8-12 
h at 4 ºC to allow development of the blue color. White colonies were selected for future 
screening steps.  
 
5.2.3.6 Shuttle Vector Cloning into pCR-Blunt 
PCR products were ligated into shuttle or expression vectors specific to each gene 
as described in later sections of this chapter. In the case of pCR-Blunt, a typical ligation 
mixture included 3.5 µL of gel purified PCR product, 0.5 µL of  pCR-Blunt vector, 2 µL 
of 5X T4 ligase buffer solution, 3.5 µL of sterile water, and 0.5 µL of T4 ligase, for a 
total reaction volume of 10 µL. The ligation mixture was incubated at room temperature 
for 30 to 60 min or overnight at 4 ºC. The ligation mixture (3-5 µL) was then mixed with 
competent E. coli DH5α (50 µL) and incubated on ice for 30 min. After incubation, the 
cells were transformed by heat shock at 42 ºC for 30 s, followed by incubation for 2 min 
on ice. LB broth (500 µL) was added to the transformed cells and incubated for 30-45 
min at 37 ºC, with 200 RPM shaking. The cells were plated on LB-agar plates containing 
50 µg/mL kanamycin. Positive transformants were selected after overnight incubation at 
37 ºC.  
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5.2.3.7 Direct Cloning into Expression Vector 
A Nanodrop-1000 instrument was use to quantify DNA solutions. A typical 
ligation mixture included 90 fmol ends of purified PCR product, 30 fmol ends of plasmid 
vector, 2 µL of T4 ligase buffer solution, 0.2-0.5 µL of T4 ligase, and sterile water to a 
volume of 10 µL. The ligation mixture was incubated at room temperature for 30 to 60 
min, or overnight at 4 ºC. The ligation mixture (3-5 µL) was then mixed with competent 
E. coli DH5α (50 µL) and incubated on ice for 30 min. After incubation, the cells were 
transformed by heat shock at 42 ºC for 30 s, followed by incubation for 2 min on ice. LB 
broth (500 µL) was added to the transformed cells and incubated for 30-45 min at 37 ºC, 
with 200 RPM shaking. The cells were plated on LB-agar plates containing selective 
antibiotic. Positive transformants were selected after overnight incubation at 37 ºC.  
 
5.2.3.8 Alkaline Lysis Procedure 
Colonies appearing after overnight incubation were screened for the presence of 
plasmid containing PCR product using a modified alkaline lysis procedure.
277
 Briefly, 2-5 
mL cultures of each positive transformant were grown overnight at 37 ºC in LB or 2X YT 
media (1.6% tryptone, 1% yeast extract, 0.5 % NaCl, pH 7.0) in the presence of selective 
antibiotic. Culture volume was dependent on the copy number of the plasmid. Cultures 
were centrifuged at 12,000 g for 30 s, the supernatant was removed and the cells were 
resuspended in 100 µL of cold resuspension solution (50 mM glucose, 25 mM Tris•HCl, 
pH 8.0, 10 mM EDTA, 100 µg/mL RNase). Cells were disrupted with the addition of 200 
µL fresh lysis solution (200 mM NaOH, 1% SDS), and inverted five times to mix. The 
lysis reaction was quenched with the addition of 150 µL of neutralization solution (3 M 
potassium acetate, 11.5% acetic acid). Reactions were mixed to ensure neutralization and 
incubated at 4 ºC for 5 min, followed by centrifugation for 5 min at 16,100 g at 4 ºC to 
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pellet cellular debris. Each supernatant containing plasmid DNA was transferred to a 
fresh tube and the DNA was precipitated by the addition of 2.5 volumes of 100% ethanol 
or one volume of isopropanol and 1/10 volume of 3 M sodium acetate pH 5.2. Each 
solution was mixed to ensure homogeneity and centrifuged at 16,100 g for 15 min at 4 
ºC. The supernatant from each sample was then removed by aspiration, taking care not to 
disturb the DNA pellet. Each DNA pellet was washed with 70% ethanol and centrifuged 
again at 16,100 g for 5 min. The final ethanol wash was removed and each pellet was 
dried using a centrifugal vacuum apparatus for 2 min at room temperature to remove any 
remaining ethanol. Each pellet containing plasmid DNA was resuspended in 30 µL of 50 
mM Tris•HCl (pH 8.5).  
 
5.2.3.9 DNA Analytical Restriction Digestion and Fragment Analysis 
Plasmid DNA obtained from the alkaline lysis preparation was then subjected to 
enzymatic digestion with the appropriate restriction enzymes. A typical reaction mixture 
contained 5 µL of DNA, 2 µL of 10X NEB reaction buffer, 0.2 µL each enzyme, and 13 
µL of sterile water, for a final volume of 20 µL. In the case of shuttle vectors pGEM-T 
easy or pCR-Blunt, a typical reaction mixture contained 3 µL of DNA, 4 µL of 10X 
EcoRI buffer, 0.5 µL of EcoRI, and 13 µL of sterile water, for a final volume of 20 µL. 
Each reaction was incubated for 2 h at 37 ºC, after which time 10 µL aliquots were 
removed and analyzed by gel electrophoresis. Samples were electrophoresed for 30 min 
at 100 V using a 0.8% TAE-agarose gel with 5 µg/mL ethidium bromide. For digestion 
products greater than 2 kB, the duration of the electrophoretic separation was increased to 
allow greater resolution of digested vector and the resulting DNA fragment. 
Electrophoretic results as visualized on agarose gels were used to determine the presence 
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of the DNA insert of the appropriate length. Colonies containing the vector with the 
ligated PCR product were grown at 37 ºC in LB media supplemented with selective 
antibiotic. After overnight incubation, cells were harvested by centrifugation at 12,000 g 
for 30 s. Plasmid DNA was extracted from the pelleted bacteria using the Qiagen 
miniprep kit, following the manufacturer‟s protocols with the following adjustments: the 
optional 500 µL PB wash was always performed to remove additional contaminants, and 
elution buffer EB was heated to 65 ºC before DNA elution.  
 
5.2.3.10 DNA Sequence Analysis  
The purified plasmid was sequenced to confirm the identity of the PCR product. 
For these genes, sequencing reactions using external and internal primers were submitted 
to ensure full sequence coverage. Specific primers used for each sequencing reaction are 
provided in later sections of this chapter. PHRED sequences obtained from the DNA 
facility were aligned against the known gene sequence. Contigs consisting of results from 
DNA sequencing reactions were assembled using the Vector NTI software program and 
compared to the original gene sequence. Both forward and reverse sequences were 
examined to determine that the correct gene sequence was obtained. When necessary, 
point mutations in the amplified sequences were compared to known Single Nucleotide 
Polymorphisms (SNPs) to determine if any of these is a result of mutations in the DNA 
template.  
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5.2.3.11 Secondary Cloning into Expression Vectors 
When shuttle vectors were used, the PCR insert was isolated after sequencing and 
ligated into a plasmid expression vector. The general protocol used to generate 
expression constructs is described below.  
STEP 1: GROWTH OF E. COLI CELLS. One colony of E. coli DH5α containing the 
gene of interest in a shuttle vector was used to inoculate 5 mL of LB media supplemented 
with the appropriate selective antibiotic. Cultures were grown overnight at 37 ºC with 
200 RPM shaking and the plasmids were isolated using the Qiagen miniprep kit 
following the manufacturer‟s protocols with additions and alterations as previously 
detailed.  
STEP 2: SHUTTLE VECTOR DIGESTION. Plasmid DNA obtained from this preparation 
was subjected to enzymatic digestion overnight with the appropriate enzymes. A typical 
preparatory digestion reaction contained: 30 µL of DNA, 4 µL of NEB 10X buffer, 2 µL 
of each enzyme and 2 µL of sterile water for a final reaction volume of 40 µL. For tmtc2 
and tmtc3 pCR-Blunt constructs, a typical reaction mixture consisted of 10 µL of DNA, 5 
µL of 10X NEBuffer, 35 µL of sterile water and 1 µL of each enzyme. Reactions were 
incubated overnight at 37 ºC. Digestion reactions were subjected to agarose gel 
electrophoresis for 30-40 min at 100 V using a 0.8% TAE-agarose gel with 5 µg/mL 
ethidium bromide. For digestion products greater than 2 kB, the duration of the 
electrophoretic separation was increased to allow greater resolution of digested vector 
and the resulting DNA fragment. Electrophoresis was required to separate the shuttle 
vector from the gene of interest.  
The gel band containing the insert of appropriate size was excised with a clean, 
sharp scalpel and purified using the Qiagen gel purification kit, following the 
manufacturer‟s protocols with the additions and alterations as previously described.  
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STEP 3: EXPRESSION VECTOR PURIFICATION AND DIGESTION. Expression vectors 
were prepared by enzymatic digestion with the appropriate enzymes overnight at 37 ºC, 
followed by the addition of 0.1 µL CIP. The reaction was incubated for 1 h at 37 ºC.  
When NEBuffer 2 was not used in the digestion reaction, 0.25 volumes of 1 M Tris•HCl, 
pH 8 was added to the reaction. To purify digested DNA, the Qiagen gel purification kit 
was employed according to manufacturer‟s instructions for purifying PCR products.  
STEP 4: DNA LIGATION AND TRANSFORMATION INTO E. COLI. A Nanodrop instrument 
was used to determine the concentration of both vector and gene insert solutions. 
Ligations were performed at room temperature for 1-2 h or overnight at 4 ºC, with a 
typical reaction mixture consisting of 90 fmol ends of gene to be inserted, 30 fmol ends 
of vector, 2 µL of 5X ligation buffer, 0.5 µL of T4 ligase, and sterile water to a final 
volume of 10 µL. A total of 5 µL of the ligation reaction was incubated with 50 µL of 
competent E. coli DH5α on ice for 30 min. The transformation procedure is identical to 
that previously described; however, when ampicillin was the selective antibiotic used, the 
recovery incubation was omitted and the transformation was plated directly onto LB-agar 
plates with 100 µg/mL ampicillin.  
STEP 5: LIGATION AND SELECTION ANALYSIS. After overnight incubation at 37 ºC, 
colonies appearing on the selection plates were screened for successful ligation by 
alkaline lysis and enzymatic digestion following the method described above with the 
following adjustments.
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 Digestion was carried out using the restriction enzymes specific 
for each construct, as indicated in the following chapter. A typical reaction mixture 
contained 5 µL of DNA, 2 µL of 10X NEB reaction buffer, 0.2 µL of each enzyme, and 
13 µL of sterile water, for a final volume of 20 µL. Each reaction was incubated for 2 h at 
37 ºC, after which time 10 µL aliquots were removed and analyzed by gel 
electrophoresis. Samples were electrophoresed for 30 min at 100 V using a 0.8% TAE-
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agarose gel with 5 µg/mL ethidium bromide. For digestion products greater than 2 kB, 
the duration of the electrophoretic separation was increased to allow greater resolution of 
digested vector and the resulting DNA fragment.  
Electrophoretic results as visualized on agarose gels were used to determine the 
presence of the DNA insert of the appropriate length. Colonies containing the vector with 
the successfully ligated gene of interest were grown at 37 ºC in LB media supplemented 
with the appropriate selective antibiotic. After overnight incubation, cells were harvested 
by centrifugation at 12,000 g for 30 s. Plasmid DNA was extracted from the pelleted 
bacteria using the Qiagen miniprep kit, following the manufacturer‟s protocols with the 
adjustments as described previously. The newly isolated gene-containing plasmids were 
used to transfect heterologous expression hosts. 
 
5.2.3.12 SDS-PAGE 
The relative molecular mass and purity of enzyme samples were determined using 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) as described by 
Laemmli.
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 Proteins were electrophoresed using a discontinuous buffer system 25 mM 
Tris•HCl, 192 mM glycine and 0.1% SDS (pH 8.3).273 Gels were cast using 75 mm 
plates, and in most cases 6 or 8% acrylamide was used for the separatory gel for proteins 
greater than 60 kDa and 12% for proteins smaller than 60 kDa. All  stacking gel used was 
4% acrylamide. Protein samples were diluted 2X with SDS-loading dye (62.5 mM 
Tris•HCl buffer pH 6.8), containing 10% glycerol, 2% SDS, 5% β-mercaptoethanol, and 
0.0025% bromophenol blue, and heated to 100 ºC for 5 min. Samples were centrifuged 
briefly to collect insoluble material at the bottom of the tubes. The protein gels were 
electrophoresed using a setting of 30 mA per gel, allowing the gel to run until the loading 
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dye eluted from the bottom of the gel. Gels were removed from the glass plates, and 
stacking gel was removed and discarded. A corner of each gel was removed to preserve 
orientation of the gel samples. Gels were stained with Coomassie blue (2.5 g/L of 
Coomassie Brilliant Blue G-250 in acetic acid:water:methanol (1:4:5) by volume) until 
dark blue.
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 Gels were removed from staining solution, rinsed in ddH2O, and submerged 
in destaining solution (ethanol:acetic acid:water in a ratio of 4:5:41 by volume).
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Protein concentrations were determined according to Bradford using bovine serum 
albumin as the standard. 
272
 
 
5.2.3.13 Western Blot Procedure  
Western blotting was used to detect the presence of IL-12b or FLAG and c-myc 
epitopes, or polyhistidine tags on heterologously expressed and purified proteins.
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 SDS-
PAGE procedures were performed in duplicate for each protein sample. The gels were 
processed as described previously until the staining step, at which point gels were 
assembled into the transfer cassettes. The cassettes were transblotted onto the 
nitrocellulose membrane at 100 V for 1 h, using a running buffer of 25 mM Tris base, 
192 mM glycine, 20% v/v methanol (pH 8.3).  Cassette assembly and electrophoresis was 
carried out according to the directions provided by BioRad. After transblotting 
electrophoresis, the membrane was carefully removed from the transfer cassette and the 
presence of the prestained marker on the blot was visually assessed to ensure transfer was 
complete. The membrane was transferred to a small plastic box and immersed in 5% non-
fat dry milk in Tris buffered saline and Tween® (TBST) (20 mM Tris•HCl, 150 mM 
NaCl, 0.5% v/v Tween® 20, pH 7.5). The membrane was blocked in this solution for 1 h, 
with agitation, overnight at 4 ºC or at room temperature for 1 h. The solution was then 
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removed and the membrane rinsed thrice in TBST to remove excess blocking solution. 
The membrane was then immersed in primary antibody solution (15 mL TBST, 1:30,000 
dilution of monoclonal anti-polyhistidine clone His-1,  or a 1:5000 dilution of αIl-12b, α-
myc, or α-FLAG antibodies. All antibody solutions contained 1:1000 dilution of 20% v/v 
NaN3), and incubated with agitation overnight at 4 ºC or room temperature for 1 h. After 
incubation, the solution was decanted and the membrane washed thrice with TBST to 
remove any excess primary antibody solution remaining on the membrane. The 
membrane was subsequently incubated in secondary antibody solution (15 mL TBST, 
1:30,000 dilution of anti-mouse IgG [Fc specific] alkaline phosphatase conjugate, 1:1000 
dilution of 20% v/v NaN3), and incubated with agitation overnight at 4 ºC or room 
temperature for 1 h. After incubation, the solution was decanted and the membrane 
washed thrice with TBST to remove any excess secondary antibody solution remaining 
on the membrane. To visualize bound antibody, the membrane was immersed in 5 mL 
color development solution (100 mM Tris•HCl, 100 mM NaCl, 5 mM MgCl2, pH 9.5) 
with the addition of 66 µL NBT and 33 µL BCIP. The membrane was incubated in the 
dark for 2-5 min or until purple bands appeared on the blot. Development was stopped by 
rinsing the membrane with ddH2O. Membranes were dried and scanned within 24 h to 
preserve coloration. 
 
5.2.3.14 In-Gel Tryptic Digest of Proteins  
Proteins were digested in acrylamide gels following the method of Shevchenko.
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Briefly, major protein bands were excised from Coomassie stained gel with a fresh razor 
blade. Gel slices were transferred to sterile Eppendorf tubes and were destained overnight 
at room temperature with slight agitation in fresh destaining solution. After most of the 
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dye was removed from the gel bands, destaining solution was removed and replaced with 
500 µL of fresh destaining solution, and destaining continued for another 2 to 3 h. The 
destaining solution was removed and discarded, and the gel slices were dehydrated in 300 
µL of HPLC grade acetonitrile. This step was repeated as necessary until the gel slices 
were an opaque white color. The acetonitrile was removed and discarded. The gel slices 
were subjected to evaporation using vacuum centrifugation for 2-3 min to evaporate any 
remaining acetonitrile and then treated with fresh 10 mM DTT (100 µL) for 1 h at room 
temperature to reduce the proteins in the gel. The sample was centrifuged briefly and the 
DTT solution was removed. The gel slices were then incubated at room temperature for 1 
h with fresh 50 mM iodoacetamide in water (100 µL). The sample was briefly 
centrifuged, and the iodoacetamide solution was removed. The gel slices were washed for 
10 min with 100 mM ammonium bicarbonate (200 µL) and centrifuged briefly before 
removing the ammonium bicarbonate solution. Gel slices were dehydrated in HPLC 
grade acetonitrile (300 µL). This step was repeated as necessary until the gel slices turned 
white, after which the acetonitrile was left on the gel slices for 5 min. The acetonitrile 
was removed and discarded. This step was repeated for two washes of 5 min each, and 
the gel was rehydrated in 100 mM ammonium bicarbonate (200 µL) for 10 min. The 
sample was then centrifuged briefly and the ammonium bicarbonate solution was 
removed. Gel slices were then dehydrated in HPLC grade acetonitrile (300 µL). This step 
was repeated twice as above, for a total of two 5 min washes. The gel slices were dried by 
evaporation using the vacuum centrifuge for 2-3 min to remove any remaining 
acetonitrile. Trypsin solution (20 ng/µL) was prepared by adding 1 mL of 50 mM 
ammonium bicarbonate to 20 µg enzyme on ice. Trypsin solution (50- 100 µL) was 
added to cover the gel slices completely, and this mixture was incubated on ice for 10-15 
min, until the gel pieces appeared swollen. Ammonium bicarbonate (50 mM, 20 µL) was 
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then added to the solution and the digestion was incubated overnight at 37 ºC. The next 
morning, the extract was centrifuged to collect the sample and the digestion solution was 
removed with a gel-loading pipette tip, ensuring exclusion of any gel pieces. Protein was 
further extracted from the gel slices by adding 50% acetonitrile/50% water with 5% 
formic acid (75 µL) and incubating at room temperature for 10 min. The sample was 
centrifuged and the resulting solution transferred to a clean eppendorf tube. This step was 
repeated for a total organic extraction volume of 150 µL.  
 
5.2.4 CLONING OF TMTC2 AND TMTC3 FOR S. FRUGIPERDA  
5.2.4.1 PCR Reactions and Product Purification 
The genes tmtc2 and tmtc3 were amplified using pESC-His constructs as template 
DNA. Primers for the tmtc2 gene were designed to have the restriction enzyme 
recognition sites for EcoRI and XbaI incorporated in the primer sequences (5′ start primer 
5′-TAAGAATTCATGATTGCAGAGTTGGTGAGC-3′ and 3′ halt primer 5′-AAATCT-
AGATCAGATCTTATCGTCGTCATCC-3′), which also included the C-terminal FLAG 
tag found in the pESC-His vector.  Primers for the tmtc3 gene were designed to have the 
restriction enzyme recognition sites for SmaI and SphI incorporated in the primer 
sequences (5′ start primer 5′-TTACCCGGGATGGCTAATATTAACCTA-
AAAGAAATAACC-3′ and 3′ halt primer 5′-ATTGCATGCTTACTCGAGGTCTTCTT-
CGG-3′), which also included the C-terminal myc epitope tag found in the pESC-His 
vector.  
Template and DNA primers were obtained and prepared for PCR as described 
previously.  The PCR reactions consisted of the following: 140 µL sterile water, 20 µL 
10X KOD buffer, 16 µL of a 2 mM dNTP solution, 12 µL of a 25 mM MgSO4 solution, 
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10 µL of dimethyl sulfoxide (DMSO), 1.0 µL of each primer (5′ and 3′) at 10 µM, 1 µL 
of template DNA, for a 200 µL total volume. The mixture was divided into two 0.5 mL 
thin-walled PCR tubes, and 2 µL KOD polymerase was added.  
PCR was carried out using an Eppendorf thermocycler with the lid temperature 
set at 105 ºC and an initial polymerase activation step of 2 min at 95 ºC.  The program 
consisted of a 20 s denaturing step at 95 ºC, an annealing step at 43.6 ºC for 10 s, an 
elongation step of 90 s at 70 ºC. This cycle was repeated thirty times, and the program 
ended with a 10 min extension at 70 ºC. The temperature was reduced to 4 ºC until the 
product was removed from the thermocycler.  PCR products were stored at 4 ºC until 
purified. 
The PCR products were purified by agarose gel electrophoresis and ligated into 
pCR-Blunt as described in sections 5.2.3.4 and 5.2.3.6 respectively, with the following 
alterations to the protocol. Ligation mixtures were incubated at 4 ºC overnight. The 
amount of the ligation mixture was used for the bacterial transformation was 5 µL. 
Colonies appearing after overnight incubation were then screened for the presence of 
plasmid containing PCR product using a modified alkaline lysis procedure, with the 
following modifications.
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 Culture volume was 3 mL and the media used was 2X YT 
media supplemented with 50 µg/mL kanamycin. Plasmid DNA obtained from this 
preparation was subjected to enzymatic digestion with EcoRI and analyzed as described 
previously. For PCR products greater than 2 kB, the duration of the electrophoretic 
separation was increased to allow greater resolution of digested vector and the resulting 
DNA fragment.  
Electrophoretic results as visualized on agarose gels were used to confirm the 
presence of the DNA insert of the appropriate length. Colonies determined to contain the 
vector and successfully ligated PCR product were grown overnight at 37 ºC with 200 
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RPM shaking in 2X YT media supplemented with 50 µg/mL kanamycin, and after 
overnight incubation, plasmid DNA was isolated using the Qiagen miniprep kit as 
described previously. The purified plasmid was sequenced using two external primers 
(M13 forward and reverse) from the cloning vector and three internal primers. PHRED 
sequences obtained from the DNA facility were aligned against the known gene 
sequence. 
 Once the DNA sequences were confirmed to be the desired genes, tmtc2 and 
tmtc3, they were transferred from shuttle vectors to expression vectors following the 
protocols in section 5.2.3.11. Briefly, the shuttle vector constructs were digested with the 
appropriate enzymes (EcoRI, XbaI for tmtc2 and SphI, SmaI for tmtc3). Expression 
vectors were amplified using DH5α cells grown in LB broth supplemented with 100 
µg/mL ampicillin. The pFastBac Dual plasmids were isolated using the Qiagen miniprep 
kit and prepared by enzymatic digestion with the corresponding enzymes (as listed 
above). Plasmid vector purification, ligation and transformation procedures are identical 
to those previously listed, with the adjustments listed for ampicillin selection.  
After overnight incubation, colonies appearing on the plates were grown in 2X 
YT media and screened using the modified alkaline lysis procedure in the previous 
section 5.2.3.8, followed by enzymatic digestion using EcoRI, EcoRV for tmtc2 and SphI, 
SmaI for tmtc3 and analysis employing agarose gel electrophoresis. Colonies positive for 
vector and insert were grown in 3 mL 2X YT media supplemented with 100 µg/mL 
ampicillin for 6 h at 37 ºC with 200 RPM shaking. The plasmids were extracted using the 
Qiagen miniprep kit with modifications to the protocol as previously described. Plasmids 
generated via this method are TMTC2-pFastBac-Dual and TMTC3-pFastBac-Dual.  
To generate TMTC2/TMTC3-pFastBac-Dual, the latter plasmid was again 
digested with EcoRI, XbaI and prepared as described above. The digested, CIP treated 
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vector was gel purified and subjected to ligation with tmtc2, also digested with the EcoRI, 
XbaI enzymes. Ligation, alkaline lysis, electrophoresis and final plasmid preparation 
were repeated as above to construct this plasmid. After construction, the dual expression 
vector containing both tmtc2 and tmtc3 was submitted to DNA sequencing to ensure that 
both genes were present in the vector. 
 
5.2.4.2 Construction of tmtc2 and tmtc3 Bacmids 
Once tmtc2 and tmtc3 genes were successfully ligated into the pFastBac Dual 
vector, the three expression plasmids were converted into bacmids.  
STEP 1: PLASMID TRANSFORMATION INTO E. COLI. Chemically competent DH10Bac 
cells were transformed with each construct, TMTC2-pFastBac-Dual, TMTC3-pFastBac-
Dual, TMTC2/TMTC3-pFastBac-Dual following the transformation procedure as 
described previously with the following alterations. After the heat shock step, 900 µL of 
2X YT was added to the transformants and cells were allowed to recover for 4 h at 37 ºC 
with 200 RPM shaking. After the 4 h recovery time, each transformation was divided into 
aliquots and plated onto LB-agar supplemented with 50 µg/mL kanamycin, 10 µg/mL 
tetracycline, 7 µg/mL gentamycin, 40 µg/mL IPTG, and 80 µg/mL 5-bromo-4-chloro-3-
indolyl-β-D-galactopyranoside (X-gal). Aliquot volumes for each transformant were: 500 
µL, 250 µL, 125 µL, 75 µL and 50 µL, and the plates were incubated for 2 days at 37 ºC. 
After this time, white colonies were clearly visible, indicating the formation of 
recombinant bacmids. White colonies were used to inoculate fresh LB-Agar 
(Kan50/Tet10/Gent7/IPTG40/X-Gal80) plates and were grown for 2 days at 37 ºC.  
STEP 2: PCR SCREENING OF POSITIVE BACMID TRANSFORMANTS. White colonies 
were screened for the presence of recombinant insert using the PCR methodology 
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provided by the Invitrogen Bac-to-Bac manual. Briefly, PCR reactions contained: 32 µL 
of sterile water, 5 µL of 10X KOD buffer, 5 µL of a 2 mM dNTP solution, 3 µL of a 25 
mM MgSO4 solution, 1.5 µL of each primer (M13 forward and reverse) (5′ and 3′) at 10 
µM, and 1 µL of KOD polymerase for a final volume of 50 µL in a 0.2 mL thin walled 
PCR tube. Colonies were picked from plates using sterile pipette tips and triturated in 
PCR reactions to introduce template DNA. PCR screening reactions used the program 
listed previously for the cloning of tmtc2 and tmtc3, with the following changes. The 
annealing temperature was set to 55 ºC, as different primers were used for this reaction. 
PCR reactions were analyzed by gel electrophoresis using the protocols previously listed; 
however, a 0.3% TAE-agarose gel was employed due to the size of the PCR product (~5 
kB). Colonies positive for insert as determined by the PCR screening method were used 
to inoculate 5 mL of LB-Kan50-Tet10-Gnt7 media and were allowed to grow overnight 
at 37 ºC with 200 RPM shaking.  
 
5.2.4.3 Bacmid Isolation for S. frugiperda Sf9 Transformations and Gene 
Expression 
DNA was prepared from E. coli DH10Bac cells using the Qiagen Maxi prep kit 
following the manufacturer‟s protocol for large constructs. Briefly, 1 mL of culture from 
the previous step was used to inoculate 500 mL of fresh LB media containing the 
selective antibiotics as listed above. After 12 h growth at 37 ºC with vigorous shaking 
(250 RPM), the culture was centrifuged for 15 min at 4 °C, 6000 g and the supernatant 
was removed. Cell pellets were either frozen at -80 ºC or processed immediately. The 
pellet was resuspended in 20 mL of P1 buffer (with 100 µg/mL RNase) and cells were 
lysed by the addition of 20 mL of P2 buffer. The solution was mixed by inversion 4-6 
times and incubated at room temperature for 5 min. The solution was neutralized by the 
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addition of 20 mL of P3 buffer, inverted 5-6 times to mix the solution thoroughly, and 
incubated on ice for 10 min. The sample was centrifuged at 4 ºC for 30 min at 20,000 g, 
and the supernatant was filtered through hydrated filter paper. The flow through was 
collected in a clean 50 mL centrifuge tube, and 0.6 sample volumes of isopropanol was 
introduced to the filtered lysate. The sample was centrifuged for 30 min at 15,000 g, 4 ºC, 
and the supernatant was carefully decanted from samples so as not to disturb the DNA 
pellet. The DNA pellet was washed with 5 mL of 70% ethanol and centrifuged for 30 min 
at 15,000 g, 4 ºC. The supernatant was decanted, and the DNA pellet was dried by 
inverting the centrifuge tubes for 2-3 min over filter paper. DNA was resuspended in 9.5 
mL of buffer EX, taking care not to shear the DNA by trituration. The samples from 
different centrifuge tubes were combined and subjected to exonuclease digestion with the 
addition of 200 µL ATP-dependent exonuclease and 300 µL (100 mM) ATP solution. 
The samples were heated at 37 ºC for 60 min. While the sample was incubating, 10 mL of 
buffer QBT was introduced to the Qiagen tip 500, which was allowed to flow through by 
gravity to equilibrate the tip. After sample incubation, 10 mL of buffer QS was applied to 
the sample and the entire volume was applied immediately to the pre-equilibrated tip 500. 
The sample was introduced by gravity, and the tip was washed 2X with 30 mL of buffer 
QC. The washes were allowed to flow through by gravity and retained for later analysis. 
Buffer QF was warmed to 65 ºC and 15 mL was introduced to the column, and the flow-
through, containing the DNA of interest was collected in a sterile 50 mL centrifuge tube. 
Room temperature isopropanol, (10.5 mL or 0.7 volumes) was added to the QF elution. 
The tube was marked to show orientation in the centrifuge rotor, and centrifuged 
immediately for 30 min at 4 ºC, 15,000 g. The glassy DNA pellet was washed with 5 mL 
of 70% cold ethanol to remove excess salts left in the isopropanol pellet. The sample was 
centrifuged as above and the supernatant was removed. The tubes were inverted over 
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filter paper for 5-10 min to completely dry the pellet, which was resuspended in a small 
volume of TE or EB buffer at 55 ºC. Bacmid concentrations were measured using a 
Nanodrop instrument and stored at -20 ºC until use. 
 
5.2.5 S. FRUGIPERDA SF9 TRANSFECTION OF BACMIDS (GENERATION OF P1 VIRAL 
STOCK) 
Sf9 cells were removed from culture flasks and counted using a standard 
hemacytometer and trypan blue dye to verify cell viability.
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 To remove Sf9 cells from 
flasks, the flasks were first incubated for 20 min at 4 ºC. After incubation, flasks were 
struck sharply with the open palm to dislodge weakly adherent cells and create a cell 
suspension in media. To count the cells, 0.2 mL of cell suspension was removed from the 
culture flask and diluted with 0.3 mL phosphate buffered saline. An aliquot (0.5 mL) of 
trypan blue solution (0.2 % w/v) was added to the dilute cell suspension and 100 µL of 
this solution was placed on the hemacytometer and counted using a compound 
microscope. A total count of all cells generates the number of cells in the flask, and 
counting again only those cells that are able to exclude the blue dye gives a number of 
viable cells. Using the equation: [(White cells/Total cells) × 100] generates a number 
equal to the “% viable” cells of the total cells in the culture.  
Cells were found to be 95% viable and were plated at a density of 2 × 10
6
 cells 
into 60 × 15 mm culture dishes and incubated overnight at 27 ºC in a humidified 
environment, in Sf-900-II SFMu.  The following day, transfection reagents were prepared 
for each bacmid. Cellfectin at room temperature was mixed well, and 8 µL was added to 
100 µL of unsupplemented Grace‟s Media. Each bacmid (500 ng or 1-2 µL) was 
combined with 100 µL of unsupplemented Grace‟s Media. The DNA and Cellfectin 
mixtures were subsequently combined and allowed to incubate for 15-30 min at room 
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temperature. The table below shows volumes used for a sample transfection, with control 
plates.  
5.1 Sample Transfection Reactions for TMTC2 and TMTC3 baculoviral stocks 
 
Plate Number/Sample Cellfectin Media DNA Media 
#1 Negative Control 0 µL 100 µL 0 µL 100 µL 
#2 Cellfectin Control 8 µL 100 µL 0 µL 100 µL 
#3 Transfection    TMTC2 8 µL 100 µL 1.7 µL 100 µL 
#4 DNA control   TMTC2 0 µL 100 µL 1.7 µL 100 µL 
#5 Transfection    TMTC3 8 µL 100 µL 2.1 µL 100 µL 
#6 DNA control   TMTC3 0 µL 100 µL 2.1 µL 100 µL 
#7 Transfection    TMTC2/3 8 µL 100 µL 1.5 µL 100 µL 
#8 DNA control   TMTC2/3 0 µL 100 µL 1.5 µL 100 µL 
 
The following day, media was removed and cells were washed gently with sterile 
phosphate buffered saline (PBS). The wash was discarded and 210 µL of transfection 
reagent was added to each dish, and incubated for 3-5 h at 27 ºC with gentle agitation. 
After incubation, 2 mL of Sf-900-II SFMu was added to each culture dish. Cultures were 
incubated at 27 ºC for 72 h in a humidified environment, or until signs of infection were 
observed in cells. Late-stage infection media was harvested from the culture and 
centrifuged at 500 g for 5 min to remove cellular debris. The supernatant was transferred 
to a fresh 15 mL conical tube, wrapped in foil to protect viral particles from light and 
stored at 4 ºC until use.  
 
 317 
5.2.6 S. FRUGIPERDA SF9 BACULOVIRUS INFECTION (GENERATION OF P2 VIRAL 
STOCK) 
 Uninfected Sf9 cells were removed from culture flasks and counted using a 
standard hemacytometer and trypan blue dye to verify cell viability. Cells were found to 
be 95% viable and were plated at a density of 2 × 10
6
 cells/mL into 60 × 15 mm culture 
dishes and incubated overnight at 27 ºC in a humidified environment and Sf-900-II 
SFMu, for a total of eight dishes.  The following day 100 µL of each viral stock 
(TMTC2, TMTC3 or TMTC2/3) was added to culture dishes in duplicate, such that two 
dishes contained each viral stock at approximately 0.1 M.O.I. (multiplicity of infection), 
leaving two dishes as negative controls for comparison. The infected cultures were 
subsequently incubated for 48 h at 27 ºC in a humidified environment, or until signs of 
infection were observed in cells. Late-stage infection media was harvested from cultures 
and centrifuged at 500 g for 5 min to remove cellular debris. The supernatant was 
transferred to a fresh 15 mL conical tube, wrapped in foil to protect viral particles from 
light and stored at 4 ºC until use.  
 
5.2.7 S. FRUGIPERDA SF9 BACULOVIRUS PLAQUE ASSAYS 
Cells were counted, assessed for viability and diluted to 5 × 10
5
 cells/mL (as 
calculated based on trypan blue exclusion assay). The diluted solution (2 mL) was plated 
in 60 × 15 mm dishes to 50% confluence in Sf-900 II SFMs, and incubated overnight at 
27 ºC in a humidified environment. After incubation, plates were examined to ensure 
50% confluence. Plaquing media was made by melting 4% agarose in a sterile 
environment, and combining this agar solution with Sf-900 media (unsupplemented). 
This plaquing media was incubated at 40 ºC until use.  Serial dilutions of each of three P2 
viral stocks was prepared by diluting 0.5 mL of P2 stock into 4.5 mL of Grace‟s Insect 
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Media (unsupplemented) to create 8 dilutions (from 10
-1
 to 10
-8
). For each stock, six 
plates were selected, the media removed and immediately replaced with: no virus, 10
-4
, 
10
-5
, 10
-6
, 10
-7 
and 10
-8
 dilutions. These cells were incubated for 1 h at room temperature 
with gentle agitation, after which time the viral dilutions were removed and plates were 
overlayed with plaquing media. Plates were incubated at 27 ºC in a humidified 
environment for 7-10 days until plaques (holes in the cellular monolayer) appeared. After 
this time, plaques were counted and titer was calculated according to the following 
formula. 
titer (pfu/mL) = # plaques × dilution factor × (1/ mL of inoculum/ well) 
 
5.2.8 S. FRUGIPERDA SF9 TMTC2 GENE EXPRESSION AND PROTEIN PURIFICATION 
STEP 1: GROWTH OF SF9 CELLS. Sf9 cells were removed from one 175 cm
2
 flask 
and transferred to a sterile 1 L cylindrical Bellco culture flask and 175 mL of fresh Sf-
900-II SFMs was added. TMTC2-P2 viral stock was added to an M.O.I. of 0.1, or an 
approximate volume of 1-3 mL. Cells were grown at 27 ºC in a humidified environment 
with the fast shaking on an orbital shaker for 96 h. Samples (50 mL) were taken at time 
points: 0, 48, 72 and 96 h post-infection. 
  STEP 2: CRUDE EXTRACT PREPARATION. The media was harvested at each time 
point by centrifugation at 2,500 g for 15 min at 4 ºC. Cells were washed with 22.5 mL of 
water and then with 17 mL of buffer B (25 mM sodium phosphate, pH 8.0, with 5 mM 
MgCl2 and 0.2% β-mercaptoethanol). The cell pellet was frozen and stored at -80 ºC until 
processing. The media was then concentrated using an Amicon YM-10 stirred cell 
apparatus at 4 ºC until the media was less than 10 mL. The media was frozen at -80 ºC 
and retained for gel electrophoresis.   
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STEP 3: TMTC2 PROTEIN ENRICHMENT. The protein TMTC2 is expressed as a C-
terminal FLAG-tagged protein and enriched by the method of Schutzbach.
124
 All 
procedures were carried out at 4 ºC or on ice. The cell pellet was thawed, resuspended in 
750 µL buffer B, and the cells were sonically ruptured at a power setting of 4.5 for 3 × 30 
s with 1 min intervals to allow cooling. After sonication, a particulate fraction was 
obtained by centrifugation at 16,100 g for 20 min (microcentrifuge maximum speed). The 
supernatant was discarded and the pellet was washed twice with 2 mL of buffer B, then 
resuspended in 375 µL of the same buffer. The suspension was diluted with 1.3 mL of 
buffer C, (10 mM sodium phosphate, pH 8.0, containing 0.5 mM EDTA, 10% glycerol, 
0.1% Nonidet P-40, and 1.0 mM dithiothreitol). A solution of Nonidet P-40 (200 µL of 
10%) was added, and the mixture was centrifuged at 16,100 g for 20 min. The 
supernatant was removed and retained as Fraction “C”. Additional enzyme was obtained 
from the pelleted fractions, solubilized by the addition of 1.5 mL of buffer D (0.1 M Tris 
acetate, pH 7.5, containing 10% (v/v) glycerol, 0.2% mercaptoethanol, and 0.1% (w/v) 
sodium dodecyl sulfate) to the precipitate. The precipitate was dispersed by vigorous 
trituration followed by the addition of 200 µL of 10% Nonidet P-40. The solution was 
centrifuged as above, and the supernatant was removed and retained. This procedure was 
repeated once more to yield a third solubilized fraction. The second and third solubilized 
supernatant fractions were combined and retained as Fraction “D”. Fractions C and D 
were stored at -20 ºC.  
STEP 4: SDS-PAGE AND WESTERN BLOT ANALYSIS. Aliquots (15 µL) were removed 
from fractions C and D isolated from each time point (0-96 h), as well as media samples 
(0-96 h). All samples were diluted 2X with SDS sample loading dye. Media samples 
were boiled for 5 min at 100 ºC, while fraction C and D samples were not boiled. SDS-
Page and Western Blot were carried out according to methods detailed in section 5.4.3.12 
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and 5.4.3.13. Western Blot employed Anti-FLAG (primary) and anti-mouse (secondary) 
antibodies to detect full-length TMTC2 transcript. 
 
5.2.9 CLONING OF IL-12B FOR S. FRUGIPERDA  
5.2.9.1 PCR Reactions and Product Purification 
The il-12b gene was amplified using pCR4-TOPO constructs from Open 
Biosystems as template DNA. IL-12B primers were designed to have the restriction 
enzyme recognition sites for HindIII and XhoI incorporated in the primer sequences (5′ 
start primer 5′- CCGAAGCTTGATGTGTCACCAGCAGTTGGTCATCTCTTGGTTTT-
CCCTG-3′ and 3′ halt primer 5′- TATCTCGAGACTGCAGGGCACAGATGCCCATTC-
GCTCCAAGATG-3′).  The PCR reactions consisted of the following: 32.8 µL of sterile 
water, 5 µL of 10X KOD buffer, 5 µL of a 2 mM dNTP solution, 3 µL of a 25 mM 
MgSO4 solution, 1.5 µL of each primer (5′ and 3′) at 10 µM, 0.2 µL of template DNA, 
and 1 µL of KOD polymerase, for a 50 µL total reaction volume in an 0.2 mL thin walled 
PCR tube.   
The PCR reactions were carried out using an Eppendorf thermocycler with the lid 
temperature set at 105 ºC and an initial polymerase activation step of 2 min at 95 ºC.  The 
program consisted of a 20 s denaturing step at 95 ºC, an annealing step at 64.3 ºC for 10 
s, an elongation step of 20 s (20 s/kb) at  70 ºC. This was repeated thirty times, with each 
cycle ending in a 10 min extension at 70 ºC.  The temperature was reduced to 4 ºC until 
the product was removed from the thermocycler.  PCR products were stored at 4 ºC until 
purified. 
The PCR products were purified by agarose gel electrophoresis and the Qiagen 
gel purification kit as described previously, with the following modifications. Elution was 
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reduced to 20 µL volume. PCR products were A-tailed and ligated into the shuttle vector 
pGEM-T easy for blue-white screening as described in section 5.2.3.5.  
White colonies appearing after incubation were screened for the presence of 
plasmid containing PCR product using a modified alkaline lysis procedure.
277
 For this 
screening experiment, 3 mL cultures of each positive transformant were grown overnight 
at 37 ºC in LB media supplemented with 100 µg/mL ampicillin, and cells were processed 
by the protocol detailed in section 5.2.3.8. Plasmid DNA obtained from this preparation 
was subjected to enzymatic digestion with EcoRI and agarose gel electrophoresis as 
described in section 5.2.3.9.  
Electrophoretic results as visualized on agarose gels were used to confirm the 
presence of the DNA insert of the appropriate length. Colonies determined to contain the 
vector and successfully ligated PCR product were grown overnight at 37 ºC with 200 
RPM shaking in LB media supplemented with 100 µg/mL ampicillin. After overnight 
incubation, plasmid DNA was extracted using the Qiagen miniprep kit and submitted for 
sequencing to confirm the identity of the PCR product. For the il-12b gene, two 
sequencing reactions, using two external primers (M13 forward and reverse) from the 
cloning vector were submitted to ensure full sequence coverage. 
PHRED sequences obtained from the DNA facility were aligned against the 
known gene sequence. Once the DNA sequence was confirmed to be the desired gene, il-
12b, the gene was digested from the shuttle vector with the appropriate enzymes (HindIII, 
XhoI) and ligated into the pMIB expression vector following the protocols described 
previously. Ligations were then performed at 4 ºC overnight. The transformation 
procedure is identical to that previously listed, with the following adjustments. The 
transformation was not incubated for 30-45 min after the heat shock, it was instead plated 
directly onto LB-agar plates containing 100 µg/mL ampicillin.  
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After overnight incubation, colonies appearing on the plates were grown in LB 
media and screened using the modified alkaline lysis procedure of the previous section 
5.2.3.8, followed by enzymatic digestion using HindIII and XhoI. The digestion reactions 
were analyzed using agarose gel electrophoresis and colonies positive for vector and 
insert were grown in 10 mL LB media with 100 µg/mL ampicillin for 8-10 h at 37 ºC 
with 200 RPM shaking. The plasmids were extracted using the Qiagen miniprep kit with 
modifications to the protocol as previously described. The plasmid generated via this 
method is pMIB/IL-12b which was used for expression of il-12b in insect cells and 
secretion of the protein into the media. 
 
5.2.10 S. FRUGIPERDA SF9 TRANSFECTION OF PMIB-IL-12B PLASMID 
Sf9 cells were removed from culture flasks and counted using a standard 
hemacytometer and trypan blue exclusion assay to verify cell viability. Cells were found 
to be 95% viable and were plated at a density of 2 × 10
6
 cells into 60 × 15 mm culture 
dishes and incubated overnight at 27 ºC in a humidified environment, in Sf-900-II SFMu.  
The following day, transfection reagents were prepared for each plasmid.  An aliquot of 
each plasmid (1 µg or 1-10 µL) was combined with 1000 µL of Grace‟s Media, 
unsupplemented. Cellfectin was mixed well and 20 µL was added to the DNA-Media 
mix. The transfection mixtures were then combined and allowed to incubate for 15-30 
min at room temperature. Table 5.2 shows sample transfection conditions with controls.  
Media was removed from each dish by aspiration and cells were washed gently 
with sterile PBS. The wash was discarded and the transfection reagent was added 
dropwise to each dish. The dishes were incubated for 4 h at room temperature with gentle 
shaking. 
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5.2 Sample Transfection Reactions for Sf9 pMIB/IL-12b  
Plate Number/Sample Cellfectin Media DNA 
#1 Negative Control 0 µL 1000 µL 0 µL 
#2 Cellfectin Control 20 µL 1000 µL 0 µL 
#3 Transfection    IL-12b #1 20 µL 1000 µL 5 µL 
#4 DNA control   IL-12b #1 0 µL 1000 µL 5 µL 
#5 Transfection    IL-12b #2 20 µL 1000 µL 7 µL 
#6 DNA control   IL-12b #2 0 µL 1000 µL 7 µL 
 
After incubation, 2 mL of Sf-900-II SFM media (unsupplemented) was added to 
each plate and culture dishes were incubated overnight at 27 ºC in a humidified 
environment. The following day, media was removed and replaced with 2 mL of Sf-900-
II SFMu. After 24 h, cells were removed from each culture dish (1-6) and transferred to 
25 cm
2
 sterile culture flasks (1-6), cells from one new dish were transferred into one new 
flask, to which 5 mL of Sf-900-II SFMs was added. The cells were incubated at 27 ºC in 
a humidified environment for an additional 24 h, and 50 µg/mL (1 µL 100X solution per 
mL culture) blasticidin was added. The media was changed every 72 h, and fresh 
blasticidin was added until cells in control samples (no DNA, no cellfectin, no treatment) 
died. It was noted that some cells in the transfection flasks died, but confluence steadily 
increased in these flasks. After 6 days, selection was stabilized and cells from transfected 
cultures (3 and 5) were transferred into two new 75 cm
2
 flasks and grown in 15 mL of Sf-
900-II SFMs supplemented with 10 µg/mL blasticidin. Cells were grown at 27 ºC in a 
humidified environment until 70% confluent. At this point cells were split 1:4 and 
cultured in 8 175 cm
2
 flasks in 25 mL of media under the same conditions as above. 
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5.2.11 S. FRUGIPERDA SF9 IL-12B GENE EXPRESSION AND PROTEIN PURIFICATION 
STEP 1: GROWTH OF SF9 CELLS. Sf9 cells expressing il-12b were removed from 
one 175 cm
2
 flask and transferred to a sterile 1 L cylindrical Bellco culture flask and 225 
mL of fresh Sf-900-II SFMp supplemented with 10 µg/mL blasticidin was added. Cells 
were grown at 27 ºC in a humidified environment with the orbital shaker on setting 4 for 
48 h. 
  STEP 2: CRUDE EXTRACT PREPARATION. The media was harvested and centrifuged 
at 2,500 g for 15 min at 4 ºC to remove the media. The cell pellet was retained and stored 
at -80 ºC until processing. The media was then concentrated using an Amicon YM-10 
stirred cell apparatus at 4 ºC until the media was less than 10 mL.   
STEP 3: NI-NTA CHROMATOGRAPHY. The protein IL-12b is generated as a C-
terminal His6 tagged protein and purified by affinity chromatography with Ni-NTA resin, 
following manufacturer‟s instructions with 10% glycerol in all buffers. Ni-NTA resin (2 
mL) was added to the concentrated media and allowed to bind at 4 ºC for 2 h on an 
orbitron rotational mixer. After binding, the slurry was introduced into a 1 × 10 cm 
column and allowed to settle by gravity. The packed column was washed with 5 column 
volumes (CV) of Wash buffer II (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 
10% glycerol, pH 8.0). IL-12b protein was eluted with 2 mL of Elution buffer II (50 mM 
NaH2PO4, 300 mM NaCl, 250 mM imidazole, 15% glycerol, pH 8.0), which was 
collected in two 1 mL fractions.  
STEP 4: SDS-PAGE AND WESTERN BLOT ANALYSIS. Aliquots (15 µL) of 
concentrated media, flow-through, wash and elution fractions were removed from 
samples, diluted 2X with SDS sample loading dye and boiled for 5 min at 100 ºC. SDS-
Page and Western Blot were carried out according to methods detailed in section 5.2.3.12 
and 5.2.3.13. 
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5.2.12 S. FRUGIPERDA SF9 IL-12B AND TMTC2 GENE CO-EXPRESSION AND PROTEIN 
PURIFICATION 
STEP 1: GROWTH OF SF9 CELLS. Sf9 cells expressing il-12b were removed from 
one 175 cm
2
 flask and transferred to a sterile 1 L cylindrical Bellco culture flask and 175 
mL of fresh Sf-900-II SFMp supplemented with 10 µg/mL blasticidin was added. 
TMTC2-P2 viral stock was added to an M.O.I. of > 1, (1-3 mL of viral stock). Cells were 
grown at 27 ºC in a humidified environment with the orbital shaker set to 4 for 96 h. 
Samples (50 mL) were taken at 0, 48, 72 and 96 h after infection. 
  STEP 2: CRUDE EXTRACT PREPARATION. The media was harvested at each time 
point and centrifuged at 2,500 g for 15 min at 4 ºC to remove the media. Cells were 
washed with 22.5 mL of water and then with 17 mL of buffer B (25 mM sodium 
phosphate, pH 8.0, with 5 mM MgCl, and 0.2% β-mercaptoethanol). The cell pellet was 
frozen and stored at -80 ºC until processing. Meanwhile, the media was then concentrated 
using an Amicon YM-10 stirred cell apparatus at 4 ºC until the media was less than 500 
µL. The media was frozen at -80 ºC and retained for gel electrophoresis.   
STEP 3: TMTC2 PROTEIN ENRICHMENT. The protein TMTC2 is produced as a C-
terminal FLAG epitope tagged protein and enriched by the method of Schutzbach.
124
 All 
procedures were carried out at 4 ºC or on ice. The pellet was thawed, resuspended in 750 
µL buffer B, and the cells were sonically ruptured at a power setting of 4.5 for 3 × 30 s 
with 1 min intervals to allow cooling. After sonication, a particulate fraction was 
obtained by centrifugation at 16,100 g for 20 min (microcentrifuge maximum speed). The 
pellet was washed twice with 2 mL of buffer B and resuspended in 375 µL of the same 
buffer. The suspension was diluted with 1.3 mL of buffer C, (10 mM sodium phosphate, 
pH 8.0, containing 0.5 mM EDTA, 10% glycerol, 0.1% Nonidet P-40, and 1.0 mM 
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dithiothreitol). Nonidet P-40 (200 µL of 10%) was added, and the mixture was 
centrifuged at 16,100 g for 20 min. The supernatant was removed and retained as 
Fraction “C”. Additional enzyme was obtained from the pelleted fractions, solubilized by 
the addition of 1.5 mL of buffer D (0.1 M Tris acetate, pH 7.5, containing 10% (v/v) 
glycerol, 0.2% mercaptoethanol, and 0.1% (w/v) sodium dodecyl sulfate) to the 
precipitate. The precipitate was dispersed by vigorous trituration followed by the addition 
of 200 µL of 10% Nonidet P-40. The solution was centrifuged as above, and the 
supernatant was saved. This procedure was repeated once more to yield a third 
solubilized fraction. The solubilized supernatant fractions were combined and retained as 
Fraction “D”. All fractions were stored at -20 ºC.  
STEP 3: IL-12B ENRICHMENT FROM MEDIA BY NI-NTA CHROMATOGRAPHY. The 
protein IL-12b is generated as a C-terminal His6 tagged protein and purified by affinity 
chromatography with Ni-NTA resin following the manufacturer‟s instructions with 10% 
glycerol in all buffers. Ni-NTA resin (250 µL) was added to the concentrated media and 
allowed to bind at 4 ºC for 2 h on an orbitron rotational mixer, then centrifuged at 1,300 g 
to pellet the resin. The supernatant was removed and the resin was washed thrice with 1.5 
mL of Wash buffer II (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 10% 
glycerol, pH 8.0). IL-12b protein was eluted with 250 µL of Elution buffer II (50 mM 
NaH2PO4, 300 mM NaCl, 250 mM imidazole, 15% glycerol, pH 8.0).  
STEP 4: SDS-PAGE AND WESTERN BLOT ANALYSIS. To assess IL-12b production, 15 
µL samples of concentrated media, flow-through, wash, and elution fractions were 
removed, diluted 2X with SDS sample loading dye and boiled for 5 min at 100 ºC. SDS-
Page and Western blot were carried out according to methods detailed earlier in this 
chapter. Western blot employed anti-IL-12b or anti-His (primary) and anti-mouse 
(secondary) antibodies to detect full-length IL-12b protein. 
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To assess TMTC2 expression, 15 µL samples of fractions C and D from each time 
point (0-96 h) were removed and diluted 2X with SDS sample loading dye. SDS-Page 
and Western Blot were carried out according to methods detailed earlier in this chapter. 
Western Blot employed anti-FLAG (primary) and anti-mouse (secondary) antibodies to 
detect full-length TMTC2 protein. 
 
5.2.13 S. FRUGIPERDA SF21 TMTC2, TMTC3 AND TMTC2/TMTC3 GENE EXPRESSION 
STEP 1: GROWTH OF SF21 CELLS. S. frugiperda SF21 cells were grown at 27 ºC in 
SF-900 II SFM, with no supplements. SF21 cells, 25 mL at 1 × 10
6
 cells per mL were 
transferred into 40 150 mm dishes and allowed to grow overnight at 27 ºC in a 
humidified environment. The following day, the cells were determined to be confluent as 
assessed by visual examination of cultures using light microscopy. Ten dishes were 
infected with each of the following recombinant baculovirus P2 stocks, TMTC2, TMTC3 
or TMTC2/TMTC3 generated in step 5.2.6, at M.O.I  >1 and harvested 48 to 60 h after 
infection.  Each experimental group consisted of 10 dishes, and 10 dishes were grown but 
remained uninfected as negative controls.   
STEP 2: CRUDE EXTRACT PREPARATION. At the time of harvesting, cells were 
scraped from plates using a sterile scraper and transferred into 50 mL sterile conical 
tubes. The cells were centrifuged at 2,000 g for 10 min, washed once with 0.9% NaCl and 
immediately frozen at -80 ºC until further manipulation.  A sample of the media was 
frozen at -80 ºC and retained for gel electrophoresis.   
STEP 3: TMTC2/TMTC3 PROTEIN ENRICHMENT. The protein TMTC2 is produced 
as a C-terminal FLAG epitope tagged protein, and the protein TMTC3 is expressed as a 
C-terminal myc epitope tagged protein. Screening for protein expression was carried out 
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by protein enrichment following the method of Schutzbach.
124
 All procedures were 
carried out at 4 ºC or on ice. The pellet was thawed, resuspended in 750 µL buffer B, and 
the cells were sonically ruptured at a power setting of 4.5 for 3 × 30 s with 1 min 
intervals to allow cooling. A particulate fraction obtained by centrifugation at 16,100 g 
for 20 min, and was washed twice with 2 mL of buffer B and resuspended in 375 µL of 
the same buffer. The suspension was diluted with 1.3 mL of Buffer C. Nonidet P-40 (200 
µL of a 10% solution) was added, and the mixture was centrifuged at 16,100 g for 20 
min. The supernatant was removed and retained as Fraction “C”. Additional enzyme was 
obtained from the pelleted fractions, solubilized by the addition of 1.5 mL of Buffer D to 
the precipitate. The precipitate was dispersed by vigorous trituration followed by the 
addition of 200 µL of 10% Nonidet P-40. The solution was centrifuged as above, and the 
supernatant was saved. This procedure was repeated again to yield a third solubilized 
fraction. The solubilized supernatant fractions were combined and retained as Fraction 
“D”. All fractions were stored at -20 ºC.  
STEP 4: SDS-PAGE AND WESTERN BLOT ANALYSIS. Aliquots (15 µL) samples of: 
fractions C and D, as well as the media samples were removed, diluted 2X with SDS 
sample loading dye and loaded onto gels without boiling. SDS-PAGE and Western Blot 
were carried out according to methods detailed in previous sections. Western Blot 
employed anti-FLAG (primary), anti-myc (primary) and anti-mouse (secondary) 
antibodies to detect full-length TMTC2 and TMTC3 proteins. 
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5.2.14 S. FRUGIPERDA SF21 TMTC2 AND TMTC3 PROTEIN PURIFICATION VIA 
MICROSOMAL ENRICHMENT 
Briefly, Sf21 cells were grown in Sf-900 II medium in suspension (4-5 × 10
6
 
cells/mL) and 1000 mL of these cultures were co-infected with baculovirus for the 
production of TMTC2, TMTC3 or TMTC2/3 for 72 h.  
MICROSOMAL PREPARATION METHOD I. Microsomes were prepared according to 
the method of Tomazin.
364
 The cell pellet was suspended in microsome lysis buffer I (10 
mM Tris acetate (pH 7.5), 1.5 mM magnesium acetate, 1 mM DTT and protease inhibitor 
cocktail (1 mM PMSF, 2 µg/mL aprotinin, 2 µg/mL leupeptin, 1 µg/mL pepstatin, 1 
µg/mL chymostatin)) for 10 min on ice, and the cells were disrupted using a Dounce 
homogenizer. Microsomal lysis buffer II (40 mM Tris acetate (pH 7.5), 250 mM sucrose, 
25 mM potassium acetate, 3.5 mM magnesium acetate, 0.5 mM calcium acetate) was 
added and nuclei were removed by centrifugation at 800 g for 10 min. Mitochondria were 
removed by centrifugation at 10,000 g for 10 min, then the crude microsomes were 
pelleted by centrifugation at 100,000 g for 60 min. The membrane pellets were 
resuspended in microsome buffer III (50 mM Tris acetate (pH 7.5), 250 mM sucrose, 25 
mM potassium acetate, 5 mM magnesium acetate, 0.5 mM calcium acetate, 1 mM DTT 
and protease inhibitor cocktail) and further purified by centrifugation through a 1.1 M 
sucrose cushion at 150,000 g for 5 h. The supernatant was discarded and membrane 
pellets were resuspended in microsome buffer III at 4-5 mg of membrane protein/mL, 
flash frozen in liquid N2 and stored at -80 ºC. The protein content of these microsomal 
preparations was determined by the Bradford method with BSA as the standard. 
272
 
MICROSOMAL PREPARATION METHOD II. Microsomes were also prepared by the 
method of Jennewein et al.
365
 The infected cells were harvested by centrifugation (700 g 
for 10 min at room temperature), and washed with 0.9% NaCl. The washed cell pellet 
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was then resuspended in 5 mL of 50 mM Hepes buffer (pH 7.5) containing 0.5 mM 
EDTA, 0.1 mM DTT, 10% (v/v) glycerol, and the cells were lysed by sonication, using 
the microtip probe. Cell debris was removed by centrifugation (10,000 g for 10 min at 
4°C), and the resulting supernatant was then centrifuged at 105,000 g for 1 h at 4°C to 
provide the microsomal enzyme preparation, which was either assayed immediately or 
frozen for later use in liquid N2 and stored at -80°C. The protein content of these 
microsomal preparations was determined by the Bradford method with BSA as 
standard.
272
 
MICROSOMAL PREPARATION METHOD III. Microsomes were also prepared by the 
method of Chaney et al.
366
 The infected cells were harvested by centrifugation (700 g for 
10 min at room temperature), and washed with 0.9% NaCl. Crude membranes were 
prepared from washed cells resuspended in 20 mM MES buffer (pH 6.0) containing 1 
mM CaCl2 and a mixture of protease inhibitors: soybean trypsin inhibitor (200 µg/mL), 
benzamidine (5 mM), and paramercurisulfonylfluoride (PMSF; 4 mM). After swelling 15 
min on ice, the cells were Dounce homogenized (75-150 strokes), centrifuged at 530 g for 
10 min at 4 °C, and the supernatant was spun at 100,000 g for 1 h at 4 °C. The membrane 
pellet was resuspended in 100 µL 1% Triton X-100 containing 20 mM MES (pH 6.0) 
with 4 mM PMSF to provide the microsomal enzyme preparation, which was either 
assayed immediately or frozen for later use in liquid N2 and stored at -80°C. The protein 
content of these microsomal preparations was determined by the Bradford method with 
BSA as the standard.
272
. 
SDS-PAGE AND WESTERN BLOT ANALYSIS. Samples (15 µl) of microsome fractions 
were aliquotted, diluted 2X with SDS sample loading dye and loaded onto gels without 
boiling. SDS-Page and Western blot were carried out according to methods detailed 
earlier in this chapter. Western blot employed anti-FLAG (primary) antibodies to detect 
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full-length TMTC2 protein and anti-myc (primary) antibodies to detect full-length 
TMTC3 protein. Cells expressing both genes were subjected to two Western blots (anti-
FLAG (primary) TMTC2 and anti-myc (primary) TMTC3) in order to ensure expression 
of both genes. Anti-mouse was the secondary antibody used in all cases. 
 
5.2.15 SGP GENE AMPLIFICATION 
5.2.15.1 Cloning for sGP Expression Constructs 
Primers were designed to incorporate the chosen restriction enzymes into the 
sequence, as indicated by the italicized underlined text within primer sequences. For 
expression in E. coli, using the pET28b vector, NdeI and HindIII were selected to yield 
an N-terminal-His6 protein tag on the protein (5′ primer 5′-ACGCACGCATATGGGCGT-
TACAGGAATATTGCAGTTACCTCG-3′, 3′ primer 5′-ACGAAGCTTAGATCGGACA-
CTGCAGCT-TCCCTTCCTTG-3′). Primers were also designed for sGP expression in 
mammalian cells as well. This was done by removing the stop codon from the gene 
sequence, using BamHI and XbaI as the restriction enzymes (5′ primer 5′-CAGGAT-
CCATGGGCGTTACAGGAATATTGCAGTTACCTCG-3′, 3′ primer 5′-CATCTAGAT-
AGATGCGACACTGCAGCTTCCCTTCCTTG-3′). This construct would yield a C-
terminal His6 tagged protein with the myc epitope when ligated into the pEF6/myc-His 
vector. The PCR reactions consisted of the following: 64 µL of sterile water, 10 µL of 
10X KOD buffer, 10 µL of a 2 mM dNTP solution, 6 µL of a 25 mM MgSO4 solution, 3 
µL of each primer (5′ and 3′) at 10 µM, 2 µL of template DNA, and 2 µL of KOD 
polymerase, for a 100 µL total reaction volume in an 0.5 mL thin walled PCR tube.  
The PCR reaction was then carried out using an Eppendorf thermocycler with the 
lid temperature set at 105 ºC and an initial denaturing step of 2 min at 95 ºC.  The 
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program consisted of a 20 s denaturing step at 95 ºC, an annealing step at 61 ºC  for 10 s, 
and an elongation step for 20 s (20 s/kb) at 70 ºC. This was repeated 30 times, with each 
cycle ending in a 10 min extension at 70 ºC. The temperature was reduced to 4 ºC until 
the product was removed from the thermocycler.  PCR products were stored at 4 ºC until 
purified. 
PCR products were purified using 0.8% TAE-agarose gel electrophoresis 
followed by use of the Qiagen Gel extraction kit as described previously, and ligated into 
StuI digested pCR-Blunt. The reactions were incubated at 25 ºC (room temperature) for 
30 to 60 min, and 5 µL of the ligation mixture was used for the transformation. Colonies 
appearing on plates after overnight incubation were used to inoculate 2-3 mL cultures in 
LB media supplemented with 50 µg/mL kanamycin. Plasmids were extracted from cells 
by alkaline lysis, digested with EcoRI, and analyzed as described previously.
277
 Samples 
that appeared to contain both vector and insert were cultured again, and plasmids were 
isolated using the Qiagen miniprep kit. The isolated plasmids were quantified, and 
samples of 500 ng with A260/280 > 1.8 and A260/230 > 1.8 were submitted for DNA 
sequencing using the M13 forward and reverse primers supplied by the University of 
Texas ICMB Core facility for forward and reverse sequencing, respectively.  
Plasmids containing PCR products with correct sequences were then digested 
with the appropriate enzymes (NdeI, HindIII for pET28b, and BamHI, XbaI for 
pEF6/myc-His) and the digested inserts were gel purified as previously described. sGP 
genes were ligated into the pET28b and pEF6/myc-His vectors. Transformations 
containing sGP-pEF6/myc-His plasmid were plated directly on LB-agar plates 
supplemented with 100 µg/mL ampicillin, while sGP-pET28b transformants were 
allowed to recover for 30-45 min before selection on LB-agar plates supplemented with 
50 µg/mL kanamycin. Colonies growing on these plates were then used to inoculate 5 mL 
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cultures grown in LB media with the appropriate selective antibiotic overnight at 37 ºC, 
and plasmids were isolated using the alkaline lysis procedure above. After isolation, 15 
µL of the plasmid solution was digested with NdeI and HindIII in the case of pET 
constructs, or BamHI and XbaI in the case of pEF constructs. All digestion reactions were 
incubated and electrophoresed following procedures detailed previously. Colonies 
containing plasmids observed to have the insert and plasmid of the correct size were then 
grown overnight in 5 mL cultures grown in LB-Kan 50 broth (pET) or LB-Amp100 broth 
(pEF) at 37 ºC with 200 RPM shaking, and the sGP expression plasmids were isolated 
using the Qiagen miniprep kit following the manufacturer‟s protocols.  
 
5.2.16 SGP PROTEIN EXPRESSION IN E. COLI 
STEP 1: GROWTH OF E. COLI CELLS. sGP-pET28b plasmid was transformed into 
chemically competent BL-21(DE3) Rosetta II cells using heat shock following the 
protocols previously described. Colonies growing on transformation plates were then 
used to inoculate two 25 mL cultures grown in LB-Kan 50-Cam 35 media overnight at 30 
or 37 ºC with 200 RPM shaking. After overnight incubation, 6 L of fresh LB-Kan50-
Cam35 were inoculated using 6 mL overnight culture per L broth. Cultures were grown 
at 30 ºC with 250 RPM shaking until the culture OD600 reached 0.6, at which point, gene 
expression was induced with 1 mL of 1 M IPTG, for a final concentration of 1 mM. The 
temperature was reduced to 25 ºC and the cultures were incubated for an additional 16-20 
h. At the end of the incubation, the cultures were harvested by centrifugation at 4,000 g 
for 20 min at 4 ºC, which yielded cell pellets of approximately 45 g. 
STEP 2: CRUDE EXTRACT PREPARATION.  Cells were resuspended in a 5X cell 
weight volume of sGP buffer (50 mM Tris buffer, pH 7 at 25 ºC, 20% v/v glycerol). 
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Lysozyme (1 mg/mL) was added to the mixture and the cells were incubated on ice for 1 
h, stirring every 15 min to disperse clumps. The cells were disrupted by sonication using 
pulses of 20 s (18 × 20s) followed by cooling periods of 40 s, for an average total pulse 
time of 6 min. Lysed cells were then centrifuged for 20 min at 4 ºC and 10,000 g.  
STEP 3: AMMONIUM SULFATE PRECIPITATION. Supernatant was decanted and 
subjected to ammonium sulfate precipitation by the addition of 64 g/L of the salt (40%), 
while the cell lysate stirred on ice for 1 h. The precipitate, which contained sGP, was 
collected by centrifugation for 20 min at 4 ºC, 10,000 g. The pellet was then resuspended 
in 40 mL of sGP buffer and dialyzed against 3 L of the same buffer at 4 ºC, exchanging 
the buffer every hour. After dialysis, the lysate was centrifuged to remove any insoluble 
protein for 20 min at 4 ºC, 10,000 g. The supernatant was retained and resulting pellets 
resuspended in 40 mL of sGP buffer.  
STEP 3: DEAE COLUMN PURIFICATION. Centrifugation was repeated and the 
supernatants from both centrifugation steps was pooled and loaded onto a 2.5  25 cm 
DEAE column equilibrated with 500 mL of sGP buffer using a peristaltic pump with the 
flow rate set at 1.5 mL/min. Fractions (22.5 mL) were collected, beginning as the sample 
was introduced to the column. After the sample was fully loaded, the column was washed 
with 50-100 mL of sGP buffer and a then linear gradient of sGP buffer (1 L) and sGP 
buffer + 1 M NaCl (1 L). The column was allowed to run overnight (for 12 h). All 
fractions were screened for the presence of protein using Bradford‟s reagent, following 
the manufacturer‟s protocols for protein microassay. Briefly, Bradford concentrate 
(BioRad) was diluted 5X with ddH2O. Aliquots of this solution (200 µL) were dispensed 
into each well of a 96 well plate. Samples (10 µL) of each fraction were added to 
individual wells of the plate and the solution was allowed to develop at room temperature 
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for 1 h, although fractions containing protein were clearly visible after only 2-3 min of 
development. 
 STEP 4: SDS-PAGE AND WESTERN BLOT.  Fractions testing positive for the 
presence of protein (including the flow-through fractions) were screened by SDS-PAGE 
and Western Blot for the presence of sGP. A sample (50 µL) of each positive fraction 
was diluted with an equal volume of 2X SDS buffer with 5 mM βME and boiled for 5 
min at 100 ºC. One gel was subjected to Coomassie staining to visualize protein bands, 
and the other was subjected to Western blotting to verify the presence of our protein of 
interest, following the protocols listed previously. Mouse anti-sGP was the primary 
antibody used for Western Blot, and the secondary antibody was anti-mouse. In general, 
our protein of interest was found in the first 10-15 flow-through fractions, and could be 
clearly visualized on both the Coomassie stain and Western Blot.  
 
5.2.17 SGP PROTEIN EXPRESSION IN HEK-293T (MAMMALIAN TISSUE CULTURE) 
CELLS 
5.2.17.1 Preparation of HEK-293T (Mammalian Tissue Culture) Cells 
sGP-pEF6/myc-His plasmid was transformed into HEK-293T cells following 
standard mammalian protocols. Briefly, low passage HEK-293T cells were grown using 
D-MEMs at 37 ºC, under a 5% CO2 atmosphere until they reached approximately 70% 
confluence in a T-75 sterile culture flask. The media was removed and cells washed with 
5 mL phosphate buffered saline (PBS). Trypsin (0.25%)-EDTA (1 mM) (2 mL), was 
introduced to the flask and incubated at 37 ºC under 5% CO2 for 5 min. After incubation, 
the mixture was triturated to mix cells and the flasks were rinsed with this mixture to 
remove any cells yet adhering to the flask walls. Aliquots (200 µL) of this mixture were 
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transferred into each of 10 × 60 mm culture dishes. Fresh D-MEMs, (1.8 mL) media was 
added to the dishes and cells were incubated overnight at 37 ºC, under 5% CO2 to allow 
the cells to recover and adhere to the plate.  
 
5.2.17.2 sGP Plasmid DNA HEK-293T Transfection and Selection 
Plasmids were prepared using the Qiagen miniprep kit, and purity was examined 
using a Nanodrop apparatus. Only high concentration (> 200 ng/µL) plasmid preparations 
with A260/280 > 1.8 and A260/230 > 1.8 were used for transfections. Serum free D-MEMt 
was used to dilute 8 µg of plasmid DNA to a final volume of 500 µL and mixed gently. 
Lipofectamine (2 mg/mL, 20 µL) was diluted with 480 µL of serum free D-MEMt and 
incubated at room temperature for 5 min. The transfection mixtures for each of 10 plates 
were prepared as shown in the following table. DNA concentrations used were 8 µg per 
transfection, and DNA volumes added to the transfection to achieve a concentration of 8 
µg were calculated using the following formula: 
 
 8000 ng/ plasmid DNA concentration ng/µL = required volume of DNA (µL)  
 
Four different plasmids were used for these transfections, and a DNA control was 
prepared for each plasmid transfection. Sample transfections are shown in table 5.3. After 
incubation, the DNA and lipofectamine solutions were mixed together and incubated at 
room temperature for 20 min. While the transfection mixture was incubating, media was 
removed from culture dishes and cells were gently washed with PBS buffer.  The 
transfection mixture was added to each dish and dishes were rocked gently to ensure even 
coverage. 
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5.3 Sample Transfection Reactions for HEK-293T/pEFmycHIS-sGP  
Plate Lipofectamine Media DNA Media 
#1 Negative Control 0 µL 500 µL 0 µL 500 µL 
#2 Lipofectamine Control 20 µL 480 µL 0 µL 500 µL 
#3 Transfection    # 1 20 µL 480 µL 20 µL 480 µL 
#4 DNA control   # 1 0 µL 500 µL 20 µL 480 µL 
#5 Transfection    # 2 20 µL 480 µL 20 µL 480 µL 
#6 DNA control   # 2 0 µL 500 µL 20 µL 480 µL 
#7 Transfection    # 3 20 µL 480 µL 23 µL 477 µL 
#8 DNA control   # 3 0 µL 500 µL 23 µL 477 µL 
#9 Transfection    # 4 20 µL 480 µL 28 µL 472 µL 
#10 DNA control # 4 0 µL 500 µL 28 µL 472 µL 
 
The dishes were incubated at 37 ºC under 5% CO2 overnight. The next day, cells 
were washed with PBS, trypsinized using 0.5 mL trypsin-EDTA as above and each 
sample was transferred into a new 25 cm
2
 culture flask, for a total of 10 flasks. Fresh D-
MEMs, 4.5 mL, was added to each flask and the cells were incubated for 24 h at 37 ºC 
under 5% CO2. 
The following day, media was removed and 5 mL of fresh media supplemented 
with 10 µg/mL blasticidin (bsd) was added to each 25 cm
2
 flask, and the cells were 
incubated at 37 ºC under 5% CO2. After 2-3 days, cells in the controls (DNA only, LF 
only, or no treatment) were found to have died. Transfection reactions also experienced 
low levels of cellular death, as noted by a few floating cells in the media. However, this 
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cell death was less than 10% of the cells in the transfection mixture as estimated by 
remaining confluence in the culture flasks. For the most part, transfected cells were 
adherent and healthy in the presence of 10 µg/mL bsd.  
 
5.2.17.3 sGP Expression in HEK-293T   
After 72 h, media was removed from the transfected cells and the cells were 
washed with PBS. Trypsin-EDTA (0.5 mL) was introduced to each culture flask and the 
flasks were incubated for 5 min at 37 ºC under 5% CO2. After incubation, cell 
suspensions were triturated to disperse clumps and to remove any remaining adherent 
cells from the flasks. Cell suspensions were transferred into 4 75 cm
2
 flasks and 14.5 mL 
of D-MEMs was added. After overnight incubation at 37 ºC under 5% CO2, media was 
replaced with 15 mL of fresh D-MEM supplemented with 10 µg/mL bsd. Cells were 
grown at 37 ºC under 5% CO2 in D-MEM supplemented with 10 µg/mL bsd until they 
reached 70% confluence. At this point, cells were again washed with PBS and trypsinized 
for transfer to 8 185 cm
2
 flasks. Cells were allowed to grow in 25 mL of D-MEMs 
supplemented with 10 µg/mL bsd at 37 ºC under 5% CO2. The media was changed every 
72-96 h and retained at 4 ºC until 500 mL was collected.  
 
5.2.17.4 N-Aza-tetraacetyl Mannose Labeling of sGP in HEK-293T   
5.2.17.5 TRIAL I 
Cells expressing sGP were grown under standard conditions, 37 ºC, 5% CO2, in 
D-MEMs . To prepare cells for ManNaz feeding,  media was removed and the cells were 
washed with PBS. Trypsin-EDTA (1 mL) was introduced to each culture flask and the 
flasks were incubated for 5 min at 37 ºC under 5% CO2. After incubation, cell 
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suspensions were triturated to disperse clumps and remove any remaining adherent cells 
from the flasks. Cell suspensions were split 1:2 into 8 75 cm
2
 flasks and 14.5 mL of D-
MEMs was added. After overnight incubation at 37 ºC under 5% CO2, media was 
replaced with 15 mL of fresh D-MEMs supplemented with 10 µg/mL bsd. Cells were 
grown at 37 ºC with 5% CO2 in D-MEMs supplemented with 10 µg/mL bsd until they 
reached 70% confluence. At this point, cells were again washed with PBS and 15 mL of 
D-MEMm was added to culture flasks. Cells were allowed to grow in the ManNaz (30 
µM) labeling media supplemented with 10 µg/mL bsd at 37 ºC with 5% CO2. The media 
was changed every 48-72 h and retained at 4 ºC.  
5.2.17.6 TRIAL II 
Cells expressing sGP were grown under standard conditions, 37 ºC, 5% CO2, in 
D-MEMs. To prepare cells for ManNaz feeding, media was removed and the cells were 
washed with PBS. Trypsin-EDTA (1 mL) was introduced to each culture flask and the 
flasks were incubated for 5 min at 37 ºC under 5% CO2. After incubation, cell 
suspensions were triturated to disperse clumps and remove any remaining adherent cells 
from the flasks. Cell suspensions were split 1:2 into 8 75 cm
2
 flasks and 14.5 mL of D-
MEMs was added. After overnight incubation at 37 ºC with 5% CO2, media was replaced 
with 15 mL of fresh D-MEMs supplemented with 10 µg/mL bsd. Cells were grown at 37 
ºC under 5% CO2 in D-MEMs supplemented with 10 µg/mL bsd until they reached 70% 
confluence. At this point, cells were again washed with PBS and 7.5 mL D-MEMm 
ManNaz feeding media was added to culture flasks. The remaining volume used in 
culture flasks was standard D-MEMs. Cells were allowed to grow in D-MEMs/D-MEMm 
media (15 µM ManNaz) supplemented with 10 µg/mL bsd at 37 ºC under 5% CO2. The 
media was changed every 48-72 h and retained at 4 ºC.  
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5.2.18 SGP PROTEIN PURIFICATION FROM HEK-293T MEDIA 
5.2.18.1 METHOD I 
STEP 1: CONCANAVALIN A LECTIN CHROMATOGRAPHY. The following purification 
method is adapted from Barrientos et al. and Falzarno et al.
230,362
 The yellow media 
samples collected from 2-3 72-96 h harvests were pooled and concentrated using an 
Amicon stirred cell unit at 4 ºC under nitrogen to an average volume of 2-5 mL. The 
concentrate was introduced to 1 mL of Concanavalin A beads and the slurry was 
incubated overnight at 4 ºC on a rotational mixer. The slurry was loaded onto a 1  10 cm 
column and allowed to flow through by gravity. The packed beads were washed with 10 
column volumes of Z-Con Wash buffer (20 mM Tris•HCl, 500 mM 
NaCl, pH 7.4) and the proteins were eluted with 2 CV of Z-Con Elution buffer (20 mM 
Tris•HCl, 500 mM, NaCl, pH 7.4 0.75 mM methyl-α-D-glucopyranoside). All fractions 
were screened for the presence of protein using Bradford‟s reagent, following the 
manufacturer‟s protocols for protein microassay. 
STEP 2: SDS-PAGE AND WESTERN BLOT.  Fractions testing positive for the 
presence of protein (including the flow-through fractions) were screened by SDS-PAGE 
and Western Blot for the presence of sGP. Samples (20 µL) of each positive fraction 
were diluted with an equal volume of 2X SDS buffer with 5 mM βME and boiled for 5 
min at 100 ºC. One gel was subjected to Coomassie staining to visualize protein bands, 
and the other was subjected to Western blotting to verify the presence of our protein of 
interest, following the protocols listed previously. Mouse anti-sGP was the primary 
antibody used for Western Blot, and the secondary antibody was anti-mouse. In general, 
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our protein of interest was found in the wash fractions, and could be clearly visualized on 
both the Coomassie stain and Western Blot. 
5.2.18.2 METHOD II 
STEP 2: DEAE COLUMN CHROMATOGRAPHY.  The yellow media samples collected 
from three 72-96 h harvests were pooled and concentrated using an Amicon stirred cell 
unit at 4 ºC under nitrogen to an average volume of 5-10 mL. The concentrate was loaded 
onto a 2.5 × 25 cm DEAE column equilibrated with 500 mL of 100 mM MES (pH 5.5 at 
25 ºC) buffer using a peristaltic pump with the flow rate set at 1.5 mL/min. Fractions 
(22.5 mL) were collected, beginning as the sample was introduced to the column. After 
the sample was fully loaded and loaded and washed with 250 mL of 100 mM MES (pH 
5.5 at 25 ºC) buffer, the column was washed with 100 mM MES (pH 5.5 at 25 ºC) buffer 
+ 1 M NaCl for 4 h. All fractions were screened for the presence of protein using 
Bradford‟s reagent, following the manufacturer‟s protocols for protein microassay. 
STEP 2: SDS-PAGE AND WESTERN BLOT.  Fractions testing positive for the 
presence of protein (including the flow-through fractions) were screened by SDS-PAGE 
and Western Blot for the presence of sGP. Samples (50 µL) of each positive fraction 
were diluted with an equal volume of 2X SDS buffer with 5 mM βME and boiled for 5 
min at 100 ºC. One gel was subjected to Coomassie staining to visualize protein bands, 
and the other was subjected to Western blotting to verify the presence of our protein of 
interest, following the protocols listed previously. Mouse anti-sGP was the primary 
antibody used for Western Blot, and the secondary antibody was anti-mouse. In general, 
our protein of interest was found in the first 2-4 flow-through fractions, and could be 
clearly visualized on both the Coomassie stain and Western Blot. 
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STEP 3: FPLC SEPHADEX 200 COLUMN CHROMATOGRAPHY.  The fractions identified 
as containing sGP from the previous step were further purified by Fast-Protein Liquid 
Chromatography (FPLC). All FPLC separations were performed using a Sephadex 200 
column with 500 µL of sample for each injection. The sample was eluted using an 
isocratic wash with 100 mM MES buffer, pH 5.5 as solvent A over two column volumes, 
or 46 mL. The flow rate was 0.5 mL/min and the detector was set at 280 nm.  The sGP 
protein eluted in a range from approximately 12 to 16 mL. Aliquots of each fraction of 
interest were taken for analysis, while the fractions themselves were immediately flash 
frozen in liquid nitrogen and stored at -80 ºC.  
STEP 4: SDS-PAGE AND WESTERN BLOT.  FPLC fractions containing protein, as 
indicated by A280, were screened by SDS-PAGE for the presence of sGP. Samples (50 
µL) of each positive fraction were diluted with an equal volume of 2X SDS buffer with 5 
mM βME and boiled for 5 min at 100 ºC. One gel was subjected to Coomassie staining to 
visualize protein bands, and the other was subjected to Western blotting to verify the 
presence of our protein of interest, following the protocols listed previously. Mouse anti-
sGP was the primary antibody used for Western blot, and the secondary antibody was 
anti-mouse. In general, our protein of interest eluted in the first or second protein peak 
ten flow-through fractions under these gradient conditions, and could be clearly 
visualized on both the Coomassie stain and Western blot.  
 
5.2.18.3 sGP Protein In-Gel and Solution Digestion 
Bands observed to contain our protein by Western blot were excised from the 
corresponding Coomassie stained gel and prepared for MS analysis following the 
protocols described previously with the following additions and adjustments. Gel slices 
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were incubated in 100 µL of fresh 10 mM DTT for 2 h at 65 ºC. Samples were also 
incubated in 100 µL of fresh 50 mM iodoacetamide solution for 2 h at 65 ºC.  
A solution of sGP protein (approximately 500 pmol) was dialyzed against 50 mM 
Tris•HCl buffer (pH 8.0) containing 8 M urea. dithiothreitol (DTT) was added to a final 
concentration of 10 mM, and the sample was incubated for 4 h at room temperature. The 
sample was then treated with 25 mM iodoacetamide for 30 min at room temperature. The 
reaction was quenched with excess DTT, and the sample was immediately dialyzed 
against 25 mM Tris•HCl buffer (pH 8.0). This generates reduced carboxymethylated 
[RCM]sGP. 
To prepare tryptic peptides for MS analysis, 500 pmol of [RCM]sGP in 25 mM 
Tris•HCl (pH 8.0) was treated at 37 °C with trypsin (enzyme to substrate ratio of 1:100 
wt/wt). The digestion was allowed to proceed overnight and then stopped by freezing the 
sample at -20 ºC. Both samples were submitted for MS analysis using MALDI and ESI 
ionization methods. 
 
5.2.18.4 HPLC Purification of sGP Trypsin Digested Peptides 
Solution and in-gel digests of sGP protein were both subjected to HPLC for 
additional purification of the target peptide VNPEIDTTIGEWAFWETK(K). After 
overnight incubation, the samples were filtered through a YM-10 centrifugal filter at 
14,000 g for 20 min at room temperature. The peptide was purified from each sample 
using HPLC, equipped with a reverse phase C-18 column. Eluent A was water, and 
eluent B was 90% acetonitrile, with 0.1 % TFA. The gradient was linear from 100% 
eluent A with increasing eluent B at 1%/min, and samples were monitored at 280 nm 
(tryptophan). Peaks with absorbance at 280 nm were collected and lyophilized to 
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concentrate fractions. The concentrated fractions were submitted for MALDI-MS 
analysis. 
 
5.2.19 MICROSOMAL IN VITRO C-MANNOSYLATION ASSAYS 
The peptides N-AC-KPPQFAWAQWFE-NH2 and N-AC-K
biotin
PPQFAWAQWF-
NH2 designed based on the RNAse2 sequence, with Thr-6 replaced by Ala to prevent 
possible O-glycosylation were selected as the mannosyl acceptor substrates.
126
 The 
peptide was incubated in the presence of microsomes from rat liver, yeast and insect 
cells, followed by HPLC purification using a reverse phase C-18 column 
(acetonitrile/TFA gradient). To ease purification, biotin labeled peptides were used. 
Briefly, 400 µg peptide (0.9 mM), 15 µL of microsomal protein (125 µg/µL), 0.2% v/v 
Triton X-100 and protease inhibitors (2 µg/mL benzamidine, 5 µg/mL pepstatin A, 5 
µg/mL leupeptin, 2 mM EDTA) in HKA buffer (20 mM Hepes pH 7.2, 110 mM 
potassium acetate) in a final volume of 240 µL. Assays were incubated overnight at 37 
ºC. 
PURIFICATION OF NON-LABELED PEPTIDE. After overnight incubation, the samples 
were filtered through a YM-10 centrifugal filter at 14,000 g for 20 min at room 
temperature. The peptide was purified from each sample using HPLC, equipped with a 
reverse phase C-18 column. Eluent A was water, and eluent B was 90% acetonitrile, with 
0.1 % TFA. The gradient was linear, increasing eluent B at 1%/min, and samples were 
monitored at 280 (tryptophan abs). Fractions displaying absorption at 280 nm were 
collected and concentrated by lyophilization. The concentrated fractions were submitted 
for MALDI-MS analysis. 
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PURIFICATION OF BIOTIN LABELED PEPTIDE.  After overnight incubation, 50 µL of 
streptavidin bead suspension was added to each sample. Slurry was mixed with gentle 
rocking for 1 h at room temperature and centrifuged at 6,000 g to pellet the beads. 
Supernatant was removed by aspiration and retained. The beads were washed in HKA 
buffer twice. Briefly, beads were resuspended in 200 µL of HKA buffer and mixed well, 
then centrifuged to pellet the beads. The HKA wash was removed and this step was 
repeated for a total of three washes. The peptide was removed from beads by gently 
agitating the beads at room temperature for 5-10 min in a solution of 90% acetonitrile and 
0.5% TFA (pH ~2). The beads were again pelleted by centrifugation and the supernatant 
containing peptide was transferred to a fresh eppendorf tube and concentrated to a 
volume of 25 µL. These samples were submitted for MALDI-MS analysis. 
 
5.2.20 SILENCING PLASMID HEK-293T TRANSFECTION AND SELECTION 
Plasmids were diluted with TE buffer to a concentration of 1 µg/mL. Serum free 
D-MEMt was used to dilute 1 µg of plasmid DNA to a final volume of 500 µL and mixed 
gently. Lipofectamine (2 mg/mL, 20 µL) was diluted with 480 µL of serum free D-MEMt 
and incubated at room temperature for 5 min. The transfection mixtures for each of the 
ten plates were prepared as shown in the following table. Four different plasmids were 
used for these transfections, and a DNA control was prepared for each plasmid 
transfection. The sample transfections are shown in table 5.4. 
After incubation, the DNA and lipofectamine solutions were mixed together and 
incubated at room temperature for 20 min. While the transfection mixture was incubating, 
media was removed from culture dishes and cells were gently washed with PBS buffer.   
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5.4 Sample Transfection Reactions for HEK-293T/Hush Vectors  
Plate Lipofectamine Media DNA Media 
#1 Transfection    tmtc2 #1 20 µL 480 µL 1 µL 500 µL 
#1a DNA control tmtc2 #1 0 µL 500 µL 1 µL 500 µL 
#2 Transfection    tmtc2 #2 20 µL 480 µL 1 µL 500 µL 
#2a DNA control tmtc2 #2 0 µL 500 µL 1 µL 500 µL 
#3 Transfection    tmtc2 #3 20 µL 480 µL 1 µL 500 µL 
#3a DNA control tmtc2 #3 0 µL 500 µL 1 µL 500 µL 
#4 Transfection    tmtc2 #4 20 µL 480 µL 1 µL 500 µL 
#4a DNA control tmtc2 #4 0 µL 500 µL 1 µL 500 µL 
#5 Transfection    tmtc3 #1 20 µL 480 µL 1 µL 500 µL 
#5a DNA control tmtc3 #1 0 µL 500 µL 1 µL 500 µL 
#6 Transfection    tmtc3 #2 20 µL 480 µL 1 µL 500 µL 
#6a DNA control tmtc3 #2 0 µL 500 µL 1 µL 500 µL 
#7 Transfection    tmtc3 #3 20 µL 480 µL 1 µL 500 µL 
#7a DNA control tmtc3 #3 0 µL 500 µL 1 µL 500 µL 
#8 Transfection    tmtc3 #4 20 µL 480 µL 1 µL 500 µL 
#8a DNA control tmtc3 #4 0 µL 500 µL 1 µL 500 µL 
#9 Transfection  sH control 1 20 µL 480 µL 1 µL 500 µL 
#9a Lipofectamine only 20 µL 500 µL 0 µL 500 µL 
#10 Transfection sH control 2 20 µL 480 µL 1 µL 500 µL 
#10a Control – no treatment 0 µL 500 µL 0 µL 500 µL 
 
The transfection mixture was added to each dish and dishes were rocked gently to 
ensure even coverage. The dishes were incubated at 37 ºC under 5% CO2 overnight. The 
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next day, cells were washed with PBS, trypsinized using 0.5 mL trypsin-EDTA as above 
and each transfection was transferred into a fresh 25 cm
2
 culture flask, for a total of 20 
flasks. Fresh D-MEMs, 4.5 mL, was added to each flask and the cells were incubated for 
24 h at 37 ºC under 5% CO2. 
The following day, 1 µg/mL puromycin (pur) was added to each 25 cm
2
 flask, and 
the cells were incubated at 37 ºC under 5% CO2. After 2-3 days, cells in the controls 
(DNA only (#a), LF only, or no treatment) were observed to have died. Transfection 
reactions (1-10) also experienced some cellular death, as noted by floating cells in the 
media. All samples were grown in D-MEMs supplemented with 1 µg/mL pur, and 
incubated at 37 ºC under 5% CO2.  Cells were monitored by light microscopy and trypan 
blue viability assays, and transferred into new flasks when necessary. 
 
5.2.21 POTENTIAL C-MANNOSYLTRANSFERASE TMTC2 AND TMTC3 SILENCING IN 
HEK-293T   
When cellular growth was observed in flasks, media was removed from 
transfected cells and the cells were washed with PBS. Trypsin-EDTA (0.5 mL) was 
introduced to each culture flask, and the flasks were incubated for 5 min at 37 ºC under 
5% CO2. After incubation, cell suspensions were triturated to disperse clumps and 
remove any remaining adherent cells from the flasks. Cell suspensions were transferred 
into 5 75 cm
2
 flasks and 14.5 mL of D-MEMs was added. After overnight incubation at 
37 ºC under 5% CO2, media was replaced with 15 mL of fresh D-MEMs supplemented 
with 1 µg/mL pur. Cells were grown at 37 ºC under 5% CO2 in D-MEMs supplemented 
with 1 µg/mL pur until cells reached 20-40% confluence. At this point, cells were again 
washed with PBS and trypsinized for transfer to 3 185 cm
2
 flasks. Cells were allowed to 
grow in 25 mL of D-MEMs supplemented with 1 µg/mL pur at 37 ºC with 5% CO2.  
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5.3 RESULTS AND DISCUSSION 
We have proposed that the TMTC2 and TMTC3 proteins are the H. sapiens C-
mannosyltransferases. To test this hypothesis a biological system with an endogenous C-
mannosylation pathway that did not recognize the WXXW motif was used for 
heterologous expression of the tmtc2 and tmtc3 genes. A gene encoding a C-
mannosylation targeted protein was coexpressed in the same host. The gene products 
were isolated and subjected to an assay to detect C-mannosylation. Previously, these 
genes were expressed in S. cerevisiae. However, difficulties were encountered in both 
obtaining microsomes and co-expression of the chosen protein target gene in yeast. Insect 
cells offer a convenient platform for in vivo assay through co-expression of target genes 
as well as the ready availability of insect cell microsomes for use in assays in vitro. 
Therefore, we generated bacmid constructs containing tmtc2, tmtc3 and a dual expression 
construct for tmtc2 and tmtc3 together for gene expression in insect cells.  
 
5.3.1 EXPRESSION OF TMTC2 AND TMTC3 IN SPODOPTERA FRUGIPERDA (SF9) CELLS 
Sf9 insect cells have been previously shown to lack C-mannosylating activity 
against the canonical WXXW sequence as found in RNase2.
228
 Therefore, to investigate 
whether tmtc2 and tmtc3 are C-mannosyltransferases, they were co-expressed with the 
target protein, IL-12b, which is known to be C-mannosylated in vivo. Ideally, the TMTC2 
and TMTC3 proteins generated through baculovirus infection would be targeted to the 
endoplasmic reticulum, and thus have access to the Dol-P-Man substrate. The il-12b 
gene, in a plasmid expression construct with an insect secretion signal, would also be 
translocated into the ER of the insect cells. The IL-12b protein would thus have the 
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opportunity to be modified in vivo while passing through the secretory pathway prior to 
secretion into the culture media. The IL-12b protein, with a C-terminal His6 tag could 
then be harvested from the media, using Ni-NTA resin, and analyzed by MALDI-MS for 
C-mannosylation.  
Both media and cellular fractions were analyzed for TMTC2 and IL-12b proteins 
to ensure that proteins were retained in their predicted locations: TMTC2 within cells and 
IL-12b secreted into the media. The TMTC2 protein was found to be enriched in the 
cellular membrane fractions as determined according to the method of Schutzbach, which 
employs the addition of increasing concentrations of detergents SDS and Nonidet P40. 
124
  
Expression of the gene tmtc2 alone was followed using SDS-PAGE and Western Blot 
over the course of 4 d. This time course study demonstrated that TMTC2 protein was 
produced 4 d after infection, as shown in the Western Blot in 5.1.  
 
5.1 TMTC2 Production in Sf9 Cells (Time Course Assay)  
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We did not expect such a delay in protein production, as many other proteins generated 
using the baculovirus system are present within 2-3 d post-infection. 
367
  
Expression of the il-12b gene was also examined. For in vivo assays to be 
effective, it is imperative that this protein passes through the secretory pathway, and thus 
be available for harvest from the media. To assess IL-12b production, media samples 
from a 4 d time course assay were concentrated and subjected to Ni-NTA batch 
extraction to isolate the His6-tagged protein. It should be noted that culture conditions for 
IL-12b expression deviated from the norm as L-glutamate strips Ni
2+
 from Ni-NTA 
beads, thus the culture conditions for TMTC2 and IL-12b generation in these time course 
experiments were not identical. The crude cell fractions and elution fractions obtained 
from Ni-NTA batch phase extraction of the media were examined using SDS-PAGE and 
Western Blot.  
 
5.2 IL-12b Production in SF9 Cells (Time Course Assay) 
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The IL-12b protein was found in both the cell and media fractions. As shown in 
Figure 5.2, IL-12b appears in the cellular fraction within 1 d and remains throughout the 
4 d time course. However, the protein only appears in the media beginning at 2d of 
growth.  
As the cells used for this experiment are stably transfected with an expression 
vector carrying the il-12b gene, we expect that the IL-12b protein should be found in all 
cellular samples from 0-4 d, as was observed. Our concern, however, is the difference in 
timing of expression of the tmtc2 gene versus the il-12b gene. If the il-12b gene is 
expressed and the protein is secreted faster than the TMTC2 protein is produced, then the 
majority of our IL-12b protein will pass through the secretory pathway before C-
mannosylation can take place.  
To ensure that the protein isolated from the Sf9 cells was in fact IL-12b, we grew 
transfected cells in suspension culture under the same conditions as above for 2 d in 
media supplemented with BSA for protein stability. The media was harvested and the IL-
12b protein was extracted from the media using Ni-NTA resin as described above. 
Fractions from the media, Ni-NTA washes, and elutions were examined by SDS-PAGE 
and Western Blot. The Western Blot showed two very clear bands in the elution fraction 
as shown in Figure 5.3. This observation differs from results described above, and we 
speculated that the additional band was BSA or a component of BSA. Both bands from 
the SDS-PAGE gel were isolated and subjected to in-gel digestion and mass spectrometry 
analysis to confirm the identity of the IL-12b protein. MS results did identify the new 
protein band as a bovine protein. It is most likely a component of the BSA mixture added 
to the media for protein stability. Unfortunately, MS results for the putative IL-12b 
protein band revealed that the band contained a complex protein mixture and thus was not 
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suitable for protein identification at this level of purity. For these reasons, we were unable 
to confirm the production of the IL-12b protein by the Sf9 cells. 
 
5.3 IL-12b His-Tag Purification from Sf9 Media (2 d Production)  
 
 
 
 
 
 
 
 
Due to the uncertainty regarding the expression 
levels and timing of both genes in Sf9 cells. We decided to co-express genes for the 
potential C-mannosyltransferase TMTC2 and the target protein IL-12b in insect cells. We 
attempted coexpression by using the TMTC2-baculoviral stock to infect cells that were 
already stably transfected with the pMIB/IL-12b plasmid. Cells were grown in 
suspension culture under the same conditions as described above. After time course assay 
over 4 d, both media and cell samples were assessed for the production of TMTC2 and 
IL-12b. The media was concentrated and subjected to protein enrichment using Ni-NTA 
beads to isolate IL-12b, while the membrane fractions containing our TMTC2 protein of 
interest were enriched from the cells using the method described previously.
124
 The 
elution fractions from the Ni-NTA enrichment and C/D fractions from the membrane 
enrichment were analyzed by SDS-PAGE and Western Blot. A 1 L culture of Sf9 cells 
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without the pMIB plasmid or TMTC2 viral stocks was grown in parallel as a negative 
control. 
 
5.4 Sf9 Negative Control (cells only, Time Course) 
 
 
 
 
 
 
 
 
 
 
5.5 Sf9 + TMTC2/IL-12b (Time Course) 
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From the SDS-PAGE, we were not able to observe the presence of either protein, 
and the Western Blots confirm these results. We hypothesized that a potential problem 
with protein production is the cell line used. Sf9 was chosen because it does not exhibit 
inherent C-mannosylation on WXXW motifs. However, this cell line is a very poor 
choice for gene expression. It was chosen because it is also well suited for baculovirus 
expression and viral stock generation.
367
 One common choice for secreted protein 
production is Trichoplusia ni, or High Five cells, however we did not choose to work in 
these cells as C-mannosylation was previously reported in this cell line.
368
  For our 
purposes, we believed it would be better to confine ourselves to S. frugiperda cell lines, 
which have not been shown to exhibit C-mannosylation of the canonical C-
mannosylation motif (WXXW). It was reported that Sf9 cells have intrinsic C-
mannosylation machinery, although C-mannosylation events are limited to modification 
of thrombospondin repeat regions. The response of High Five cells to the canonical 
WXXW signal sequence is unknown, and therefore we could not ensure that any C-
mannosylation that may be observed on our target protein is due to the heterologous 
expression of tmtc2 or tmtc3.  
 
5.3.2 C-MANNOSYLTRANSFERASE TMTC2 AND TMTC3 EXPRESSION IN SPODOPTERA 
FRUGIPERDA (SF21) CELLS 
As previously stated, Sf cells are not ideal for producing secreted proteins; 
therefore, we decided instead to focus on an in vitro approach. This entailed expression of 
tmtc2, tmtc3 and the dual expression of tmtc2/3 in insect cells, followed by purification of 
endoplasmic reticulum as microsomes. To alleviate the difficulties in protein production, 
the Sf21 cell line was chosen. It is unknown whether this cell line exhibits C-
mannosylating activity; as it has never been tested in this capacity. Nevertheless, the 
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protein production capacity of this cell line is significantly greater than that of Sf9 cells. 
Therefore, to ensure the validity of any observed C-mannosylation in microsomes, we 
also purified microsomes from cells with no additional expression constructs to serve as 
controls for background activity. 
Sf21 cells were cultured as adherent monolayers and infected with P2 baculovirus 
stocks for the expression of tmtc2, tmtc3 and the dual expression of tmtc2/3. Cells were 
harvested at various time points during growth to examine protein production and crude 
cellular fractions by SDS-PAGE without purification. Small (10 µL) aliquots of cells 
were removed and subjected to SDS-PAGE and Western Blot. From these samples, it 
was determined that 2-3 d growth yielded the best production of the proteins.  
 
5.3.3 PURIFICATION OF MICROSOMES CONTAINING THE POTENTIAL C-
MANNOSYLTRANSFERASES TMTC2 AND TMTC3 FROM SPODOPTERA 
FRUGIPERDA (SF21) CELLS 
The TMTC2 and TMTC3 proteins are multipass transmembrane proteins, and if 
they exhibit CMT activity, they will work on a membrane bound substrate, Dol-P-Man. 
Purification of these proteins presents several challenges. Proper orientation of protein 
domains may be affected by purification. Purification with detergents may perturb the 
folding and structure of protein domains not contained within the membrane. Once the 
protein is isolated from the membrane fraction of the cells, it is also removed from the 
membrane fractions that contain its natural substrate, thus limiting the protein‟s access to 
substrate. Furthermore, the substrate Dol-P-Man is no longer commercially available and 
must be synthesized from dolichol using both chemical and biological methods or 
directly extracted from microsomes and added into the reaction. These difficulties may be 
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overcome by using microsomes, because both the Dol-P-Man substrate and the TMTC2/3 
proteins are present and in the proper orientation for activity. 
To generate microsomes containing TMTC2, TMTC3 and TMTC2/3, cells were 
grown as described in the previous section. Different methodologies were utilized to 
purify microsomes, as described previously. Generally, cells were resuspended in a lysis 
buffer and manually disrupted (homogenized) to break the cell membranes. Low-speed 
centrifugation was employed to remove cellular debris and large organelles (nuclei and 
mitochondria). The supernatant from the low-speed centrifugation was subjected to high-
speed centrifugation, which removed soluble proteins from the cell lysate. The pellet 
from this ultracentrifugation step contained the endoplasmic reticulum and could be 
further purified through additional ultracentrifugation employing a sucrose gradient step 
to separate heavier rough endoplasmic reticulum from lighter smooth ER fractions, 
although a crude microsomal fraction was sufficient for our purposes. 
The microsomal pellets containing rough ER or total ER fractions were 
resuspended in buffer (usually HEPES based with multiple protease inhibitors) and the 
total protein concentration was determined by Bradford assay. Microsomal fractions had 
average protein concentrations at approximately 2 mg/µL, which varied slightly 
depending on the purification method used. The microsome samples were divided into 
aliquots, flash frozen, and stored at –80 ºC until use. Due to the complexity of the 
mixture, when SDS-PAGE was attempted on these samples, the protein bands were 
unresolvable. The protein samples were too concentrated to visualize any discrete bands, 
and dilution of these samples until discrete bands were seen yielded very poor Western 
blot results, although we could see very faint bands at the top of the membrane. 
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5.6 Sf21 Microsomes Containing TMTC2 and TMTC3 Coomassie Gel and 
Western Blot 
 
 
 
 
 
 
 
 
 
 
 
5.3.4 INSECT CELL MICROSOMAL ASSAYS TO DETECT C-MANNOSYLTRANSFERASE 
ACTIVITY  
By taking the ER portion of the secretory pathway, we can then add any designed 
peptide substrate to the assay, thus overcoming the issue of targeted protein production.  
Thus an advantage of this assay design is that we are no longer limited by naturally 
occurring substrates. Potentially, any synthetic substrate with the WXXW motif could be 
used in this assay however, we chose the protein substrate derived from RNAse2 as it had 
been previously shown to be an accepted peptide substrate for C-mannosylation.
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 The 
microsomes from the previous section, which contained the proteins believed to have C-
mannosylating activity, were incubated overnight with the synthetic peptide substrate, 
0.2% Triton X-100 to solubilize microsomes, and a protease inhibitor cocktail in HKA 
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(Hepes-potassium acetate) buffer. Assays were incubated both at room temperature and at 
37 ºC.  
After incubation the reaction solution was filtered to remove proteins above 10 
kDa and an attempt to isolate the peptide substrates by HPLC was made. Using a linear 
gradient of water/0.1% TFA and 90% acetonitrile/ 0.1% TFA we were able to establish a 
retention time for the unmodified substrate peptide  ~ 37 min. The peptide substrate used 
has two tryptophan residues and absorbances at 280 and 214 nm. Therefore, each assay 
sample was divided and run twice on the HPLC, collecting peaks displaying absorbance 
at both wavelengths. These samples were concentrated and submitted for MS analysis. 
The desired peptide could not be identified in the microsome assay samples submitted. 
The MS results show a mixture of peptides, none matching the expected or previously 
found molecular weight (m/z 1798) of the peptide. It appears that the purification method 
used was not suitable for the sample. 
To overcome the purification issues, a biotin label was introduced at the lysine 
residue generating the peptide: N-AC-K
biotin
PPQFAWAQWFE-NH2. Introduction of this
label improved our ability to recover the peptide from the complex microsomal mixture. 
The microsomal experiment was repeated, substituting the biotinylated peptide for 
unlabelled substrate, and the peptide was purified using streptavidin beads.  
The MS analysis of isolated biotinylated peptide show some differences between 
the control samples and the experimental samples, however the expected increase of 162 
Da was not observed in any samples. We observed an addition of 114 Da in every 
experimental sample (TMTC2, TMTC3, and TMTC2/TMTC3). We did not see the 
addition in the control sample (no TMTC2/TMTC3). It is possible that the harsh elution 
conditions (0.1% TFA) cause a fragmentation of the mannose pyranose ring, thus altering 
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the observed molecular weight of the modified peptide.   These are promising results, but 
certainly not definitive enough to conclude that C-mannosylation is occurring. 
It is also possible that the TMTC2 and TMTC3 proteins are not functional in 
insect cells due to a number of factors. First, the proteins may not be retained in the ER as 
hoped. In this case, the protein activity would not be observed using microsomal assays. 
To solve this problem, complete membrane fractions could be isolated from insect cells 
and applied to the assays. Complete membrane fractions would include the ER as well as 
the plasma membrane, thus providing both protein and Dol-P-Man substrate in the assay. 
Second, it is possible that the conditions in the insect cells do not mirror those found in 
human cells closely enough to facilitate C-mannosyl transfer. This could result from 
protein misfolding or key residues at improper protonation state, as the pH of the insect 
cell is 6.1-6.4, which is ten-fold more acidic than that of a human cell. Despite these 
possibilities, recovery of intact peptide from the control reactions demonstrated that the 
peptide substrate itself did not undergo cleavage or other modification under the assay 
conditions. 
5.3.5 SILENCING PUTATIVE C-MANNOSYLTRANSFERASES
Another option that was explored was silencing those genes in human cells that 
are candidates for being C-mannosyltransferases. The expression of the sGP gene from 
Zaire ebolavirus (Zebov) was attempted, using human HEK-293T cells. Purification of 
this protein from mammalian cell culture would provide a positive control for C-
mannosylation. This protein could be digested, and the peptides separated to isolate the 
C-mannosylated peptide. Silencing constructs could then be introduced to the HEK-293T 
cells and the sGP expressed again and examined for C-mannosylation. A lack of C-
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mannosylation on the protein purified from the silenced cell lines would be strong 
evidence that the proteins TMTC2 and TMTC3 were are very likely responsible for C-
mannosylation.  
 The sGP gene was amplified by PCR and ligated into plasmids for expression in 
mammalian, insect, yeast and bacterial cells. Attempts to express the gene in yeast and 
insect cells were unsuccessful. To our knowledge, no previous attempts had been made to 
express sGP in yeast cells. Surprisingly, S. cerevisiae died when transformed with the 
plasmid containing sGP. Despite multiple attempts at transformation both in liquid 
culture and on plates, no growth of treated yeast cells was observed. Likewise, no sGP 
protein could be obtained from Sf21 insect cells transfected with the sGP gene. 
When expressed in E. coli, the protein was found to be an aggregate, most likely 
due to the lack of N-glycosylation and thus in proper protein folding in E. coli. Properly 
folded protein may not be necessarily required for our assays, as the goal is to assay for 
C-mannosylation rather than protein activity. Thus, we persevered and attempted to 
purify the His6 tagged sGP protein using Ni-NTA resin under both native and denaturing 
conditions. Both attempts failed, and sGP eluted in the wash fractions. The protein 
appeared to have no affinity for the Ni-NTA beads, although hybridization with α-His 
antibodies clearly demonstrated the presence of the tag by Western Blot. In cases such as 
this, often the polyhistidine tag is buried and inaccessible. However, if this is the reason 
the sGP protein should have bound to the resin under the harsh denaturing conditions 
employed in the second attempt. We reasoned that the protein does not bind to the resin 
due to its highly positively charged nature. At pH 7, sGP carries a charge of +12, which is 
significantly different from most soluble proteins. The isoelectric point of the protein is 
approximately 9.4, thus a Tris buffer with a pH of 8 at room temperature (or 8.5 at 4 ºC) 
may potentially facilitate salting out of our protein as we encroach on the isoelectric point 
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of sGP. A viral extraction of adenovirus producing sGP was noted to have a bright yellow 
hue to the solution (culture media), indicating a pH far below the neutral 7. A small 
sample of the viral preparation was then obtained and dialyzed against pH 7 buffer until 
the sample turned pink. At this point, protein precipitate was observed in the solution. 
This observation suggested that sGP is not stable at higher pH. Thus, buffer conditions 
were adjusted accordingly to lower pH.  
Next, the His6-tag was circumvented, and purification using size exclusion, cation 
and anion exchange columns was attempted instead. In all cases, sGP either did not bind 
the column or precipitated during elution. A final method using low pH buffer and 
ammonium sulfate precipitation, followed by DEAE anion exchange chromatography 
was also attempted. While this approach was successful by SDS-PAGE and Western 
Blot, MS was unable to identify the peptide of interest, VNPEIDTTIGEWAFWETK(K) 
(m/z 2136, 2264).  
Attempts to express the sGP protein in mammalian cells were much more 
successful. Confluent cells transfected with the pEF/mycHis-sGP construct were grown in 
D-MEMt supplemented with 10 µg/mL bsd under standard conditions, and time course 
assays were performed to determine the optimum time to harvest media for protein 
purification. SDS-PAGE and Western Blot results indicated that a 4 d incubation yielded 
the highest level of protein production. It should be noted that the 3 and 4 d sample media 
were quite yellow, indicating the pH of the culture media had become much lower than 
the optimal (slightly) basic pH for normal cell growth.   
The media was concentrated and subjected to a variety of purification methods.  
These include cation exchange, anion exchange, size exclusion, and lectin 
chromatography. In contrast to expression in E. coli, we believed that the protein 
generated by mammalian cells should be more stable in solution due to its glycosylation 
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state, and thus be properly folded. Since the protein at pH 7 should be positively charged, 
we attempted cation exchange chromatography using Sepharose-Q and CM-Cellulose 
resins. The protein again precipitated in both columns under high salt concentrations, thus 
we could not elute the protein from either of the cation exchange columns.  
Lectin chromatography had previously been used to purify sGP from culture 
media, thus media concentrate was subjected to affinity chromatography using 
concanavalin A lectin, which binds to the terminal mannose residues of glycoproteins.
230, 
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 This procedure failed as the protein did not bind to the ConA beads, but was eluted 
from the column under wash conditions. This result implies that of the 5 N-glycans 
present on the protein, there are no terminal mannose residues on the sGP protein when 
purified from HEK-293T cells. It is possible that this discrepancy may arise from the use 
of different cell lines. Published procedures from Barrientos et al. and Falzarno et al. used 
sGP protein produced by Vero cells for lectin affinity purification methods, while the 
current work employed HEK-293T cells.
230, 362
The next purification attempt involved anion exchange chromatography. Tris 
buffer was chosen for these attempts based on previous successful use of Tris-NaCl  (TN 
buffer) in hemagluttinin (HA) affinity chromatography.
230
 Unfortunately, the protein
again precipitated. Changing the buffer to MES pH 5.5 yielded improved results, and the 
protein appeared in the first 2-4 “flow-through” fractions of the DEAE anion-exchange 
chromatography. This adequately separated the target sGP protein from the BSA in the 
culture media. Fractions containing the protein were subjected to size exclusion 
chromatography using an FPLC equipped with a Sephadex 200 column. MES (pH 5.5) 
buffers were used in the isocratic elution. Fractions judged to contain the protein were 
combined based on purity, flash frozen, and stored at  –80 ºC (see Figure 5.8) 
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5.7 Western Blot of sGP DEAE Column Fractions 1-4 
5.8 sGP DEAE Column Fractions and Sephadex Purification 
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detected using mass spectrometry. Accordingly, the sGP protein isolated from HEK-293T 
cells was subjected to in-gel tryptic digestion and mass spectrometry to confirm the 
identity of the protein. Unfortunately, the protein in question could not be identified after 
repeated rounds of MALDI-TOF and MALDI-TOF/TOF analysis. Most importantly, the 
potential C-mannosylated peptide in question: VNPEIDTTIGEWAFWETK(K) (m/z 
2136, 2264) was not observed. Even in the previously published work, this peptide was 
barely detected by spectroscopy, quite close to background.
230
 Undaunted, we attempted 
to purify the peptide from both in-gel digestions and solution digests using HPLC as 
described previously. These efforts were unsuccessful and MS results showed a mixture 
of peptides in the samples, but no peaks corresponding to the peptide of interest, either 
modified (m/z 2298, 2426) or unmodified (m/z 2136, 2264) were observed.  
 
5.3.6.1 N-Azido Sialyl Labeling of sGP in HEK-293T   
 We next attempted to express the sGP gene in the presence of N-Aza-tetraacetyl-
mannose (Ac4ManNAz), such that glycosylated proteins would be fractionally labeled 
with N-azido-sialic acid. Previously, the Bertozzi group had shown that tetraacetylated 
azidomannose could be taken up by cells under normal culture conditions with low 
glucose. The cellular machinery could convert the azido sugar to SiaNaz which is the 
incorporated into complex glycans associated with many types of glycoproteins.
369
 
Through this expression method, the introduced azide moiety on the sialic acid residues 
could be coupled to Cu(I)-mediated alkyne-biotin conjugates and the resulting proteins 
could be isolated using streptavidin affinity chromatography. The protein of interest 
could be further purified from this mixture of proteins using methods already developed. 
sGP has 6 known glycosylation sites, five of which are believed to have one or more 
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terminal sialic acid moieties.
362
 However, two attempts to grow adherent monolayers in 
the presence of 30 and 15 µM tetraacetyl azidomannose (D-MEMm) were unsuccessful. 
In both cases all cells in the flasks died within 4 - 7 d, as judged by morphology and non-
adherence. 
 The cause of cell death is not clear, but may be a result of toxicity due to sGP. We 
had noted previously that monolayer cultures producing sGP were not as healthy as the 
control cells. Compared to control cells grown under the same culture conditions, cells 
expressing sGP divided much more slowly. For example, a flask of HEK-293T control 
cells was passaged (1:10) approximately every week. Cells transfected with sGP were 
only confluent enough to passage every two weeks at a 1:2 split. These cells died after  
approximately 10-15 passages. From this we concluded that the production of sGP 
protein causes cell death, as compared to control HEK-293T cells grown in parallel under 
identical conditions. Under labeling conditions, control HEK-293T cells grown in parallel 
(low glucose supplemented with 4Ac-ManNaz) were not as robust. Cells under low 
glucose conditions were passaged approximately every week at a 1:4 split, but still grew. 
Cells producing sGP under labeling conditions never survived long enough to split, as 
they died within 4 days. Even under adjusted conditions, these cells survived for less than 
two weeks before cell death. We propose that the addition of ManNaz to these cells 
causes a stress on the cellular system that, when combined with the apparent toxicity of 
sGP, becomes too great a burden on the cell.  
 
5.3.7 SILENCING TMTC2 AND TMTC3 IN HEK-293T CELLS 
Due to the problems in obtaining the sGP protein or modified peptide for use as a 
positive control for in vivo assays with HEK-293T cells, we concentrated our efforts on 
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designing a new microsomal assay for use with synthetic peptides. In these experiments 
we would silence tmtc2 and tmtc3 in HEK-293T cells using shRNA. Microsomes from 
normal HEK-293T cells and silenced cells could then be harvested and applied to the 
previously described in vitro microsomal assay that employs a synthetic peptide. If we 
could silence the genes, thus preventing production of the TMTC2 or TMTC3 proteins, 
microsomes harvested from these cells could be investigated for a deficiency in C-
mannosylation. 
Briefly, 4 plasmids, each expressing a different shRNA designed to target either 
tmtc2 or tmtc3 expression were transfected into HEK-293T cells as described previously. 
Cells transfected with both control vectors (empty vector and non-effective silencing 
vector) recovered quickly and were at a confluence (70%) that could be passaged within a 
week of transfection.  In contrast, cells transfected with silencing shRNA showed poor 
growth and recovery even after one month despite regular media exchange. Experimental 
cells never surpassed 10 – 20% confluence except in the case of constructs 1 and 4 for 
tmtc2 and 4 for tmtc3 silencing, which only reached 40%. In all experimental cases, cell 
death was observed continuously during growth as monitored by microscopy. The 
viability of cells transfected with silencing shRNA were examined using the trypan blue 
assay and in all cases were found to be less than 5% viable. 
Even if transfection rates were originally low, cells would have recovered within 
several weeks of the procedure. Our conclusion is that regardless of whether tmtc2 and 
tmtc3 are indeed the C-mannosyltransferase genes or not, inhibition of the expression of 
these genes appears to be deleterious to human cells. Our original intent was to isolate 
microsomes from these cells, however this was not possible as silencing seems to cause 
cell death. These results are of some interest, as the deletion or removal of important 
glycosyltransferases such as β-OGT and POMT1/2 also leads to cell death. 205, 213, 352, 354
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5.4 CONCLUSIONS AND FUTURE DIRECTIONS 
 
Our efforts to produce the TMTC2 and TMTC3 proteins in insect cells were 
successful; however, assays to detect C-mannosylation require more development. Our 
current efforts are focused on work in insect cell lines and attempts to perfect the 
microsomal assays with TMTC2 and TMTC3 proteins. 
Silencing of these genes in the mammalian cell line HEK-293T has demonstrated 
interesting results. Whether these proteins are C-mannosyltransferases or not, it appears 
that their presence is essential to cells under culture conditions.  This result is quite 
informative as it suggests that these predicted glycosyltransferases of unknown function 
may be required for cellular viability and growth. The functions of these proteins may be 
more important now than ever, as we search for the protein sources of CDGs with 
unknown etiology.  
Once a suitable assay is fully developed, further characterization based on the 
methods employed by Hofsteenge can be undertaken. 
227
 Target proteins could be 
assayed for C-mannosylation by digesting with a protease such as elastase, and resultant 
peptide fragments fractionated by reversed phase HPLC using a C-18 column 
(acetonitrile/TFA gradient).
126
 The purified fragments can then be subjected to MS and/or 
Edman degradation to determine the exact position of the mannose residue in the peptide. 
1
H-NMR and TOCSY-NMR studies of the subpeptides can also be performed to verify 
the presence of a mannose residue. 
370
 Another proof of the presence of the C-C bond is 
acid hydrolysis followed by derivatization of the mannose. Since this residue is not 
attached to the tryptophan in a “typical” glycosidic linkage, acid hydrolysis will not break 
this bond.  This method has been employed in gas chromatography/mass spectrometry 
(GC/MS) studies of C-mannosylation in which three divergent steps of GC/MS were used 
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in tandem with chemical modification. The methodology involves first a mild acid 
hydrolysis, followed by an acid-catalyzed methanolysis under anhydrous conditions, and 
finally a classical hydrolysis for peptide bond cleavage.
371
 Derivatives of tryptophan were 
found to be stable under acid hydrolysis, while mannose derivatives were also stabilized 
as per-heptafluorobutyrate derivatives, and can be easily identified in the (positive) EI 
mode of ionization.
371
  
Once a C-mannosyltransferase is identified, high throughput assays could be 
carried out to identify novel protein substrates, including proteins in infectious agents and 
the human immune system. The gene(s) could be knocked out and cellular viability, as 
well as the appearance of novel CDGs could be assessed. If we are correct in our 
assessment of the TMTC2 proteins, C-mannosylation is essential for cellular viability in 
higher eukaryotes. The enzyme mechanism of the protein could be probed, which would 
provide valuable insight into general C-glycosyltransferase mechanisms. The 
introduction of the CMT protein to heterologous systems could provide a platform by 
which to obtain C-mannosylated therapeutic proteins with improved serum half-lives. 
Above all, studies could be undertaken to elucidate the role of this novel posttranslational 
protein modification, C-mannosylation. 
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Appendices 
ALIGNMENT OF TMTC2 HOMOLOGS USING CLUSTALX 
Human ------------------------------------------------------------ 
Mouse ------------------------------------------------------------ 
Rat ------------------------------------------------------------ 
Cow ------------------------------------------------------------ 
Macaque ------------------------------------------------------------ 
Xenopus ------------------------------------------------------------ 
Dog ------------------------------------------------------------ 
Chicken         MGKGQKADGSLCYWPCVKKHAPCEIPSGCSSLTAAPVHCLSSAVTAEIGPAPELWCELAC 
CElegans ------------------------------------------------------------ 
Human ------------------------------------------------------------ 
Mouse ------------------------------------------------------------ 
Rat ------------------------------------------------------------ 
Cow ------------------------------------------------------------ 
Macaque ------------------------------------------------------------ 
Xenopus ------------------------------------------------------------ 
Dog ------------------------------------------------------------ 
Chicken         STLRAVTALMESCWQVVSSVKAMPTPRCLELYERHPEIKVGRCLEIRRRQDREGRKELWL 
CElegans ------------------------------------------------------------ 
Human ------------------------------------------------------------ 
Mouse ------------------------------------------------------------ 
Rat ------------------------------------------------------------ 
Cow ------------------------------------------------------------ 
Macaque ------------------------------------------------------------ 
Xenopus ------------------------------------------------------------ 
Dog ------------------------------------------------------------ 
Chicken         NAWWLLGMWDAEDPEPVHRAGGKLPSQSCRGSGNLALTPAELIEIRAAALPVKRMLLPYF 
CElegans ------------------------------------------------------------ 
Human ------------------------------------------------------------ 
Mouse ------------------------------------------------------------ 
Rat ------------------------------------------------------------ 
Cow ------------------------------------------------------------ 
Macaque ------------------------------------------------------------ 
Xenopus ------------------------------------------------------------ 
Dog --------------------------------------------MSMSEVGGGPGIFSGS 
Chicken         NSVQAELKRTALLVYPEKLSKMLNTFVKFPYQHTDTGNCSLGKYRGDTKLVTYLILTSEI 
CElegans ------------------------------------------------------------ 
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Human           ------------------------------------------------------------ 
Mouse           ------------------------------------------------------------ 
Rat             ------------------------------------------------------------ 
Cow             ------------------------------------------------------------ 
Macaque         ------------------------------------------------------------ 
Xenopus         ------------------------------------------------------------ 
Dog             SAGPAAEELPGGMIAGPRRSPRTCQDGPRRSPHTCQDGLRRSPHTCQDGPRRSPHTCQDG 
Chicken         DDFSVFPLTEAECNQWELSVARLQFQIYALRDQSFQQSFSGDVSLELSYLCNTESPFLIK 
CElegans        --------------------------------------------------------MKKE 
                                                                             
 
Human           ---------------MIAELVSSALGLALYLNTLSADFCYDDSRAIKTNQDLLPETPWT- 
Mouse           ---------------MIAELVSSALGLALYLNTLSADFCYDDSRAIKTNQDLLPETPWT- 
Rat             ---------------MIAELVSSALGLALYLNTLSADFCYDDSRAIKTNQDLLPETPWT- 
Cow             ---------------MIAELVSSALGLALYLNTLSADFCYDDSRAIKTNQDLLPETPWT- 
Macaque         ---------------MIAELVSSALGLALYLNTLSADFCYDDSRAIKTNQDLLPETPWT- 
Xenopus         ---------------MIAELLSSALGLLLYLNTLGADFCYDDSRAIKTNQDLLPETPWN- 
Dog             PRRSPHTCQDGLRRSPHTCQDGPRRSPPKEALCPGSEALWMHTRAIKTNQDLLPETPWT- 
Chicken         ITTELQFTFSISFLNVYCLFEQMEKKGSKCSALLQVIPDCAMSRAIKTNQDLLPETPWT- 
CElegans        KRKQKSVEPTILSHIPYQYLLVALFASIVYRITLNADFVYDDRPAILTNDDVLGRTPWRS 
                                                            ** **:*:* .***   
 
Human           HIFYNDFWGTLLTHSGSHKSYRPLCTLSFRLNHAIGGLNPWSYHLVNVLLHAAVTGLFTS 
Mouse           HIFYNDFWGTLLTHSGSHKSYRPLCTLSFRLNHAIGGLNPWSYHLVNVLLHAAVTGLFTR 
Rat             HIFYNDFWGTLLTHSGSHKSYRPLCTLSFRLNHAIGGLNPWSYHLVNVLLHAAVTGLFTR 
Cow             HIFYNDFWGTLLTHSGSHKSYRPLCTLSFRLNHAIGGLNPWSYHLVNVLLHAAVTGLFTN 
Macaque         HIFYNDFWGTLLTHSGSHKSYRPLCTLSFRLNHAIGGLNPWSYHLVNVLLHAAVTGLFTS 
Xenopus         HIFFNDFWGTLLTHSGSHKSYRPLCTLSFRLNYLFGGLDPWNYHLVNVLLHSAVTGLFTN 
Dog             HIFYNDFWGTLLTHSGSHKSYRPLCTLSFRLNHAVGGLDPWSYHLVNVLLHAAVTGVFTS 
Chicken         HIFYNDFWGTLLTHSGSHKSYRPLCTLSFRINHAIGGMDPWGYHLVNILLHAAVTGLFTN 
CElegans        LIVHNDFWGNPIGLQGSHKSYRPLITASFRLQFAVHGLKAELFHGVNLICHMINSMLVLK 
                 *..*****. :  .********* * ***::. . *:..  :* **:: *   : :.   
 
Human           FSKILLGDG-YWTFMAGLMFASHPIHTEAVAGIVGRADVGASLFFLLSLLCYIKHCSTRG 
Mouse           FSKALLGDG-YWTFMAGLMFASHPIHTEAVAGIVGRADVGASLFFLLSLLCYIKHCSTRG 
Rat             FSKALLGDG-YWTFMAGLMFASHPIHTEAVAGIVGRADVGASLFFLLSLLCYTKHCSTRG 
Cow             FSKILLGDG-YWTFMAGLMFASHPIHTEAVAGIVGRADVGASFFFLLSLLCYMKHCSTRG 
Macaque         FSKILLGDG-YWTFMAGLMFASHPIHTEAVAGIVGRADVGASLFFLLSLLCYIKHCSTRG 
Xenopus         LCKALFGSG-CWTLIAGLLFASHPIHTEAVSGIVGRADVGSGLFFLLSLLCYMKHCSTRG 
Dog             FSKTLLGDG-CWTFMAGLLFASHPIHTEAVAGIVGRADVGASLFFLLSLLCYIKHCSTRG 
Chicken         FSRILFGDG-YWTLIAGLLFASHPIHTEAVAGIVGRADIGACLFFLLSLMCYVKHCSTRS 
CElegans        LARQMRIMGNEFSLLSALIFACHPITSEAVCSIVGRADLLSTMLILLAITCHTSDPSTFR 
                :.: :   *  :::::.*:**.*** :***..******: : :::**:: *: .. **   
 
Human           YSARTWGWFLGSGLCAGCSMLWKEQGVTVLAVSAVYDVFVFHRLKIKQILPTIYKRKNLS 
Mouse           YSARTWGWFLGTGLCAGCSMLWKEQGVTVLAVSAVYDVFVFHRLKMKQILPTIYKRKNLS 
Rat             YSARTWGWFLGTGLCAGCSMLWKEQGVTVLAVSAVYDVFVFHRLKMRQILPTIYKRKNLS 
Cow             SSARTWGWFLGTGMCAGCSMLWKEQGVTVLAVSAVYDVFVFHRLKMKQILPTIYKRKNLS 
Macaque         YSARTWGWFLGTGLCAGCSMLWKEQGVTVLAVSAVYDVFVFHRLKIKQILPTIYKRKNLS 
Xenopus         YSLSSWCWILCAGFWAACSMLWKEQGVTVLAVSAVYDVFVFHKLKMNQIISVVFKEKNVS 
Dog             SSARTWGWFLGTGLCAGCSMLWKEQGVTVLAVSAVYDVFVFHRLKVKQILPAICKRKNLS 
Chicken         SSARTWGWILGAGLCAGCSMLWKEQGVTVLAISAVYDIFVVHRLKMHQIIPALYKRKNLN 
CElegans        -----------TIVLSILAVTAKETGIILLPLITLYDVLFKT-------------SNTKQ 
                           : . :  ::  ** *: :*.: ::**::.                :. .  
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Human           LFLSISLLIFWGSSLLGARLYWMGNKPPSFSNSDNPAADSDSLLTRTLTFFYLPTKNLWL 
Mouse           LFLSISLLTFWGTCLLGARLYWMGNKPPSFSNSDNPAADSDSLLARTLTFLYLPTKNLWL 
Rat             LFLSISLLTFWGTSLLGARLYWMGNKPPSFSNSDNPAADSDSLLARTLTFFYLPTKNLWL 
Cow             LFLSISLLTFWGTSLLGARLYWMGNKPPSFSNSDNPAADSDSLLARTLTFFYLPTKNLWL 
Macaque         LFLSISLLTFWGSSLLGARLYWMGNKPPSFSNSDNPAADSDSLLTRTLTFFYLPTKNLWL 
Xenopus         FFFSVGLLFAWGVILLGARFYWMGNTPPSFSNSDNPAADCEVLLTRTLTFFYLPTKNLWL 
Dog             LFLSISLLTFWGTSLLGARLYWMGNKPPSFSNSDNPAADSDSLLARTLTFFYLPTKNLWL 
Chicken         LFFSIGLLTSWGTALLGVRLYWMGNKPPSFSNSDNPAADSDSFLTRMLTFLYLPTKNLWL 
CElegans        FRRDVTAYLISLLALCYLRLSINNFQSPKFSKNDNPIAHEPNSLTRALTFMYLPVFHLNL 
               :  .:         *   *:   .  .*.**:.*** *.    *:* ***:***. :* * 
 
Human           LLCPDTLSFDWSMDAVPLLKTVCDWRNLHTVAFYTGLLLLAYYGLKSPSVDRECNGKTVT 
Mouse           LLCPDTLSFDWSMDAVPLLKTVCDWRNLHTVAFYSGLLLLAYCGLKNPSLEGECNGKALT 
Rat             LLCPDTLSFDWSMDAVPLLKTVCDWRNLHTVAFYSGLLLLAYCGLKSPSLEGECNGKAVT 
Cow             LLCPDTLSFDWSMDAVPLLKTISDWRNLHTVAFYTGLLLLAYFGLKSPSIERECNGKFVT 
Macaque         LLCPDTLSFDWSMDAVPLLKTVCDWRNLHTVAFYTGLLLLAYYGLKSPSVDRECNGKTVT 
Xenopus         LFCPDTLSFDWSMDAVPLIKTITDWRNIHTVAFYILLILLAYSSLKGSAIKRDCNGKVFM 
Dog             LLCPDTLSFDWSMDAVPLLRTVCDWRNLHTVAFYTGLLLLAYYGLKSPGVERECNGKVVT 
Chicken         LFCPDTLSFDWSMDAVPLLKAVSDWRNLHTVAFYAGLFLLAYFSLKGSSNERECNGKTVM 
CElegans        IVFPKTLSYDWSMDAIPKVESLIDSRIILTFIVIG--------------VGEHVLLKLLL 
                :. *.***:******:* :.:: * * : *. .                   .   * . 
 
Human           NGKQNANGHSCLSDVEYQNSETKSSFASKVENGIKNDVSQRTQLPSTENIVVLSLSLLII 
Mouse           NGKQNANGHSCHSDVEYRNSEMKPSFASKVENGIKNCVPQRTQLPSTENIVILSLSLLII 
Rat             NGKQNANGHSCYSDVEYRNSEIKPSFASKVENGIKSCVSQRPQLPSTENIVILSLSLLII 
Cow             NGKQNANGHSCHSEVEYGNSEIKPSFASKVENGIRNNASQRTQLPSTENIVVLSLSLLII 
Macaque         NGKQNANGHSCLSDVEYQNSETKSSFASKVENGINNDVSQRTQLPSTENIVVLSLSLLII 
Xenopus         NGKQNTNGHSCQSDLEHKNAEQNPVIASKLENGVKHHNSHEMQLPSTENIVVLALSLLIV 
Dog             NGKQNANGHSCHSDGEYRNSESKPSLAAKAENGIKNNAAQRSPLPSTENIVVLSLSLLII 
Chicken         NGKQNANGHSCHSEMEYKTLEGKSSFASKEENGIKKHEILKLQLPSTENIVILSLSLLIV 
CElegans        GLRNSENSHENRS-------------------------------------LLFLFALFTT 
. ::. *.*.  *                                     ::: ::*:  
 
Human           PFVPATNLFFYVGFVIAERVLYIPSMGFCLLITVGARALYVKVQKRFLKSLIFYATATLI 
Mouse           PFIPATNLFFYVGFVIAERVLYIPSMGFCLLITVGARALYVKVQKRFLKSLVFYATATLI 
Rat             PFIPATNLFFYVGFVIAERVLYIPSMGFCLLITVGARALYVKVQKRFLKSLVFYATATLI 
Cow             PFVPATNLFFYVGFVIAERVLYIPSMGFCLLITVGARALYVKVQKRFLKSLIFYATAALI 
Macaque         PFVPATNLFFYVGFVIAERVLYIPSMGFCLLITVGARALYVKVQKRFLKSLIFYATATLI 
Xenopus         PFVPASNLFFYVGFVIAERVLYIPSMGFCLLVTVGARALYIKAQKNILKNLLFYATAALI 
Dog             PFVPATNLFFYVGFVIAERVLYIPSMGFCLLVTVGARALYVKVQKRFLKSLIFYATATLI 
Chicken         PFIPATNLFFYVGFVIAERVLYVPSMGFCLLVTVGVRALYVKAQKRFLKNLVFCSTAALI 
CElegans        PHILSSNLLTHVGFVAAERILYLNTVAYCILAAFLAEMCSKRSSP----KSVLPLYILLL 
*.: ::**: :**** ***:**: ::.:*:* :. ..    : .     . ::     *: 
 
Human           VFYGLKTAIRNGDWQNEEMLYRSGIKVNPAKAWGNLGNVLKSQSKISEAESAYRNALYYR 
Mouse           VFYGVKTAIRNGDWQNEEMLYRSGIKVNPAKAWGNLGNVLKSQSKISEAESAYRNALFYR 
Rat VFYGLKTAIRNGDWQNEEMLYRSGIKVNPAKAWGNLGNVLKSQSKISEAEIAYRNALYYR 
Cow             VFYGLKTAIRNGDWQNEEMLYRSGIKVNPAKAWGNLGNVLKSQSKISEAESAYRNALYYR 
Macaque         VFYGLKTAIRNGDWQNEEMLYRSGIKVNPAKAWGNLGNVLKSQSKISEAESAYRNALYYR 
Xenopus         VFYGLKTVVRNGDWKNEEMLYRSGIKVNPAKAWGNLGNVLKSQSKIDEAENAYRNALYYR 
Dog             VFYGLKTAIRNGDWQNEEMLYRSGIKVNPAKAWGNLGNVLKSQSKISEAERAYRNALYYR 
Chicken         VFYGLKTVVRNGDWQNEEMLYRSGIKVNPAKAWGNLGNVLKSQSKISEAESAYRNALYYR 
CElegans        SLFTIRTMQRVDDWKTEESLFKSALEVNPTKANMNLGYVYTTQKKYELAKYHYRQALKRQ 
                 :: ::*  * .**:.** *::*.::***:**  *** * .:*.* . *:  **:**  : 
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Human           SNMADMLYNLGLLLQENSR-FAEALHYYKLAIGSRPTLASAYLNTGIILMNQGRTEEARR 
Mouse           SNMADMLYNLGLLLQENSR-FAEALHYYKLAIGSRPTLASAYLNTGIILMNQGKTEEARR 
Rat SNMADMLYNLGLLLQENSR-FAEALHYYKLAVGSRPTLASAYLNTGIILMNQGKTEEARR 
Cow             SNMADMLYNLGLLLQENSR-FAEALHYYKLAIGSRPTLASAYLNTGIILMNQGKSEEARR 
Macaque         SNMADMLYNLGLLLQENSR-FSEALHYYKLAIGSRPTLASAYLNTGIILMNQGRTEEARR 
Xenopus         SNMADMLYNLGLLLQENSK-FSEALHYYKLAIGSRPTLASGYLNTGIILMNQGRTEEARR 
Dog             SNMADMLYNLGLLLQENSR-FAEALHYYKLAIGSRPTLASAYLNTGIILMNQGKTEEARR 
Chicken         SNMADMLYNLGLLLQENNR-FSEALHYYKLAIGSRPTLASAYLNTGIILMNQGKTEEARR 
CElegans        GNLADAWYNLGILTSKTSNNSNGSIHCYQMALQSRSTYAAAHLNLALLLHDAGHHMAAFS 
.*:**  ****:* .:...    ::* *::*: **.* *:.:** .::* : *:   *  
Human           TFLKCSEIPDENLKDPHAHKSSVTSCLYNLGKLYHEQGHYEEALS--------------- 
Mouse           TFLKCSEIPDENLKDPHAHKSSVTSCLYNLGKLYHEQGRYEEALS--------------- 
Rat TFLKCSEIPDENLKDPHAHKSSVTSCLYNLGKLYHEQGRYEEALS--------------- 
Cow             TFLKCSEIPDENLKDPHAHKSSVTSCLYNLGKLYHEQGHYEVRPEPLCPVPPPCSDLVSM 
Macaque         TFLKCSEIPDENLKDPHAHKSSVTSCLYNLGKLYHEQGHYEEALS--------------- 
Xenopus         TFLKCSEIPDENLKDPNAHKSSVTSCLYNLGKLYHEQGQYEDALI--------------- 
Dog             TFLKCSEIPDENLKDPHAHKSSVTSCLYNLGKLYHEQGHYEDALS--------------- 
Chicken         TFLKCSEIPDENLKDPHAHKSSVTSCLYNLGKLFHEQGHYEDALT--------------- 
CElegans        HLDKCLNNTGEFLKFYHVNRKTQATCAFNKGRLLQKSGNFHVAIEN-------------- 
: ** : ..* **  :.::.: ::* :* *:* ::.*.:.                   
Human -----------VYKEAIQKMPRQFAPQSLYNMMG-------------------------- 
Mouse -----------VYREAIQKMPRHFAPQSLYNMMG-------------------------- 
Rat -----------VYREAIQKMPRQFAPQSLYNMMG-------------------------- 
Cow             TSTCDLIDALSVYKEAIQKMPRQFAPQSLYNMMG-------------------------- 
Macaque -----------VYKEAIQKMPRQFAPQSLYNMMG-------------------------- 
Xenopus -----------VYKEAIQKMPRQFSPQSLYNMMG-------------------------- 
Dog -----------VYKEAIQKMPRQFAPQSLYNMMG-------------------------- 
Chicken -----------VYKEAIQKMPRQFAPQSLYNMMAFAEKPGLASHSLLRCGLLAPLQRQSK 
CElegans -----------FELALKLGGPHFEHTPSVLNSMG-------------------------- 
                           .        *:   . *: * *.                          
Human ---------------------EAYMRLSKLPEAEHWYMESLRSKTDHIPAHLTYGKLLAL 
Mouse ---------------------EAYMRLSKLPEAEHWYMESLRSKTDHIPAHLTYGKLLAL 
Rat ---------------------EAYMRLSKLPEAEHWYMESLRSKTDHIPAHLTYGKLLAL 
Cow ---------------------EAYMRLSMLPEAEHWYMESLRSKTDHIPAHLTYGKLLAL 
Macaque ---------------------EAYMRLSKLPEAEHWYMESLRSKTDHIPAHLTYGKLLAL 
Xenopus ---------------------EAYMRLNVVSEAEHWYTESLKSKPDHIPAHLTYGKLLTL 
Dog ---------------------EAYMRLSKLPEAEHWYMESLRSKTDHIPAHLTYGKLLAL 
Chicken         RLGKSQMVTSTELSAAMLTAGEAYMRMSRLPEAERWYVESLRSKSDHIPAHLTYGKLLAL 
CElegans ---------------------TCYNELGDEQSAEKFFGKAIG--ENHVNSYLTMAHLKIR 
                                      .* .:.   .**::: :::    :*: ::** .:*   
Human           TGRKSEAEKLFLKAIELDPTKGNCYMHYGQFLLEEARLIEAAEMAKKAAELDSTEFDVVF 
Mouse           TGRKSEAEKFFLKAIELDPTKGNCYMHYGQFLLEESRLTEAAEMAKKAAELDNTEFDVVF 
Rat             TGRKSEAEKFFLKAIELDPTKGNCYMHYGEWHYQKQRLYEICRQMRKATDLF----ELIL 
Cow             TGRKSEAEKFFLKAIELDPTKGNCYMHYGQFLLEEARLIEAAEMAKKAAELDSTEFDVVF 
Macaque         TGRKSEAEKLFLKAIELDPTKGNCYMHYGEWLIAFFHVPHIYY----------------- 
Xenopus         TGRKNEAERYFLKAIQLDPNKGNCYMHYGQFLLEEGRILEAAEMAKKAAELDSSEFDVVF 
Dog             TGRKSEAEKFFLKAIELDPTKGNCYMHYGQFLLEEARLIEAAEMAKKAAELDSTEFDVVF 
Chicken         TGRKSEAEKYFVKAIQLDPTKGNCYMHYGQFLLEESRLIEAAEMAKKAAELDNTEFDVVF 
CElegans        QNRSFEVENLLRKAMTLAPESVTVLQNIALAEFHMQNYNRSLLFYRKALHLDPTHLDSLQ 
                 .*. *.*. : **: * * . .   : .       .  .                    
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Human           NAAHMLRQASLNEAAEKYYDLAARLRPN-------------------------------- 
Mouse           NAAHMLRQASLNEAAEKYYDLAARLRPN-------------------------------- 
Rat             YPATLLKQASLNEAAEKYYDLAARLRPN-------------------------------- 
Cow             NAAHMLRQASLNEAAEKYYDLAARLRPN-------------------------------- 
Macaque         ------------------------------------------------------------ 
Xenopus         NAAHMLRQASLNEEAEKFYKLAAGLRQN-------------------------------- 
Dog             SAAHMLRQASLNEAAEKYYDLAARLRPN-------------------------------- 
Chicken         NAAHMLRQASLNEEAEKYYEMAAGLRPNNAFSTKLSDPRQFTVAILSNFLEIVALVRIHV 
CElegans        GIANLLQQTQNHVESETFYRKVMEAQPN-------------------------------- 
                                                                             
 
Human           -----------------------------------YPAALMNLGAILHLNGRLQKAEANY 
Mouse           -----------------------------------YPAALMNLGAILHLNGRLQKAEANY 
Rat             -----------------------------------YPAALMNLGAILHLNGRLQKAEANY 
Cow             -----------------------------------YPAALMNLGAILHLNGRLQKAEANY 
Macaque         ------------------------------------------------------------ 
Xenopus         -----------------------------------YPAALMNLGAILHLNGKLEEAEYNY 
Dog             -----------------------------------YPAALMNLGAILHLNGRLQKAEANY 
Chicken         LFGTKYQMQHLQTPLLKRFSSATAQRTRIKEAGGKYPAALMNLGAILHLNGKLKEAEENY 
CElegans        -----------------------------------SYAAHANYGAILHLNQKYDLALKEY 
                                                                             
 
Human           LRALQLKPDDVITQSNLRKLWNIMEKQGLKTSKT 
Mouse           LRALQLKPDDVITQSNLRKLWNIMEKQGLKTSKT 
Rat             LRALQLKPDDVITQSNLRKLWNIMEKQGLKTSKT 
Cow             LRALQLKPDDIITQSNLRKLWNIMEKQGLKTSKT 
Macaque         ---------------------------------- 
Xenopus         LRALQLKPDDAITQSNLRKLWNIMEKQGLKNSKT 
Dog             LRALQLKPDDVITQSNLRKLWNIMEKQGLKTSKT 
Chicken         LLALQLKPDDVITQSNLRKLWNIMEKQGLKTSKT 
CElegans        EIALILDPTSDVARENRKKVIRILRRKRNL----  
 
ALIGNMENT OF THE DUF 1736 DOMAIN OF TMTC2 HOMOLOGS 
 
Human     SISLLIFWGSSLLGARLYWMGNKPPSFSNSDNPAADSDSLLTRTLTFFYLPTKNLWLLLCPDTLSFDWSMDAVPLLKTVCDWRNLHTVAFYTGLLLL 
Mouse     SISLLTFWGTCLLGARLYWMGNKPPSFSNSDNPAADSDSLLARTLTFLYLPTKNLWLLLCPDTLSFDWSMDAVPLLKTVCDWRNLHTVAFYSGLLLL 
Rat       SISLLTFWGTSLLGARLYWMGNKPPSFSNSDNPAADSDSLLARTLTFFYLPTKNLWLLLCPDTLSFDWSMDAVPLLKTVCDWRNLHTVAFYSGLLLL 
Cow       SISLLTFWGTSLLGARLYWMGNKPPSFSNSDNPAADSDSLLARTLTFFYLPTKNLWLLLCPDTLSFDWSMDAVPLLKTISDWRNLHTVAFYTGLLLL 
Macaque   SISLLTFWGSSLLGARLYWMGNKPPSFSNSDNPAADSDSLLTRTLTFFYLPTKNLWLLLCPDTLSFDWSMDAVPLLKTVCDWRNLHTVAFYTGLLLL 
Xenopus   SVGLLFAWGVILLGARFYWMGNTPPSFSNSDNPAADCEVLLTRTLTFFYLPTKNLWLLFCPDTLSFDWSMDAVPLIKTITDWRNIHTVAFYILLILL 
Dog       SISLLTFWGTSLLGARLYWMGNKPPSFSNSDNPAADSDSLLARTLTFFYLPTKNLWLLLCPDTLSFDWSMDAVPLLRTVCDWRNLHTVAFYTGLLLL 
Chicken   SIGLLTSWGTALLGVRLYWMGNKPPSFSNSDNPAADSDSFLTRMLTFLYLPTKNLWLLFCPDTLSFDWSMDAVPLLKAVSDWRNLHTVAFYAGLFLL 
CElegans  DVTAYLISLLALCYLRLSINNFQSPKFSKNDNPIAHEPNSLTRALTFMYLPVFHLNLIVFPKTLSYDWSMDAIPKVESLIDSRIILTFIVIG----- 
          .:         *   *:   .  .*.**:.*** *.    *:* ***:***. :* *:. *.***:******:* :.:: * * : *. .         
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ALIGNMENT OF THE DUF 1736 DOMAIN ACROSS MULTIPLE HOMOLOGS 
 
 
 
 
 
 
 
 
Q9VF81_DROME/237-334   SYLFYLLGTLGLLTAR.LWWQDFETPTFKEVDNPVAHNEHVLTRGLSQQYLLVMNIWLMLCPHWLCYDW...........
Q29BE3_DROPS/242-339   SYIVYILGTSALLTAR.LWWQNFESPKFKEVDNPIAHNDHILTRVLSQQYLLVMNLWLMLCPHWLCYDW...........
Q7Q9A0_ANOGA/222-318   RVFILACLSLATVALR.LWIMDFESPRFHRMDNPIGATNSTISRLLSQSYLYWLNSWLLICPDWLSFDW...........
Q16JI9_AEDAE/222-318   RIITLFVMTCILIYAR.LRVQNFASPQFRDKDNIVAFSHG-ITKTLSQNYLYCLNLWLLLCPDWLSFDW...........
Q9V3X5_DROME/249-346   SVCIVLGALFCMAYCR.LVIVPGPQTAFSSADNPIARTPSAWTRLLTFLYLPVFNLRLLLQPNVLSFDW...........
Q29NN5_DROPS/219-316   SVCIVLGALFCSAYCR.LVIVPGPQTAFSSADNPISRTPSAWTRLLTFLYLPVFNFRLMLQPQVLSFDW...........
Q8T3V2_DROME/236-333   SLSILGFTLLCALYCR.LSLLPRPSTAFSAADNPTAHESCFWTRTLTFLYLPVANFGILLWPQELSFDW...........
Q7KU17_DROME/268-365   SLSILGFTLLCGLYCR.LSLLPRPSTAFSAADNPTAHESCFWTRTLTFLYLPVANFGILLWPQELSFDW...........
Q9VQE9_DROME/236-333   SLSILGFTLLCGLYCR.LSLLPRPSTAFSAADNPTAHESCFWTRTLTFLYLPVANFGILLWPQELSFDW...........
Q29KX4_DROPS/216-313   SLCILSVFLFCALYCR.LSLLPRPATPFAAADNPTAHEACWWTRTLTFLYLPAANFRLLLWPQVLSFDW...........
Q7PW27_ANOGA/5-101   SLGIIALSLAFIVHCR.LTL-PRPATLFSTADNPTARSGSLWTRFLTFTYLPVVNFKLLLLPDVLSFDW...........
Q16UX9_AEDAE/209-305   SVGILALALGSIMHTR.LSL-PQPTVLFSTADNPTAKIGSRWTRFLTFAYLPVFNFRLLLYPDVLSFDW...........
Q8N394_HUMAN/227-323   SISLLIFWGSSLLGAR.LYWMGNKPPSFSNSDNPAADSDSLLTRTLTFFYLPTKNLWLLLCPDTLSFDW...........
Q56A06_MOUSE/227-323   SISLLTFWGTCLLGAR.LYWMGNKPPSFSNSDNPAADSDSLLARTLTFLYLPTKNLWLLLCPDTLSFDW...........
Q8C787_MOUSE/227-323   SISLLTFWGTCLLGAR.LYWMGNKPPSFSNSDNPAADSDSLLARTLTFLYLPTKNLWLLLCPDTLSFDW...........
Q6DCD5_XENLA/227-323   SVGLLFAWGVILLGAR.FYWMGNTPPSFSNSDNPAADCEVLLTRTLTFFYLPTKNLWLLFCPDTLSFDW...........
Q4SKH7_TETNG/210-307   NVSLLALWGVVLLACR.FYWMGNKPPNFSNSDNPAADSPSLLTRTLTFFYLPAVNFWLLLCPDMLSFDW...........
Q5RG42_BRARE/206-302   SLAWLVGWGIILLTAR.FHWMGNKPPNFSNSDNPAADSPHFLTRALTFLYLPSVNAWLLLCPDKLSFDW...........
Q4SBS0_TETNG/206-302   SLVALASWGVVLLLVR.LYWMGNKPPHFSSSDNPAADSPLFLTRALTFLYLPAANAWLLLCPDRLSFDW...........
Q60LE5_CAEBR/221-318   DITNHFIALSIICYLR.LSINNIQSPKFSKNDNPIAHDPNFFTRALTFLYLPIFHLKLIVFPKTLSFDW...........
O16296_CAEEL/224-321    DVTAYLISLLALCYLR.LSINNFQSPKFSKNDNPIAHEPNSLTRALTFMYLPVFHLNLIVFPKTLSYDW...........
Q9BGZ6_MACFA/55-152  RMTLLTSGGAGMLYVR.WRIMGTGPPAFTEVDNPASFADSMLVRAINYNYYYSLNAWLLLCPWWLCFDW...........
Q5T4D3_HUMAN/291-388   RMTLLTSGGAGMLYVR.WRIMGTGPPAFTEVDNPASFADSMLVRAVNYNYYYSLNAWLLLCPWWLCFDW...........
Q5T4D6_HUMAN/215-312   RMTLLTSGGAGMLYVR.WRIMGTGPPAFTEVDNPASFADSMLVRAVNYNYYYSLNAWLLLCPWWLCFDW...........
Q8WV63_HUMAN/55-152  RMTLLTSGGAGMLYVR.WRIMGTGPPAFTEVDNPASFADSMLVRAVNYNYYYSLNAWLLLCPWWLCFDW...........
Q96SU8_HUMAN/10-107  RMTLLTSGGAGMLYVR.WRIMGTGPPAFTEVDNPASFADSMLVRAVNYNYYYSLNAWLLLCPWWLCFDW...........
Q8BG19_MOUSE/272-369   RIALLTIGGTSMLYIR.WKIMGTGPPAFTEVDNPASFADSMLVRAINYNYYYSLNAWLLLCPWWLCFDW...........
Q8BT03_MOUSE/272-369   RIALLTIGGTSMLYIR.WKIMGTGPPAFTEVDNPASFADSMLVRAINYNYYYSLNAWLLLCPWWLCFDW...........
Q8C4D2_MOUSE/152-249   RIALLTIGGTSMLYIR.WKIMGTGPPAFTEVDNPASFADSMLVRAINYNYYYSLNAWLLLCPWWLCFDW...........
Q8CAC3_MOUSE/272-369   RIALLTIGGTSMLYIR.WKIMGTGPPAFTEVDNPASFADSMLVRAINYNYYYSLNAWLLLCPWWLCFDW...........
Q8K0I2_MOUSE/55-152  RIALLTIGGTSMLYIR.WKIMGTGPPAFTEVDNPASFADSMLVRAINYNYYYSLNAWLLLCPWWLCFDW...........
Q4RWE0_TETNG/240-337   RLALMALGGLSMLYAR.WRIMGTGPPAFTEVDNPASFEENVFLRIVNYNYYYCLNAWLLLCPWWLCFDW...........
Q8IUR5_HUMAN/170-259   RFPHKGAWGG--CHSP.LPP-EPKSSGFPVS--PRAVWSM--MRFLTYSYLLAFNVWLLLAPVTLCYDW...........
Q6ZSM5_HUMAN/225-321   RAILVLSYVLVILYFR.LWIMGGSMPLFSEQDNPASFSPYILTRFLTYSYLLAFNVWLLLAPVTLCYDW...........
Q96N52_HUMAN/34-130  RAILVLSYVLVILYFR.LWIMGGSMPLFSEQDNPASFSPYILTRFLTYSYLLAFNVWLLLAPVTLCYDW...........
Q3UV71_MOUSE/331-427   RAILVISYVTVILYFR.LWIMGGTMPLFSEQDNPASFSPYILTRFLTYSYLLAFNVWLLLAPITLCYDW...........
Q8BQV5_MOUSE/31-127  RAILVISYVTVILYFR.LWIMGGTMPLFSEQDNPASFSPYILTRFLTYSYLLAFNVWLLLAPITLCYDW...........
Q4SZ08_TETNG/182-276   RAGFISVCVIIVLSVR.LWLMGGSMPLFSEQDNPASFSPYLLTRILTYSYLLSFNAWLLLVPAVLCYDW...........
Q1L8G1_BRARE/181-304   RACVVSLHVTVIMSVR.LWLMGGSMPLFSEQDNPASFSPYLLTRFLTYCYLLAFNAWLLLAPIMLCYDWqvndnhrktll
Q7Q249_ANOGA/146-241   RVSRVLLSMGVLLAVR.LALLQGSLPRFSQQDNPTAFHPNLYVRLLTFCYLAAFNWWLLLCPSTLSHDW...........
Q17C55_AEDAE/162-257   RVSRVLLSMGVLLAVR.LALLQGSLPKFSQQDNPTAFHPNLYVRLLTFCYLAAFNWWLLLCPSTLSHDW...........
Q7Q8R7_ANOGA/18-113  RLAVLCVTTVALLFAR.LQIMGSQLPVFTRFDNPASVAVT-PARQLSYNYLVSVNLWLLLFPCDLCCDW...........
Q17MP1_AEDAE/1-79   ----------------.-MAQQQRSVKFAKFDNPASVSVT-PTRQLSYNYLASVNLWLLLFPCDLCCDW...........
Q5H9T6_HUMAN/238-333   KLIVLMFSTLLLVVIR.VQVIQSQLPVFTRFDNPAAVSPT-PTRQLTFNYLLPVNAWLLLNPSELCCDW...........
Q68DQ6_HUMAN/238-333   KLIVLMFSTLLLVVIR.VQVIQSQLPVFTRFDNPAAVSPT-PTRQLTFNYLLPVNAWLLLNPSELCCDW...........
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